{
  "questions": [
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36113495"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 2839,
          "offsetInEndSection": 3023,
          "text": "INTERPRETATION: Erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and CGRP probably does not have an important role in paroxysmal pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36113495"
        },
        {
          "offsetInBeginSection": 2356,
          "offsetInEndSection": 2656,
          "text": "There was no difference between groups in the number of responders at 4 weeks in the intention-to-treat population (14 [35%] of 40 with erenumab vs 18 [45%] of 40 with placebo; estimated effect size -10% [95% CI -31 to 11]; p\u003d0·36). 20 (50%) of 40 participants reported adverse events in each group. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36113495"
        }
      ],
      "body": "Is erenumab effective for trigeminal neuralgia?",
      "type": "yesno",
      "id": "63f73f1b33942b094c000008",
      "ideal_answer": [
        "No. In a randomized clinical trial erenumab was not effective for treatment of trigeminal neuralgia."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21446639",
        "http://www.ncbi.nlm.nih.gov/pubmed/26771990",
        "http://www.ncbi.nlm.nih.gov/pubmed/33572131",
        "http://www.ncbi.nlm.nih.gov/pubmed/25698146",
        "http://www.ncbi.nlm.nih.gov/pubmed/24955752",
        "http://www.ncbi.nlm.nih.gov/pubmed/22364325",
        "http://www.ncbi.nlm.nih.gov/pubmed/32124704",
        "http://www.ncbi.nlm.nih.gov/pubmed/26316760",
        "http://www.ncbi.nlm.nih.gov/pubmed/29962579",
        "http://www.ncbi.nlm.nih.gov/pubmed/22146224",
        "http://www.ncbi.nlm.nih.gov/pubmed/25852975",
        "http://www.ncbi.nlm.nih.gov/pubmed/21177242",
        "http://www.ncbi.nlm.nih.gov/pubmed/26755968",
        "http://www.ncbi.nlm.nih.gov/pubmed/34534629"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 508,
          "text": "Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26771990"
        },
        {
          "offsetInBeginSection": 1,
          "offsetInEndSection": 168,
          "text": "he Effectiveness of Lurasidone Add-On for Residual Aggressive Behavior and Obsessive Symptoms in Antipsychotic-Treated Children and Adolescents with Tourette Syndrome:",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33572131"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "text": "This article briefly reviews the novel atypical second-generation antipsychotic drugs iloperidone (Fanapt®), asenapine (Saphris®), and lurasidone (Latuda®), all of which have been approved by the U.S. Food and Drug Administration since 2009. Each is indicated for the treatment of schizophrenia, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21446639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 265,
          "text": "Lurasidone (Latuda(®)), a benzisothiazole derivative antipsychotic, is approved in the USA and Canada for the treatment of adults with major depressive episodes (MDE) associated with bipolar I disorder; this article reviews studies of lurasidone in this indication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25698146"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 509,
          "text": "Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26771990"
        },
        {
          "offsetInBeginSection": 453,
          "offsetInEndSection": 610,
          "text": "Lurasidone is a drug in the benzisothiazole class approved by the US Food and Drug Administration in June 2013 for the acute treatment of bipolar depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26316760"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application Lurasidone (Latuda, Sunovion Pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13-17 years of age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29962579"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Lurasidone is one of several antipsychotics approved in the recent past by the US FDA for the treatment of schizophrenia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22364325"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 304,
          "text": "Lurasidone is a novel benzoisothiazol antipsychotic that has recently been approved for the treatment of schizophrenia in the U.S. Like many other second-generation antipsychotics, it has a high affinity for dopamine D(2) and serotonin 5-HT(2A) receptors as well as a high affinity for 5-HT(7) receptors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22146224"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 326,
          "text": "Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK, and is also approved in the USA and Canada for the treatment of major depressive episodes associated with bipolar I disorder as either a monotherapy or adjunctive therapy with lithium or valproate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26755968"
        },
        {
          "offsetInBeginSection": 207,
          "offsetInEndSection": 333,
          "text": "Recently, lurasidone was approved to treat bipolar depression either as monotherapy or adjunctively with lithium or valproate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852975"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Lurasidone is a second-generation antipsychotic newly approved by the U.S. Food and Drug Administration for the treatment of schizophrenia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177242"
        },
        {
          "offsetInBeginSection": 99,
          "offsetInEndSection": 276,
          "text": "cide risk. Lurasidone is an atypical antipsychotic agent indicated for the treatment of schizophrenia and for the treatment of major depressive episodes associated with bipolar ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24955752"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 93,
          "text": "Update on the development of lurasidone as a treatment for patients with acute schizophrenia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22675261"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 53,
          "text": "Lurasidone: a new treatment option for schizophrenia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22146224"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Lurasidone is an important antipsychotic drug indicated for the treatment of schizophrenia and bipolar disorder, with an oral bioavailability of 9-19% owing to its poor aqueous solubility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34534629"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "Background: Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia in 2010.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34860899"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Lurasidone was approved by the United States Food and Drug Administration (FDA) for the treatment of schizophrenia, as well as for the treatment of bipolar depression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32124704"
        }
      ],
      "body": "What is the first indication for lurasidone?",
      "type": "list",
      "id": "643d41e757b1c7a315000037",
      "ideal_answer": [
        "Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia and bipolar depression.",
        "Lurasidone\u0027s initial indication is the treatment of bipolar depression.",
        "The first indication for lurasidone is the treatment of schizophrenia.",
        "Lurasidone is an atypical antipsychotic drug that was initially developed for the treatment of schizophrenia"
      ],
      "exact_answer": [
        [
          "schizophrenia"
        ],
        [
          "Bipolar depression."
        ],
        [
          "Tourette syndrome"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34304240",
        "http://www.ncbi.nlm.nih.gov/pubmed/34774197",
        "http://www.ncbi.nlm.nih.gov/pubmed/35417663"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 3147,
          "offsetInEndSection": 3590,
          "text": "Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine raises no safety concerns and preserves antibody responses to both vaccines. Concomitant vaccination with both COVID-19 and influenza vaccines over the next immunisation season should reduce the burden on health-care services for vaccine delivery, allowing for timely vaccine administration and protection from COVID-19 and influenza for those in need.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34774197"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 535,
          "text": "It is unknown if the efficacy of the coronavirus disease-19 (COVID-19) vaccine is affected by the co-administration of other vaccines. The Centers for Disease Control and Prevention (CDC) has shifted their recommendations recently, allowing for the co-administration of the currently available COVID-19 vaccines with other vaccines. This is based on the experience with non-COVID-19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34304240"
        },
        {
          "offsetInBeginSection": 1188,
          "offsetInEndSection": 1387,
          "text": "Although the administration of Tdap with COVID-19 vaccine in our case caused delay in immunogenicity, it did not negate the ability of the BNT162B2 mRNA vaccine to elicit an adequate immune response.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34304240"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 243,
          "text": "Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34774197"
        },
        {
          "offsetInBeginSection": 252,
          "offsetInEndSection": 571,
          "text": "In this multicentre, randomised, controlled, phase 4 trial, adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned (1:1) to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34774197"
        }
      ],
      "body": "Can other vaccines be given with COVID-19 vaccine?",
      "type": "yesno",
      "id": "643c88a257b1c7a315000030",
      "ideal_answer": [
        "Although there are no data regarding safety and efficacy when COVID-19 vaccines are co-administered with other vaccines, the Centers for Disease Control and Prevention (CDC) has stated that COVID-19 vaccines can be administered at any time in relation to other non-COVID-19 vaccines, and if needed, can be administered on the same day as other vaccines. This is based on the experience with non-COVID-19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone.\n\nFurthermore, in a randomized trial, frequency of adverse effects and immunogenicity were largely similar when a COVID-19 vaccine (BNT162b2 or ChAdOx1) was given concomitantly with either an influenza vaccine or placebo."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32499082"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1293,
          "offsetInEndSection": 1472,
          "text": "Sublocade® is a one-month-long depot formulation that is indicated in switch from sublingual buprenorphine, and which proposes only two dose schemes, i.e., 100 and 300mg monthly. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32499082"
        }
      ],
      "body": "What is Sublocade?",
      "type": "summary",
      "id": "64403c4257b1c7a31500004f",
      "ideal_answer": [
        "Sublocade® is a one-month-long depot formulation that is indicated in switch from sublingual buprenorphine, and which proposes only two dose schemes, i.e., 100 and 300mg monthly."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34919292",
        "http://www.ncbi.nlm.nih.gov/pubmed/31532835",
        "http://www.ncbi.nlm.nih.gov/pubmed/25467598"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 950,
          "offsetInEndSection": 1328,
          "text": "This review supports the beneficial effects of music-based interventions on the health of preterm infants in a neonatal intensive care unit; however, it also offers suggestions for future studies in order to increase the number of interventions with music therapists, since the results of music therapy approaches were more consistent for physiological and behavioural outcomes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34919292"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "No effect of a musical intervention on stress response to venepuncture in a neonatal population.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31532835"
        },
        {
          "offsetInBeginSection": 1359,
          "offsetInEndSection": 1496,
          "text": "Our findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31532835"
        },
        {
          "offsetInBeginSection": 1547,
          "offsetInEndSection": 1686,
          "text": "BF could significantly reduce pain response in healthy-term neonates during heel lance. MT did not enhance the effect of pain relief of BF.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25467598"
        }
      ],
      "body": "Is music therapy effective for pain management in neonates?",
      "type": "yesno",
      "id": "6441302d57b1c7a315000056",
      "ideal_answer": [
        "No, although there are beneficial effects of music-based interventions, there are no clear evidence of their effectiveness on pain management in neonates.",
        "No, music therapy has not been proven to effectively manage procedural pain in neonate\u0027s. This study suggests that breastfeeding may provide better pain relief than music therapy alone. Therefore, it would be appropriate to focus more efforts on promoting breast feeding rather than providing music therapy to neonate at risk of experiencing procedural pain.",
        "No, although music therapy has been used with babies it does not seem to have any added benefits when compared to traditional methods such as nursing. Music can provide an emotional release which may help children feel more comfortable but there is little evidence to suggest that it directly reduces pain levels in infants. It\u0027s important to use treatments based on scientific research rather than subjective beliefs, and further studies are needed to fully understand how music affects infant development and wellbeing.\"",
        "Yes, according to the results of the study, music therapy can effectively manage pain in neonates by reducing pain scores and improving their neurological development. This suggests that it could play an important role in helping babies recover from birth trauma or other sources of discomfort. Despite these positive findings, more research is needed to confirm whether music therapy is truly beneficial in all cases.",
        "Music therapy has shown beneficial effects on the health of preterm infants in a neonatal intensive care unit, especially for physiological and behavioural outcomes. However, there is no clear evidence that music therapy is effective for pain management in neonates, as some studies have shown mixed results and even negative effects such as increased heart rate and crying time. Further studies with interventions implemented by music therapists are needed to evaluate the effectiveness of music therapy for pain management in neonates.",
        "Yes, music therapy is effective for pain management in neonates.",
        "Yes, music therapy has been found to be effective for pain management in neonates. Studies have shown that music therapy can reduce pain levels in neonates, as well as reduce the need for pain medications. Music therapy has also been found to reduce stress and anxiety in neonates, which can further help to reduce pain levels.",
        "Yes, music therapy has been found to be effective for pain management in neonates. Studies have shown that music therapy can reduce pain intensity, distress, and anxiety in neonates undergoing painful procedures.",
        "Yes, music therapy has been shown to be effective for pain management in neonates. Several studies have demonstrated that music therapy can reduce pain responses and improve physiological and behavioral outcomes in neonates undergoing painful procedures such as heel lances and venipunctures.",
        "Yes, music therapy has been shown to be effective for pain management in neonates, particularly when combined with other interventions such as breastfeeding or non-nutritive sucking. However, more research is needed to further understand its effectiveness.",
        "Music therapy has been suggested as a non-pharmacological intervention for pain management in neonates. Several studies have investigated the effectiveness of music therapy in reducing pain and distress during painful procedures such as heel stick, venipuncture, and circumcision. A systematic review and meta-analysis of 11 randomized controlled trials found that music therapy was associated with a significant reduction in pain scores compared to standard care or no intervention. The effect size was moderate, suggesting that music therapy can be an effective adjunctive intervention for pain management in neonates. However, the optimal type, timing, and duration of music therapy interventions are still unclear. Further research is needed to determine the most effective approach to implementing music therapy for neonatal pain management.",
        "Music therapy has been shown to have beneficial effects on the health of preterm infants in neonatal intensive care units, particularly for physiological and behavioral outcomes. However, a study examining the effect of music intervention on neonatal stress response to venepuncture in preterm infants did not find any additional benefit. Another study found that breastfeeding could significantly reduce pain response in healthy-term neonates during heel lance, but music therapy did not enhance the effect of pain relief from breastfeeding. While there is some evidence supporting the use of music therapy for pain management in neonates, further research is needed to fully understand its effectiveness and potential limitations. It may be useful to explore how music therapy can be integrated with other interventions, such as breastfeeding or pharmacological treatments, to optimize pain management in this population.",
        "Music therapy has shown promising results in pain management for neonates. Several studies have demonstrated its effectiveness in reducing pain and stress levels in newborns undergoing various medical procedures. A systematic review by Hartling et al. (2009) found that music therapy, specifically live or recorded lullabies, can lead to significant reductions in heart rate, respiratory rate, and behavioral distress during painful interventions such as heel lance and venipuncture. Another study by Loewy et al. (2013) reported that music therapy reduced the need for analgesic medications and improved vital signs in premature infants receiving intensive care. Additionally, a meta-analysis by van der Heijden et al. (2016) concluded that music intervention significantly decreased pain scores in neonates during minor painful procedures. However, it is important to note that the quality of evidence varies across studies, and more rigorous research is needed to establish optimal protocols for music therapy implementation in neonatal pain management. Overall, current evidence suggests that music therapy can be an effective non-pharmacological intervention for managing pain in neonates when used alongside standard medical care.",
        "Music therapy has shown some beneficial effects on the health of preterm infants in neonatal intensive care units, particularly for physiological and behavioral outcomes (PMID: 34919292). However, its effectiveness in pain management during specific procedures like venepuncture and heel lance is not consistently supported. One study found no additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants (PMID: 31532835). Another study reported that while breastfeeding significantly reduced pain response during heel lance in healthy-term neonates, music therapy did not enhance the effect of pain relief provided by breastfeeding (PMID: 25467598). In summary, although music-based interventions may have some positive effects on preterm infants\u0027 overall health, their effectiveness in pain management during specific procedures remains inconclusive. Further research involving music therapists is needed to better understand the potential benefits of music therapy for neonatal pain management."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34350585",
        "http://www.ncbi.nlm.nih.gov/pubmed/35637252",
        "http://www.ncbi.nlm.nih.gov/pubmed/35625776"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 631,
          "offsetInEndSection": 980,
          "text": "Many of the hopeful predictions outlined in our AML review of 2018 are now therapeutic realities: gemtuzumab ozogamicin, venetoclax, FLT3 inhibitors (midostaurin, gilteritinib), IDH inhibitors (ivosidenib, enasidenib), CPX-351, glasdegib, oral decitabine, and oral azacitidine. Others may soon be (quizartinib, APR246 magrolimab, menin inhibitors). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34350585"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 253,
          "text": "The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemotherapy (SC). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35637252"
        },
        {
          "offsetInBeginSection": 729,
          "offsetInEndSection": 961,
          "text": "Similarly high rates of composite complete remission (CRc) were observed in patients who received a FLT3 TKI before gilteritinib (CHRYSALIS, 42%; ADMIRAL, 52%) and those without prior FLT3 TKI therapy (CHRYSALIS, 43%; ADMIRAL, 55%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35637252"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 522,
          "text": "In this study, to identify therapeutic targets responsible for the survival and proliferation of leukemic cells (blasts) with FLT3 mutations after gilteritinib (GILT, a 2nd generation tyrosine kinase inhibitor (TKI)) treatment, we performed proteomic screening of cytokine release and in vitro/ex vivo studies to investigate their associated signaling pathways and transcriptional regulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35625776"
        }
      ],
      "body": "What is the mechanisms of action of Gilteritinib?",
      "type": "summary",
      "id": "63f042e2f36125a426000022",
      "ideal_answer": [
        "The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory FLT3-mutated acute myeloid leukemia."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35997897",
        "http://www.ncbi.nlm.nih.gov/pubmed/35867041",
        "http://www.ncbi.nlm.nih.gov/pubmed/36250252",
        "http://www.ncbi.nlm.nih.gov/pubmed/34154993",
        "http://www.ncbi.nlm.nih.gov/pubmed/25730476",
        "http://www.ncbi.nlm.nih.gov/pubmed/25434769",
        "http://www.ncbi.nlm.nih.gov/pubmed/35505960",
        "http://www.ncbi.nlm.nih.gov/pubmed/25786782",
        "http://www.ncbi.nlm.nih.gov/pubmed/34413198",
        "http://www.ncbi.nlm.nih.gov/pubmed/29792572",
        "http://www.ncbi.nlm.nih.gov/pubmed/34091052",
        "http://www.ncbi.nlm.nih.gov/pubmed/36281788",
        "http://www.ncbi.nlm.nih.gov/pubmed/32170309",
        "http://www.ncbi.nlm.nih.gov/pubmed/28988716",
        "http://www.ncbi.nlm.nih.gov/pubmed/30820542",
        "http://www.ncbi.nlm.nih.gov/pubmed/26011654",
        "http://www.ncbi.nlm.nih.gov/pubmed/31303442",
        "http://www.ncbi.nlm.nih.gov/pubmed/28129130",
        "http://www.ncbi.nlm.nih.gov/pubmed/36345805"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 193,
          "offsetInEndSection": 507,
          "text": "Two decades after the discovery of the RNA interference mechanism, the first siRNA drugs received approval for clinical use by the US Food and Drug Administration and the European Medicines Agency between 2018 and 2022. These are mainly based on an siRNA conjugation with a targeting moiety for liver hepatocytes, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35997897"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35867041"
        },
        {
          "offsetInBeginSection": 1272,
          "offsetInEndSection": 1591,
          "text": "Patisiran (hereditary transthyretin-mediated amyloidosis) was the first licensed siRNA, followed by givosiran (acute hepatic porphyria), lumasiran (primary hyperoxaluria type 1) and inclisiran (familial hypercholesterolaemia), which all use N-acetylgalactosamine (GalNAc) linkage for effective liver-directed delivery. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36250252"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 226,
          "text": "Conjugation of oligonucleotide therapeutics, including small interfering RNAs (siRNAs) or antisense oligonucleotides, to N-acetylgalactosamine (GalNAc) ligands has become the primary strategy for hepatocyte-targeted delivery, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34154993"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "We recently demonstrated that siRNAs conjugated to triantennary N-acetylgalactosamine (GalNAc) induce robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25786782"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434769"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 261,
          "text": "Inclisiran is a novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) therapy designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in the liver for the treatment of hypercholesterolemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36281788"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "N-Acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) are a leading RNA interference (RNAi) platform allowing targeted inhibition of disease-causing genes in hepatocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34091052"
        },
        {
          "offsetInBeginSection": 379,
          "offsetInEndSection": 568,
          "text": "GalNAc binds the asialoglycoprotein receptor (ASGPR) that is highly expressed on hepatocytes and exploits this scavenger receptor to deliver siRNA across the plasma membrane by endocytosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35505960"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Asialoglycoprotein receptor (ASGPR) mediated delivery of triantennary N-acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) to hepatocytes is a promising paradigm for RNAi therapeutics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25730476"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25786782"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35867041"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Conjugation of triantennary N-acetyl galactosamine (GalNAc) to oligonucleotide therapeutics results in marked improvement in potency for reducing gene targets expressed in hepatocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26011654"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 521,
          "text": " The conjugation of ASOs to a receptor ligand can dramatically increase their entry into certain cells and tissues, as demonstrated by the implementation of N-acetylgalactosamine (GalNAc)-conjugated ASOs for Asialoglycoprotein Receptor (ASGR)-mediated uptake into liver hepatocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069408"
        },
        {
          "offsetInBeginSection": 345,
          "offsetInEndSection": 550,
          "text": " In pre-clinical models, attachment of a triantennary N-acetylgalactosamine (GalNAc) ligand to an siRNA mediates hepatocyte uptake via the asialoglycoprotein receptor enabling RNAi-mediated gene silencing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129130"
        },
        {
          "offsetInBeginSection": 260,
          "offsetInEndSection": 480,
          "text": " The development of GalNAc-siRNA conjugates, in which a synthetic triantennary N-acetylgalactosamine-based ligand is conjugated to chemically modified siRNA, has enabled efficient, ASGPR-mediated delivery to hepatocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28988716"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 457,
          "text": " One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, which results in selective uptake by asialoglycoprotein receptor (ASGR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31303442"
        },
        {
          "offsetInBeginSection": 993,
          "offsetInEndSection": 1198,
          "text": " Moreover, we found that conjugation of α-N-acetylgalactosamine (GalNAc) with two lncRNA-directed siRNAs allows for direct liver cell targeting of this lncRNA and functional enhanced uptake of cholesterol.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31279228"
        },
        {
          "offsetInBeginSection": 475,
          "offsetInEndSection": 592,
          "text": " Foremost of these has been the development of N-acetylgalactosamine (GalNAc) siRNA conjugates for delivery to liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29792572"
        },
        {
          "offsetInBeginSection": 105,
          "offsetInEndSection": 240,
          "text": " This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32771924"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Conjugation of small interfering RNA (siRNA) to tris N-acetylgalactosamine [(GalNAc)3] can enable highly selective, potent, and durable knockdown of targeted proteins in the liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34413198"
        },
        {
          "offsetInBeginSection": 422,
          "offsetInEndSection": 572,
          "text": "conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Exposure to 2\u0027-F-monomer metabolites was low and transien",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30820542"
        },
        {
          "offsetInBeginSection": 344,
          "offsetInEndSection": 494,
          "text": "d to a trivalent N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Sense and antisense strands of the parent duplex were syn",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32170309"
        },
        {
          "offsetInBeginSection": 94,
          "offsetInEndSection": 244,
          "text": "from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to hepatocytes in vitro and in vivo. The ligands derived from GalNAc ar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25434769"
        },
        {
          "offsetInBeginSection": 1380,
          "offsetInEndSection": 1530,
          "text": "ine (GalNAc) moieties to ASOs or siRNAs facilitates receptor-mediated uptake by the asialoglycoprotein receptor. In summary, ATTR is a progressive dis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36345805"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 240,
          "text": "This is particularly the result of successful and efficient delivery of N-acetylgalactosamine (GalNAc)-conjugated siRNAs to the liver.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32771924"
        }
      ],
      "body": "What is the reason for N-acetylgalactosamine (GalNAc) conjugation of siRNAs?",
      "type": "summary",
      "id": "64184483690f196b51000038",
      "ideal_answer": [
        "N-acetylgalactosamine (GalNAc) is used as a targeting moiety for Hepatocytes. Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases and this has become a primary strategy for hepatocyte-targeted delivery,",
        "Small interfering RNAs (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs to treat liver diseases.",
        "The reason for N-acetylgalactosamine (GalNAc) conjugation of siRNAs is to improve liver uptake and facilitate targeted delivery of siRNA to hepatocytes, which is the primary strategy for hepatocyte-targeted delivery. This conjugation induces robust RNAi-mediated gene silencing in the liver, owing to uptake mediated by the asialoglycoprotein receptor (ASGPR). GalNAc-siRNA conjugates also have a remarkable durability of activity that can persist for months in preclinical species and humans, making them an emerging class of drugs to treat liver diseases.",
        "N-acetylgalactosamine (GalNAc) conjugation of siRNAs is the primary strategy for hepatocyte-targeted delivery, followed by conjugation to a targeting moiety for improved liver uptake.",
        "N-acetylgalactosamine (GalNAc) conjugation is used to improve liver uptake of siRNAs. It is a targeting moiety used to deliver siRNAs to liver hepatocytes. This strategy has been successful in the development of siRNA drugs that target various liver diseases",
        "N-acetylgalactosamine (GalNAc) conjugation of siRNAs is used to improve liver uptake and target hepatocytes. This strategy enhances the delivery and therapeutic potential of siRNA drugs for treating liver-related diseases"
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28649135",
        "http://www.ncbi.nlm.nih.gov/pubmed/21094158",
        "http://www.ncbi.nlm.nih.gov/pubmed/16110319",
        "http://www.ncbi.nlm.nih.gov/pubmed/30059974",
        "http://www.ncbi.nlm.nih.gov/pubmed/31675556",
        "http://www.ncbi.nlm.nih.gov/pubmed/18586941",
        "http://www.ncbi.nlm.nih.gov/pubmed/24864230",
        "http://www.ncbi.nlm.nih.gov/pubmed/16118434",
        "http://www.ncbi.nlm.nih.gov/pubmed/32883316",
        "http://www.ncbi.nlm.nih.gov/pubmed/26451775",
        "http://www.ncbi.nlm.nih.gov/pubmed/34050264",
        "http://www.ncbi.nlm.nih.gov/pubmed/34070674",
        "http://www.ncbi.nlm.nih.gov/pubmed/30125975",
        "http://www.ncbi.nlm.nih.gov/pubmed/25171417",
        "http://www.ncbi.nlm.nih.gov/pubmed/18789146",
        "http://www.ncbi.nlm.nih.gov/pubmed/21737609",
        "http://www.ncbi.nlm.nih.gov/pubmed/36069976",
        "http://www.ncbi.nlm.nih.gov/pubmed/19690570",
        "http://www.ncbi.nlm.nih.gov/pubmed/31671773",
        "http://www.ncbi.nlm.nih.gov/pubmed/26085504",
        "http://www.ncbi.nlm.nih.gov/pubmed/20976469",
        "http://www.ncbi.nlm.nih.gov/pubmed/34589394",
        "http://www.ncbi.nlm.nih.gov/pubmed/31627702",
        "http://www.ncbi.nlm.nih.gov/pubmed/30682083",
        "http://www.ncbi.nlm.nih.gov/pubmed/27113746",
        "http://www.ncbi.nlm.nih.gov/pubmed/24893124",
        "http://www.ncbi.nlm.nih.gov/pubmed/30594981",
        "http://www.ncbi.nlm.nih.gov/pubmed/34454516",
        "http://www.ncbi.nlm.nih.gov/pubmed/30971823",
        "http://www.ncbi.nlm.nih.gov/pubmed/34590269",
        "http://www.ncbi.nlm.nih.gov/pubmed/26427375",
        "http://www.ncbi.nlm.nih.gov/pubmed/23447678",
        "http://www.ncbi.nlm.nih.gov/pubmed/29421999",
        "http://www.ncbi.nlm.nih.gov/pubmed/26516187",
        "http://www.ncbi.nlm.nih.gov/pubmed/26431531",
        "http://www.ncbi.nlm.nih.gov/pubmed/36446128",
        "http://www.ncbi.nlm.nih.gov/pubmed/29171189",
        "http://www.ncbi.nlm.nih.gov/pubmed/22864477",
        "http://www.ncbi.nlm.nih.gov/pubmed/35170959",
        "http://www.ncbi.nlm.nih.gov/pubmed/26630128",
        "http://www.ncbi.nlm.nih.gov/pubmed/33795234",
        "http://www.ncbi.nlm.nih.gov/pubmed/31811941",
        "http://www.ncbi.nlm.nih.gov/pubmed/33992077"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 373,
          "text": "Two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death. So, targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only cancer cells and spare normal cells. Synthetic lethality therefore provides a conceptual framework for the development of cancer-specific cytotoxic agents.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16110319"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Synthetic lethality occurs when the simultaneous perturbation of two genes results in cellular or organismal death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21094158"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 359,
          "text": "A synthetic lethal interaction occurs between two genes when the perturbation of either gene alone is viable but the perturbation of both genes simultaneously results in the loss of viability. Key to exploiting synthetic lethality in cancer treatment are the identification and the mechanistic characterization of robust synthetic lethal genetic interactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649135"
        },
        {
          "offsetInBeginSection": 249,
          "offsetInEndSection": 455,
          "text": "Synthetic lethality describes the phenomenon of the interplay between two genes in which deficiency of a single gene does not abolish cell viability but combined deficiency of two genes leads to cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34050264"
        },
        {
          "offsetInBeginSection": 416,
          "offsetInEndSection": 558,
          "text": "Synthetic lethality refers to cell death caused by simultaneous perturbations of two genes while change of any one of them alone is nonlethal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34070674"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "Synthetic lethality is an extreme form of negative genetic epistasis that arises when a combination of functional deficiency in two or more genes results in cell death, whereas none of the single genetic perturbations are lethal by themselves.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30594981"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer therapeutics1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30971823"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 202,
          "text": "Synthetic lethality is a genetic interaction that results in cell death when two genetic deficiencies co-occur but not when either deficiency occurs alone, which can be co-opted for cancer therapeutics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36069976"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "Synthetic lethality is inviability of a double-mutant combination of two fully viable single mutants, commonly interpreted as redundancy at an essential metabolic step.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18586941"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "Synthetic dosage lethality (SDL) is a type of genetic interaction that occurs when increasing the expression of a gene causes a fitness defect, such as lethality, in a specific mutant background but has little effect on fitness in a wild-type background.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34590269"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Synthetic lethality is a genetic interaction wherein two otherwise nonessential genes cause cellular inviability when knocked out simultaneously.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26451775"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 191,
          "text": "Synthetic lethality is a potential strategy for cancer treatment by specifically promoting the death of cancer cells with particular defects such as the loss of the RB (RB1) tumor suppressor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23447678"
        },
        {
          "offsetInBeginSection": 668,
          "offsetInEndSection": 836,
          "text": "Synthetic lethality occurs when simultaneous inactivation of two genes or their products causes cell death whereas individual inactivation of either gene is not lethal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29421999"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 249,
          "text": "Synthetic lethality (SL) is a type of genetic interaction between two genes such that simultaneous perturbations of the two genes result in cell death or a dramatic decrease of cell viability, while a perturbation of either gene alone is not lethal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26516187"
        },
        {
          "offsetInBeginSection": 298,
          "offsetInEndSection": 542,
          "text": "Synthetic lethality is a type of genetic interaction between two genes such that simultaneous perturbations of the two genes result in cell death or a dramatic decrease of cell viability, while a perturbation of either gene alone is not lethal.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31675556"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 162,
          "text": "Synthetic lethality refers to a lethal phenotype that results from the simultaneous disruptions of two genes, while the disruption of either gene alone is viable.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171189"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Synthetic lethality arises when a combination of mutations in two or more genes leads to cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26431531"
        },
        {
          "offsetInBeginSection": 376,
          "offsetInEndSection": 493,
          "text": " Global analysis of synthetic lethality promises to identify cellular pathways that \u0027buffer\u0027 each other biologically.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16309778"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Synthetic lethality is the synthesis of mutations leading to cell death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30125975"
        },
        {
          "offsetInBeginSection": 184,
          "offsetInEndSection": 366,
          "text": "Exploiting a phenomenon known as synthetic lethality, in which simultaneous loss of two interacting genes leads to loss of viability, aids in the investigation of these interactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22107871"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 265,
          "text": "One such genetic interaction is synthetic lethality, in which the combination of two non-lethal mutations leads to loss of organism viability.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17189863"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 349,
          "text": "pment of novel anticancer therapies. SL can be described as lethality (cell death) resulting from the combination of the two mutations, wherein the mu",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26211783"
        },
        {
          "offsetInBeginSection": 282,
          "offsetInEndSection": 471,
          "text": " Synthetic lethality occurs when inhibition or mutation in two or more separate genes leads to cell death while inhibition or mutations of either gene alone has no lethal effect on the cell",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26630128"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "Synthetic lethality is a promising strategy for specific targeting of cancer cells that carry mutations that are absent in normal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22864477"
        },
        {
          "offsetInBeginSection": 470,
          "offsetInEndSection": 613,
          "text": "Synthetic lethality exploits cancer cell dependency on a protein or pathway, which arises when the function of a tumor suppressor is defective.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34163025"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 160,
          "text": "Synthetic lethality is based on the incompatibility of cell survival with the loss of function of two or more genes, not with loss of function of a single gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737609"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Synthetic lethality is a proven effective antitumor strategy that has attracted great attention.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34589394"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 150,
          "text": "Synthetic lethality is a state when simultaneous loss of two genes is lethal to a cancer cell, while the loss of the individual genes is not.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30059974"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 251,
          "text": "Synthetic lethality describes a genetic interaction between two perturbations, leading to cell death, whereas neither event alone has a significant effect on cell viability. This concept can be exploited to specifically target tumor cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34454516"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 338,
          "text": "Synthetic lethality describes a relationship between two genes where single loss of either gene does not trigger significant impact on cell viability, but simultaneous loss of both gene functions results in lethality. Targeting synthetic lethal interactions with drug combinations promises increased efficacy in tumor therapy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30682083"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 418,
          "text": "Synthetic lethality (SL) refers to the genetic interaction between two or more genes where only their co-alteration (e.g. by mutations, amplifications or deletions) results in cell death. In recent years, SL has emerged as an attractive therapeutic strategy against cancer: by targeting the SL partners of altered genes in cancer cells, these cells can be selectively killed while sparing the normal cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26427375"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 356,
          "text": "Synthetic lethality defines a genetic interaction where the combination of mutations in two or more genes leads to cell death. The implications of synthetic lethal screens have been discussed in the context of drug development as synthetic lethal pairs could be used to selectively kill cancer cells, but leave normal cells relatively unharmed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18789146"
        }
      ],
      "body": "What is synthetic lethality?",
      "type": "summary",
      "id": "643de76757b1c7a315000039",
      "ideal_answer": [
        "Synthetic lethality occurs between two genes when the perturbation of either gene alone is viable but the perturbation of both genes simultaneously results in the loss of viability. So, two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death. Targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only cancer cells and spare normal cells. Therefore, synthetic lethality provides a conceptual framework for the development of cancer-specific cytotoxic agents.",
        "Two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death. So, targeting a gene that is synthetic lethal to a cancer-relevant mutation should kill only cancer cells and spare normal cells. Synthetic lethality therefore provides a conceptual framework for the development of cancer-specific cytotoxic agents.",
        "Synthetic lethality is a phenomenon in which two or more genetic mutations interact in a way that causes the death of an organism, even though each mutation alone would not be lethal. It is a form of genetic interaction that can be used to identify potential drug targets for cancer therapy.",
        "Synthetic lethality is a phenomenon in which the simultaneous inactivation of two or more genes leads to cell death, while the inactivation of either gene alone has no effect. It is a promising approach for cancer therapy, as it can be used to target cancer cells while leaving normal cells unaffected.",
        "Synthetic lethality is a phenomenon in which the simultaneous occurrence of two genetic mutations leads to cell death, while each mutation alone has no effect on cell viability. This concept has been extensively studied in cancer research, as it provides a potential therapeutic strategy for targeting cancer cells with minimal toxicity to normal cells. The idea is to identify pairs of genes that, when mutated together, result in synthetic lethality and then develop drugs that target one of these genes. For example, PARP inhibitors have been developed for the treatment of BRCA-mutated cancers because BRCA-deficient cells are sensitive to PARP inhibition due to synthetic lethality between these two genes. Synthetic lethality has also been explored in other areas such as infectious diseases and neurodegenerative disorders. Overall, understanding synthetic lethality can provide insights into disease mechanisms and lead to the development of novel therapies.",
        "Synthetic lethality is a genetic concept that occurs when the simultaneous disruption of two or more genes leads to cell death, while the individual disruption of each gene does not have a lethal effect. This phenomenon has gained significant attention in cancer research as it offers a promising therapeutic strategy for selectively targeting cancer cells with specific genetic alterations. By exploiting the unique vulnerabilities of cancer cells, synthetic lethality can be used to develop targeted therapies that minimize damage to healthy cells and reduce side effects. One well-known example of synthetic lethality in cancer therapy is the use of PARP inhibitors in BRCA1/2-mutated cancers, where the combined deficiency in DNA repair pathways results in cell death specifically in tumor cells."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34322164"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 711,
          "offsetInEndSection": 1109,
          "text": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34322164"
        }
      ],
      "body": "How many injections of CLS-TA did the patients participating in the PEACHTREE trial receive?",
      "type": "factoid",
      "id": "64403ab057b1c7a31500004d",
      "ideal_answer": [
        "The patients participating in the PEACHTREE trial received two suprachoroidal injections of CLS-TA at 0 and 12 weeks."
      ],
      "exact_answer": [
        [
          "two",
          "2"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35218518",
        "http://www.ncbi.nlm.nih.gov/pubmed/35929940",
        "http://www.ncbi.nlm.nih.gov/pubmed/36281417",
        "http://www.ncbi.nlm.nih.gov/pubmed/33734897",
        "http://www.ncbi.nlm.nih.gov/pubmed/34327855",
        "http://www.ncbi.nlm.nih.gov/pubmed/12022080",
        "http://www.ncbi.nlm.nih.gov/pubmed/30453357",
        "http://www.ncbi.nlm.nih.gov/pubmed/24300647",
        "http://www.ncbi.nlm.nih.gov/pubmed/25271841",
        "http://www.ncbi.nlm.nih.gov/pubmed/23381834",
        "http://www.ncbi.nlm.nih.gov/pubmed/33552634",
        "http://www.ncbi.nlm.nih.gov/pubmed/35359537",
        "http://www.ncbi.nlm.nih.gov/pubmed/26037351",
        "http://www.ncbi.nlm.nih.gov/pubmed/8745379",
        "http://www.ncbi.nlm.nih.gov/pubmed/2669113"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 184,
          "offsetInEndSection": 289,
          "text": "Whole-exome sequencing was utilized to detect disease-causing variants in 40 MLPA-negative DMD patients. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35218518"
        },
        {
          "offsetInBeginSection": 421,
          "offsetInEndSection": 524,
          "text": "WES analysis revealed that nonsense variant was the most common type in our study (23/36 of the cases).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35218518"
        },
        {
          "offsetInBeginSection": 818,
          "offsetInEndSection": 992,
          "text": ". The present study has demonstrated the importance of performing WES to detect disease-causing point mutations in MLPA-negative DMD patients and to identify carrier females.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35218518"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 299,
          "text": "Whole exome sequencing (WES) and multiple ligation-dependent probe amplification (MLPA) were used to detect potential deletions in the STS and DMD genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35929940"
        },
        {
          "offsetInBeginSection": 462,
          "offsetInEndSection": 619,
          "text": "The newborns with retest positive result were recalled again for serum creatine kinase (CK) and multiplex ligation-dependent probe amplification (MLPA) test.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36281417"
        },
        {
          "offsetInBeginSection": 620,
          "offsetInEndSection": 684,
          "text": "Whole exon sequencing was performed when MLPA test was negative.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36281417"
        },
        {
          "offsetInBeginSection": 247,
          "offsetInEndSection": 446,
          "text": " In this study we aimed to determine the mutational spectrum of multiplex ligation-dependent probe amplification (MLPA)-negative muscular dystrophy patients in Pakistan using whole-exome sequencing. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33734897"
        },
        {
          "offsetInBeginSection": 1665,
          "offsetInEndSection": 1803,
          "text": "Whole-exome sequencing identified a nonsense variant in Pakistani muscular dystrophy patients, which is amenable to treatment by Ataluren ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33734897"
        },
        {
          "offsetInBeginSection": 220,
          "offsetInEndSection": 345,
          "text": " We used the combination of multiplex ligation-dependent probe amplification (MLPA) and sequencing analysis of the DMD gene. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34327855"
        },
        {
          "offsetInBeginSection": 422,
          "offsetInEndSection": 592,
          "text": "We performed DNA tests in 152 patients, checking first exon deletion/duplication by MLPA, and subsequently, if negative, samples were sequenced to detect point mutations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34327855"
        },
        {
          "offsetInBeginSection": 387,
          "offsetInEndSection": 628,
          "text": "The strategy for molecular diagnostic testing for DMD involves initial screening for deletions/duplications using microarray-based comparative genomic hybridization (array-CGH) followed by full-sequence analysis of DMD for sequence variants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25271841"
        },
        {
          "offsetInBeginSection": 762,
          "offsetInEndSection": 1045,
          "text": "Thus, NGS-based multigene panel testing for muscular dystrophy-associated genes or clinical exome sequencing rather than targeted DMD gene sequencing appears to be a more cost-effective testing modality with better diagnostic yield, for MLPA-negative patients with the DMD phenotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33552634"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 416,
          "text": "OBJECTIVE: To optimize the methods for genetic detection and prenatal diagnosis of Duchenne muscular dystrophy (DMD).METHODS: Denaturing high-performance liquid chromatography (DHPLC), multiplex PCR (mPCR), sequencing and other molecular techniques were used in combination for molecular diagnosis of 8 cases diagnosed as DMD.RESULTS: Among the 8 cases, 4 have carried large deletions, 3 have point mutations, among ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26037351"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 228,
          "text": "BACKGROUND: Genetic testing for Duchenne/Becker muscular dystrophy (DMD/BMD) mutations initially involved multiplex polymerase chain reaction (mPCR), which targeted two mutation hotspots in the gene and detected deletions in aff",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24300647"
        },
        {
          "offsetInBeginSection": 1080,
          "offsetInEndSection": 1344,
          "text": "Most frequently performed first step diagnostic tests in Group I and Group II were muscle biopsy and MLPA.Our study reflects the change in the age at genetic diagnosis and diagnostic approach to nm-DMD depending on the advances and availability of genetic testing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30453357"
        },
        {
          "offsetInBeginSection": 555,
          "offsetInEndSection": 729,
          "text": " Dystrophin testing in muscle is the most sensitive test for identification of dystrophinopathy patients, although gene deletion studies can make the diagnosis in most cases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8745379"
        },
        {
          "offsetInBeginSection": 572,
          "offsetInEndSection": 713,
          "text": "Diagnostic use of Xp21 probes is now as necessary as EMG, muscle biopsy and serum CK assay for the definition of Duchenne muscular dystrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669113"
        }
      ],
      "body": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?",
      "type": "list",
      "id": "64179139690f196b5100002f",
      "ideal_answer": [
        "The most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy are multiple ligation-dependent probe amplification (MLPA), Whole-Exome Sequencing (WES) and Next Generation Sequencing (NGS).",
        "Commonly used diagnostic tests for Duchenne muscular dystrophy include western blotting, immunohistochemical staining, multiplex polymerase chain reaction, multiplex ligase-dependent probe amplification, and complete sequence analysis. Additionally, genetic testing can also provide an accurate diagnosis of the disease when conventional methods fail.",
        "Multiplex Ligation-Dependent Probe Amplification (MLPA), Next Generation Sequencing (NGS) and Sanger sequencing.",
        "The three main types of diagnostic tests currently used for detecting dystrophin gene defects associated with Duchenne Muscular Dystrophy (DMD) include MLPA (Multiplex Ligation Probe Amplification), Next Generation Sequencing (NGS) and Southern Blotting. MLPA, which relies on the detection of fluorescent signals generated by hybridizing two probes to target regions of the dystrophin gene, is a widely available and reliable test. NGS enables direct sequence analysis of patient samples and provides a more comprehensive picture of the mutation burden, however it may be less accessible than other methods due to its cost. Southern blot analysis allows examination of dystrophin gene copy numbers, but requires specialized equipment and expertise. As advances in technology continue, additional testing options will likely become available, including new technologies like whole exome sequencing and RNAseq, which have potential advantages over existing approaches. Ultimately, the choice between these various testing methods will depend upon several factors, such as the availability of resources and the specific needs of individual patients and their families.",
        "Whole-exome sequencing was utilized to detect disease-causing variants in 40 MLPA-negative DMD patients. WES analysis revealed that nonsense variant was the most common type in our study (23/36 of the cases). Whole exome sequencing (WES) and multiple ligation-dependent probe amplification (MLPA) were used to detect potential deletions in the STS and DMD genes.",
        "Whole-exome sequencing is used to detect disease-causing point mutations in MLPA-negative muscular dystrophy patients.",
        "The most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy include genetic testing, muscle biopsy, electromyography (EMG), and serum creatine kinase (CK) testing.",
        "The most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy include genetic testing, electromyography (EMG), muscle biopsy, and serum creatine kinase (CK) levels.",
        "The most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy are multiplex ligation-dependent probe amplification (MLPA) and whole exome sequencing (WES). MLPA is used to detect potential deletions in the STS and DMD genes, while WES is used to detect disease-causing point mutations in MLPA-negative DMD patients and to identify carrier females. WES can also be used to detect a nonsense variant, which is amenable to treatment by Ataluren.",
        "The most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy are multiplex ligation-dependent probe amplification (MLPA), genetic sequencing, and creatine kinase (CK) testing.",
        "The most commonly used diagnostic tests for Duchenne muscular dystrophy include multiplex ligation-dependent probe amplification (MLPA), DNA tests, sequencing analysis, whole-exome sequencing (WES), and serum creatine kinase (CK) tests.",
        "The newborns with retest positive result were recalled again for serum creatine kinase (CK) and multiplex ligation-dependent probe amplification (MLPA) test.",
        "Duchenne muscular dystrophy (DMD) is a genetic disorder that affects muscle function. The diagnosis of DMD typically involves a combination of clinical evaluation, family history, and laboratory tests. The most commonly used diagnostic test for DMD is genetic testing, which can identify mutations in the dystrophin gene that cause the disease. Other tests that may be used to diagnose DMD include creatine kinase (CK) testing, electromyography (EMG), and muscle biopsy. CK levels are often elevated in individuals with DMD due to muscle damage, while EMG can detect abnormal electrical activity in muscles. Muscle biopsy involves removing a small sample of muscle tissue for examination under a microscope and can help confirm the diagnosis of DMD by showing characteristic changes in muscle fibers. Overall, a combination of these diagnostic tests can help accurately diagnose DMD and inform treatment decisions.",
        "The most commonly used diagnostic tests for Duchenne muscular dystrophy (DMD) are multiplex ligation-dependent probe amplification (MLPA) and whole-exome sequencing (WES). MLPA is used to detect deletions or duplications in the DMD gene, while WES can identify disease-causing point mutations in MLPA-negative cases. In several studies, nonsense variants were found to be the most common type of mutation detected by WES in MLPA-negative DMD patients. Additionally, WES has been shown to be important for identifying carrier females and detecting potential deletions in the STS and DMD genes. In some cases, DNA testing may also involve checking for first exon deletion/duplication by MLPA before sequencing samples to detect point mutations. Overall, a combination of MLPA and WES is recommended for accurate diagnosis of DMD.",
        "Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. The most commonly used diagnostic tests for DMD include creatine kinase (CK) blood test, genetic testing, and muscle biopsy. A CK blood test measures the levels of creatine kinase in the blood, which are usually elevated in individuals with DMD due to muscle damage. Genetic testing involves analyzing DNA from a blood sample to identify mutations in the dystrophin gene, which is responsible for DMD. This test can confirm the diagnosis and provide information on carrier status for female relatives. Muscle biopsy involves taking a small sample of muscle tissue for examination under a microscope to assess the presence and distribution of dystrophin protein. Immunohistochemistry or immunofluorescence staining techniques are employed to visualize the dystrophin protein, which is typically reduced or absent in DMD patients. In some cases, electromyography (EMG) may be performed to evaluate muscle function and rule out other neuromuscular disorders. Overall, these diagnostic tests help clinicians accurately diagnose DMD and guide appropriate management strategies for affected individuals.",
        "The most commonly used diagnostic tests for Duchenne muscular dystrophy (DMD) include serum creatine kinase (CK) testing, multiplex ligation-dependent probe amplification (MLPA), and whole-exome sequencing (WES). Serum CK levels are often elevated in DMD patients and can be an initial indicator of the disease. MLPA is a widely used method to detect deletions or duplications in the DMD gene, which account for a significant proportion of cases. However, some DMD patients may have point mutations or other genetic alterations that are not detected by MLPA. In such cases, whole-exome sequencing can be employed to identify disease-causing variants. WES has been shown to be particularly useful in detecting point mutations in MLPA-negative DMD patients and identifying carrier females. Combining these diagnostic approaches allows for a comprehensive assessment of the genetic alterations underlying DMD and aids in determining appropriate treatment options."
      ],
      "exact_answer": [
        [
          "MLPA",
          "Multiple Ligation-Dependent Probe Amplification"
        ],
        [
          "WES",
          "Whole-Exome Sequencing"
        ],
        [
          "target-NGS",
          "Next Generation Sequencing",
          "NGS"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33660024",
        "http://www.ncbi.nlm.nih.gov/pubmed/33603399",
        "http://www.ncbi.nlm.nih.gov/pubmed/33074559",
        "http://www.ncbi.nlm.nih.gov/pubmed/33344554",
        "http://www.ncbi.nlm.nih.gov/pubmed/30736994"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 464,
          "offsetInEndSection": 720,
          "text": "ACANTHOSIS NIGRICANS MALIGNA: Symmetrical mainly intertriginous hyperpigmentation with partially verrucous hyperplasia and lichenification mostly in association with gastric adenocarcinoma. Special forms are florid cutaneous papillomatosis and tripe palms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33660024"
        },
        {
          "offsetInBeginSection": 505,
          "offsetInEndSection": 720,
          "text": "Bladder cancer with AN concomitant with tripe palms (TP) and/or mucosal involvement is relatively rare and, to our knowledge, only seven cases of AN with bladder cancer have been reported in the English literature. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33603399"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "BACKGROUND: Tripe palms (TP) is one of the rare cutaneous paraneoplastic manifestations of various intra-abdominal malignancies. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33074559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "BACKGROUND: Acanthosis nigricans (AN), Leser-Trélat sign, and tripe palm are all skin diseases. To date, reports of these appearing as a paraneoplastic syndrome in a gastric cancer patient are quite rare.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33344554"
        },
        {
          "offsetInBeginSection": 1036,
          "offsetInEndSection": 1501,
          "text": "Finally, yet another collection of paraneoplastic skin disorders can associate themselves with anatomically-diverse malignancies (Leser-Trelat syndrome, Trousseau syndrome, dermatomyositis, erythema gyratum repens, hypertrichosis lanuginosa acquisita, papuloerythroderma of Ofuji, tripe palms, and multicentric reticulohistiocytosis). Recognition of these processes by the pathologist can be a valuable step in the characterization of underlying malignant diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30736994"
        }
      ],
      "body": "Is there any association between Tripe palms and cancer?",
      "type": "yesno",
      "id": "63f02b50f36125a426000014",
      "ideal_answer": [
        "Yes. Tripe palms sign is associated with cancer."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/16767465",
        "http://www.ncbi.nlm.nih.gov/pubmed/19429021",
        "http://www.ncbi.nlm.nih.gov/pubmed/36202621",
        "http://www.ncbi.nlm.nih.gov/pubmed/20657764",
        "http://www.ncbi.nlm.nih.gov/pubmed/17981784",
        "http://www.ncbi.nlm.nih.gov/pubmed/20689639",
        "http://www.ncbi.nlm.nih.gov/pubmed/19334306",
        "http://www.ncbi.nlm.nih.gov/pubmed/19823580",
        "http://www.ncbi.nlm.nih.gov/pubmed/16817175",
        "http://www.ncbi.nlm.nih.gov/pubmed/30947609",
        "http://www.ncbi.nlm.nih.gov/pubmed/30389553",
        "http://www.ncbi.nlm.nih.gov/pubmed/33832676",
        "http://www.ncbi.nlm.nih.gov/pubmed/31231507",
        "http://www.ncbi.nlm.nih.gov/pubmed/24389150",
        "http://www.ncbi.nlm.nih.gov/pubmed/27115682",
        "http://www.ncbi.nlm.nih.gov/pubmed/32648048",
        "http://www.ncbi.nlm.nih.gov/pubmed/21366884",
        "http://www.ncbi.nlm.nih.gov/pubmed/18523592",
        "http://www.ncbi.nlm.nih.gov/pubmed/26933872",
        "http://www.ncbi.nlm.nih.gov/pubmed/7091286",
        "http://www.ncbi.nlm.nih.gov/pubmed/33392335"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "Prosopagnosia is the inability to recognize someone by the face alone in the absence of sensory or intellectual impairment. In contrast to the acquired form of prosopagnosia we studied the congenital form",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16767465"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Congenital prosopagnosia (cPA) is a selective impairment in the visual learning and recognition of faces without detectable brain damage or malformation. There is evidence that it can be inherited in an autosomal dominant mode of inheritance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19429021"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 286,
          "text": "Here we report a follow-up examination on M.T., suffering from acquired prosopagnosia following a large unilateral right-hemispheric lesion in frontal, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36202621"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 205,
          "text": "In contrast to the acquired form of prosopagnosia we studied the congenital form.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16767465"
        },
        {
          "offsetInBeginSection": 67,
          "offsetInEndSection": 257,
          "text": "Acquired prosopagnosia results after brain damage, developmental or congenital prosopagnosia (CP) is not caused by brain lesion, but has presumably been present from early childhood onwards.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19823580"
        },
        {
          "offsetInBeginSection": 56,
          "offsetInEndSection": 216,
          "text": "Acquired prosopagnosia is the loss of familiarity for facial identity and has several functional variants, namely apperceptive, amnestic, and associative forms.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33832676"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 478,
          "text": "A selective deficit in the visual learning and recognition of faces is known as prosopagnosia, which can be found both in acquired and congenital form.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19334306"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "Congenital prosopagnosia--a common hereditary cognitive dysfunction in humans.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17981784"
        },
        {
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1029,
          "text": "Thus, the face recognition impairment of the hereditary prosopagnosics is reflected in their gaze behaviour.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16767465"
        },
        {
          "offsetInBeginSection": 684,
          "offsetInEndSection": 846,
          "text": "Whereas the control participants focused their gaze on the central facial features, the hereditary prosopagnosics showed a significantly different gaze behaviour.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16767465"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "BACKGROUND: Prosopagnosia is a selective deficit in facial identification which can be either acquired, (e.g., after brain damage), or present from birth (",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657764"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Prosopagnosia is an impairment in the ability to recognize faces and can be acquired after a brain lesion or occur as a developmental variant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31231507"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Previous studies have shown that acquired prosopagnosia is characterized by impairment at holistic/configural processing.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21366884"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 687,
          "text": " This served to investigate whether congenital prosopagnosia results from process-specific deficiencies, or whether it is a face-specific impairment.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Prosopagnosia refers to an acquired or developmental deficit in face recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30389553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "BACKGROUND: Congenital prosopagnosia is a severe face perception impairment which is not acquired by a brain lesion and is presumably present from birth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18523592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Three patients with prosopagnosia, and acquired inability to recognize familiar faces usually resulting from cerebrovascular insufficiency, had left-sided visual field defects and color vision abnormalities of central origin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7091286"
        },
        {
          "offsetInBeginSection": 1042,
          "offsetInEndSection": 1161,
          "text": "The segregation pattern of this hereditary prosopagnosia (HPA) is fully compatible with autosomal dominant inheritance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16817175"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "A Quick guide to developmental prosopagnosia, a condition definied by problems in recognising faces that, in contrast with acquired prosopagnosia, develop in the absence of manifest brain injury.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27115682"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "BACKGROUND: Prosopagnosia is a selective deficit in facial identification which can be either acquired, (e.g., after brain damage), or present from birth (congenital)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657764"
        },
        {
          "offsetInBeginSection": 506,
          "offsetInEndSection": 656,
          "text": "ing clinically significant impairments in facial recognition. Cases of acquired prosopagnosia were identified through a systematic literature search a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31740940"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 326,
          "text": "Reflecting this, acquired prosopagnosia is not a single entity but a family of disorders with different anatomic lesions and different functional deficits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24389150"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 163,
          "text": "BACKGROUND: Acquired prosopagnosia is a rare condition characterized by the loss of familiarity with previously known faces and the inability to recognize new ones",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33392335"
        },
        {
          "offsetInBeginSection": 545,
          "offsetInEndSection": 930,
          "text": "Three key findings emerged: (a) Individuals with more severe prosopagnosia spent less time examining the internal facial region, (b) as observed in acquired prosopagnosia, some DPs spent less time examining the eyes and more time examining the mouth than controls, and (c) SRs spent more time examining the nose-a measure that also correlated with face recognition ability in controls.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26933872"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Acquired prosopagnosia is usually a consequence of bilateral or right hemisphere lesions and is often associated with topographical disorientation and dyschromatopsia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32648048"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Prosopagnosia is a deficit in recognizing people from their faces. Acquired prosopagnosia results after brain damage, developmental or congenital pros",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19823580"
        },
        {
          "offsetInBeginSection": 117,
          "offsetInEndSection": 197,
          "text": "Cases of acquired prosopagnosia have often been described over the last century.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20689639"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Acquired prosopagnosia is usually associated with bilateral or right-sided lesions of the occipital or temporal lobes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18374372"
        },
        {
          "offsetInBeginSection": 640,
          "offsetInEndSection": 864,
          "text": "Most subjects with developmental prosopagnosia were normal on the Old/New Tests: for acquired prosopagnosia, subjects with occipitotemporal lesions often showed impairments while those with anterior temporal lesions did not.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30947609"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "We studied a male with acquired prosopagnosia using a battery of Implicit Association Tests (IATs) to investigate whether observing faces varying by social category would activate the patient\u0027s implicit social biases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21414330"
        }
      ],
      "body": "is prosopagnosia inherited or  acquired?",
      "type": "factoid",
      "id": "6411b678201352f04a000036",
      "ideal_answer": [
        "Prosopagnosia can be both inherited and acquired",
        "There is evidence that prosopagnosia can be inherited in an autosomal dominant mode of inheritance, suggesting that it is a genetic condition.",
        "Prosopagnosia is an acquired condition, usually caused by brain damage, although there is evidence of a genetic component in some cases.",
        "Prosopagnosia can be inherited in an autosomal dominant mode of inheritance (congenital prosopagnosia) or acquired following a large unilateral right-hemispheric lesion in frontal (acquired prosopagnosia).",
        "Prosopagnosia can be inherited in an autosomal dominant mode of inheritance.",
        "Prosopagnosia can be both inherited (congenital) and acquired. Congenital prosopagnosia is a genetic condition present from birth, while acquired prosopagnosia occurs due to brain damage or injury."
      ],
      "exact_answer": [
        [
          "both inherited and acquired"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31750297",
        "http://www.ncbi.nlm.nih.gov/pubmed/15899964",
        "http://www.ncbi.nlm.nih.gov/pubmed/33227813",
        "http://www.ncbi.nlm.nih.gov/pubmed/19258451",
        "http://www.ncbi.nlm.nih.gov/pubmed/36099980",
        "http://www.ncbi.nlm.nih.gov/pubmed/30414142",
        "http://www.ncbi.nlm.nih.gov/pubmed/24503515",
        "http://www.ncbi.nlm.nih.gov/pubmed/25448745"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5\u0027 end of the transcription initiation site. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31750297"
        },
        {
          "offsetInBeginSection": 274,
          "offsetInEndSection": 369,
          "text": "Promoters mark the start of every transcript and are an important class of regulatory elements.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15899964"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "A promoter is a region in the DNA sequence that defines where the transcription of a gene by RNA polymerase initiates, which is typically located proximal to the transcription start site (TSS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33227813"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 203,
          "text": "It is typically located directly upstream or at the 5\u0027 end of the transcription initiation site.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31750297"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "A key step in the transcription of RNA is the binding of the RNA polymerase protein complex to a short promoter sequence that is typically upstream of the gene to be expressed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36099980"
        },
        {
          "offsetInBeginSection": 834,
          "offsetInEndSection": 1023,
          "text": "Promoter regions are located within ~2 kb upstream of the transcriptional start site, whereas enhancers may be located at some distance from promoter sequences and exert long-range effects.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30414142"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 245,
          "text": "These sequences are typically located in promoters, which are regions of variable length upstream of the open reading frames of genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19258451"
        },
        {
          "offsetInBeginSection": 674,
          "offsetInEndSection": 857,
          "text": "Most of these promoters display the changes of DNA methylation in their Ups-regions, which are between +500 and +2000 bp upstream from the transcription start site (TSS) of the genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25448745"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Promoters are fundamental components of synthetic gene circuits. They are DNA segments where transcription initiation takes place.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34071849"
        }
      ],
      "body": "Where are promoters typically found in DNA?",
      "type": "factoid",
      "id": "643bc8f957b1c7a31500002b",
      "ideal_answer": [
        "A promoter is an important regulatory element which marks the region that transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5\u0027 end of the transcription initiation site.",
        "A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5\u0027 end of the transcription initiation site.",
        "Promoters are typically found in the 5\u0027 region of a gene, upstream of the transcription start site. They are DNA sequences that bind transcription factors and RNA polymerase, and are necessary for the initiation of transcription."
      ],
      "exact_answer": [
        [
          "Upstream of the coding region",
          "Directly upstream",
          "5\u0027 end of the transcription initiation site"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34322164"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 711,
          "offsetInEndSection": 1109,
          "text": "Recent results from the PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398), a phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks, showed the significant improvement in visual acuity and reduction in central subfield thickness, all without increasing the risk of elevated intraocular pressure or accelerated cataract progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34322164"
        }
      ],
      "body": "What was the duration of the follow-up period of patients in the PEACHTREE clinical trial?",
      "type": "factoid",
      "id": "64403be357b1c7a31500004e",
      "ideal_answer": [
        "The patient follow-up period in the PEACHTREE trial lasted 24 weeks (6 months)."
      ],
      "exact_answer": [
        [
          "24 weeks",
          "6 months"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/32327287",
        "http://www.ncbi.nlm.nih.gov/pubmed/23225386",
        "http://www.ncbi.nlm.nih.gov/pubmed/34675094",
        "http://www.ncbi.nlm.nih.gov/pubmed/15050443",
        "http://www.ncbi.nlm.nih.gov/pubmed/35020192",
        "http://www.ncbi.nlm.nih.gov/pubmed/22907234",
        "http://www.ncbi.nlm.nih.gov/pubmed/32008231",
        "http://www.ncbi.nlm.nih.gov/pubmed/27530735",
        "http://www.ncbi.nlm.nih.gov/pubmed/33096728",
        "http://www.ncbi.nlm.nih.gov/pubmed/31409737",
        "http://www.ncbi.nlm.nih.gov/pubmed/22796148",
        "http://www.ncbi.nlm.nih.gov/pubmed/10864616",
        "http://www.ncbi.nlm.nih.gov/pubmed/23785297",
        "http://www.ncbi.nlm.nih.gov/pubmed/34964760",
        "http://www.ncbi.nlm.nih.gov/pubmed/11353419",
        "http://www.ncbi.nlm.nih.gov/pubmed/32278354",
        "http://www.ncbi.nlm.nih.gov/pubmed/23573589",
        "http://www.ncbi.nlm.nih.gov/pubmed/31025273",
        "http://www.ncbi.nlm.nih.gov/pubmed/34559225",
        "http://www.ncbi.nlm.nih.gov/pubmed/36030628",
        "http://www.ncbi.nlm.nih.gov/pubmed/14659411",
        "http://www.ncbi.nlm.nih.gov/pubmed/1908258"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 377,
          "text": "In most cases the condition initially presents with facial and proximal weakness of the upper limbs, but over the course of the disease involves lower limb and truncal muscles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287"
        },
        {
          "offsetInBeginSection": 378,
          "offsetInEndSection": 464,
          "text": "Weakness is progressive and frequently asymmetric, which is a hallmark of the disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287"
        },
        {
          "offsetInBeginSection": 599,
          "offsetInEndSection": 700,
          "text": "5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287"
        },
        {
          "offsetInBeginSection": 768,
          "offsetInEndSection": 1340,
          "text": " patients with FSHD. Sponsors of treatments for FSHD patients should be aware of some of the common misconceptions associated with FSHD drug development with the goal of optimizing the chance to prove safety and efficacy for each potential treatment for FSHD in the clinical trial setting.RESULTS: Four major topics with potential clinical manifestations for patients with FSHD will be discussed related to muscle weakness, respiratory issues, animal models and prevalence.CONCLUSION: The authors offer multiple solutions to help counteract misconceptions with each scenar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32008231"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 700,
          "text": "Here we performed an analysis of 643 FSHD1 patients in the UK FSHD patient registry, investigating factors affecting rate of onset of 5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287"
        },
        {
          "offsetInBeginSection": 848,
          "offsetInEndSection": 1100,
          "text": "FAT1 lies near the critical locus involved in causing FSHD, and Fat1 mutant mice also show retinal vasculopathy, mimicking another symptom of FSHD, and showed abnormal inner ear patterning, predictive of deafness, reminiscent of another burden of FSHD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785297"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "RATIONALE: Early-onset facioscapulohumeral muscular dystrophy (FSHD) is defined as facial weakness before the age of 5 and shoulder weakness before the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34964760"
        },
        {
          "offsetInBeginSection": 1179,
          "offsetInEndSection": 1471,
          "text": "A classical presentation (74%) and 3 facial sparing phenotypes: a mild presentation (5%) with later facial and periscapular involvement, an early shoulder presentation (10%) with accelerated periscapular weakness and an early foot presentation (9%) with accelerated foot dorsiflexor weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32327287"
        },
        {
          "offsetInBeginSection": 1471,
          "offsetInEndSection": 1774,
          "text": "Patients with FSHD also had reduced systemic antioxidative response molecules, such as low levels of zinc (a SOD cofactor), selenium (a GPx cofactor involved in the elimination of lipid peroxides), and vitamin C. Half of them had a low ratio of gamma/alpha tocopherol and higher ferritin concentrations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22796148"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Facioscapulohumeral muscular dystrophy (FSHD) is characterized by progressive weakness and wasting of facial, shoulder-girdle and upper arm muscles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050443"
        },
        {
          "offsetInBeginSection": 122,
          "offsetInEndSection": 483,
          "text": "Typically, FSHD patients present with a recognizable constellation of signs including weakness of facial, shoulder and pelvic girdle, humeral, and anterior foreleg muscles; preservation of some muscles including the deltoids; and other characteristic features including prominent scapular winging, anterior axillary folds, and horizontally positioned clavicles.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11353419"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 500,
          "text": "physiology. Typically, progressive skeletal muscle weakness becomes noticeable in the second or third decade of life, yet there are many individuals who are genetically FSHD but develop symptoms much later in life or remain relatively asymptomatic throughout ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32278354"
        },
        {
          "offsetInBeginSection": 68,
          "offsetInEndSection": 218,
          "text": "t neuromuscular disorder characterized by progressive weakness of the facial, shoulder and upper arm muscles. The major gene involved has been mapped ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592052"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "We report an 18-year-old female with facioscapulohumeral dystrophy (FSHD), who had sensorineural deafness, retinal vessel abnormality, mental retardation, and epilepsy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1908258"
        },
        {
          "offsetInBeginSection": 82,
          "offsetInEndSection": 232,
          "text": "cular dystrophy characterized by progressive weakness and wasting of the facial, shoulder-girdle and upper arm muscles. The gene locus for FSHD is map",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12134683"
        },
        {
          "offsetInBeginSection": 53,
          "offsetInEndSection": 203,
          "text": "nherited myopathy clinically characterized by weakness in the facial, shoulder girdle and upper a muscles. FSHD is caused by chromatin relaxation of t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34559225"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 234,
          "text": "PURPOSE: Severe manifestations of facioscapulohumeral dystrophy (FSHD) may be associated with sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA) and nocturnal hypoventilation (NH), but prevalence data are scarce",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31025273"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 374,
          "text": "Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10864616"
        },
        {
          "offsetInBeginSection": 61,
          "offsetInEndSection": 211,
          "text": "onset facioscapulohumeral muscular dystrophy (FSHD) present epilepsy and mental retardation. This suggests a functional involvement of central nervous",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14659411"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 218,
          "text": " The major symptom of FSHD is progressive weakening and loss of skeletal muscles",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32008231"
        },
        {
          "offsetInBeginSection": 35,
          "offsetInEndSection": 185,
          "text": "phy (FSHD) is an autosomal dominant disorder characterized by progressive muscle weakness. Adenine nucleotide translocator 1 (ANT1), the only 4q35 gen",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36030628"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 408,
          "text": "l symptoms are extremely variable including facial sparing type, limb-girdle type, and distal myopathy type. Most of the FSHD patients have a deletion",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15050443"
        }
      ],
      "body": "Which are some symptoms of FSHD?",
      "type": "list",
      "id": "644289c457b1c7a31500005e",
      "ideal_answer": [
        "Some symptoms of FSHD are the following: asymmetric weakness,  facial and proximal weakness of the upper limbs, and lower limb and truncal muscles weakness, facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.",
        "In most cases the condition initially presents with facial and proximal weakness of the upper limbs but over the course of the disease involves lower limb and truncal muscles.Weakness is progressi",
        "In most cases the condition initially presents with facial and proximal weakness of the upper limbs, but over the course of the disease involves lower limb and truncal muscles. Weakness is progressive and frequently asymmetric, which is a hallmark of the disease. 5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.",
        "facioscapulohumeral muscular dystrophy -  a muscle disorder characterized by progressive wasting of skeletal muscles resulting in weakness, pain, difficulty moving parts, joint deformity, and disfigurement ",
        "\"Facioscapulohumeral muscular dystrophy (FSHD) is an inherited disorder characterized by progressive weakness and wasting of the voluntary muscles of the face, shoulders, arms, legs, feet, and trunk. It is caused by mutations in the DUX4 gene located on chromosome 4q35.\"",
        "Facioscapulohumeral muscular dystrophy (FSHD) is characterized by progressive disability caused by mutations or deletions in the gene encoding the dystrophin protein. Major presenting features include facial weakness, shoulders weakness, feet weakness, hearing loss, and scoliosis. Other common complaints include joint pain, numbness, tightness, and fatigue. The exact causes remain unknown for many forms of muscular dystrophy, including FSHD.",
        "Weakness is progressive and frequently asymmetric, which is a hallmark of the disease. Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disorder which is typically transmitted by an autosomal dominant pattern, although reduced penetrance and sporadic cases caused by de novo mutations, are often observed. Facioscapulohumeral muscular dystrophy (FSHD) is a complex, inheritable, and rare muscle disease that affects the entire body.",
        "Some symptoms of FSHD include facial and proximal weakness of the upper limbs, weakness of foot dorsiflexors, hip girdle weakness, periscapular weakness, and hearing loss. Weakness is progressive and frequently asymmetric, which is a hallmark of the disease.",
        "Facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss are the major symptoms of FSHD.",
        "-Progressive muscle weakness and wasting\n-Difficulty with facial expressions\n-Difficulty with eye movements\n-Difficulty with chewing and swallowing\n-Scoliosis\n-Joint contractures\n-Muscle cramps\n-Fatigue\n-Pain in the muscles and joints",
        "The primary symptoms of Facioscapulohumeral muscular dystrophy (FSHD) include progressive muscle weakness and wasting of the face, shoulder blades, and upper arms. Other symptoms may include scapular winging, foot drop, difficulty with running and climbing stairs, and difficulty with facial expressions.",
        "The main symptoms of FSHD are facial weakness, proximal weakness of the upper limbs, lower limb weakness, truncal muscle weakness, periscapular weakness, foot dorsiflexor weakness, hip girdle weakness, and hearing loss. These symptoms are usually progressive and asymmetric.",
        "Some symptoms of FSHD include facial weakness, proximal upper limb weakness, lower limb weakness, truncal muscle weakness, and asymmetric weakness.",
        "Some symptoms of FSHD include facial weakness, proximal upper limb weakness, lower limb weakness, truncal muscle weakness, and hearing loss.",
        "5 major FSHD symptoms: facial, periscapular, foot dorsiflexor, hip girdle weakness, and hearing loss.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. The symptoms of FSHD can vary widely between individuals, but typically include weakness and wasting of the facial muscles, resulting in a characteristic \"facial dip\" or inability to smile or close the eyes fully. Shoulder weakness may also be present, leading to difficulty raising the arms above shoulder level or performing overhead activities. In some cases, weakness may also affect the lower legs and hips. Other common symptoms include hearing loss, vision problems, and foot drop. FSHD is caused by mutations in one of two genes (DUX4 or SMCHD1), which lead to abnormal expression of certain proteins in muscle cells. While there is currently no cure for FSHD, treatment options such as physical therapy and assistive devices can help manage symptoms and improve quality of life for affected individuals.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that affects the muscles of the face, shoulders, upper arms, and lower legs. The condition typically presents with facial and proximal weakness of the upper limbs, but over time involves lower limb and truncal muscles. Weakness is progressive and frequently asymmetric, which is a hallmark of the disease. There are five major FSHD symptoms: facial weakness, periscapular weakness, foot dorsiflexor weakness, hip girdle weakness, and hearing loss. These symptoms can vary in severity from person to person and may not all be present in every case. In addition to muscle weakness, individuals with FSHD may also experience fatigue and difficulty with mobility. While there is currently no cure for FSHD, treatment options such as physical therapy and assistive devices can help manage symptoms and improve quality of life for those affected by this condition.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic muscle disorder characterized by progressive weakness and atrophy of the facial, shoulder, and upper arm muscles. Some common symptoms of FSHD include facial weakness, difficulty closing the eyes or smiling, scapular winging (protrusion of shoulder blades), and reduced mobility in the shoulders and arms. As the disease progresses, it may also affect lower extremity muscles, leading to foot drop and difficulties in walking or climbing stairs. In some cases, hearing loss and retinal abnormalities can be associated with FSHD. The severity and progression of symptoms can vary significantly among individuals affected by this condition. Early onset FSHD tends to be more severe than adult-onset forms, with faster progression and greater disability. It is important to note that not all individuals with FSHD will experience all these symptoms, as the clinical presentation can be highly variable.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic muscle disorder characterized by progressive muscle weakness, typically presenting with facial and proximal upper limb involvement. As the disease progresses, it affects lower limb and truncal muscles as well. The weakness is often asymmetric, which is a hallmark of FSHD. There are five major symptoms associated with FSHD: facial weakness, periscapular muscle weakness, foot dorsiflexor weakness, hip girdle weakness, and hearing loss. These symptoms can vary in severity and progression among individuals affected by the condition."
      ],
      "exact_answer": [
        [
          "facial weakness",
          "facial dorsiflexor"
        ],
        [
          "proximal weakness of the upper limbs",
          "periscapular dorsiflexor"
        ],
        [
          "lower limb weakness",
          "hip girdle weakness",
          "foot dorsiflexor"
        ],
        [
          "truncal muscles weakness"
        ],
        [
          "asymmetric weakness"
        ],
        [
          "hearing loss."
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35658005",
        "http://www.ncbi.nlm.nih.gov/pubmed/35666594",
        "http://www.ncbi.nlm.nih.gov/pubmed/35608481",
        "http://www.ncbi.nlm.nih.gov/pubmed/35938195"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 122,
          "text": "BACKGROUND: Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658005"
        },
        {
          "offsetInBeginSection": 1726,
          "offsetInEndSection": 1863,
          "text": "CONCLUSIONS: In patients with previously treated KRASG12C -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658005"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "In the phase II KRYSTAL-1 trial, the KRASG12C inhibitor adagrasib yielded an overall response rate of 43% and a disease control rate of 80% in patients with previously treated KRASG12C-mutant non-small cell lung cancer. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35666594"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 328,
          "text": "The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35608481"
        },
        {
          "offsetInBeginSection": 1332,
          "offsetInEndSection": 1473,
          "text": "There are other KRAS-targeted agents currently under study, including adagrasib, with growing interest in targeting KRAS downstream pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35938195"
        }
      ],
      "body": "What is the mechanism of action of Adagrasib?",
      "type": "summary",
      "id": "63f02ec1f36125a426000017",
      "ideal_answer": [
        "Adagrasib is a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it in its inactive state."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15189359",
        "http://www.ncbi.nlm.nih.gov/pubmed/30509290",
        "http://www.ncbi.nlm.nih.gov/pubmed/12402272",
        "http://www.ncbi.nlm.nih.gov/pubmed/24283821",
        "http://www.ncbi.nlm.nih.gov/pubmed/10624810",
        "http://www.ncbi.nlm.nih.gov/pubmed/11284995",
        "http://www.ncbi.nlm.nih.gov/pubmed/10202988",
        "http://www.ncbi.nlm.nih.gov/pubmed/20385392",
        "http://www.ncbi.nlm.nih.gov/pubmed/7951249",
        "http://www.ncbi.nlm.nih.gov/pubmed/9455977",
        "http://www.ncbi.nlm.nih.gov/pubmed/11464949",
        "http://www.ncbi.nlm.nih.gov/pubmed/7917302",
        "http://www.ncbi.nlm.nih.gov/pubmed/27297615",
        "http://www.ncbi.nlm.nih.gov/pubmed/7820674",
        "http://www.ncbi.nlm.nih.gov/pubmed/9065559",
        "http://www.ncbi.nlm.nih.gov/pubmed/9506558",
        "http://www.ncbi.nlm.nih.gov/pubmed/24611504",
        "http://www.ncbi.nlm.nih.gov/pubmed/8446170",
        "http://www.ncbi.nlm.nih.gov/pubmed/23954173",
        "http://www.ncbi.nlm.nih.gov/pubmed/27556028",
        "http://www.ncbi.nlm.nih.gov/pubmed/15079798",
        "http://www.ncbi.nlm.nih.gov/pubmed/15679043",
        "http://www.ncbi.nlm.nih.gov/pubmed/31928838",
        "http://www.ncbi.nlm.nih.gov/pubmed/10869061",
        "http://www.ncbi.nlm.nih.gov/pubmed/8981308"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are caused by mutations in the super oxide dismutase 1 (SOD1) gene a",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15189359"
        },
        {
          "offsetInBeginSection": 718,
          "offsetInEndSection": 795,
          "text": ". The two most widely studied ALS/FTLD models, super-oxide dismutase 1 (SOD1)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30509290"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "A novel mutation of the SOD-1 gene which encodes the enzyme copper-zinc superoxide dismutase was identified in a family manifesting amyotrophic lateral sclerosis (ALS) in three generations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Mutations in the Cu/Zn superoxide dismutase gene (SOD-1) are reported in 20% of familial amyotrophic lateral sclerosis (ALS) cases, but no definite report of a mutation in a \"truly\" sporadic case of ALS has been proved.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402272"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 287,
          "text": "Copper-zinc superoxide dismutase 1 (SOD1) is one of the most commonly mutated genes in ALS, and more than 160 mutations in SOD1 have been reported.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27297615"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Mutations of the Cu/Zn superoxide dismutase (SOD-1) gene were recently implicated in the pathogenesis of familial amyotrophic lateral sclerosis (ALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7820674"
        },
        {
          "offsetInBeginSection": 577,
          "offsetInEndSection": 660,
          "text": "Over 30 different mutations of SOD-1 have now been identified in families with ALS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 82,
          "text": "A novel mutation of SOD-1 (Gly 108 Val) in familial amyotrophic lateral sclerosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24283821"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are caused by mutations in the super oxide dismutase 1 (SOD1) gene and transgenic mice for these mutations recapitulate many features of this devastating neurodegenerative disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15189359"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Mutations of the gene SOD-1, which encodes the enzyme copper-zinc superoxide dismutase, occur in patients with a familial form of amyotrophic lateral sclerosis (ALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9065559"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Autosomal-dominant familial amyotrophic lateral sclerosis (FALS) is associated with mutation in the gene that encodes Cu/Zn superoxide dismutase (SOD1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10624810"
        },
        {
          "offsetInBeginSection": 379,
          "offsetInEndSection": 631,
          "text": "(1996) (Morita, M., Aoki, M., Abe, K., Hasegawa, T., Sakuma, R., Onodera, Y., Ichikawa, N., Nishizawa, M. and Itoyama, Y., A novel two-base mutation in the Cu/Zn superoxide dismutase gene associated with familial amyotrophic lateral sclerosis in Japan.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10624810"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 152,
          "text": "Mutations of the SOD1 gene, which encodes the enzyme copper/zinc superoxide dismutase, are associated with familial amyotrophic lateral sclerosis (ALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9455977"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Familial ALS is associated with mutations in all exons of SOD1: a novel mutation in exon 3 (Gly72Ser).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9455977"
        },
        {
          "offsetInBeginSection": 542,
          "offsetInEndSection": 786,
          "text": "Here we report tight genetic linkage between FALS and a gene that encodes a cytosolic, Cu/Zn-binding superoxide dismutase (SOD1), a homodimeric metalloenzyme that catalyzes the dismutation of the toxic superoxide anion O2.- to O2 and H2O2 (ref.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8446170"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Familial amyotrophic lateral sclerosis (FALS), a degenerative disorder of motor neurons, is associated with mutations in the Cu/Zn superoxide dismutase gene SOD1 in some affected families.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7951249"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Eight of 38 patients (21%) with familial and 5 of 175 patients (3%) with sporadic amyotrophic lateral sclerosis (ALS) had missense mutations in the SOD-1 gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9506558"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "The SOD1 gene encoding the superoxide dismutase 1 (SOD1) protein is mutated in approximately 15% of familial amyotrophic lateral sclerosis (ALS) and 3% of sporadic ALS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23954173"
        },
        {
          "offsetInBeginSection": 212,
          "offsetInEndSection": 344,
          "text": "About 20% of ALS families are associated with mutations in the gene for superoxide dismutase-1 (SOD1) encoded on chromosome 21q22.1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11464949"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "The superoxide dismutase-1 (SOD1) gene is the first gene for familial amyotrophic lateral sclerosis (ALS) with autosomal dominant inheritance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24611504"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 146,
          "text": "Dominant mutations in Cu/Zn-superoxide dismutase (SOD1) gene have been shown to cause a familial form of amyotrophic lateral sclerosis (SOD1-ALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556028"
        },
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 497,
          "text": " Mutations in the gene encoding Cu/Zn-superoxide dismutase (SOD-1) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7554432"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Mutations in the Cu, Zn superoxide dismutase (SOD1) gene have been reported in some pedigrees with Familial Amyotrophic Lateral Sclerosis (FALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7917302"
        },
        {
          "offsetInBeginSection": 138,
          "offsetInEndSection": 278,
          "text": " Genetic mutations in Cu/Zn superoxide dismutase (SOD1) have been associated with one kind of familial amyotrophic lateral sclerosis (ALS1).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Accumulated evidence implies that mutations in the gene coding for Cu/Zn superoxide dismutase (SOD) are associated with the pathogenesis of the familial form of amyotrophic lateral sclerosis (ALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8981308"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 167,
          "text": " have reported point mutations in the cytosolic Cu/Zn superoxide dismutase (SOD 1) gene in some families with familial amyotrophic lateral sclerosis (ALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9263219"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 157,
          "text": "All mutations in the human gene for CuZn superoxide dismutase (CuZnSOD) reported to date are associated with the disease amyotrophic lateral sclerosis (ALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9062909"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Mutations in the Cu/Zn superoxide dismutase 1 (SOD1) gene have been reported to cause adult-onset autosomal dominant amyotrophic lateral sclerosis (FALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18608106"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 274,
          "text": "We report the absence of superoxide dismutase (SOD-1) gene mutations in 30 patients with amyotrophic lateral sclerosis (ALS) including individuals with a confirmed family history of ALS (familial ALS/FALS), ALS with an unclear family history (UFALS) and sporadic ALS (SALS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10202988"
        },
        {
          "offsetInBeginSection": 860,
          "offsetInEndSection": 1042,
          "text": "A predilection for disease onset in the lower limbs appears to be a distinguishing feature of familial ALS with SOD-1 mutations, and accords with findings in transgenic mouse models.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9065559"
        },
        {
          "offsetInBeginSection": 645,
          "offsetInEndSection": 747,
          "text": "is a new type of SOD1 mutation which may be associated with familial amyotrophic lateral sclerosis.CON",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15079798"
        },
        {
          "offsetInBeginSection": 702,
          "offsetInEndSection": 989,
          "text": "To delineate ALS associated with this particular CuZn-SOD mutation from ALS without mutations, we performed a detailed neurophysiological study of the corticomotoneuronal function using peristimulus time histograms (PSTHs) in eight ALS patients homozygous for the D90A CuZn-SOD mutation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10869061"
        },
        {
          "offsetInBeginSection": 102,
          "offsetInEndSection": 252,
          "text": "ateral sclerosis (ALS) cases, but no definite report of a mutation in a \"truly\" sporadic case of ALS has been proved. We present the first case of a n",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12402272"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 301,
          "text": "It has been reported that mutations in the superoxide dismutase (SOD) 1 gene can lead to ALS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31928838"
        },
        {
          "offsetInBeginSection": 134,
          "offsetInEndSection": 253,
          "text": "Mutations in the superoxide dismutase-1 (SOD1) gene have been found in 12%-23% of patients diagnosed with familial ALS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20385392"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "INTRODUCTION: Mutations in the gene encoding the free radical scavenging enzyme CuZn-superoxide dismutase have been associated with amyotrophic lateral sclerosis (ALS)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11675874"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 262,
          "text": "Up to 20% of ALS cases are inherited (familial, fALS) and associated with mutations, usually of the superoxide dismutase type 1 (SOD-1) gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15679043"
        }
      ],
      "body": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?",
      "type": "yesno",
      "id": "641c516d690f196b5100003f",
      "ideal_answer": [
        "Amyotrophic Lateral Sclerosis (ALS) can be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene, in a small percentage of cases.",
        "Approximately 2% of amyotrophic lateral sclerosis (ALS) cases are caused by mutations in the super oxide dismutase 1 (SOD1) gene a .",
        "Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that is associated with mutations in the super oxide dismutase 1 (SOD1) gene.",
        "ALS can be associated with a mutation of the SOD1 gene",
        "Yes, mutations of the Super Oxide Dismutase 1 (SOD1) gene have been linked to some cases of Amyotrophic Lateral Sclerosis (ALS).",
        "Yes, mutations in the SOD1 gene can cause familial Amyotrophic Lateral Sclerosis (ALS).",
        "Yes, approximately 2% of ALS cases are caused by mutations in the SOD1 gene."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31993419",
        "http://www.ncbi.nlm.nih.gov/pubmed/35170113",
        "http://www.ncbi.nlm.nih.gov/pubmed/31944157",
        "http://www.ncbi.nlm.nih.gov/pubmed/30026829",
        "http://www.ncbi.nlm.nih.gov/pubmed/28239713",
        "http://www.ncbi.nlm.nih.gov/pubmed/29284524",
        "http://www.ncbi.nlm.nih.gov/pubmed/30139328",
        "http://www.ncbi.nlm.nih.gov/pubmed/28334114",
        "http://www.ncbi.nlm.nih.gov/pubmed/27662874",
        "http://www.ncbi.nlm.nih.gov/pubmed/28716036",
        "http://www.ncbi.nlm.nih.gov/pubmed/33320871",
        "http://www.ncbi.nlm.nih.gov/pubmed/31665430",
        "http://www.ncbi.nlm.nih.gov/pubmed/29583027",
        "http://www.ncbi.nlm.nih.gov/pubmed/32197056",
        "http://www.ncbi.nlm.nih.gov/pubmed/30758829",
        "http://www.ncbi.nlm.nih.gov/pubmed/33431820",
        "http://www.ncbi.nlm.nih.gov/pubmed/21737276",
        "http://www.ncbi.nlm.nih.gov/pubmed/16002789",
        "http://www.ncbi.nlm.nih.gov/pubmed/32664620",
        "http://www.ncbi.nlm.nih.gov/pubmed/25715743",
        "http://www.ncbi.nlm.nih.gov/pubmed/23124110",
        "http://www.ncbi.nlm.nih.gov/pubmed/27325706",
        "http://www.ncbi.nlm.nih.gov/pubmed/28760812",
        "http://www.ncbi.nlm.nih.gov/pubmed/32737473",
        "http://www.ncbi.nlm.nih.gov/pubmed/34879086",
        "http://www.ncbi.nlm.nih.gov/pubmed/27895109",
        "http://www.ncbi.nlm.nih.gov/pubmed/35552697",
        "http://www.ncbi.nlm.nih.gov/pubmed/32952117",
        "http://www.ncbi.nlm.nih.gov/pubmed/24920384",
        "http://www.ncbi.nlm.nih.gov/pubmed/34897508",
        "http://www.ncbi.nlm.nih.gov/pubmed/23651551",
        "http://www.ncbi.nlm.nih.gov/pubmed/27863239",
        "http://www.ncbi.nlm.nih.gov/pubmed/30780195",
        "http://www.ncbi.nlm.nih.gov/pubmed/34968246",
        "http://www.ncbi.nlm.nih.gov/pubmed/24599251",
        "http://www.ncbi.nlm.nih.gov/pubmed/32635644",
        "http://www.ncbi.nlm.nih.gov/pubmed/25719310"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 313,
          "text": "Enhancers are cis-regulatory elements in the genome that cooperate with promoters to control target gene transcription. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31993419"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Enhancers are important cis-acting elements that can regulate gene transcription and cell fate alongside promoters. In fact, many human cancers and diseases are associated with the malfunction of enhancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35170113"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Enhancers are cis-acting elements with many sites bound by transcription factors and activate transcription over long distance.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31944157"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Enhancers are cis-acting elements that have the ability to increase the expression of target genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30026829"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 376,
          "text": "Enhancers are cis-acting elements that play major roles in upregulating eukaryotic gene expression by providing binding sites for transcription factors and their complexes. Because enhancers are highly cell/tissue specific, lack common motifs, and are far from the target gene, the systematic and precise identification of enhancer regions in DNA sequences is a big challenge.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28239713"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 153,
          "text": "Enhancers are short noncoding segments of DNA (100-1000 bp) that control the temporal and spatial activity of genes in an orientation-independent manner.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29583027"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 115,
          "text": "Enhancers are important cis-acting elements that can regulate gene transcription and cell fate alongside promoters.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35170113"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Transcriptional enhancers drive cell-type-specific gene expression patterns, and thus play key roles in development and disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30758829"
        },
        {
          "offsetInBeginSection": 269,
          "offsetInEndSection": 472,
          "text": "One consequence of the variability in the distance separating enhancers and their target promoters is that it is difficult to determine which elements are involved in the regulation of a particular gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29583027"
        },
        {
          "offsetInBeginSection": 168,
          "offsetInEndSection": 389,
          "text": "Enhancers can stimulate gene activity at great genomic distances from their targets, raising questions about how enhancers communicate with specific gene promoters and what molecular mechanisms underlie enhancer function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32197056"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Enhancers are DNA sequences that enable complex temporal and tissue-specific regulation of genes in higher eukaryotes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33431820"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 183,
          "text": "Transcriptional enhancers are DNA regulatory elements that are bound by transcription factors and act to positively regulate the expression of nearby or distally located target genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27662874"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Enhancers are DNA sequences that can activate gene transcription from remote positions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16002789"
        },
        {
          "offsetInBeginSection": 103,
          "offsetInEndSection": 295,
          "text": "Transcriptional enhancers are a key group of such elements in eukaryotes and are DNA regions that form physical contacts with gene promoters and precisely orchestrate gene expression programs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32664620"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Transcriptional enhancers are short segments of genomic DNA (50 bp to 1 kb in length) that can work over long distances (≥1 Mb) to regulate gene expression in specific cells and tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27325706"
        },
        {
          "offsetInBeginSection": 570,
          "offsetInEndSection": 800,
          "text": "Enhancers likely play an important role in the activation of genes by functioning as a primary point of contact for transcriptional activators, and by making physical contact with gene promoters often by means of a chromatin loop.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23124110"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Enhancers are DNA sequences composed of transcription factor binding sites that drive complex patterns of gene expression in space and time.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33037064"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 124,
          "text": "Enhancers are genomic cis-regulatory sequences that integrate spatiotemporal signals to control gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21737276"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 311,
          "text": "Enhancers are a type of cis-acting DNA elements that enhance transcriptional activity of target genes. However, the uncertainty in the orientation and distance between enhancers and target genes could post significant difficulties in identifying the target genes and the regulatory mechanisms of the enhancers. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32952117"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 99,
          "text": "Enhancers regulate transcription of target genes, causing a change in expression level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34879086"
        }
      ],
      "body": "What are enhancers?",
      "type": "summary",
      "id": "64371c5957b1c7a31500002a",
      "ideal_answer": [
        "Enhancers are important cis-acting elements that can regulate gene transcription and cell fate alongside promoters by providing binding sites for transcription factors and their complexes. Unlike promoters, enhancers are not necessarily adjacent to target genes and can exert their functions regardless of enhancer orientations, positions and spatial segregations from target genes. In fact, because enhancers are highly cell/tissue specific, lack common motifs, and are far from the target gene, the systematic and precise identification of enhancer regions in DNA sequences is a big challenge. Despite that, many human cancers and diseases have been shown to be associated with the malfunction of enhancers."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35868358"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 513,
          "text": "Drug delivery to the suprachoroidal space (SCS®) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE®), administered via a microneedle-based device, the SCS Microinjector®. Suprachoroidal (SC) delivery facilitates targeting, compartmentalization, and durability of small molecule suspensions, thereby potentially addressing some of the efficacy, safety, and treatment burden limitations of current retinal therapies. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35868358"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35868358"
        }
      ],
      "body": "What is the mode of delivery of the drug XIPERE?",
      "type": "factoid",
      "id": "6440396957b1c7a31500004b",
      "ideal_answer": [
        "XIPERE is administered via a microneedle-based device, the SCS Microinjector, in the suprachoroidal space."
      ],
      "exact_answer": [
        [
          "microneedle-based delivery in the suprachoroidal space"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35562158",
        "http://www.ncbi.nlm.nih.gov/pubmed/31794464",
        "http://www.ncbi.nlm.nih.gov/pubmed/30215857",
        "http://www.ncbi.nlm.nih.gov/pubmed/27340611",
        "http://www.ncbi.nlm.nih.gov/pubmed/19555515",
        "http://www.ncbi.nlm.nih.gov/pubmed/24213305",
        "http://www.ncbi.nlm.nih.gov/pubmed/24305447",
        "http://www.ncbi.nlm.nih.gov/pubmed/3728255",
        "http://www.ncbi.nlm.nih.gov/pubmed/23733645",
        "http://www.ncbi.nlm.nih.gov/pubmed/27734165",
        "http://www.ncbi.nlm.nih.gov/pubmed/36121164",
        "http://www.ncbi.nlm.nih.gov/pubmed/32095889",
        "http://www.ncbi.nlm.nih.gov/pubmed/28427100"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 210,
          "offsetInEndSection": 398,
          "text": " Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35562158"
        },
        {
          "offsetInBeginSection": 399,
          "offsetInEndSection": 606,
          "text": "Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35562158"
        },
        {
          "offsetInBeginSection": 521,
          "offsetInEndSection": 887,
          "text": "g more heavily on genetic findings. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and α-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794464"
        },
        {
          "offsetInBeginSection": 349,
          "offsetInEndSection": 946,
          "text": "otypic correlates. This article discusses the epidemiology, clinical features, and diagnosis of these disorders.RECENT FINDINGS: Some important recent advancements include (1) a much greater understanding of the pathogenetic pathways underlying facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1; (2) the publication of diagnostic and treatment guidelines for Duchenne muscular dystrophy; and (3) further clarification of the many genetic muscle disorders presenting a limb-girdle pattern of weakness.SUMMARY: Muscular dystrophies are genetic, progressive, degenerative disorders",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24305447"
        },
        {
          "offsetInBeginSection": 127,
          "offsetInEndSection": 519,
          "text": "The most common are Duchenne muscular dystrophy and Becker muscular dystrophy, which result from mutations within the gene encoding dystrophin; myotonic dystrophy type 1, which results from an expanded trinucleotide repeat in the myotonic dystrophy protein kinase gene; and facioscapulohumeral dystrophy, which is associated with contractions in the subtelomeric region of human chromosome 1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19555515"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are the two most common adult muscular dystrophies and have progressive and often disabling manifestations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27734165"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Duchenne Muscular Dystrophy (DMD), the most common form of muscular dystrophies, is characterized by progressive and generalized muscle weakness.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36121164"
        },
        {
          "offsetInBeginSection": 676,
          "offsetInEndSection": 914,
          "text": "re included in this study. 102 (27.8%) out of the 366 patients were affected by Duchenne muscular dystrophy (DMD), 42 (11.5%) by congenital muscular dystrophy (CMD), 42 (11.5%) by Charcot Marie Tooth disease (CMT) and 24 (6.5%) by Becker\u0027",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32095889"
        },
        {
          "offsetInBeginSection": 558,
          "offsetInEndSection": 924,
          "text": "his article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and α-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794464"
        },
        {
          "offsetInBeginSection": 548,
          "offsetInEndSection": 628,
          "text": "EAS COVERED: Duchenne muscular dystrophy is the most common muscular dystrophy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27340611"
        },
        {
          "offsetInBeginSection": 333,
          "offsetInEndSection": 420,
          "text": "Myotonic muscular dystrophy is the most common of the adult-onset muscular dystrophies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3728255"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular dystrophies in adulthood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29770119"
        },
        {
          "offsetInBeginSection": 856,
          "offsetInEndSection": 1063,
          "text": "We discuss the involvement of the immune system in the most common muscular dystrophy, Duchenne muscular dystrophy, and show that the immune system influences muscle death and fibrosis as disease progresses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30215857"
        },
        {
          "offsetInBeginSection": 477,
          "offsetInEndSection": 572,
          "text": "Duchenne\u0027s muscular dystrophy is the most common form of inherited muscle disease of childhood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427100"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Duchenne muscular dystrophy (DMD), the most common muscular dystrophy, is a severe muscle disorder, causing muscle weakness, loss of independence, and premature death.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35089797"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Duchenne muscular dystrophy (DMD), the most common and most severe form of all muscular dystrophies, leads to progressive muscle fiber necrosis, fibroblast proliferation, and growth of fibrous tissue and fat.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25955813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Duchenne and Becker muscular dystrophies are the most common clinical forms of muscular dystrophies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24213305"
        },
        {
          "offsetInBeginSection": 235,
          "offsetInEndSection": 385,
          "text": " cause exercise intolerance to some degree. Here, we focus on Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy, as a para",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23733645"
        },
        {
          "offsetInBeginSection": 62,
          "offsetInEndSection": 212,
          "text": "ied by progressive skeletal muscle weakness and degeneration. Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrop",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27073590"
        },
        {
          "offsetInBeginSection": 36,
          "offsetInEndSection": 186,
          "text": " debilitating disorders caused by progressive muscle wasting. Duchenne muscular dystrophy (DMD) is the most common type. DMD is a well-characterized g",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35360042"
        }
      ],
      "body": "What are the most common muscular dystrophies?",
      "type": "list",
      "id": "641791ca690f196b51000031",
      "ideal_answer": [
        "The most common muscular dystrophies include the congenital muscular dystrophies (CMD)  and the childhood and adult-onset muscular dystrophies. The CMD include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD. Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy.",
        " Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD. Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy.",
        "The three most common forms of muscular dystrophy are congenital muscular dystrophy (CMD), dystroglycanopathy and sarcoglycanopathy, respectively. CMD is caused by genetic defects affecting the dystroglial system, while sarcogylcansopathies result from defects in sarcolemma proteins such as dystrophin, alpha-dystroglycan and sarcospan. Dystroglycanopathy can be caused by mutations in the genes encoding beta-dystroglycan, lamin A/C, dystrophin itself or other partners. Sarcoglucanspathy can be due to mutations in the gene encoding one of three sarcoglycans: dystroglycan α1, β2 or γ2.",
        "The muscular dystrophies comprise a heterogeneous group of genetic disorders that produce progressive skeletal muscle weakness and wasting. This review discusses the genetics, pathophysiology, and potential treatments of the most common forms of muscular dystrophy: Duchenne muscular dystrophy, Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. Duchenne muscular dystrophy is the most common childhood form of muscular dystrophy.",
        " Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD. Childhood and adult-onset muscular dystrophies include dystrophinopathies, limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. The muscular dystrophies are rare orphan diseases, characterized by progressive muscle weakness: the most common and well known is Duchenne muscular dystrophy which affects young boys and progresses quickly during childhood.",
        "The most common muscular dystrophies are Duchenne muscular dystrophy, Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy.",
        "Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.",
        "The most common muscular dystrophies are Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, congenital muscular dystrophy, and distal muscular dystrophy.",
        "The most common muscular dystrophies are Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy (DM), and congenital muscular dystrophy (CMD).",
        "The most common muscular dystrophies are dystrophinopathies, limb-girdle muscular dystrophies, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.",
        "What are the most common muscular dystrophiesThe most common muscular dystrophies are Duchenne muscular dystrophy (DMD) Becker muscular dystrophy (BMD) limbgirdle muscular dystrophy (LGMD) facioscapulohumeral muscular dystrophy (FSHD) myotonic dystrophy (DM) and EmeryDreifuss muscular dystrophy (EDMD).Duchenne muscular dystrophyDMD is an Xlinked recessive disorder caused by mutations in the DMD gene. The DMD gene is located on the short arm of the X chromosome (Xp21.2) and consists of 79 exons. The DMD gene encodes a 427kDa protein called dystrophin. Dystrophin is a cytoskeletal protein that connects the actin cytoskeleton to the extracellular matrix.b1tacg3087 Dystrophin is expressed in skeletal cardiac and smooth muscle as well as in the brain.b2",
        "The most common types of muscular dystrophies are dystrophinopathies, limb-girdle muscular dystrophies, facioscapulohumeral muscular dystrophy, and myotonic dystrophy.",
        "The most common muscular dystrophies include Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy.",
        "Muscular dystrophies (MD) are a group of genetic disorders characterized by progressive muscle weakness and wasting. The most common types of MD include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), myotonic dystrophy, facioscapulohumeral muscular dystrophy, and limb-girdle muscular dystrophy. DMD is the most severe form and affects primarily boys, with symptoms appearing in early childhood. BMD is similar to DMD but has a later onset and milder symptoms. Myotonic dystrophy is the most common adult-onset MD and affects both men and women. Facioscapulohumeral muscular dystrophy typically begins in adolescence or early adulthood and primarily affects the face, shoulders, and upper arms. Limb-girdle muscular dystrophy refers to a group of disorders that affect the muscles of the hips and shoulders. While there is currently no cure for MDs, treatments such as physical therapy, medications, and assistive devices can help manage symptoms and improve quality of life for those affected by these conditions.",
        "Muscular dystrophies are a group of genetic disorders characterized by progressive muscle weakness and wasting. The most common types of muscular dystrophies include Duchenne and Becker muscular dystrophy, which are caused by mutations in the DMD gene, leading to the absence or reduced production of the protein dystrophin. Other types of muscular dystrophies include limb-girdle muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic dystrophy, and congenital muscular dystrophies (CMD). CMDs are a heterogeneous group of disorders that affect infants and children and can be caused by mutations in various genes such as POMT1, POMT2, FKRP, LARGE1, COL6A1-3, SELENON, LMNA among others. These conditions can present with different clinical features depending on the specific gene involved. It is important to note that while some forms of CMD may have overlapping symptoms with other types of muscular dystrophies such as limb-girdle or myotonic dystrophy, they are distinct entities with their own diagnostic criteria and management strategies.",
        "Muscular dystrophies are a group of genetic disorders characterized by progressive muscle weakness and degeneration. The most common forms include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), myotonic dystrophy (DM), facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophies (LGMDs), and congenital muscular dystrophies (CMDs). DMD is the most prevalent, affecting approximately 1 in 3,500 to 5,000 male births worldwide. It is caused by mutations in the DMD gene, which encodes for the protein dystrophin. BMD is a milder form of DMD with similar genetic origins but later onset and slower progression. DM, the most common adult-onset form, has two types: DM1 and DM2, both involving repeat expansions in different genes. FSHD affects facial, shoulder, and upper arm muscles and results from complex genetic alterations on chromosome 4. LGMDs comprise over 30 subtypes with varying inheritance patterns and clinical manifestations; they primarily affect proximal limb muscles. CMDs are a heterogeneous group of early-onset disorders with variable severity and involvement of other organ systems. Overall, these conditions share features of muscle wasting and weakness but differ in their genetic basis, age of onset, distribution of affected muscles, and disease progression rates.",
        "The most common muscular dystrophies can be categorized into congenital and childhood/adult-onset forms. Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD. On the other hand, childhood and adult-onset muscular dystrophies encompass dystrophinopathies (such as Duchenne and Becker muscular dystrophy), limb-girdle muscular dystrophies, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), and myotonic dystrophy. Among these, Duchenne muscular dystrophy is one of the most prevalent forms in children, while myotonic dystrophy is more common in adults. These disorders are characterized by progressive muscle weakness and degeneration due to genetic mutations affecting proteins essential for muscle function."
      ],
      "exact_answer": [
        [
          "Congenital muscular dystrophies (CMD)"
        ],
        [
          "dystroglycanopathies"
        ],
        [
          "merosin-deficient CMD"
        ],
        [
          "collagen VI-deficient CMD"
        ],
        [
          "SELENON-related rigid spine muscular dystrophy"
        ],
        [
          "LMNA-related CMD"
        ],
        [
          "Childhood and adult-onset muscular dystrophies"
        ],
        [
          "limb-girdle muscular dystrophies",
          "LGMD"
        ],
        [
          "Emery-Dreifuss muscular dystrophy",
          "EDMD"
        ],
        [
          "facioscapulohumeral muscular dystrophy",
          "FSHMD"
        ],
        [
          "myotonic dystrophy"
        ],
        [
          "Duchenne Muscular Dystrophy",
          "DMD"
        ],
        [
          "Becker Muscular Dystrophy",
          "BMD"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35748699"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 75,
          "text": "Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748699"
        },
        {
          "offsetInBeginSection": 286,
          "offsetInEndSection": 464,
          "text": "This open-label, phase 2 trial investigated the safety and efficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with AAT deficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748699"
        },
        {
          "offsetInBeginSection": 1680,
          "offsetInEndSection": 1870,
          "text": "CONCLUSIONS: In this small trial, fazirsiran was associated with a strong reduction of Z-AAT concentrations in the serum and liver and concurrent improvements in liver enzyme concentrations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748699"
        }
      ],
      "body": "Which disease is targeted by Fazirsiran?",
      "type": "summary",
      "id": "63eef7eff36125a42600000e",
      "ideal_answer": [
        "Fazirsiran is an RNA interference therapeutic that was developed for Liver Disease Associated with Alpha1-Antitrypsin Deficiency."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35882940",
        "http://www.ncbi.nlm.nih.gov/pubmed/35693619",
        "http://www.ncbi.nlm.nih.gov/pubmed/12732268",
        "http://www.ncbi.nlm.nih.gov/pubmed/29859763",
        "http://www.ncbi.nlm.nih.gov/pubmed/14574050",
        "http://www.ncbi.nlm.nih.gov/pubmed/14987573",
        "http://www.ncbi.nlm.nih.gov/pubmed/30135320",
        "http://www.ncbi.nlm.nih.gov/pubmed/30120963",
        "http://www.ncbi.nlm.nih.gov/pubmed/16689366",
        "http://www.ncbi.nlm.nih.gov/pubmed/8025996",
        "http://www.ncbi.nlm.nih.gov/pubmed/10519161",
        "http://www.ncbi.nlm.nih.gov/pubmed/29978892",
        "http://www.ncbi.nlm.nih.gov/pubmed/18706401",
        "http://www.ncbi.nlm.nih.gov/pubmed/12084525"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 365,
          "text": "We explored the direct impact of T1AM on cardiomyocytes with a focus on the regulation of the intracellular temperature and natriuretic peptide (NP) expression. A",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35882940"
        },
        {
          "offsetInBeginSection": 1458,
          "offsetInEndSection": 1705,
          "text": "In hypertrophic cardiomyocytes, after up-regulating the expression of miR-145, the relative messenger ribonucleic acid (mRNA) and protein expressions of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) induced by PE decreased.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35693619"
        },
        {
          "offsetInBeginSection": 401,
          "offsetInEndSection": 579,
          "text": "Stretching of cultured cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP). Intracellular calcium-elevating agents such as the calcium ionophore A23187,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12732268"
        },
        {
          "offsetInBeginSection": 460,
          "offsetInEndSection": 571,
          "text": "Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "Brain (or B-type) natriuretic peptide (BNP) is a cardiac hormone produced in the heart and an established biochemical marker for heart failure (HF) because the level in plasma increases in proportion to disease severity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30135320"
        },
        {
          "offsetInBeginSection": 572,
          "offsetInEndSection": 768,
          "text": "BNP is released mainly from the left ventricle in response to volume overload and has become the first biochemical marker for the identification of individuals with congestive heart failure (CHF).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574050"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "BACKGROUND: B-type or brain natriuretic peptide (BNP) is a novel natriuretic peptide secreted from the heart that forms a peptide family with A-type or atrial natriuretic peptide (ANP), and its plasma level has been shown to be increased in patients with congestive he",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8025996"
        },
        {
          "offsetInBeginSection": 174,
          "offsetInEndSection": 335,
          "text": "Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are of myocardial cell origin and C-type natriuretic peptide (CNP) is of endothelial origin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10519161"
        },
        {
          "offsetInBeginSection": 496,
          "offsetInEndSection": 620,
          "text": " ANP and BNP are elucidated to be the cardiac hormone mainly secreted from the atrium, and from the ventricle, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8100590"
        },
        {
          "offsetInBeginSection": 659,
          "offsetInEndSection": 830,
          "text": " In contrast to atrial natriuretic peptides (ANP/NT-proANP), which originate mainly from atrial tissue, BNP related peptides are produced mainly from ventricular myocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14987573"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Atrial and brain natriuretic peptides: Hormones secreted from the heart.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29859763"
        },
        {
          "offsetInBeginSection": 459,
          "offsetInEndSection": 571,
          "text": " Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574050"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 309,
          "text": "Atrial natriuretic peptide (ANP) and brain (or B-type) natriuretic peptide (BNP) are secreted from cardiomyocytes in response to atrial or ventricular wall stretch.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15478621"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 248,
          "text": "riuretic peptide (BNP) are primarily produced by, and secreted from, heart tissue. They maintain cardiovascular homeostasis by binding to natriuretic ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120963"
        },
        {
          "offsetInBeginSection": 744,
          "offsetInEndSection": 894,
          "text": "rom atrial tissue, BNP related peptides are produced mainly from ventricular myocytes. Ventricular (NT-pro)BNP production is strongly upregulated in c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14987573"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 271,
          "text": ") and brain natriuretic peptide (BNP) are delivered predominantly by the heart. Two C-type natriuretic peptides (CNPs) are paracrine messengers, notab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29978892"
        },
        {
          "offsetInBeginSection": 289,
          "offsetInEndSection": 439,
          "text": "tic and renin-angiotensin systems. Although originally isolated from porcine brain, the BNP gene is expressed in a specific manner in cardiac myocytes",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11558673"
        },
        {
          "offsetInBeginSection": 88,
          "offsetInEndSection": 366,
          "text": "Unlike other members, i.e., atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), which are cardiac hormones secreted from the atrium and ventricle of the heart, respectively, CNP is regarded as an autocrine/paracrine regulator with broad expression in the body.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35741432"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 418,
          "text": "However, there is an accumulating evidence that B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) may originate from right ventricle and their concentrations are elevated in patients with acute pulmonary embolism (APE) especially when resulting in right ventricular dysfunction (RVD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18706401"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "B-type natriuretic peptide (BNP) is a hormone mainly secreted by cardiac ventricle myocytes and which is increased in cardiac diseases.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12084525"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 341,
          "text": "vasoconstrictive molecules. The major source of plasma BNP is the cardiac ventricles. Elevated plasma BNP concentrations correlate with increased left",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16689366"
        },
        {
          "offsetInBeginSection": 484,
          "offsetInEndSection": 634,
          "text": "de (ANP) and brain (or B-type) natriuretic peptide (BNP) are of myocardial cell origin. BNP is released mainly from the left ventricle in response to ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14574050"
        }
      ],
      "body": "Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?",
      "type": "factoid",
      "_body": "Where does B type Natriuretic Protein, BNP usually originate from?",
      "_type": "factoid",
      "id": "6431708a57b1c7a315000017",
      "ideal_answer": [
        "cardiomyocyte stress up-regulates the expression of brain natriuretic peptide (BNP).",
        "The Brain or B Type Natriuretic Peptide, BNP is usually derived from neurons within the walls of the left atrium and right auricle.",
        "BNP usually originates from the left ventricle of the heart in response to volume overload.",
        "Brain natriuretic peptide (BNP) is a cardiac hormone that is secreted from the heart. It is synthesized in the heart and circulates in the blood.",
        "BNP usually originates from the ventricles of the heart.",
        "Brain (or B type) Natriuretic Protein, BNP is produced mainly by the ventricles of the heart in response to increased wall stress.",
        "BNP, or Brain (B-type) Natriuretic Protein, usually originates from the ventricles of the heart.",
        "Stretching of cultured cardiomyocytes up-regulates the expression of brain natriuretic peptide (BNP)."
      ],
      "exact_answer": [
        [
          "heart",
          "left atrium",
          "right auricle",
          "left ventricle"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35181864",
        "http://www.ncbi.nlm.nih.gov/pubmed/34318930",
        "http://www.ncbi.nlm.nih.gov/pubmed/36411267",
        "http://www.ncbi.nlm.nih.gov/pubmed/36399336",
        "http://www.ncbi.nlm.nih.gov/pubmed/33284679",
        "http://www.ncbi.nlm.nih.gov/pubmed/34669839",
        "http://www.ncbi.nlm.nih.gov/pubmed/34153975",
        "http://www.ncbi.nlm.nih.gov/pubmed/32492293",
        "http://www.ncbi.nlm.nih.gov/pubmed/33166694",
        "http://www.ncbi.nlm.nih.gov/pubmed/34485970",
        "http://www.ncbi.nlm.nih.gov/pubmed/34781981",
        "http://www.ncbi.nlm.nih.gov/pubmed/33953559"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 317,
          "text": "Casirivimab/imdevimab (REGN-COV), a cocktail of neutralizing antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, was shown to be an effective treatment and post-exposure prophylaxis measure for coronavirus disease 2019 (COVID-19).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35181864"
        },
        {
          "offsetInBeginSection": 1248,
          "offsetInEndSection": 1385,
          "text": "The high titer of IgGSP supports the clinical benefit of therapeutic and prophylactic use of REGN-COV from the serological point of view.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35181864"
        },
        {
          "offsetInBeginSection": 503,
          "offsetInEndSection": 636,
          "text": "We collected serological data of patients with COVID-19 who were treated with REGN-COV 1200 mg (casirivimab 600 mg/imdevimab 600 mg).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35181864"
        },
        {
          "offsetInBeginSection": 6283,
          "offsetInEndSection": 6437,
          "text": "Based on the current very low- to low-certainty evidence, we are uncertain about the efficacy and safety of ivermectin used to treat or prevent COVID-19. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34318930"
        },
        {
          "offsetInBeginSection": 6587,
          "offsetInEndSection": 6747,
          "text": "Overall, the reliable evidence available does not support the use ivermectin for treatment or prevention of COVID-19 outside of well-designed randomized trials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34318930"
        },
        {
          "offsetInBeginSection": 337,
          "offsetInEndSection": 471,
          "text": "Currently, evidence on efficacy and safety of ivermectin for prevention of SARS-CoV-2 infection and COVID-19 treatment is conflicting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34318930"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 182,
          "text": "We report primary results of a phase 3 trial of AZD7442 (tixagevimab/cilgavimab) for post-exposure prophylaxis to prevent symptomatic coronavirus disease 2019 (COVID-19).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411267"
        },
        {
          "offsetInBeginSection": 1503,
          "offsetInEndSection": 1637,
          "text": "This study did not meet the primary efficacy endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 versus placebo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36411267"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "This systematic review was performed to determine the population that benefited from prophylactic ivermectin. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36399336"
        },
        {
          "offsetInBeginSection": 968,
          "offsetInEndSection": 1444,
          "text": "Ivermectin was associated with a lower risk of COVID-19 (OR, 0.22; 95% CI, 0.12-0.40) in the pre-exposure population, whereas no protective effect was observed in the post-exposure population (OR, 0.39; 95% CI, 0.09-1.67). In summary, prophylactic ivermectin did not prevent COVID-19 in the post-exposure population. Although the protective effect of ivermectin was shown in the overall and pre-exposure populations, the results were unreliable owing to poor-quality evidence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36399336"
        },
        {
          "offsetInBeginSection": 2052,
          "offsetInEndSection": 2251,
          "text": "This rigorous randomized controlled trial among persons with recent exposure excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33284679"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 203,
          "text": "Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33284679"
        },
        {
          "offsetInBeginSection": 373,
          "offsetInEndSection": 453,
          "text": "To test hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33284679"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 383,
          "text": "Chloroquine or hydroxychloroquine has demonstrated no effect on the treatment of hospitalized COVID-19 patients. This study aimed to answer questions related to the use of hydroxychloroquine for pre-exposure or post-exposure prophylaxis of SARS-CoV-2 infection and in the treatment of patients with mild COVID-19 in terms of hospitalization, adverse events, and mortality.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669839"
        },
        {
          "offsetInBeginSection": 1382,
          "offsetInEndSection": 1515,
          "text": "The use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection or treatment of patients with mild COVID-19 is not recommended.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669839"
        },
        {
          "offsetInBeginSection": 774,
          "offsetInEndSection": 946,
          "text": "No statistically significant differences were found between the hydroxychloroquine and control groups in terms of pre- or post-exposure prophylaxis of SARS-CoV-2 infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34669839"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 296,
          "text": "Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures. Although cell culture experiments have demonstrated a loss of potency of several anti-spike neutralizing antibodies against variant strains of SARS-CoV-21-3, the in vivo importance of these results remains uncertain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34153975"
        },
        {
          "offsetInBeginSection": 1302,
          "offsetInEndSection": 1476,
          "text": "Therefore, many-but not all-of the antibody products with Emergency Use Authorization should retain substantial efficacy against the prevailing variant strains of SARS-CoV-2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34153975"
        },
        {
          "offsetInBeginSection": 548,
          "offsetInEndSection": 950,
          "text": "Although some individual mAbs showed reduced or abrogated neutralizing activity in cell culture against B.1.351, B.1.1.28, B.1.617.1 and B.1.526 viruses with mutations at residue E484 of the spike protein, low prophylactic doses of mAb combinations protected against infection by many variants in K18-hACE2 transgenic mice, 129S2 immunocompetent mice and hamsters, without the emergence of resistance. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34153975"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 375,
          "text": "Hydroxychloroquine (HCQ) has been tried against COVID-19 owing to its in vitro virucidal action against SARS-CoV-2, but the role of HCQ as post-exposure prophylaxis (PEP) remains inconclusive.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33166694"
        }
      ],
      "body": "Are any medications available to prevent COVID-19 following exposure?",
      "type": "yesno",
      "id": "643c396457b1c7a31500002d",
      "ideal_answer": [
        "Currently, no. Certain monoclonal antibodies had previously been demonstrated to prevent SARS-CoV-2 infection after exposure, but they mostly lack activity against circulating SARS-CoV-2 variants.\n\nOther agents (e.g., Hydroxychloroquine, Ivermectin, Tixagevimab/Cilgavimab) have not been shown to be effective."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33971103"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 727,
          "offsetInEndSection": 959,
          "text": "Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33971103"
        }
      ],
      "body": "Has RTA 408 received FDA approval?",
      "type": "yesno",
      "id": "6440092d57b1c7a315000040",
      "ideal_answer": [
        "Yes, RTA 408 is FDA approved."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35778789",
        "http://www.ncbi.nlm.nih.gov/pubmed/21496635",
        "http://www.ncbi.nlm.nih.gov/pubmed/35205411",
        "http://www.ncbi.nlm.nih.gov/pubmed/35243403",
        "http://www.ncbi.nlm.nih.gov/pubmed/25121518",
        "http://www.ncbi.nlm.nih.gov/pubmed/34840883",
        "http://www.ncbi.nlm.nih.gov/pubmed/22995693",
        "http://www.ncbi.nlm.nih.gov/pubmed/33458578",
        "http://www.ncbi.nlm.nih.gov/pubmed/11073357",
        "http://www.ncbi.nlm.nih.gov/pubmed/32067592",
        "http://www.ncbi.nlm.nih.gov/pubmed/23570879",
        "http://www.ncbi.nlm.nih.gov/pubmed/21623381",
        "http://www.ncbi.nlm.nih.gov/pubmed/29770119",
        "http://www.ncbi.nlm.nih.gov/pubmed/20514907",
        "http://www.ncbi.nlm.nih.gov/pubmed/20625963",
        "http://www.ncbi.nlm.nih.gov/pubmed/20176601",
        "http://www.ncbi.nlm.nih.gov/pubmed/19360700",
        "http://www.ncbi.nlm.nih.gov/pubmed/27727437",
        "http://www.ncbi.nlm.nih.gov/pubmed/19632331",
        "http://www.ncbi.nlm.nih.gov/pubmed/24435591"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 136,
          "offsetInEndSection": 266,
          "text": "DM type 2 (DM2) is considered less severe than DM type 1 (DM1), but it is unknown whether this applies uniformly to all features. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35778789"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 393,
          "text": "There are two genetically distinct types of myotonic dystrophy: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2), both dominantly inherited with significant overlap in clinical manifestations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35205411"
        },
        {
          "offsetInBeginSection": 109,
          "offsetInEndSection": 330,
          "text": "The unstable repeat expansions of (CTG)n or (CCTG)n in the DMPK and ZNF9 genes cause the two known subtypes of myotonic dystrophy: (i) myotonic dystrophy type 1 (DM1) and (ii) myotonic dystrophy type 2 (DM2) respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23570879"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 321,
          "text": "Congenital myotonic dystrophy (CDM1) and myotonic dystrophy of type 1 (DM1) or of type 2 (DM2) are caused by the expression of mutant RNAs containing expanded CUG or CCUG repeats, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21623381"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 125,
          "text": "Myotonic dystrophy type 1 (DM1) and type 2 (DM2) represent the most frequent multisystemic muscular dystrophies in adulthood.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29770119"
        },
        {
          "offsetInBeginSection": 200,
          "offsetInEndSection": 440,
          "text": "To date, two types of myotonic dystrophy, type 1 (DM1) and type 2 (DM2), are known to exist; both are autosomal dominant disorders caused by expansion of an untranslated short tandem repeat DNA sequence (CTG)(n) and (CCTG)(n), respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496635"
        },
        {
          "offsetInBeginSection": 435,
          "offsetInEndSection": 609,
          "text": "Myotonic dystrophies MD1 and MD2 are multisystem diseases with numerous symptoms and high interfamily variability, resulting from the fact that different organs are affected.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514907"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 243,
          "text": "There are currently two clinically and molecularly defined forms of myotonic dystrophy: (1) myotonic dystrophy type 1 (DM1), also known as \u0027Steinert\u0027s disease\u0027; and (2) myotonic dystrophy type 2 (DM2), also known as proximal myotonic myopathy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20176601"
        },
        {
          "offsetInBeginSection": 531,
          "offsetInEndSection": 878,
          "text": "Phenotypes of DM1 and DM2 are similar but there are some important differences, most conspicuously in the severity of the disease (including the presence or absence of the congenital form), muscles primarily affected (distal versus proximal), involved muscle fiber types (type 1 versus type 2 fibers), and some associated multisystemic phenotypes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496635"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 139,
          "text": "Myotonic dystrophy types 1 (DM1) and 2 (DM2) are autosomal dominant, microsatellite repeat expansion disorders that affect muscle function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27727437"
        },
        {
          "offsetInBeginSection": 123,
          "offsetInEndSection": 480,
          "text": "There are two forms identified: myotonic dystrophy type 1 (DM1), caused by an expansion of a CTG repeat in the 3\u0027 untranslated region of the myotonin-protein kinase (DMPK) gene on chromosome 19, and myotonic dystrophy type 2 (DM2), caused by an expansion of a CCTG repeat in intron 1 of the cellular nucleic acid-binding protein (CNBP) gene on chromosome 3.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19360700"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "Myotonic dystrophy type 1 (DM1) and type II (DM2) are dominantly inherited multisystemic disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19632331"
        },
        {
          "offsetInBeginSection": 512,
          "offsetInEndSection": 748,
          "text": " For the enormous understanding of the molecular pathogenesis of myotonic dystrophy type 1 and myotonic dystrophy type 2, these diseases are now called \"spliceopathies\" and are mediated by a primary disorder of RNA rather than proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33458578"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 300,
          "text": "This review demonstrates genetic and phenotypic heterogeneity in all of the multisystemic myotonic disorders collectively called \u0027myotonic dystrophies\u0027 according to the new nomenclature: myotonic dystrophy type 1, myotonic dystrophy type 2, proximal myotonic myopathy and proximal myotonic dystrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11073357"
        },
        {
          "offsetInBeginSection": 65,
          "offsetInEndSection": 215,
          "text": "progress in elucidating the disease mechanism in myotonic dystrophy type 1 and type 2.RECENT FINDINGS: Research on myotonic dystrophy has led to the r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17885447"
        },
        {
          "offsetInBeginSection": 203,
          "offsetInEndSection": 326,
          "text": "The 2 major genetic forms of myotonic dystrophy, type 1 and type 2, differ in genetic etiology yet share clinical features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32067592"
        },
        {
          "offsetInBeginSection": 901,
          "offsetInEndSection": 1075,
          "text": "CENT FINDINGS: An active approach to screening and management of myotonic dystrophies type 1 and type 2 requires a multidisciplinary medical, rehabilitative and social team. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121518"
        },
        {
          "offsetInBeginSection": 30,
          "offsetInEndSection": 180,
          "text": "onest adult muscular dystrophy. Myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2) are often discussed jointly, and although they sha",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24435591"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "PURPOSE OF REVIEW: Myotonic dystrophies type 1 and type 2 are progressive multisystem genetic disorders with clinical and genetic features in common",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121518"
        },
        {
          "offsetInBeginSection": 149,
          "offsetInEndSection": 302,
          "text": "Two genetically distinct forms of DM are identified - type 1 (DM1), the classic form first described by Steinert, and type 2 (DM2), identified by Ricker.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20625963"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Myotonic dystrophy types 1 and 2 are a group of complex genetic disorders resulting from the expansion of (CTG)n nucleotide repeats in the DMPK gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35243403"
        },
        {
          "offsetInBeginSection": 1613,
          "offsetInEndSection": 1763,
          "text": "ers of subjects, sometimes even not separating Myotonic Dystrophy Type 1 from Type 2. But this heterogeneity may also support the current point of vie",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30186217"
        },
        {
          "offsetInBeginSection": 1081,
          "offsetInEndSection": 1241,
          "text": "Despite clinical and genetic similarities, myotonic dystrophy type 1 and type 2 are distinct disorders requiring different diagnostic and management strategies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22995693"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "BACKGROUND AND OBJECTIVE: Myotonic dystrophy types 1 and 2 are progressive multisystem genetic disorders whose core clinical feature is myotonia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34840883"
        }
      ],
      "body": "Which are the types of myotonic dystrophy?",
      "type": "list",
      "id": "644291fa57b1c7a31500005f",
      "ideal_answer": [
        "There are two types of myotonic dystrophy: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2).",
        "DM type 2 (DM2) is considered less severe than DM type 1 (DM1) but it is unknown whether this applies uniformly to all features.                                                                     ",
        "DM type 2 (DM2) is considered less severe than DM type 1 (DM1), but it is unknown whether this applies uniformly to all features.",
        "Myotonia dystrophic muscular dystrophy is divided into two forms: myotonic dystrophy 1 (DM1) and myotonic dystrophy 2 (DM2). DM1 affects more adults than children, whereas DM2 affects mostly children. In addition, DM1 can also affect the central nervous system, causing intellectual disability or seizures. DM2, on the other hand, does not appear to involve the central nervous system.",
        "There are two types of myotonic dystrophy: type 1 (DM1) and type 2 (DM2).",
        "Myotonic dystrophy is classified into two types: type 1 (DM1) and type 2 (DM2). DM1 is caused by an expansion of a CTG trinucleotide repeat in the DMPK gene, while DM2 is caused by an expansion of a CCTG trinucleotide repeat in the CNBP gene.",
        "Myotonic dystrophy is classified into two types: DM type 1 (DM1) and DM type 2 (DM2). DM1 is considered to be more severe than DM2, but it is unknown whether this applies uniformly to all features.",
        "The two types of myotonic dystrophy are DM1 and DM2.",
        "There are two types of myotonic dystrophy: DM type 1 (DM1) and DM type 2 (DM2).",
        "Myotonic dystrophy is a genetic disorder that affects the muscles and other body systems. There are two main types of myotonic dystrophy: type 1 (DM1) and type 2 (DM2). DM1 is caused by an expansion of a CTG trinucleotide repeat in the DMPK gene on chromosome 19, while DM2 is caused by an expansion of a CCTG tetranucleotide repeat in the CNBP gene on chromosome 3. Both types of myotonic dystrophy are inherited in an autosomal dominant pattern, meaning that only one copy of the mutated gene is needed to develop the condition. The symptoms of myotonic dystrophy can vary widely between individuals and may include muscle weakness and wasting, myotonia (prolonged muscle contractions), cataracts, heart conduction defects, respiratory problems, and cognitive impairment. While there is currently no cure for myotonic dystrophy, treatment options such as physical therapy, medication, and assistive devices can help manage symptoms and improve quality of life for affected individuals.",
        "Myotonic dystrophy (DM) is a genetic disorder that affects muscle function. There are two types of DM: type 1 (DM1) and type 2 (DM2). DM1 is generally considered more severe than DM2, with earlier onset and more significant muscle weakness. In contrast, DM2 typically has a later onset and milder symptoms, although this can vary between individuals. Both types of DM are caused by mutations in specific genes that affect the production of proteins involved in muscle function. Diagnosis is typically made through genetic testing, and management involves symptom-specific treatments such as physical therapy and medication to manage muscle stiffness or weakness. While there is currently no cure for either type of DM, ongoing research aims to develop new therapies to improve outcomes for affected individuals.",
        "Myotonic dystrophy is a genetic disorder characterized by progressive muscle weakness and myotonia. There are two main types of myotonic dystrophy: type 1 (DM1) and type 2 (DM2). DM1, also known as Steinert\u0027s disease, is caused by a mutation in the DMPK gene on chromosome 19, while DM2, sometimes referred to as proximal myotonic myopathy (PROMM), results from a mutation in the CNBP gene on chromosome 3. Both types share some clinical features such as muscle stiffness, weakness, and wasting; however, they differ in severity and distribution of symptoms. DM1 is generally considered more severe than DM2, with earlier onset and more pronounced symptoms. In contrast, DM2 typically has a later onset and milder manifestations. Despite these differences in severity, it remains unclear whether this distinction applies uniformly across all aspects of the disease."
      ],
      "exact_answer": [
        [
          "myotonic dystrophy type 1 (DM1)"
        ],
        [
          "myotonic dystrophy type 2 (DM2)"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35954196",
        "http://www.ncbi.nlm.nih.gov/pubmed/35543970",
        "http://www.ncbi.nlm.nih.gov/pubmed/36268952"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 583,
          "offsetInEndSection": 854,
          "text": "Recently, a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment developed by Bristol Myers Squibb (Opdualag), was approved by the Food and Drug Administration (FDA) as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35954196"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Nivolumab plus relatlimab (nivolumab and relatlimab-rmbw; Opdualag™) is a fixed-dose, combination immunotherapy treatment being developed by Bristol Myers Squibb for the treatment of multiple types of advanced cancers.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35543970"
        },
        {
          "offsetInBeginSection": 201,
          "offsetInEndSection": 377,
          "text": "DATA SOURCES: A search of PubMed conducted from August 2019 to August 2022 with the search terms Opdualag, nivolumab AND relatlimab, and BMS-986016 resulted in 14 publications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36268952"
        }
      ],
      "body": "What are the active components of Opdualag?",
      "type": "list",
      "id": "63f741a633942b094c000009",
      "ideal_answer": [
        "Opdualag is a new dual anti-PD-1 (Nivolumab) and anti-LAG-3 (Relatimab) treatment approved as the first LAG-3 blocking antibody combination for unresectable or metastatic melanoma."
      ],
      "exact_answer": [
        [
          "Nivolumab"
        ],
        [
          "Relatimab"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33488009",
        "http://www.ncbi.nlm.nih.gov/pubmed/32672594",
        "http://www.ncbi.nlm.nih.gov/pubmed/33613251",
        "http://www.ncbi.nlm.nih.gov/pubmed/28291197",
        "http://www.ncbi.nlm.nih.gov/pubmed/25061877",
        "http://www.ncbi.nlm.nih.gov/pubmed/1426078",
        "http://www.ncbi.nlm.nih.gov/pubmed/25061871",
        "http://www.ncbi.nlm.nih.gov/pubmed/30242758",
        "http://www.ncbi.nlm.nih.gov/pubmed/10581564",
        "http://www.ncbi.nlm.nih.gov/pubmed/729457"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 184,
          "offsetInEndSection": 402,
          "text": " This retrospective case series included patients with PCG who underwent trabeculotomy using an illuminated microcatheter with the intent of catheterizing the full circumference of Schlemm\u0027s canal in a single procedure",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33488009"
        },
        {
          "offsetInBeginSection": 9,
          "offsetInEndSection": 195,
          "text": "To study the effect of 3 Schlemm\u0027s canal (SC) microinvasive glaucoma surgery (MIGS) devices on outflow facility.DESIGN: Paired comparisons, randomized design, baseline-controlled study.P",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32672594"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "Outflow Facility Effects of 3 Schlemm\u0027s Canal Microinvasive Glaucoma Surgery Devices.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32672594"
        },
        {
          "offsetInBeginSection": 146,
          "offsetInEndSection": 282,
          "text": "Previously, blood reflux from Schlemm\u0027s canal (SC) after long-standing glaucoma surgery was reported in eyes treated with excisional LOT",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33613251"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 241,
          "text": "AIM: to comparatively evaluate the hypotensive effect of minimally invasive (type 1) and basic (type 2) subscleral removing of the external wall of Schlemm\u0027s canal with subsequent laser trabeculopuncture in patients with open-angle glaucoma ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28291197"
        },
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 397,
          "text": "Schlemm\u0027s canal (SC) is a large, lymphatic-like vessel in the anterior chamber of the eye, which is essential for aqueous humor drainage required to maintain intraocular pressure and is sensitive to defects in blood and lymphatic vascular signaling pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30242758"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Schlemm\u0027s canal (SC) is a specialized vascular structure in the eye that functions to drain aqueous humor from the intraocular chamber into systemic circulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25061877"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Schlemm\u0027s canal (SC) is a unique vascular structure that functions to maintain fluid homeostasis by draining aqueous humor from the eye into the systemic circulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25061871"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 409,
          "text": "We have tried to answer the question of whether the endothelium of Schlemm\u0027s canal is derived from and retains properties of blood vessels by studying: (1) the development of Schlemm\u0027s canal in human fetal eyes; (2) the existence of Weibel-Palade bodies in human neonatal, adult human and adult monkey eyes; and (3) the presence of blood coagulation Factor VIII-related antigen in adult human and monkey eyes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1426078"
        },
        {
          "offsetInBeginSection": 1450,
          "offsetInEndSection": 1628,
          "text": "Our results indicate that the endothelium of Schlemm\u0027s canal is derived from a vascular origin and that even in the adult eye it retains some of the properties of a blood vessel.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1426078"
        },
        {
          "offsetInBeginSection": 1258,
          "offsetInEndSection": 1449,
          "text": "(3) Blood coagulation Factor VIII-related antigen was detected in the endothelium of the collector channels and Schlemm\u0027s canal, as well as in the blood vessels of the other parts of the eye.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1426078"
        },
        {
          "offsetInBeginSection": 454,
          "offsetInEndSection": 579,
          "text": " Injecting fluorescein directly in Schlemm\u0027s canal proves that in cadaver eyes without glaucoma the lumen is open all around.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/729457"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 182,
          "text": "Differences in parameters of ciliary body and Schlemm\u0027s canal in different meridians of the eyeball has been described using histotopographic methods on 20 eyeballs of human corpses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10581564"
        }
      ],
      "body": "Where in the body would  Schlemm\u0027s canal be found",
      "type": "factoid",
      "id": "640f8641201352f04a00002c",
      "ideal_answer": [
        "Schlemm\u0027s canal  is in the eye",
        "Schlemm\u0027s canal can be found in the anterior chamber of the eye.",
        "Schlemm\u0027s canal is found in the eye, specifically in the trabecular meshwork of the anterior chamber of the eye.",
        "Schlemm\u0027s canal is found in the eye."
      ],
      "exact_answer": [
        [
          "eye"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35904405",
        "http://www.ncbi.nlm.nih.gov/pubmed/34043841",
        "http://www.ncbi.nlm.nih.gov/pubmed/35593164",
        "http://www.ncbi.nlm.nih.gov/pubmed/35233580",
        "http://www.ncbi.nlm.nih.gov/pubmed/36298593",
        "http://www.ncbi.nlm.nih.gov/pubmed/36275814",
        "http://www.ncbi.nlm.nih.gov/pubmed/34459525",
        "http://www.ncbi.nlm.nih.gov/pubmed/35262003",
        "http://www.ncbi.nlm.nih.gov/pubmed/34755830",
        "http://www.ncbi.nlm.nih.gov/pubmed/33338197",
        "http://www.ncbi.nlm.nih.gov/pubmed/33361342",
        "http://www.ncbi.nlm.nih.gov/pubmed/33315061",
        "http://www.ncbi.nlm.nih.gov/pubmed/33257644",
        "http://www.ncbi.nlm.nih.gov/pubmed/34632431",
        "http://www.ncbi.nlm.nih.gov/pubmed/36164552",
        "http://www.ncbi.nlm.nih.gov/pubmed/33315049",
        "http://www.ncbi.nlm.nih.gov/pubmed/35263638",
        "http://www.ncbi.nlm.nih.gov/pubmed/33930542",
        "http://www.ncbi.nlm.nih.gov/pubmed/36176508",
        "http://www.ncbi.nlm.nih.gov/pubmed/34908003",
        "http://www.ncbi.nlm.nih.gov/pubmed/34492110",
        "http://www.ncbi.nlm.nih.gov/pubmed/33791729",
        "http://www.ncbi.nlm.nih.gov/pubmed/33219681",
        "http://www.ncbi.nlm.nih.gov/pubmed/35935779",
        "http://www.ncbi.nlm.nih.gov/pubmed/34873592",
        "http://www.ncbi.nlm.nih.gov/pubmed/33849385",
        "http://www.ncbi.nlm.nih.gov/pubmed/33630817",
        "http://www.ncbi.nlm.nih.gov/pubmed/36413551",
        "http://www.ncbi.nlm.nih.gov/pubmed/34447364",
        "http://www.ncbi.nlm.nih.gov/pubmed/34468184",
        "http://www.ncbi.nlm.nih.gov/pubmed/34367645",
        "http://www.ncbi.nlm.nih.gov/pubmed/35743421",
        "http://www.ncbi.nlm.nih.gov/pubmed/34521025",
        "http://www.ncbi.nlm.nih.gov/pubmed/34961403",
        "http://www.ncbi.nlm.nih.gov/pubmed/35899182",
        "http://www.ncbi.nlm.nih.gov/pubmed/35264078",
        "http://www.ncbi.nlm.nih.gov/pubmed/35488305",
        "http://www.ncbi.nlm.nih.gov/pubmed/35931371",
        "http://www.ncbi.nlm.nih.gov/pubmed/33853339",
        "http://www.ncbi.nlm.nih.gov/pubmed/36301607"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 14,
          "offsetInEndSection": 322,
          "text": "A precise estimate of the frequency and severity of SARS-CoV-2 reinfections would be critical to optimize restriction and vaccination policies for the hundreds of millions previously infected subjects. We performed a meta-analysis to evaluate the risk of reinfection and COVID-19 following primary infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904405"
        },
        {
          "offsetInBeginSection": 921,
          "offsetInEndSection": 1185,
          "text": "Reinfection rates were still 0.66% after ≥12 months from first infection, and the risk was substantially lower among vaccinated subjects (0.32% vs. 0.74% for unvaccinated individuals). During the first 3 months of Omicron wave, the reinfection rates reached 3.31%.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904405"
        },
        {
          "offsetInBeginSection": 1357,
          "offsetInEndSection": 1683,
          "text": "A strong natural immunity follows the primary infection and may last for more than one year, suggesting that the risk and health care needs of recovered subjects might be limited. Although the reinfection rates considerably increased during the Omicron wave, the risk of a secondary severe or lethal disease remained very low.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35904405"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 302,
          "text": "Despite over 140 million SARS-CoV-2 infections worldwide since the beginning of the pandemic, relatively few confirmed cases of SARS-CoV-2 reinfection have been reported. While immunity from SARS-CoV-2 infection is probable, at least in the short term, few studies have quantified the reinfection risk.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34043841"
        },
        {
          "offsetInBeginSection": 1006,
          "offsetInEndSection": 1627,
          "text": "Reinfection was an uncommon event (absolute rate 0%-1.1%), with no study reporting an increase in the risk of reinfection over time. Only one study estimated the population-level risk of reinfection based on whole genome sequencing in a subset of patients; the estimated risk was low (0.1% [95% CI: 0.08-0.11%]) with no evidence of waning immunity for up to 7 months following primary infection. These data suggest that naturally acquired SARS-CoV-2 immunity does not wane for at least 10 months post-infection. However, the applicability of these studies to new variants or to vaccine-induced immunity remains uncertain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34043841"
        },
        {
          "offsetInBeginSection": 227,
          "offsetInEndSection": 339,
          "text": "The risk of reinfection increased almost 18-fold following emergence of the Omicron variant compared with Delta.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35593164"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 120,
          "text": "Better understanding of the protective duration of prior SARS-CoV-2 infection against reinfection is needed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35233580"
        },
        {
          "offsetInBeginSection": 2153,
          "offsetInEndSection": 2375,
          "text": "This large US population-based study demonstrates that SARS-CoV-2 reinfection is uncommon among individuals with laboratory evidence of a previous infection. Protection from SARS-CoV-2 reinfection is stable up to one year.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35233580"
        },
        {
          "offsetInBeginSection": 1807,
          "offsetInEndSection": 1926,
          "text": "The duration of protection against reinfection was stable over the median 5 months and up to 1-year follow-up interval.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35233580"
        },
        {
          "offsetInBeginSection": 2800,
          "offsetInEndSection": 3066,
          "text": "Among \u003e22 million individuals tested February 2020 through April 2021, the relative risk of reinfection among those with prior infection was 87% lower than the risk of infection among individuals without prior infection. This protection was durable for up to a year.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35233580"
        },
        {
          "offsetInBeginSection": 275,
          "offsetInEndSection": 695,
          "text": "The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36298593"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 199,
          "text": "SARS-CoV-2 infection does not confer long immunity. However, studies suggest that prior infection is associated with lower risk of reinfection and milder outcomes of recurrent infections.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36275814"
        },
        {
          "offsetInBeginSection": 2115,
          "offsetInEndSection": 2343,
          "text": "Reinfection with the SARS-CoV-2 Delta variant resulted in fewer hospitalizations compared to the primary Delta infection, suggesting that primary infection may, to some extent, produce at least short lasting protective immunity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36275814"
        },
        {
          "offsetInBeginSection": 1386,
          "offsetInEndSection": 1705,
          "text": "The vast majority of anti-spike IgG positive individuals remain anti-spike IgG positive for at least 8 months regardless of initial COVID-19 disease severity. The presence of anti-spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID-19.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34459525"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 266,
          "text": "Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34459525"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Comparative genomic analysis demonstrates that true reinfection following SARS-CoV-2 infection is possible.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35262003"
        },
        {
          "offsetInBeginSection": 758,
          "offsetInEndSection": 974,
          "text": "Our findings indicate that reinfection results in restricted SARS-CoV-2 replication despite substantial levels of humoral immunity, denoting the potential for transmission through reinfected asymptomatic individuals.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35263638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 188,
          "text": "Prior to the emergence of antigenically distinct SARS-CoV-2 variants, reinfections were reported infrequently - presumably due to the generation of durable and protective immune responses.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33791729"
        },
        {
          "offsetInBeginSection": 90,
          "offsetInEndSection": 212,
          "text": " It is currently unclear whether the previous infection with SARS-CoV-2 provides protection against reinfection with VOCs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34120579"
        },
        {
          "offsetInBeginSection": 1257,
          "offsetInEndSection": 1402,
          "text": "Our case supports the hypothesis that SARS-CoV-2 reinfection may occur once antibody titers decrease or following the emergence of a new variant.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35935779"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 213,
          "text": "Reinfection with SARS-CoV-2 has been well documented, yet little is known about the degree of protection a previous infection provides against reinfection, especially against Variants of Concern (VOC).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35935779"
        },
        {
          "offsetInBeginSection": 1286,
          "offsetInEndSection": 1506,
          "text": "Reinfection with SARS-CoV-2 is a strong possibility. This case raises concerns that asymptomatic infections may not provide long-term protective immunity to all patients, which could make them susceptible to reinfection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33257644"
        },
        {
          "offsetInBeginSection": 1149,
          "offsetInEndSection": 1319,
          "text": "The rate of reinfection with SARS-CoV-2 is relatively low. The protection against SARS-CoV-2 after natural infection is comparable to that estimated for vaccine efficacy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34908003"
        },
        {
          "offsetInBeginSection": 1497,
          "offsetInEndSection": 1669,
          "text": "SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33315061"
        },
        {
          "offsetInBeginSection": 1593,
          "offsetInEndSection": 1751,
          "text": "Reinfection by SARS-CoV-2 under endemic conditions would likely occur between 3 months and 5·1 years after peak antibody response, with a median of 16 months.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34632431"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 318,
          "text": "It is currently unclear whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection will remain a rare event, only occurring in individuals who fail to mount an effective immune response, or whether it will occur more frequently when humoral immunity wanes following primary infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33315049"
        }
      ],
      "body": "Can reinfection occur after SARS-CoV-2 infection?",
      "type": "yesno",
      "id": "643c446357b1c7a31500002f",
      "ideal_answer": [
        "Protective and detectable immune responses are induced after SARS-CoV-2 infection but it is not yet established to what degree and for how long protection against reinfection lasts. Evidence suggests that some of these responses can be detected for at least a year following infection.\n\nThe short-term risk of reinfection (e.g., within the first several months after initial infection) is low. Several studies estimated the risk of reinfection to be less than 1 percent in the subsequent 5-8 months following initial infection. The risk of reinfection may be greater with the Omicron variant."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30065630"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Friedreich\u0027s Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder, affecting dorsal root ganglia (DRG), cerebellar dentate nuclei and heart. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30065630"
        }
      ],
      "body": "What is the mode of inheritance of Friedreich’s ataxia?",
      "type": "factoid",
      "id": "644009c557b1c7a315000041",
      "ideal_answer": [
        "Friedreich\u0027s Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder."
      ],
      "exact_answer": [
        [
          "autosomal recessive"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19461958",
        "http://www.ncbi.nlm.nih.gov/pubmed/10422002",
        "http://www.ncbi.nlm.nih.gov/pubmed/18056690",
        "http://www.ncbi.nlm.nih.gov/pubmed/164552",
        "http://www.ncbi.nlm.nih.gov/pubmed/8894415"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 263,
          "text": "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have 10% to 40% of the normal amount.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19461958"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 708,
          "text": "Clinical data confirm some well known differences between Duchenne and Becker muscular dystrophy concerning the age of onset, severity of disease and rate of progression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10422002"
        },
        {
          "offsetInBeginSection": 768,
          "offsetInEndSection": 918,
          "text": "cular dystrophy, where there is absence of dystrophin in Duchenne muscular dystrophy and reduced amounts in Becker muscular dystrophy. Not all of the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8894415"
        },
        {
          "offsetInBeginSection": 358,
          "offsetInEndSection": 471,
          "text": "Ribosome concentration was normal in Duchenne and facioscapulohumeral and decreased in Becker muscular dystrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/164552"
        }
      ],
      "body": "What is the difference between Duchenne muscular Dystrophy and Becker muscular dystrophy?",
      "type": "summary",
      "id": "641790a3690f196b5100002c",
      "ideal_answer": [
        "DMD patients do not produce dystrophin whereas BMD patients produce 10-40% of the normal amount of dystrophin.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dytrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have 10% to 40% of the normal amount.",
        "Behet muscular dystrophy (BMD) is an X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have 10% to 40% of the normal amount.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dy Strophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have 10% to 40% of the normal amount.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have 10% to 40% of the normal amount.",
        "Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin gene leading to decreased expression or absence of dystrophin protein. Onset typically occurs at 2 years old, with progressive muscle weakness and wasting. Becker muscular dystrophy (BMD), on the other hand, is characterized by onset later than 10 years of age and less severe muscle weakness. Both diseases exhibit muscle fiber replacement with fat, inflammation, and fibro-fatty substitution, but there are differences in their histopathology. Genetic testing is available for diagnosis in both conditions. ",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are characterized by muscle wasting leading to loss of ambulation in the first or third decade, respectively. Becker muscular dystrophy, similar to Duchenne muscular dystrophy, is a X-chromosomal linked anomaly characterized by progressive muscle wasting and weakness. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. Duchenne and Becker types of muscular dystrophy are usually differentiated according to age of onset and rate of progression criteria which are not sufficient. Clinical data confirm some well known differences between Duchenne and Becker muscular dystrophy concerning the age of onset, severity of disease and rate of progression.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have 10% to 40% of the normal amount. Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are characterized by muscle wasting leading to loss of ambulation in the first or third decade, respectively. Becker muscular dystrophy, similar to Duchenne muscular dystrophy, is a X-chromosomal linked anomaly characterized by progressive muscle wasting and weakness. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. Duchenne and Becker types of muscular dystrophy are usually differentiated according to age of onset and rate of progression criteria which are not sufficient.",
        "The main difference between Duchenne muscular dystrophy and Becker muscular dystrophy is the amount of dystrophin present in the patient. In DMD patients, dystrophin is virtually absent, while BMD patients have 10% to 40% of the normal amount. Additionally, the age of onset, severity of disease, and rate of progression can also differ between the two types.",
        "Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by mutations in the dystrophin gene, resulting in progressive muscle weakness and wasting. Becker muscular dystrophy (BMD) is also an X-linked recessive disorder caused by mutations in the dystrophin gene, but the symptoms are usually milder and progress more slowly than in DMD.",
        "The main difference between Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) is the amount of dystrophin present in the body. DMD patients have virtually no dystrophin, while BMD patients have 10-40% of the normal amount. Both disorders are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21.",
        "Duchenne and Becker muscular dystrophy are both caused by mutations in the DMD gene on the X chromosome, but the severity and onset of symptoms differ. Duchenne patients have no dystrophin while Becker patients have some, and Duchenne typically presents in early childhood while Becker may not present until adolescence or adulthood",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both X-linked recessive disorders caused by mutations in the DMD gene. The key difference is that DMD patients completely lack dystrophin, leading to more severe symptoms, while BMD patients have a reduced amount (10%-40%) of normal dystrophin, resulting in milder symptoms",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystraphy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients have 10% to 40% of the normal amount.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both genetic disorders that affect muscle function. DMD is caused by a mutation in the dystrophin gene, which leads to a complete absence of the dystrophin protein. This results in progressive muscle weakness and wasting, typically starting in early childhood and leading to loss of ambulation by adolescence. BMD is also caused by a mutation in the dystrophin gene, but the resulting protein is partially functional rather than completely absent. As a result, symptoms of BMD tend to be milder and progress more slowly than those of DMD. Individuals with BMD may retain their ability to walk into adulthood, although they may experience muscle weakness and fatigue. Both conditions are diagnosed through genetic testing and can be managed with supportive care such as physical therapy and respiratory support. There is currently no cure for either condition, although ongoing research into gene therapies and other treatments offers hope for future interventions.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both X-linked recessive disorders caused by mutations of the DMD gene located at Xp21. The main difference between the two is that in DMD patients, dystrophin is virtually absent, while BMD patients have 10% to 40% of the normal amount. This leads to a more severe phenotype in DMD patients, who typically present with symptoms before age 5 and experience rapid disease progression resulting in loss of ambulation by their early teens. In contrast, BMD patients may not show symptoms until adolescence or adulthood and have a slower disease progression. Both conditions affect skeletal muscles, leading to muscle weakness and wasting, but can also impact cardiac and respiratory function. Treatment options for both conditions are limited, with current approaches focusing on managing symptoms and improving quality of life. However, ongoing research into gene therapy and other novel treatments offers hope for future interventions that could slow or even halt disease progression.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both X-linked recessive genetic disorders caused by mutations in the dystrophin gene. The primary difference between the two lies in the severity and progression of muscle weakness. DMD is more severe, with symptoms typically appearing in early childhood (around 2-5 years of age), leading to loss of ambulation by adolescence and a life expectancy into the late twenties or early thirties. In contrast, BMD has a milder clinical course, with symptoms manifesting later in life (usually during late childhood or adolescence), slower progression, and a longer life expectancy that may extend into middle age or beyond. The molecular basis for this difference is related to the nature of the mutations: DMD mutations result in complete absence or non-functionality of dystrophin protein, while BMD mutations allow for production of partially functional or reduced amounts of dystrophin. Consequently, individuals with BMD experience less severe muscle degeneration compared to those with DMD. Both conditions currently have no cure; however, treatment options focus on managing symptoms and improving quality of life through physical therapy, medications, and assistive devices.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both X-linked recessive disorders caused by mutations in the DMD gene located at Xp21. The primary difference between the two lies in the severity of symptoms and the amount of dystrophin protein present. In DMD patients, dystrophin is virtually absent, leading to more severe muscle weakness and a faster progression of the disease. On the other hand, BMD patients have 10% to 40% of the normal amount of dystrophin, resulting in milder symptoms and a slower disease progression compared to DMD."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35952340",
        "http://www.ncbi.nlm.nih.gov/pubmed/35220777",
        "http://www.ncbi.nlm.nih.gov/pubmed/36213707",
        "http://www.ncbi.nlm.nih.gov/pubmed/35530854"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 65,
          "text": "Lance Adams Syndrome After Hypoxic Cardiac Arrest: A Case Report.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35952340"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 131,
          "text": "Lance-Adams syndrome (chronic post-hypoxic myoclonus) is a rare syndrome occurring in patients after cardiopulmonary resuscitation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35952340"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Hypoxic myoclonus, also known as Lance Adams syndrome, is a rare syndrome that results from the serious brain damage caused by cerebral hypoxia that often follows cardiopulmonary resuscitation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35220777"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "Lance Adams syndrome is the term used to describe late post-hypoxic myoclonus. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36213707"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 254,
          "text": "Lance-Adams syndrome (LAS) is a rare complication of successful cardiopulmonary resuscitation, often accompanied by action myoclonus. Myoclonus may occur as generalized, focal, or multifocal movements and can include the face, trunk, and/or extremities. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35530854"
        }
      ],
      "body": "What is Lance-Adams syndrome?",
      "type": "summary",
      "id": "63f56dc533942b094c000001",
      "ideal_answer": [
        "Lance-Adams syndrome is a rare complication of successful cardiopulmonary resuscitation, often accompanied by action myoclonus. Myoclonus may occur as generalized, focal, or multifocal movements and can include the face, trunk, and/or extremities."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34987744",
        "http://www.ncbi.nlm.nih.gov/pubmed/31483964",
        "http://www.ncbi.nlm.nih.gov/pubmed/35417638",
        "http://www.ncbi.nlm.nih.gov/pubmed/35964609",
        "http://www.ncbi.nlm.nih.gov/pubmed/35988546",
        "http://www.ncbi.nlm.nih.gov/pubmed/35576529",
        "http://www.ncbi.nlm.nih.gov/pubmed/36124781",
        "http://www.ncbi.nlm.nih.gov/pubmed/31974203",
        "http://www.ncbi.nlm.nih.gov/pubmed/36260990",
        "http://www.ncbi.nlm.nih.gov/pubmed/34889443"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 348,
          "text": "Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. Mitapivat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744"
        },
        {
          "offsetInBeginSection": 112,
          "offsetInEndSection": 202,
          "text": "Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31483964"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 294,
          "text": "mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638"
        },
        {
          "offsetInBeginSection": 118,
          "offsetInEndSection": 347,
          "text": "Mitapivat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744"
        },
        {
          "offsetInBeginSection": 104,
          "offsetInEndSection": 332,
          "text": "In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35576529"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34987744"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 236,
          "text": "BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 490,
          "text": "tic anemia. In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency.METHODS: In this global, phase 3, randomized, placebo-controlled trial, we evaluated the efficacy and safety of mitapivat in adults with pyruvate kinase deficiency who were not receiving regular r",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 175,
          "text": "Kuo and colleagues1 evaluated the safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion-dependent α-thalassemia or β-thalassemia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36260990"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 186,
          "text": "Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31974203"
        },
        {
          "offsetInBeginSection": 853,
          "offsetInEndSection": 962,
          "text": "Mitapivat, a pyruvate kinase activator, represents a unique mechanism to mitigate ineffective erythropoiesis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34889443"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 477,
          "text": " We aimed to investigate the safety and efficacy of mitapivat (Agios Pharmaceuticals, Cambridge, MA, USA), a pyruvate kinase activator, in adults with non-transfusion-dependent (NTD) α-thalassaemia or NTD β-thalassaemia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35964609"
        },
        {
          "offsetInBeginSection": 754,
          "offsetInEndSection": 899,
          "text": "RT OPINION: Mitapivat is a first-in-class allosteric activator of pyruvate kinase and the first FDA-approved disease directed therapy for PKD. It",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36124781"
        },
        {
          "offsetInBeginSection": 121,
          "offsetInEndSection": 293,
          "text": " In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35417638"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "BACKGROUND: Mitapivat, an oral activator of pyruvate kinase (PK) in red blood cells (RBCs), has shown significant improvements in haemoglobin and haemolysis among patients with pyruvate kinase deficiency who were not receiving regular transfusions",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35988546"
        }
      ],
      "body": "What does mitapivat do?",
      "type": "summary",
      "id": "643def7057b1c7a31500003a",
      "ideal_answer": [
        "Mitapivat is a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemia",
        "Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. It has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruve kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate.",
        "Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme.  Mitapvat has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte Pyruvates kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate.",
        "Mitapivat (AG-348) is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. MitapivAT has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte Pyruvates (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate.",
        "Mitapivat is an investigational drug that inhibits the activity of dihydroorotate dehydrogenase (DHODH), an enzyme involved in the de novo pyrimidine biosynthesis pathway. It is being studied as a potential treatment for pyruvate kinase deficiency, a rare inherited metabolic disorder.",
        "Mitapivat is a novel, first-in-class oral small molecule allosteric activator of the pyruvate kinase enzyme. It has been shown to significantly upregulate both wild-type and numerous mutant forms of erythrocyte pyruvate kinase (PKR), increasing adenosine triphosphate (ATP) production and reducing levels of 2,3-diphosphoglycerate. It has been used for the treatment of hereditary hemolytic anemias, and has been shown to increase the hemoglobin level in patients with pyruvate kinase deficiency.",
        "Mitapivat is an oral drug that activates the pyruvate kinase enzyme, increasing ATP production and reducing levels of 2,3-diphosphoglycerate. It is used for the treatment of hereditary hemolytic anemias",
        "Mitapivat is an oral, first-in-class medication that activates the pyruvate kinase enzyme in red blood cells. This activation increases ATP production and reduces 2,3-diphosphoglycerate levels, ultimately helping to treat hereditary hemolytic anemias such as pyruvate kinase deficiency by increasing hemoglobin levels",
        "Mitapivat is an oral, small-molecule allosteric activator of pyruvate kinase in red cells."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35934590",
        "http://www.ncbi.nlm.nih.gov/pubmed/32209657",
        "http://www.ncbi.nlm.nih.gov/pubmed/24012761",
        "http://www.ncbi.nlm.nih.gov/pubmed/16755590",
        "http://www.ncbi.nlm.nih.gov/pubmed/15487932",
        "http://www.ncbi.nlm.nih.gov/pubmed/17671982",
        "http://www.ncbi.nlm.nih.gov/pubmed/18269733",
        "http://www.ncbi.nlm.nih.gov/pubmed/26543854",
        "http://www.ncbi.nlm.nih.gov/pubmed/33483546",
        "http://www.ncbi.nlm.nih.gov/pubmed/21690561",
        "http://www.ncbi.nlm.nih.gov/pubmed/12220896",
        "http://www.ncbi.nlm.nih.gov/pubmed/30635413"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 336,
          "text": "Coordinated gene expression allows spatiotemporal control of cellular processes and is achieved by the cotranscription/translation of functionally related genes/proteins. Prokaryotes evolved polycistronic messages (operons) to confer expression from a single promoter to efficiently cotranslate proteins functioning on the same pathway.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35934590"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 212,
          "text": "The arrangement of functionally-related genes in operons is a fundamental element of how genetic information is organized in prokaryotes. This organization ensures coordinated gene expression by co-transcription.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32209657"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 106,
          "text": "Clustering of functionally related genes in operons allows for coregulated gene expression in prokaryotes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24012761"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 124,
          "text": "Operons are clusters of genes that are transcribed as a single message, and regulated by the same gene expression machinery.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16755590"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Bacterial genes are commonly encoded in clusters, known as operons, which share transcriptional regulatory control and often encode functionally related proteins that take part in certain biological pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21690561"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "In prokaryotic genomes, related genes are frequently clustered in operons and higher-order arrangements that reflect functional context.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15487932"
        },
        {
          "offsetInBeginSection": 956,
          "offsetInEndSection": 1213,
          "text": " Genes in operons are located next to each other in the same DNA strand, and thus their presence should result in a higher proportion of predicted functional interactions among adjacent genes in the same strand than among adjacent genes in opposite strands.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671982"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "Genes that are part of the same operon in prokaryotes, or have the same expression pattern in eukaryotes, are transcriptionally co-regulated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12220896"
        },
        {
          "offsetInBeginSection": 809,
          "offsetInEndSection": 956,
          "text": "The presence of operons (polycistronic transcription units formed of functionally related genes) in prokaryotic genomes offers such an alternative.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17671982"
        }
      ],
      "type": "factoid",
      "body": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?",
      "id": "64371a4257b1c7a315000029",
      "ideal_answer": [
        "Prokaryotes often have functionally-related genes joined together under the direction of a single promoter. These structures are called operons. Clustering of functionally-related genes in operons allows for coordinated gene expression and spatiotemporal control of cellular processes.",
        "In prokaryotes, functionally related genes are often arranged in operons, which are polycistronic messages transcribed from a single promoter. This organization allows for coordinated gene expression and efficient cotranslation of proteins involved in the same pathway. Operons can be regulated by the same regulatory machinery, ensuring that all genes within an operon are coregulated. The clustering of functionally related genes in operons is a fundamental element of how genetic information is organized in prokaryotes and plays a crucial role in their ability to adapt to changing environments. Overall, operons provide a mechanism for spatiotemporal control of cellular processes and allow prokaryotes to efficiently coordinate gene expression.",
        "In prokaryotes, functionally related genes that are positioned adjacent to each other in the genome and under the control of the same regulatory machinery are called operons. Operons are a unique feature of prokaryotic gene organization, allowing for coordinated expression of multiple genes involved in a specific metabolic pathway or cellular process. An operon typically consists of a promoter region, an operator site, and a cluster of functionally related genes. The promoter region is where RNA polymerase binds to initiate transcription, while the operator site serves as a binding location for regulatory proteins called repressors or activators. These regulatory proteins modulate gene expression by either inhibiting or promoting transcription based on environmental conditions or cellular needs. One well-known example of an operon is the lac operon in Escherichia coli, which regulates lactose metabolism in response to glucose availability. Overall, operons provide an efficient mechanism for prokaryotes to regulate gene expression and adapt to changing environments.",
        "In prokaryotes, functionally related genes are often organized into operons. Operons are clusters of adjacent genes that are transcribed together under the control of a single promoter, allowing for coordinated gene expression and efficient co-translation of proteins involved in the same cellular pathway. This organization is a fundamental element of how genetic information is arranged in prokaryotes and ensures that coregulated gene expression occurs through co-transcription. The arrangement of functionally-related genes in operons provides spatiotemporal control over cellular processes, contributing to the overall regulation and efficiency of prokaryotic gene expression."
      ],
      "exact_answer": [
        [
          "Operons"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35868358"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "Drug delivery to the suprachoroidal space (SCS®) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE®), administered via a microneedle-based device, the SCS Microinjector®. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35868358"
        }
      ],
      "body": "What is the active ingredient of Xipere?",
      "type": "factoid",
      "id": "6440377c57b1c7a315000049",
      "ideal_answer": [
        "The active ingredient of Xipere is triamcinolone acetonide."
      ],
      "exact_answer": [
        [
          "triamcinolone acetonide"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35359537",
        "http://www.ncbi.nlm.nih.gov/pubmed/35897138",
        "http://www.ncbi.nlm.nih.gov/pubmed/33531685",
        "http://www.ncbi.nlm.nih.gov/pubmed/33101180",
        "http://www.ncbi.nlm.nih.gov/pubmed/29771942",
        "http://www.ncbi.nlm.nih.gov/pubmed/30544634",
        "http://www.ncbi.nlm.nih.gov/pubmed/27009627"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 889,
          "offsetInEndSection": 956,
          "text": "Distal hotspot exons 47, 48 and 50 were the commonly deleted exons.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35359537"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 149,
          "text": "Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35897138"
        },
        {
          "offsetInBeginSection": 1662,
          "offsetInEndSection": 1803,
          "text": "We confirmed that del45-55 segregates a high proportion of benign phenotypes, severe cases, and isolated cardiac and cognitive presentations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35897138"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 285,
          "text": "In particular, exons 45-52 constitute a hotspot for DMD mutations. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33531685"
        },
        {
          "offsetInBeginSection": 1099,
          "offsetInEndSection": 1238,
          "text": "An exon deletion hotspot, located in exons 45-54, was observed in DMD, and intron 44 was the most frequent deletion starting point (26.5%).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33101180"
        },
        {
          "offsetInBeginSection": 383,
          "offsetInEndSection": 563,
          "text": "In-frame exon skipping of dystrophin exons 45-55 represents a significant approach to treating DMD, as a large proportion of patients harbor mutations within this \"hotspot\" region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29771942"
        },
        {
          "offsetInBeginSection": 783,
          "offsetInEndSection": 1045,
          "text": "Here, we provide an update on DMD genotype-phenotype associations using a global DMD database and further provide the rationale for multiple exon skipping development, particularly for exons 45⁻55 skipping and an emerging therapeutic concept, exons 3⁻9 skipping.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30544634"
        },
        {
          "offsetInBeginSection": 494,
          "offsetInEndSection": 649,
          "text": " A deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene was detected, and dystrophin protein expression was ∼15% that of control level.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009627"
        }
      ],
      "body": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?",
      "type": "list",
      "id": "64163568690f196b5100001b",
      "ideal_answer": [
        "The most common mutation locations in DMD gene are exons 3-9 and 45-55.",
        "Distal hotspot exons 47, 48 and 50 were the commonly deleted exons. Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients An exon deletion hotspot, located in exons 45-54, was observed in DMD, and intron 44 was the most frequent deletion starting point (26.5%).",
        "The location of mutations in the dystrophin gene varies between individuals with Duchenne muscular dystrophy. However, some regions of the dystrophin gene have been identified as being more frequently associated with mutations than others. These include the 5\u0027 end of the gene, which contains important regulatory elements; the central rod domain; and the carboxyterminal region, which provides structural support to the sarcolemma. ",
        "The majority of mutations detected in the dystrophin gene occur at specific sites called mutational hot spots, which can vary between individuals. The most frequently mutated site is located near the end of exon 46 and accounts for around 60–70% of all mutations identified in affected individuals. Other important mutational hotspots include positions 45, 49 and 52, but these account for fewer than 10% of all mutations.",
        "The most common mutation locations in dystrophin gene in Duchenne muscular dystrophy include deletion of dystrophin exon 3a (DYS3A), deletion of dystrophin exon 4 (DYS4), deletion of dystrophin exon 7 (DYS7), duplication of dystrophin exon 8 (DYS8), duplications of dystrophin Exon 10 (DYS10), point mutations, insertions, and splice site variants.",
        "Distal hotspot exons 47, 48 and 50 were the commonly deleted exons. Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients We confirmed that del45-55 segregates a high proportion of benign phenotypes, severe cases, and isolated cardiac and cognitive presentations.",
        "The most common mutation locations in dystrophin gene in Duchenne muscular dystrophy are the distal hotspot exons, specifically exons 47, 48, and 50. Additionally, mutations in the proximal portion of the gene not involving Dp140 have been found to be less severe. Duplications spanning one or more exons are also a common cause of the disease.",
        "The most common mutation locations in the dystrophin gene in Duchenne muscular dystrophy are exon 51, exon 45, exon 44, exon 43, and exon 50.",
        "The most common mutation locations in the dystrophin gene in Duchenne muscular dystrophy are exon deletions, exon duplications, and point mutations. These mutations are typically located in exons 45-55, which encode the rod domain of the dystrophin protein.",
        "The most common mutation locations in the dystrophin gene in Duchenne muscular dystrophy are exons 45-54, which constitute a hotspot for DMD mutations, and exons 3-9, which encompass a mutational hot spot. Distal hotspot exons 47, 48 and 50 are also commonly deleted.",
        "Distal hotspot exons 47, 48 and 50 were the commonly deleted exons. Duchenne muscular dystrophy (DMD) exon 45-55 deletion (del45-55) has been postulated as a model that could treat up to 60% of DMD patients In particular, exons 45-52 constitute a hotspot for DMD mutations.",
        "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophyDuchenne muscular dystrophy (DMD) is an Xlinked recessive disorder caused by mutations in the dystrophin gene. The aim of this study was to determine the most common mutation locations in the dystrophin gene in Iranian patients with DMD. In this crosssectional study the dystrophin gene was screened for mutations using multiplex ligationdependent probe amplification (MLPA) and Sanger sequencing. A total of 50 patients with DMD were included in this study. The most common mutation location in the dystrophin gene in Iranian patients with DMD was exons 4547 (28). The second most common mutation location in the dystrophin gene in Iranian patients with DMD was exons 23 (20). The third most common mutation location in the dystrophin gene in Iranian patients with DMD was exons 12 (16). The fourth most common mutation location in the dystrophin gene in Iranian patients with DMD was exons 34 (12). The fifth most common mutation location in the dystrophin gene in Iranian patients with DMD was exons 56 (8). The sixth most common mutation location in the dystrophin gene in Iranian patients with DMD was exons 78 (8). The seventh most common mutation location in the dystrophin gene in Iranian patients with DMD",
        "The most common mutation locations in the dystrophin gene in Duchenne muscular dystrophy are within exons 45-55, which is considered a hotspot region for mutations.",
        "The most common mutation locations in the dystrophin gene in Duchenne muscular dystrophy are found in the exons 45-55 region, particularly exons 45-52. Additionally, exons 47, 48, and 50 are commonly deleted.",
        "An exon deletion hotspot, located in exons 45-54, was observed in DMD, and intron 44 was the most frequent deletion starting point (26.5%).",
        "Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, with exons 45-55 being a hotspot for deletions. Specifically, exons 47, 48, and 50 are commonly deleted. Intron 44 is the most frequent deletion starting point (26.5%). In-frame exon skipping of exons 45-55 represents a significant approach to treating DMD, as a large proportion of patients harbor mutations within this \"hotspot\" region. Multiple exon skipping development, particularly for exons 45-55 skipping and an emerging therapeutic concept, exons 3-9 skipping, are being explored. A deletion of exons 3-9 encompassing a mutational hotspot in the DMD gene was detected in some cases. Overall, these findings highlight the importance of understanding the mutation locations in the dystrophin gene for developing effective treatments for DMD patients.",
        "Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by mutations in the dystrophin gene, which is one of the largest human genes. The most common mutation locations in the dystrophin gene associated with DMD are large deletions, accounting for approximately 60-70% of cases. These deletions typically occur within two hotspots: one spanning exons 45-55 and another encompassing exons 2-20. The exon 45-55 deletion hotspot is particularly prevalent, as it represents around 80% of all deletion events. In addition to large deletions, duplications account for about 10% of DMD cases, while small mutations such as point mutations or small insertions/deletions make up the remaining 20-30%. Notably, these mutations often lead to a disruption of the open reading frame, resulting in a nonfunctional or truncated dystrophin protein that compromises muscle fiber stability and function. Early identification of specific mutation locations can help guide therapeutic strategies and inform prognosis for individuals affected by DMD.",
        "The most common mutation locations in the dystrophin gene in Duchenne muscular dystrophy (DMD) are found within specific hotspots. One major hotspot is located in exons 45-55, with exon deletions in this region potentially treatable for up to 60% of DMD patients. In particular, exons 45-52 constitute a significant portion of DMD mutations. Another deletion hotspot is observed in exons 45-54, where intron 44 is the most frequent deletion starting point (26.5%). In-frame exon skipping of dystrophin exons 45-55 represents a significant therapeutic approach for DMD due to the large proportion of patients harboring mutations within this region. Additionally, distal hotspot exons 47, 48, and 50 are commonly deleted exons. An emerging therapeutic concept involves skipping exons 3-9, as a deletion encompassing this mutational hotspot has been detected with dystrophin protein expression at approximately 15% of control levels."
      ],
      "exact_answer": [
        [
          "exon 45-55",
          "exon 45-54",
          "exon 45-52",
          "exons 47, 48 and 50"
        ],
        [
          "exons 3-9",
          "exon 3"
        ],
        [
          "exon 3"
        ],
        [
          "exon 4"
        ],
        [
          "exon 5"
        ],
        [
          "exon 6"
        ],
        [
          "exon 7"
        ],
        [
          "exon 8"
        ],
        [
          "exon 9"
        ],
        [
          "exon 45"
        ],
        [
          "exon 51"
        ],
        [
          "exon 44"
        ],
        [
          "exon 47"
        ],
        [
          "exon 48"
        ],
        [
          "exon 49"
        ],
        [
          "exon 50"
        ],
        [
          "exon 51"
        ],
        [
          "exon 55"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35729475",
        "http://www.ncbi.nlm.nih.gov/pubmed/35801871",
        "http://www.ncbi.nlm.nih.gov/pubmed/35773051",
        "http://www.ncbi.nlm.nih.gov/pubmed/36385359"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 780,
          "offsetInEndSection": 923,
          "text": "RESULTS: Seven infants were diagnosed with SCID, yielding an incidence of 1 in 22,819 live births. Four of these infants had Artemis-type SCID.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35729475"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 426,
          "text": "Artemis deficiency disrupts development of adaptive immunity and leads to radiosensitive T- B- severe combined immunodeficiency (RS-SCID).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35801871"
        },
        {
          "offsetInBeginSection": 507,
          "offsetInEndSection": 667,
          "text": "Encouraging data for X-SCID and preclinical work for Artemis-SCID and RAG1-SCID are paving the way for the therapy to become a viable curative treatment option.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35773051"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 350,
          "text": "Pathogenic variants in DCLRE1C encoding Artemis cause T-B-NK+ severe combined immunodeficiency (SCID), and patients with Artemis-deficient SCID (ART-SCID) require definitive therapy with allogeneic hematopoietic cell transplantation (HCT).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36385359"
        }
      ],
      "body": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?",
      "type": "yesno",
      "id": "63ee5eeaf36125a426000002",
      "ideal_answer": [
        "Artemis mutation disrupts development of adaptive immunity and leads to severe combined immunodeficiency."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35322347",
        "http://www.ncbi.nlm.nih.gov/pubmed/8757902",
        "http://www.ncbi.nlm.nih.gov/pubmed/30646728",
        "http://www.ncbi.nlm.nih.gov/pubmed/23542331",
        "http://www.ncbi.nlm.nih.gov/pubmed/23583003",
        "http://www.ncbi.nlm.nih.gov/pubmed/12508671",
        "http://www.ncbi.nlm.nih.gov/pubmed/31345362",
        "http://www.ncbi.nlm.nih.gov/pubmed/22774841",
        "http://www.ncbi.nlm.nih.gov/pubmed/24266916",
        "http://www.ncbi.nlm.nih.gov/pubmed/8984578",
        "http://www.ncbi.nlm.nih.gov/pubmed/34341141",
        "http://www.ncbi.nlm.nih.gov/pubmed/34289020",
        "http://www.ncbi.nlm.nih.gov/pubmed/17505988",
        "http://www.ncbi.nlm.nih.gov/pubmed/9093597",
        "http://www.ncbi.nlm.nih.gov/pubmed/22098612",
        "http://www.ncbi.nlm.nih.gov/pubmed/33573009",
        "http://www.ncbi.nlm.nih.gov/pubmed/36381061",
        "http://www.ncbi.nlm.nih.gov/pubmed/11787982",
        "http://www.ncbi.nlm.nih.gov/pubmed/21886393",
        "http://www.ncbi.nlm.nih.gov/pubmed/8114295",
        "http://www.ncbi.nlm.nih.gov/pubmed/33175593",
        "http://www.ncbi.nlm.nih.gov/pubmed/25704483"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 261,
          "text": "Wilson\u0027s disease (WD), an inherited disorder of copper metabolism that mostly affects the liver and brain;",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35322347"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Wilsons disease is a rare autosomal recessive disorder of copper transportation, which is fatal if not treated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8757902"
        },
        {
          "offsetInBeginSection": 398,
          "offsetInEndSection": 570,
          "text": "Wilsons disease and idiopathic toxicosis are examples of severe chronic liver diseases that are the results of genetic predisposition to the hepatic accumulation of copper.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30646728"
        },
        {
          "offsetInBeginSection": 19,
          "offsetInEndSection": 116,
          "text": "Wilson disease is a genetic copper storage disorder that causes hepatic and neurologic symptoms. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542331"
        },
        {
          "offsetInBeginSection": 483,
          "offsetInEndSection": 536,
          "text": "Wilson\u0027s disease represents a copper storage disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984578"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 130,
          "text": "Hereditary hemochromatosis and Wilson disease are autosomal recessive storage disorders of iron and copper overload, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24266916"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 224,
          "text": "Hereditary deposition of iron (primary haemochromatosis) or copper (Wilson\u0027s disease) are autosomal recessive metabolic disease characterized by progressive liver pathology and subsequent involvement of various other organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17505988"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "OBJECTIVES: Wilson\u0027s disease (WD) is a metabolic disorder leading to hepatic and extrahepatic copper",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31345362"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 73,
          "text": "Wilson\u0027s disease (WD) is a rare hereditary disorder of copper metabolism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33555495"
        },
        {
          "offsetInBeginSection": 748,
          "offsetInEndSection": 884,
          "text": "Wilson\u0027s disease, a copper storage disorder, in which biliary copper excretion is reduced, is inherited as an autosomal recessive trait.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12508671"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "BACKGROUND \u0026 AIMS: Wilson disease is a genetic copper storage disorder that causes hepatic and n",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23542331"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 156,
          "text": "UNLABELLED: Wilson disease (WD) is a rare inherited disorder of copper metabolism, which can lead to severe liver failure and to a variety of neuropsychiatr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22098612"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 206,
          "text": "Wilson disease (WD) (OMIM# 277900) is an autosomal recessive inherited disorder characterized by excess copper (Cu) storage in different human tissues, such as the brain, liver, and the corneas of the eyes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33573009"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "UNLABELLED: Wilson\u0027s disease (WND) and hereditary hemochromatosis (HH) are two metal loading diseases of copper and iron, respectively, and are both recessivel",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22774841"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "Wilson\u0027s disease is an autosomal recessive inherited disease with congenital copper metabolism disorder, characterized by decreased ceruloplasmin and increased urine copper, which can involve multiple organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36381061"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 176,
          "text": "Wilson\u0027s disease is an autosomal recessive disease of copper metabolism which is widely recognized as a disease occurring clinically in children, adolescents, and young adults.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8229372"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 110,
          "text": "Hereditary copper-associated hepatitis in dogs resembles Wilson\u0027s disease, a copper storage disease in humans.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583003"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Wilson\u0027s disease is a rare inherited disorder of copper metabolism causing severe damage to vital organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21886393"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Inherited copper toxic disease, Wilson\u0027s disease, is an autosomal recessive disorder arising from a defect in biliary copper excretion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9093597"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "Wilson\u0027s disease is a genetic disorder of copper metabolism with a hepatic or neurologic presentation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14738953"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 81,
          "text": "Wilson\u0027s disease is an autosomal recessive disease of abnormal copper metabolism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30271060"
        },
        {
          "offsetInBeginSection": 579,
          "offsetInEndSection": 683,
          "text": " Hemochromatosis and Wilson\u0027s disease are known as iron and copper accumulation disorders, respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8114295"
        },
        {
          "offsetInBeginSection": 482,
          "offsetInEndSection": 536,
          "text": " Wilson\u0027s disease represents a copper storage disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984578"
        },
        {
          "offsetInBeginSection": 796,
          "offsetInEndSection": 904,
          "text": " In the new paradigm, Wilson\u0027s disease is seen as a hereditary disorder associated with copper intoxication.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16466879"
        },
        {
          "offsetInBeginSection": 434,
          "offsetInEndSection": 584,
          "text": "ve determination of elevated liver iron content. Wilson\u0027s disease represents a copper storage disease. Prominent clinical features are hepatomegaly an",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8984578"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Wilson\u0027s disease is an autosomal recessive disorder in which the liver does not properly release copper into bile, resulting in prominent copper accumulation in various tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25704483"
        },
        {
          "offsetInBeginSection": 337,
          "offsetInEndSection": 498,
          "text": "Wilson\u0027s disease is one such hereditary disease that creates chaos in tissues, usually the brain and liver, via deposition of abnormal amounts of copper in them.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28168129"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Wilson\u0027s disease is rare autosomal-recessive disorder originated on the basis of metabolic copper over-storage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1306026"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "Wilson\u0027s disease is an autosomal-recessive disorder of copper metabolism caused by mutations in ATP7B and associated with neurological, psychiatric, ophthalmological and hepatic manifestations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34341141"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "PROJECT: Wilson\u0027s disease (WD) is an inherited disorder of copper metabolism characterised by juvenile liver cirrhosis and by neurological symptoms",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11787982"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 78,
          "text": "OBJECTIVE: Wilson\u0027s disease (WD) is a hereditary disorder of copper metabolism",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33175593"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Wilson\u0027s disease is an autosomal-recessive disorder of copper metabolism with neurological and hepatic presentations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34289020"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 121,
          "text": "Wilson\u0027s disease is an inherited disorder associated with copper accumulation in the liver, brain and other vital organs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32738633"
        }
      ],
      "body": "Is Wilson\u0027s disease described as an iron storage disease?",
      "type": "yesno",
      "id": "640c821c201352f04a000023",
      "ideal_answer": [
        "Wilson\u0027s disease is a rare inherited disorder that causes copper to accumulate in your liver, brain and other vital organs.",
        "Yes. Wilson disease is a copper storage disease caused by mutations in ATP7B, which leads to excessive copper accumulation throughout the body. This excess metal results in damage to various organs such as the liver and brain, causing severe neurological problems and ultimately requiring lifelong chelation therapy.",
        "Yes, Wilson\u0027s Disease is characterized by excessive accumulation of copper due to impaired transport or decreased metabolism of Cu2+. This results in disruption of vital organs such as the liver and brain leading to symptoms like neurological damage, pigment abnormalities, pancytopenia and even death if left untreated.",
        "Wilson\u0027s disease is a genetic copper storage disorder that causes hepatic and neurologic symptoms.",
        "No, Wilson\u0027s disease is not described as an iron storage disease. It is an inherited disorder that affects the body\u0027s ability to regulate copper.",
        "No, Wilson\u0027s disease is an autosomal recessive disorder caused by a mutation in the ATP7B gene, which leads to an accumulation of copper in the body. It is not an iron storage disease.",
        "No, Wilson\u0027s disease is a copper storage disorder, not an iron storage disorder.",
        "No, Wilson\u0027s disease is not an iron storage disease. It is a copper storage disorder that affects the liver and brain.",
        "Wilson disease is a genetic copper storage disorder that causes hepatic and neurologic symptoms."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18436437",
        "http://www.ncbi.nlm.nih.gov/pubmed/31750297",
        "http://www.ncbi.nlm.nih.gov/pubmed/36192696",
        "http://www.ncbi.nlm.nih.gov/pubmed/35379293",
        "http://www.ncbi.nlm.nih.gov/pubmed/27557757",
        "http://www.ncbi.nlm.nih.gov/pubmed/35533969",
        "http://www.ncbi.nlm.nih.gov/pubmed/33488763",
        "http://www.ncbi.nlm.nih.gov/pubmed/22392219",
        "http://www.ncbi.nlm.nih.gov/pubmed/33227813",
        "http://www.ncbi.nlm.nih.gov/pubmed/33958766",
        "http://www.ncbi.nlm.nih.gov/pubmed/24503515",
        "http://www.ncbi.nlm.nih.gov/pubmed/23080252",
        "http://www.ncbi.nlm.nih.gov/pubmed/23020586",
        "http://www.ncbi.nlm.nih.gov/pubmed/12948648",
        "http://www.ncbi.nlm.nih.gov/pubmed/24467902",
        "http://www.ncbi.nlm.nih.gov/pubmed/25934543",
        "http://www.ncbi.nlm.nih.gov/pubmed/36377861",
        "http://www.ncbi.nlm.nih.gov/pubmed/17130462"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 204,
          "text": "A promoter is a short region of DNA (100-1,000 bp) where transcription of a gene by RNA polymerase begins. It is typically located directly upstream or at the 5\u0027 end of the transcription initiation site. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31750297"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 531,
          "text": "The RNA polymerase II core promoter is generally defined to be the sequence that directs the initiation of transcription. This simple definition belies a diverse and complex transcriptional module. There are two major types of core promoters - focused and dispersed. Focused promoters contain either a single transcription start site or a distinct cluster of start sites over several nucleotides, whereas dispersed promoters contain several start sites over 50-100 nucleotides and are typically found in CpG islands in vertebrates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18436437"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "A promoter is a region in the DNA sequence that defines where the transcription of a gene by RNA polymerase initiates, which is typically located proximal to the transcription start site (TSS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33227813"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "Promoters are crucial for gene regulation. They vary greatly in terms of associated regulatory elements, sequence motifs, the choice of transcription start sites and other features.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22392219"
        },
        {
          "offsetInBeginSection": 253,
          "offsetInEndSection": 710,
          "text": "Similarly, promoters are modular. They consist of combinations of cis-acting elements that are the binding sites for transcription factors. It is this promoter architecture that largely determines the expression pattern of a gene. The modular nature of promoters is supported by the observation that many cis-acting elements retain their activities when they are taken out of their native promoter context and used as building blocks in synthetic promoters.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27557757"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 252,
          "text": "The main function of gene promoters appears to be the integration of different gene products in their biological pathways in order to maintain homeostasis. Generally, promoters have been classified in two major classes, namely TATA and CpG.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23020586"
        }
      ],
      "body": "What are promoters?",
      "type": "summary",
      "id": "643c9b4057b1c7a315000032",
      "ideal_answer": [
        "A promoter is generally defined to be the sequence that directs the initiation of transcription. This simple definition belies a diverse and complex transcriptional module. There are two major types of core promoters - focused and dispersed. Focused promoters contain either a single transcription start site or a distinct cluster of start sites over several nucleotides, whereas dispersed promoters contain several start sites over 50-100 nucleotides.\n\nIn summary, promoters are short regions of DNA (100-1,000 bp) where transcription by RNA polymerase begins. They are typically located directly upstream or at the 5\u0027 end of the transcription initiation site.",
        "Promoters are short regions of DNA (100-1,000 bp) located upstream or at the 5\u0027 end of the transcription initiation site. They are responsible for directing the initiation of transcription by RNA polymerase II and can be either focused or dispersed. Focused promoters contain either a single transcription start site or a distinct cluster of start sites over several nucleotides, while dispersed promoters contain several start sites over 50-100 nucleotides and are typically found in CpG islands in vertebrates.",
        "Promoters are short regions of DNA, typically ranging from 100 to 1,000 base pairs, that play a crucial role in gene transcription by serving as the binding site for RNA polymerase. They are usually located directly upstream or at the 5\u0027 end of the transcription initiation site. The RNA polymerase II core promoter is responsible for directing the initiation of transcription and can be classified into two major types: focused and dispersed. Focused promoters contain either a single transcription start site or a distinct cluster of start sites spanning several nucleotides, while dispersed promoters feature multiple start sites spread across 50-100 nucleotides and are commonly found in CpG islands in vertebrates."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34573098"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 690,
          "offsetInEndSection": 853,
          "text": "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NFκB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098"
        }
      ],
      "body": "Is omaveloxolone an activator of NFkB?",
      "type": "yesno",
      "id": "6440084357b1c7a31500003e",
      "ideal_answer": [
        "No, omaveloxolone is an inhibitor of NFκB."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35626783",
        "http://www.ncbi.nlm.nih.gov/pubmed/33904220",
        "http://www.ncbi.nlm.nih.gov/pubmed/35628840",
        "http://www.ncbi.nlm.nih.gov/pubmed/34599744",
        "http://www.ncbi.nlm.nih.gov/pubmed/35361254"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 634,
          "offsetInEndSection": 736,
          "text": " Face, leg, activity, cry, and consolability (FLACC) scores for postoperative pain were also assessed.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35626783"
        },
        {
          "offsetInBeginSection": 994,
          "offsetInEndSection": 1051,
          "text": "The FLACC and COMFORT scales were utilized to assess pain",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33904220"
        },
        {
          "offsetInBeginSection": 683,
          "offsetInEndSection": 862,
          "text": "Postoperative pain was assessed using the Visual Analogue Scale (VAS), the Wong-Baker Faces Pain Rating Scale, and the Face, Legs, Activity, Cry, and Consolability (FLACC) scale. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35628840"
        },
        {
          "offsetInBeginSection": 656,
          "offsetInEndSection": 791,
          "text": "The pain experience (intense, moderate, or mild) was evaluated by the Face, Legs, Activity, Cry, Consolability-revised scale (FLACC-r).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34599744"
        },
        {
          "offsetInBeginSection": 1301,
          "offsetInEndSection": 1508,
          "text": " Daily assessment and documentation for pain (81%) and sedation (87%) was reported by most of the PICUs, using the preferred validated FLACC scale (54%) and the COMFORT Behavioural scale (48%), respectively.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35361254"
        }
      ],
      "body": "What is the most commonly used pain scale for the measurement of pain in children?",
      "type": "factoid",
      "id": "6441057657b1c7a315000052",
      "ideal_answer": [
        "The most pain scale used to measure pain in children is FLACC (Face, leg, activity, cry, and consolability) score.",
        "The Faces Pain Scale (FPS) is one of the most commonly used scales for measuring pain in children.",
        "The Faces Pain Scale - Revision (FPS-R) is the most frequently used pain scale for measuring pain in children.",
        "The Faces Pain Scale-Revised (FPS-R) is the most commonly used pain scale for measuring pain in children due to its ease of use, validation among multiple populations, and its ability to capture changes over time.",
        "Numerous faces scales have been developed for the measurement of pain intensity in children. one of the most used scales for the evaluation of children\u0027s pain is the CHEOPS.",
        "The most commonly used pain scale for the measurement of pain in children is the Face, Legs, Activity, Cry, and Consolability (FLACC) scale.",
        "Face, leg, activity, cry, and consolability (FLACC) pain scale is used for postoperative pain assessment in children.",
        "The most commonly used pain scale for the measurement of pain in children is the Faces Pain Scale-Revised (FPS-R).",
        "The most commonly used pain scale for the measurement of pain in children is the Face, Legs, Activity, Cry, and Consolability (FLACC) scale. This scale is reported to be used by 54% of pediatric intensive care units (PICUs) for daily assessment and documentation of pain.",
        "The most commonly used pain scale for measuring pain in children is the Faces, Legs, Activity, Cry, Consolability (FLACC) scale.",
        "The FLACC and COMFORT scales were utilized to assess pain",
        "The most commonly used pain scale for the measurement of pain in children is the Wong-Baker FACES Pain Rating Scale. This scale uses a series of faces with different expressions to help children describe their level of pain. The faces range from a happy face (no hurt) to a crying face (hurts worst). The child is asked to choose the face that best represents how they are feeling. The Wong-Baker FACES Pain Rating Scale has been found to be reliable and valid for use in children as young as three years old, and it has been translated into multiple languages. Other pain scales that may be used in children include the Numeric Rating Scale, which asks the child to rate their pain on a scale from 0-10, and the Visual Analog Scale, which uses a line with endpoints labeled \"no pain\" and \"worst possible pain\" for the child to mark where their pain falls on the line. However, the Wong-Baker FACES Pain Rating Scale remains the most widely used and recommended pain scale for children due to its ease of use and ability to accurately capture a child\u0027s subjective experience of pain.",
        "The Face, Legs, Activity, Cry, and Consolability (FLACC) scale is the most commonly used pain scale for measuring pain in children. This was reported by 54% of PICUs who documented daily assessment and documentation for pain. The FLACC scale assesses five categories of behavior: facial expression, leg movement, activity level, cry, and consolability. It has been validated for use in children aged 2 months to 7 years old and is considered a reliable tool for assessing postoperative pain in this population. Other scales such as the COMFORT Behavioral Scale were also utilized but less frequently than the FLACC scale. Overall, the FLACC scale appears to be widely accepted as a valid and reliable tool for measuring pain in children.",
        "The most commonly used pain scale for the measurement of pain in children is the Faces Pain Scale-Revised (FPS-R). The FPS-R is a self-report tool that consists of six facial expressions representing increasing levels of pain intensity, ranging from 0 (no pain) to 10 (worst possible pain). This scale has been validated for use in children aged 4-16 years and is widely employed due to its simplicity, ease of administration, and ability to accommodate various developmental stages. The FPS-R allows children to communicate their pain level by selecting the face that best represents their current experience. It has demonstrated good reliability, validity, and responsiveness across diverse pediatric populations and settings, including postoperative care, emergency departments, and chronic pain management. Additionally, it has been translated into multiple languages and adapted for use with different cultural backgrounds.",
        "The Face, Legs, Activity, Cry, and Consolability (FLACC) scale is a commonly used pain assessment tool for measuring pain in children. It has been utilized in various clinical settings, including postoperative pain assessment and pediatric intensive care units (PICUs). The FLACC scale evaluates five categories: facial expression, leg movement, activity level, crying, and consolability. Each category is scored from 0 to 2, resulting in a total score ranging from 0 (no pain) to 10 (severe pain). In addition to the FLACC scale, other pain assessment tools like the Visual Analogue Scale (VAS), Wong-Baker Faces Pain Rating Scale, and COMFORT scales are also used for evaluating pediatric pain. However, the FLACC scale remains a preferred choice due to its simplicity and effectiveness in assessing pain in children who may have difficulty expressing their discomfort verbally."
      ],
      "exact_answer": [
        [
          "FLACC",
          "Face, leg, activity, cry, and consolability",
          "COMFORT Behavioural scale",
          "Faces Pain Scale - Revised",
          "FPS-R",
          "FLACC-r"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35426136",
        "http://www.ncbi.nlm.nih.gov/pubmed/36473030",
        "http://www.ncbi.nlm.nih.gov/pubmed/35306405",
        "http://www.ncbi.nlm.nih.gov/pubmed/35298826"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 217,
          "offsetInEndSection": 363,
          "text": "Here, we examined driving performance following administration of daridorexant, a new dual orexin receptor antagonist developed to treat insomnia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35426136"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 91,
          "text": "Daridorexant is a novel dual orexin receptor antagonist used in treating insomnia disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36473030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 173,
          "text": "Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 276,
          "text": "BACKGROUND: The dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and nocturnal oxygen saturation (SpO2) and improved sleep in patients with mild to moderate obstructive sleep apnea (OSA). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35306405"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Daridorexant (Quviviq™; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35298826"
        }
      ],
      "body": "What is the mechanism of action of daridorexant?",
      "type": "summary",
      "id": "6402c71f201352f04a00000a",
      "ideal_answer": [
        "Daridorexant is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist that is being developed for the treatment of insomnia."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35266155",
        "http://www.ncbi.nlm.nih.gov/pubmed/36174069"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 139,
          "offsetInEndSection": 327,
          "text": "We utilised a novel DILI causality assessment tool (DILI-CAT), which uses drug-specific liver injury phenotypes, to examine potential DILI in early phase ximelagatran clinical development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35266155"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35266155"
        },
        {
          "offsetInBeginSection": 1633,
          "offsetInEndSection": 1808,
          "text": "DILI-CAT, a clinically intuitive, data-driven, computer-assisted scoring algorithm, is a useful tool for early detection of drug\u0027s hepatotoxicity in clinical drug development.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35266155"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 102,
          "text": "A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36174069"
        }
      ],
      "body": "What is DILI-CAT used for?",
      "type": "factoid",
      "id": "64257c9c690f196b5100004b",
      "ideal_answer": [
        "DILI-CAT, ia a clinically intuitive, data-driven, computer-assisted scoring algorithm and is a useful tool for early detection of drug\u0027s hepatotoxicity in clinical drug development.",
        "We utilised a novel DILI causality assessment tool (DILICAT) which uses drugspecific liver injury phenotypes to examine potential DILI in early phase ximelagatran clinical development.A novel p",
        "The DILI-CAT is a novel computer-assisted drug induced liver injury causality assessment tool designed to help differentiate drugs causing severe liver injuries from those causing mild or moderate liver damage.",
        "DILI-CAT, a novel phenotype-based drug-induced liver injury causality assessment tool, is a useful tool for early detection of drug\u0027s hepatotoxicity in clinical drug development.",
        "DILI-CAT is a web-based tool used to assess the risk of drug-induced liver injury (DILI) in clinical trials. It uses a combination of clinical and laboratory parameters to predict the risk of DILI.",
        "DILI-CAT is a clinically intuitive, data-driven, computer-assisted scoring algorithm used for early detection of drug\u0027s hepatotoxicity in clinical drug development. It is a novel phenotype-based drug-induced liver injury causality assessment tool that allows for signal confirmation in early drug development.",
        "DILI-CAT, a clinically intuitive, data-driven, computer-assisted scoring algorithm, is a useful tool for early detection of drug\u0027s hepatotoxicity in clinical drug development."
      ],
      "exact_answer": [
        [
          "Drug induced hepatotoxicity scoring algorithm"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33077007",
        "http://www.ncbi.nlm.nih.gov/pubmed/35186791",
        "http://www.ncbi.nlm.nih.gov/pubmed/33029620",
        "http://www.ncbi.nlm.nih.gov/pubmed/33089317",
        "http://www.ncbi.nlm.nih.gov/pubmed/33049331",
        "http://www.ncbi.nlm.nih.gov/pubmed/33626020",
        "http://www.ncbi.nlm.nih.gov/pubmed/32782867",
        "http://www.ncbi.nlm.nih.gov/pubmed/35470069",
        "http://www.ncbi.nlm.nih.gov/pubmed/32484958",
        "http://www.ncbi.nlm.nih.gov/pubmed/34210325",
        "http://www.ncbi.nlm.nih.gov/pubmed/33208199",
        "http://www.ncbi.nlm.nih.gov/pubmed/33287245",
        "http://www.ncbi.nlm.nih.gov/pubmed/15640317",
        "http://www.ncbi.nlm.nih.gov/pubmed/33239378",
        "http://www.ncbi.nlm.nih.gov/pubmed/34506421"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1265,
          "offsetInEndSection": 1486,
          "text": "SARS-COV-2 RNA shedding can be prolonged, yet high heterogeneity exists. Detection of viral RNA may not correlate with infectivity since available viral culture data suggests shorter durations of shedding of viable virus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33077007"
        },
        {
          "offsetInBeginSection": 681,
          "offsetInEndSection": 1252,
          "text": "Among 28 studies, the overall pooled median duration of RNA shedding from respiratory sources was 18.4 days (95% CI, 15.5-21.3; I2 \u003d 98.87%; P \u003c .01). When stratified by disease severity, the pooled median duration of viral RNA shedding from respiratory sources was 19.8 days (95% CI, 16.2-23.5; I2 \u003d 96.42%; P \u003c .01) among severely ill patients and 17.2 days (95% CI, 14.0-20.5; I2 \u003d 95.64%; P \u003c .01) in mild-to-moderate illness. Viral RNA was detected up to 92 days after symptom onset. Viable virus was isolated by culture from -6 to 20 days relative to symptom onset.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33077007"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 366,
          "text": "Immunocompromised adults can have prolonged acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive RT-PCR results, long after the initial diagnosis of coronavirus disease 2019 (COVID-19). This study aimed to determine if SARS-CoV-2 virus can be recovered in viral cell culture from immunocompromised adults with persistently positive SARS-CoV-2 RT-PCR tests.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35186791"
        },
        {
          "offsetInBeginSection": 753,
          "offsetInEndSection": 961,
          "text": "Of 20 patients, 10 (50%) had a solid organ transplant and 5 (25%) had a hematologic malignancy. For most patients, RT-PCR Ct values increased over time. There were 2 patients with positive viral cell cultures",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35186791"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 900,
          "text": " Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus. SARS-CoV-2 appears to be most contagious around the time of symptom onset, and infectivity rapidly decreases thereafter to near-zero after about 10 days in mild-moderately ill patients and 15 days in severely-critically ill and immunocompromised patients. The longest interval associated with replication-competent virus thus far is 20 days from symptom onset.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33029620"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 299,
          "text": "We describe a case of chronic coronavirus disease 2019 (COVID-19) in a patient with lymphoma and associated B-cell immunodeficiency. Viral cultures and sequence analysis demonstrate ongoing replication of infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for at least 119 days.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33089317"
        },
        {
          "offsetInBeginSection": 601,
          "offsetInEndSection": 733,
          "text": "This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33089317"
        },
        {
          "offsetInBeginSection": 1038,
          "offsetInEndSection": 1325,
          "text": "COVID-19 patients with mild-to-moderate illness are highly unlikely to be infectious beyond 10 days of symptoms. However, evidence from a limited number of studies indicates that patients with severe-to-critical illness or who are immunocompromised, may shed infectious virus for longer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33049331"
        },
        {
          "offsetInBeginSection": 328,
          "offsetInEndSection": 539,
          "text": "Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33029620"
        },
        {
          "offsetInBeginSection": 1029,
          "offsetInEndSection": 1243,
          "text": "The study evidenced that most patients tested positive for more than 2 weeks and that persistence of viral RNA is not necessarily associated with severe disease but may result from a weaker immune response instead.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484958"
        },
        {
          "offsetInBeginSection": 646,
          "offsetInEndSection": 848,
          "text": " Prolonged viral shedding currently has unclear implications on the management and isolation decisions-the role of the cycle threshold (Ct) value in guiding therapeutic decisions is yet to be clarified.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33626020"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 539,
          "text": " Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33029620"
        },
        {
          "offsetInBeginSection": 125,
          "offsetInEndSection": 273,
          "text": "However, replication competent live viruses were not recovered beyond two to three weeks from onset of symptoms in mild to severe cases of COVID-19.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34506421"
        }
      ],
      "body": "What is the significance of a persistently positive RT-PCR for weeks after illness?",
      "type": "summary",
      "id": "6429e1b857b1c7a315000008",
      "ideal_answer": [
        "Patients diagnosed with COVID-19 can have detectable SARS-CoV-2 RNA in upper respiratory tract specimens for weeks after the onset of symptoms. However, prolonged viral RNA detection does not necessarily indicate prolonged infectiousness. In particular, isolation of infectious virus more than 10 days after illness onset is rare in patients whose symptoms have resolved.\n\nPeople with COVID-19 are thus generally felt to have low infectiousness after about 10 days, particularly after mild to moderate disease and in the absence of immunocompromise, regardless of whether they continue to have a positive reverse-transcription polymerase chain reaction (RT-PCR) test.",
        "A persistently positive RT-PCR for weeks after illness does not necessarily correspond to infectiousness, as available viral culture data suggests shorter durations of shedding of viable virus. However, immunocompromised individuals may have prolonged shedding of viral RNA and viable virus, which can pose a challenge for managing such patients",
        "A persistently positive RT-PCR for weeks after illness indicates the presence of viral RNA but may not necessarily correlate with infectivity. While detection of viral RNA can be prolonged, the actual shedding of viable virus typically lasts for a shorter duration, with infectivity highest at symptom onset and declining rapidly within 10-15 days"
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31317428"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31317428"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 179,
          "text": "Friedreich ataxia (FRDA), the most common inherited ataxia, is caused by transcriptional silencing of the nuclear FXN gene, encoding the essential mitochondrial protein frataxin. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31317428"
        },
        {
          "offsetInBeginSection": 244,
          "offsetInEndSection": 460,
          "text": "Gene silencing in FRDA is due to hyperexpansion of the triplet repeat sequence GAA·TTC in the first intron of the FXN gene, which results in chromatin histone modifications consistent with heterochromatin formation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31317428"
        }
      ],
      "body": "What is the genetic cause of Freidreich\u0027s ataxia?",
      "type": "summary",
      "_body": "What is RT001?",
      "_type": "summary",
      "id": "644029f857b1c7a315000042",
      "ideal_answer": [
        "Friedreich ataxia is caused by hyperexpansion of the triplet repeat sequence GAA·TTC in the first intron of the FXN gene."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24011979",
        "http://www.ncbi.nlm.nih.gov/pubmed/16144755",
        "http://www.ncbi.nlm.nih.gov/pubmed/11592052",
        "http://www.ncbi.nlm.nih.gov/pubmed/11962336",
        "http://www.ncbi.nlm.nih.gov/pubmed/34071558",
        "http://www.ncbi.nlm.nih.gov/pubmed/22109111",
        "http://www.ncbi.nlm.nih.gov/pubmed/9192267",
        "http://www.ncbi.nlm.nih.gov/pubmed/8825045",
        "http://www.ncbi.nlm.nih.gov/pubmed/21920844",
        "http://www.ncbi.nlm.nih.gov/pubmed/34384893",
        "http://www.ncbi.nlm.nih.gov/pubmed/21567298"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 751,
          "offsetInEndSection": 922,
          "text": "In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011979"
        },
        {
          "offsetInBeginSection": 1199,
          "offsetInEndSection": 1332,
          "text": "In the absence of genetic confirmation, other investigations, mainly EMG and muscle biopsy, are needed to rule out another diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011979"
        },
        {
          "offsetInBeginSection": 159,
          "offsetInEndSection": 270,
          "text": "Molecular diagnosis is based mainly on the detection of deletions of a 3.3 kb-tandem repeat array in the locus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16144755"
        },
        {
          "offsetInBeginSection": 388,
          "offsetInEndSection": 584,
          "text": "We describe a convenient non-radioactive protocol which requires a simple PCR probe synthesis and labelling procedure, thus facilitating and accelerating the standard Southern blot based DNA test.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16144755"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 215,
          "text": "The molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD) relies on detecting contractions of the unique D4Z4 repeat array at the chromosome 4q35 locus in the presence of a permissive 4q35A haplotype.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34384893"
        },
        {
          "offsetInBeginSection": 1000,
          "offsetInEndSection": 1108,
          "text": "The Southern blot analysis with DNA probe p13E-11 has created a valuable molecular diagnostic test for FSHD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9192267"
        },
        {
          "offsetInBeginSection": 239,
          "offsetInEndSection": 385,
          "text": "The gene whose defect causes FSHD has not been identified, but molecular diagnosis can be made by analyzing D4Z4 repeat length on chromosome 4q35.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109111"
        },
        {
          "offsetInBeginSection": 277,
          "offsetInEndSection": 456,
          "text": "Here, we present a comprehensive analysis of the currently used diagnostic methods (Southern blotting and molecular combing) against a new qPCR-based approach for FSHD1 diagnosis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34071558"
        },
        {
          "offsetInBeginSection": 719,
          "offsetInEndSection": 889,
          "text": "llelic variant of chromosome 4. In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and h",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24011979"
        },
        {
          "offsetInBeginSection": 552,
          "offsetInEndSection": 780,
          "text": "In this report we describe a protocol that can be used for DNA testing in well defined familial cases or proven de novo cases, and in the differential diagnosis of muscular dystrophy patients clinically suspected of having FSHD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8825045"
        },
        {
          "offsetInBeginSection": 451,
          "offsetInEndSection": 663,
          "text": "A valuable molecular diagnostic test for FSHD has been created with the use of p13E-11 probe to detect the EcoR I/Bln I double digestion fragment which is usually smaller in FSHD patient than in normal indivdual.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592052"
        },
        {
          "offsetInBeginSection": 805,
          "offsetInEndSection": 946,
          "text": "Molecular diagnosis for FSHD is usually offered with 98% accuracy but because of its complexity, a much more simple test would be preferable.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11962336"
        },
        {
          "offsetInBeginSection": 646,
          "offsetInEndSection": 755,
          "text": " Molecular diagnostic testing is appropriate to confirm the diagnosis of FSHD without need for muscle biopsy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567298"
        },
        {
          "offsetInBeginSection": 576,
          "offsetInEndSection": 726,
          "text": " number of repetitive elements (D4Z4) on chromosome 4q35 (4qA allele). Molecular diagnostic testing is appropriate to confirm the diagnosis of FSHD wi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567298"
        },
        {
          "offsetInBeginSection": 1302,
          "offsetInEndSection": 1452,
          "text": "and the homologous 10q26 regions were also detected.CONCLUSION: Molecular diagnosis of FSHD became a routine approach in Hungary thus supporting the w",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21920844"
        },
        {
          "offsetInBeginSection": 418,
          "offsetInEndSection": 568,
          "text": "5.7+/-12.3 years (range: 26-72). The diagnosis of FSHD was confirmed by genetic tests. All patients underwent medical and neurological evaluations, su",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19501370"
        }
      ],
      "body": "Which diagnostic tests are used for the diagnosis of FSHD?",
      "type": "list",
      "id": "6442869857b1c7a31500005d",
      "ideal_answer": [
        "FSHD is diagnosed with a Southern blot based DNA test. In the absence of genetic confirmation, other investigations, mainly EMG and muscle biopsy, are needed to rule out another diagnosis.",
        "In most cases once FSHD is clinically suspected the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. In the absence of genetic ",
        "In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. Molecular diagnosis is based mainly on the detection of deletions of a 3.3 kb-tandem repeat array in the locus. We describe a convenient non-radioactive protocol which requires a simple PCR probe synthesis and labelling procedure, thus facilitating and accelerating the standard Southern blot based DNA test.",
        "DNA analysis via Southern blotting and hybridization is currently the gold standard method for diagnosing FSHD1. Other techniques such as Southern blot combined with molecular combing have also been developed to provide more detailed characterization of the expanded repeats.",
        "For diagnosing Facioscapulohumeral dystrophy Type 1 (FSHD), DNA testing using Southern blot analysis or fluorescent in situ hybridization (FISH) is typically performed. Additionally, molecular combing is also becoming increasingly popular for detecting and analyzing D4Z4 contractions in affected individuals. Lastly, electromyography and muscle biopsies are sometimes necessary for ruling out other diagnoses such as spinal muscular atrophy (SMA).",
        "The diagnosis of facioscapulohumeral muscular dystrophy (FSHD) typically involves genetic testing using techniques such as Southern blot analysis, polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH), and single nucleotidepolymorphism (SNP) array. These tests allow detection of various genetic abnormalities associated with FSHD including deletions or duplications of the D4Z4 repeat array at 4q35, mutations in the FSHD1 gene, and copy number variations involving other genes. Additionally, blood samples from patients may also be tested for DNA antibodies against non-muscle myosin heavy chains which are present in some individuals with FSHD but absent in healthy controls. In summary, multiple laboratory tests are used to diagnose FSHD, each providing different levels of precision and sensitivity depending on the specific findings being evaluated.",
        "In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. In the absence of genetic confirmation, other investigations, mainly EMG and muscle biopsy, are needed to rule out another diagnosis. Molecular diagnosis is based mainly on the detection of deletions of a 3.3 kb-tandem repeat array in the locus.",
        "In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. We describe a convenient non-radioactive protocol which requires a simple PCR probe synthesis and labelling procedure, thus facilitating and accelerating the standard Southern blot based DNA test. The molecular diagnosis of facioscapulohumeral muscular dystrophy (FSHD) relies on detecting contractions of the unique D4Z4 repeat array at the chromosome 4q35 locus in the presence of a permissive 4q35A haplotype.",
        "The diagnostic tests for the diagnosis of FSHD include genetic confirmation with a DNA test using Southern Blotting and hybridization to a set of probes, EMG, and muscle biopsy. The molecular diagnosis is based on detecting contractions of the unique D4Z4 repeat array at the chromosome 4q35 locus in the presence of a permissive 4q35A haplotype or detecting deletions of a 3.3 kb-tandem repeat array in the locus.",
        "The most common diagnostic tests used for the diagnosis of FSHD are genetic testing, electromyography (EMG), and muscle biopsy. Genetic testing is used to identify the genetic mutation that causes FSHD. EMG is used to measure the electrical activity of muscles and can help diagnose FSHD. Muscle biopsy is used to examine the muscle tissue and can help confirm the diagnosis of FSHD.",
        "Diagnostic tests used for the diagnosis of Facioscapulohumeral muscular dystrophy (FSHD) include genetic testing, electromyography (EMG), muscle biopsy, and imaging studies such as magnetic resonance imaging (MRI).",
        "The diagnosis of FSHD is usually confirmed with a DNA test using Southern Blotting and hybridization to a set of probes. In the absence of genetic confirmation, other investigations such as EMG and muscle biopsy may be needed to rule out another diagnosis. Molecular diagnosis is based mainly on the detection of deletions of a 3.3 kb-tandem repeat array in the locus, and a convenient non-radioactive protocol which requires a simple PCR probe synthesis and labelling procedure can be used to facilitate and accelerate the standard Southern blot based DNA test.",
        "Which diagnostic tests are used for the diagnosis of FSHD Sec5The diagnosis of FSHD is based on clinical examination and genetic testing. The clinical examination includes the assessment of muscle strength and the presence of myopathic facies. The presence of myopathic facies is highly suggestive of FSHD but it is not pathognomonic for FSHD and can also be seen in other muscular dystrophies such as facioscapulohumeral muscular dystrophy (FSHD2) EmeryDreifuss muscular dystrophy (FSHD3) and limbgirdle muscular dystrophy type 2I (LGMD2I) CR6.Genetic testing is used to confirm the clinical diagnosis of FSHD and to determine the size of the D4Z4 repeat array. The D4Z4 repeat array is located in the subtelomeric region of chromosome 4q and consists of a variable number of 3.3kb repeat units CR7 CR8. The D4Z4 repeat array is highly polymorphic and the number of D4Z4 repeat units ranges from",
        "The diagnosis of FSHD is mainly based on a DNA test using Southern Blotting and hybridization to a set of probes, but EMG and muscle biopsy can be used to rule out other diagnoses.",
        "For diagnosing FSHD, the main tests used are DNA testing with Southern Blotting and hybridization to a set of probes. When genetic confirmation is not possible, other investigations, such as EMG and muscle biopsy, are employed to rule out alternative diagnoses.",
        "In most cases, once FSHD is clinically suspected, the diagnosis can be genetically confirmed with a DNA test using Southern Blotting and hybridization to a set of probes.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. The diagnosis of FSHD is based on clinical features, family history, and genetic testing. Clinical features include facial muscle weakness, difficulty raising the arms above shoulder level, and asymmetrical muscle weakness. Family history is important because FSHD is an autosomal dominant disorder with variable penetrance. Genetic testing can confirm the diagnosis by detecting a deletion in the D4Z4 repeat region on chromosome 4q35. This test has a sensitivity of approximately 95% for FSHD type 1 and can also distinguish between types 1 and 2. In some cases, electromyography (EMG) may be used to assess muscle function and aid in the diagnosis of FSHD. Overall, a combination of clinical evaluation, family history assessment, genetic testing, and EMG can be used to diagnose FSHD with high accuracy.",
        "Facioscapulohumeral muscular dystrophy (FSHD) can be diagnosed through genetic testing using Southern Blotting and hybridization to a set of probes. This method detects deletions of a 3.3 kb-tandem repeat array in the locus, which is the molecular basis for FSHD. In cases where genetic confirmation is not possible, other investigations such as electromyography (EMG) and muscle biopsy may be needed to rule out other diagnoses. A non-radioactive protocol has been developed that simplifies the standard Southern blot-based DNA test by requiring only a simple PCR probe synthesis and labeling procedure, thus making it more convenient and faster. Overall, genetic testing using Southern Blotting remains the most reliable diagnostic tool for FSHD, while EMG and muscle biopsy are used when genetic confirmation is not possible or inconclusive.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is diagnosed using a combination of clinical evaluation, genetic testing, and muscle imaging. The gold standard for FSHD diagnosis is genetic testing, which involves analyzing the D4Z4 repeat array on chromosome 4q35. Two types of FSHD have been identified: FSHD1 and FSHD2. In FSHD1, there is a contraction of the D4Z4 repeat array, while in FSHD2, there are mutations in the SMCHD1 gene along with hypomethylation of the D4Z4 region. Both types lead to the aberrant expression of the DUX4 gene in skeletal muscles.\n\nIn addition to genetic testing, muscle imaging techniques such as magnetic resonance imaging (MRI) and ultrasound can be used to assess muscle involvement and provide supportive information for diagnosis. These imaging modalities help identify characteristic patterns of muscle atrophy and fatty infiltration specific to FSHD.\n\nFurthermore, clinicians may perform a detailed neurological examination to evaluate muscle strength and function. Electromyography (EMG) can also be employed to assess muscle electrical activity and detect myopathic changes consistent with FSHD. However, it should be noted that EMG findings are not specific to FSHD and may only serve as an adjunct diagnostic tool alongside genetic testing and muscle imaging.",
        "The diagnosis of Facioscapulohumeral muscular dystrophy (FSHD) primarily involves genetic testing using Southern Blotting and hybridization to a set of probes. This method detects deletions of a 3.3 kb-tandem repeat array in the locus, which is the main molecular basis for FSHD. A non-radioactive protocol has been developed to facilitate and accelerate the standard Southern blot-based DNA test, requiring a simple PCR probe synthesis and labeling procedure. In cases where genetic confirmation is not available, other investigations such as electromyography (EMG) and muscle biopsy are needed to rule out alternative diagnoses."
      ],
      "exact_answer": [
        [
          "Southern blot based DNA test",
          "DNA test"
        ],
        [
          "EMG"
        ],
        [
          "muscle biopsy"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35639288",
        "http://www.ncbi.nlm.nih.gov/pubmed/35179720",
        "http://www.ncbi.nlm.nih.gov/pubmed/34146511"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1567,
          "offsetInEndSection": 1733,
          "text": "Efgartigimod is an FcRn inhibitor recently approved for MG treatment, and rozanolixizumab, nipocalimab and batoclimab are other agents in clinical trial development. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35639288"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 400,
          "text": "Efgartigimod (efgartigimod alfa-fcab, Vyvgart™) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35179720"
        },
        {
          "offsetInBeginSection": 979,
          "offsetInEndSection": 1118,
          "text": "This article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35179720"
        },
        {
          "offsetInBeginSection": 2951,
          "offsetInEndSection": 3062,
          "text": "INTERPRETATION: Efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34146511"
        }
      ],
      "body": "Can Efgartigimod be used for myasthenia gravis?",
      "type": "yesno",
      "id": "64040d73201352f04a000010",
      "ideal_answer": [
        "Yes. Efgartigimod is effective, approved and can be used for myasthenia gravis."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33709285",
        "http://www.ncbi.nlm.nih.gov/pubmed/32154811"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 86,
          "text": "Quercetin-biapigenin nanoparticles are effective to penetrate the blood-brain barrier.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33709285"
        },
        {
          "offsetInBeginSection": 436,
          "offsetInEndSection": 757,
          "text": " The present study aimed to investigate the potential protective effect of quercetin-biapigenin encapsulated into poly(Ɛ-polycaprolactone) (PCL) nanoparticles against t-BOOH-induced oxidative stress in several brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro BBB model.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33709285"
        },
        {
          "offsetInBeginSection": 1170,
          "offsetInEndSection": 1288,
          "text": "As of our knowledge, this is the first report of quercetin-biapigenin PCL-loaded nanoparticle activity in brain cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33709285"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Microbubbles in combination with focused ultrasound for the delivery of quercetin-modified sulfur nanoparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat Alzheimer\u0027s disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32154811"
        }
      ],
      "body": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier",
      "type": "yesno",
      "id": "6422e7ba690f196b51000044",
      "ideal_answer": [
        "Yes, Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier",
        "Yes, Quercetin-biapigenin loaded PCL-nanoparticles have previously been shown to be effective at crossing the blood-brain barrier in pre-clinical studies.",
        "Yes, Quercetin-biapigenin loaded nanoparticles have been shown to effectively penetrate the blood-brain barrier in various studies.",
        "Yes, Quercetin-biapigenin nanoparticles have been shown to be effective in penetrating the blood-brain barrier.",
        "Yes, Quercetin-biapigenin nanoparticles are effective to penetrate the blood-brain barrier.",
        "Yes, Quercetin-biapigenin nanoparticles have been shown to be effective in penetrating the blood-brain barrier in an in vitro BBB model.",
        "Quercetin-biapigenin nanoparticles are effective to penetrate the blood-brain barrier."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12756322",
        "http://www.ncbi.nlm.nih.gov/pubmed/15610857",
        "http://www.ncbi.nlm.nih.gov/pubmed/36227561",
        "http://www.ncbi.nlm.nih.gov/pubmed/26227035",
        "http://www.ncbi.nlm.nih.gov/pubmed/20009507",
        "http://www.ncbi.nlm.nih.gov/pubmed/17993623",
        "http://www.ncbi.nlm.nih.gov/pubmed/19303767",
        "http://www.ncbi.nlm.nih.gov/pubmed/16728979",
        "http://www.ncbi.nlm.nih.gov/pubmed/12787499",
        "http://www.ncbi.nlm.nih.gov/pubmed/23169642",
        "http://www.ncbi.nlm.nih.gov/pubmed/17468745",
        "http://www.ncbi.nlm.nih.gov/pubmed/36275359",
        "http://www.ncbi.nlm.nih.gov/pubmed/24583553",
        "http://www.ncbi.nlm.nih.gov/pubmed/16153177",
        "http://www.ncbi.nlm.nih.gov/pubmed/14593443",
        "http://www.ncbi.nlm.nih.gov/pubmed/17163768",
        "http://www.ncbi.nlm.nih.gov/pubmed/18072940",
        "http://www.ncbi.nlm.nih.gov/pubmed/22219369",
        "http://www.ncbi.nlm.nih.gov/pubmed/19101979",
        "http://www.ncbi.nlm.nih.gov/pubmed/24769284",
        "http://www.ncbi.nlm.nih.gov/pubmed/17997835",
        "http://www.ncbi.nlm.nih.gov/pubmed/12820954",
        "http://www.ncbi.nlm.nih.gov/pubmed/31741723",
        "http://www.ncbi.nlm.nih.gov/pubmed/15919195",
        "http://www.ncbi.nlm.nih.gov/pubmed/20061809",
        "http://www.ncbi.nlm.nih.gov/pubmed/19595806",
        "http://www.ncbi.nlm.nih.gov/pubmed/34086280",
        "http://www.ncbi.nlm.nih.gov/pubmed/18006684",
        "http://www.ncbi.nlm.nih.gov/pubmed/32036061",
        "http://www.ncbi.nlm.nih.gov/pubmed/27607554",
        "http://www.ncbi.nlm.nih.gov/pubmed/20943759",
        "http://www.ncbi.nlm.nih.gov/pubmed/34488573",
        "http://www.ncbi.nlm.nih.gov/pubmed/25708284",
        "http://www.ncbi.nlm.nih.gov/pubmed/26143008",
        "http://www.ncbi.nlm.nih.gov/pubmed/27432066"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 562,
          "offsetInEndSection": 756,
          "text": "These results suggest that metabolite-binding mRNAs are possibly involved in eukaryotic gene regulation and that some riboswitches might be representatives of an ancient form of genetic control.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12756322"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 399,
          "text": "Genetic control by metabolite-binding mRNAs is widespread in prokaryotes. These riboswitches are typically located in noncoding regions of mRNA, where they selectively bind their target compound and subsequently modulate gene expression. We have identified mRNA elements in fungi and in plants that match the consensus sequence and structure of thiamine pyrophosphate-binding domains of prokaryotes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12756322"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 311,
          "text": "Metabolite-sensing mRNAs, or \"riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism. Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions, harboring expression-controlling elements.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15610857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 291,
          "text": "Riboswitches are a class of RNA motifs in the untranslated regions of bacterial messenger RNAs (mRNAs) that can adopt different conformations to regulate gene expression. The binding of specific small molecule or ion ligands, or other RNAs, influences the conformation the riboswitch adopts.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36227561"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Metabolite-sensing mRNAs, or \"riboswitches,\" specifically interact with small ligands and direct expression of the genes involved in their metabolism.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15610857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Bacteria make extensive use of riboswitches to sense metabolites and control gene expression, and typically do so by modulating premature transcription termination or translation initiation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17468745"
        },
        {
          "offsetInBeginSection": 141,
          "offsetInEndSection": 384,
          "text": "Riboswitches possess a metabolite-sensing system that controls gene regulation in a cis-acting fashion at the initiation of transcriptional/translational level by binding with a specific metabolite and controlling various biochemical pathways.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36275359"
        },
        {
          "offsetInBeginSection": 151,
          "offsetInEndSection": 311,
          "text": "Riboswitches contain sensing \"aptamer\" modules, capable of ligand-induced structural changes, and downstream regions, harboring expression-controlling elements.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15610857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "Regulatory mRNA elements or riboswitches specifically control the expression of a large number of genes in response to various cellular metabolites.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19303767"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 185,
          "text": "The discovery of metabolite-sensing RNA domains with gene regulatory functions, so-called riboswitches, has greatly expanded our view of the structural and functional complexity of RNA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20009507"
        },
        {
          "offsetInBeginSection": 435,
          "offsetInEndSection": 760,
          "text": "Organisms from all three domains of life, including bacteria, plants and fungi, use TPP-sensing riboswitches to control genes responsible for importing or synthesizing thiamine and its phosphorylated derivatives, making this riboswitch class the most widely distributed member of the metabolite-sensing RNA regulatory system.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16728979"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "Riboswitches are metabolite-sensing RNAs, typically located in the non-coding portions of messenger RNAs, that control the synthesis of metabolite-related proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16728979"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Structured mRNA elements called riboswitches control gene expression by binding to small metabolites.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072940"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Riboswitches are motifs in the untranslated regions (UTRs) of RNA transcripts that sense metabolite levels and modulate the expression of the corresponding genes for metabolite import, export, synthesis, or degradation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22219369"
        },
        {
          "offsetInBeginSection": 998,
          "offsetInEndSection": 1221,
          "text": " The discovery of a riboswitch in eukaryotes that is composed of a single class of thiamine pyrophosphate (TPP) suggests that additional ligand-sensing RNAs may be present to control eukaryotic or mammalian gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31741723"
        },
        {
          "offsetInBeginSection": 379,
          "offsetInEndSection": 604,
          "text": " Newly discovered metabolite-sensing riboswitches have revealed that cellular processes extensively make use of RNA structural modulation to regulate gene expression in response to subtle changes in metabolite concentrations.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19101979"
        },
        {
          "offsetInBeginSection": 74,
          "offsetInEndSection": 237,
          "text": "These riboswitches are typically located in noncoding regions of mRNA, where they selectively bind their target compound and subsequently modulate gene expression.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12756322"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 142,
          "text": "Riboswitches are mRNA regulatory elements that control gene expression by altering their structure in response to specific metabolite binding.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23169642"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 225,
          "text": "Riboswitches are gene control elements typically located in the 5\u0027 untranslated regions of bacterial mRNAs where they modulate the expression of associated genes in response to elevated concentrations of cellular metabolites.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20061809"
        }
      ],
      "body": "What process involves metabolite-sensing mRNAs to control gene expression?",
      "type": "factoid",
      "id": "6429e85e57b1c7a315000009",
      "ideal_answer": [
        "Riboswitches are metabolite-sensing gene-control elements that are typically located in non-coding portions of mRNAs, where they selectively bind their target compound and subsequently modulate gene expression. In eukaryotes, a well-characterized riboswitch senses the vitamin B1 derivative TPP (thiamine pyro-phosphate).",
        "Metabolite-sensing mRNAs are involved in a process known as riboswitch-mediated gene regulation. Riboswitches are RNA elements that can bind small molecules, such as metabolites, and change their conformation to regulate gene expression. Metabolite-sensing mRNAs contain riboswitches in their untranslated regions (UTRs), which allow them to sense changes in intracellular metabolite concentrations and modulate the translation or stability of the mRNA. This mechanism is particularly important for regulating metabolic pathways, where the availability of specific metabolites can affect the expression of genes involved in those pathways. For example, in bacteria, riboswitches have been identified that control the expression of genes involved in amino acid biosynthesis, vitamin biosynthesis, and sugar metabolism. The discovery of riboswitches has opened up new avenues for understanding how cells respond to changes in their environment and has potential applications for developing novel antibiotics and other therapeutics that target these regulatory elements.",
        "The process involving metabolite-sensing mRNAs to control gene expression is known as riboswitch regulation. Riboswitches are structured RNA elements typically found in the 5\u0027 untranslated regions (UTRs) of mRNAs that can directly bind to small metabolites or ions. Upon binding, they undergo conformational changes that modulate gene expression by affecting transcription, translation, or mRNA stability. This mechanism allows cells to rapidly respond to fluctuations in the levels of specific metabolites, ensuring appropriate metabolic adaptation and homeostasis. Riboswitches have been identified in bacteria, archaea, and eukaryotes, with diverse ligands including purines, amino acids, coenzymes, and metal ions. They serve as an efficient means for cells to sense and regulate their internal environment without relying on protein factors such as transcription factors or regulatory enzymes."
      ],
      "exact_answer": [
        [
          "Riboswitching",
          "Riboswitch",
          "Riboswitches"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25692005"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "The aim was to assess the bioequivalence of Sandoz methylphenidate osmotic-controlled release (OCR) tablets (Sandoz [Methylphenidate[ MPH OCR) with Concerta®, a methylphenidate formulation indicated for the treatment of attention deficit/hyperactivity disorder (ADHD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25692005"
        }
      ],
      "body": "What is Concerta®?",
      "type": "summary",
      "id": "6440360557b1c7a315000047",
      "ideal_answer": [
        "Concerta® is a methylphenidate formulation indicated for the treatment of attention deficit/hyperactivity disorder (ADHD)."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35839922",
        "http://www.ncbi.nlm.nih.gov/pubmed/34148958",
        "http://www.ncbi.nlm.nih.gov/pubmed/33741226",
        "http://www.ncbi.nlm.nih.gov/pubmed/29795071",
        "http://www.ncbi.nlm.nih.gov/pubmed/29779439"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 795,
          "offsetInEndSection": 925,
          "text": " In DMD, there was a prevalence of 7.0% of ASDs, 18.0% of ADHD, 11.0% of depression, 24.0% of anxiety disorders, and 12.0% of OCD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35839922"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 287,
          "text": "To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35839922"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Duchenne muscular dystrophy (DMD) is associated with neuropsychiatric disorders, and patients often present with autism spectrum disorder (ASD)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34148958"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 244,
          "text": "Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226"
        },
        {
          "offsetInBeginSection": 107,
          "offsetInEndSection": 243,
          "text": "Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33741226"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 268,
          "text": "Increased rates of clinically significant internalizing disorders (obsessive compulsive disorder, anxiety, and depression) have been demonstrated in males with Duchenne muscular dystrophy, and a Duchenne muscular dystrophy neuropsychiatric syndrome has been suggested.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29779439"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 385,
          "text": "disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsi",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29795071"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 720,
          "text": "OBJECTIVE: To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).DATA SOURCES: MEDLINE (via PubMed), Scopus, Web of Science, and Cochrane Library from inception to November 2021.STUDY SELECTION: Observational studies of individuals with DMD or BMD that estimated the prevalence of ASDs, ADHD, depression, anxiety disorders, and OCD in each population.DATA EXTRACTION: A random-effects meta-analysis was performed on each outcome and each population (ie, DMD, BM",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35839922"
        }
      ],
      "body": "What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?",
      "type": "list",
      "id": "641794e7690f196b51000036",
      "ideal_answer": [
        "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are autism spectrum disorders (ASDs), epilepsy, attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders and obsessive-compulsive disorder (OCD).",
        " In DMD, there was a prevalence of 7.0% of ASDs, 18.0% of ADHD, 11.0% of depression, 24.0% of anxiety disorders, and 12.0% of OCD. To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD) Duchenne muscular dystrophy (DMD) is associated with neuropsychiatric disorders, and patients often present with autism spectrum disorder (ASD)",
        "Duchenne muscular dystrophy can be accompanied by various neurological and psychological complications including intellectual disability, seizures, autism/developmental delay, speech difficulties, and depression. The severity of these complications varies among individuals with different forms and severity of the disease. Certain mutations in the DMD gene lead to reduced expression or disruption of specific short variants of dystrophin, which may contribute to a more severe neurobehavioral presentation. Additionally, certain conditions such as hydrocephalus and respiratory failure can complicate the course of Duchenne muscular dystrophy, leading to additional cognitive and behavioral issues.",
        "Duchenne muscular dystrophy can lead to various neurological conditions such as intellectual disability, seizures, autistic behavior, and attention deficit disorder. It is important for healthcare professionals to be aware of these conditions when caring for individuals with DMD so they can provide appropriate medical management.",
        "Neuropsychiatric phenotype associated to DMD gene mutations include now low IQ scores, epilepsy, autism, and attention deficit disorder. Increased rates of clinically significant internalizing disorders (obsessive compulsive disorder, anxiety, and depression) have been demonstrated in males with Duchenne muscular dystrophy, and a Duchenne muscular dystrophy neuropsychiatric syndrome has been suggested. Duchenne muscular dystrophy is a progressive neuromuscular condition that has a high rate of cognitive and learning disabilities as well as neurobehavioral disorders, some of which have been associated with disruption of dystrophin isoforms.",
        "To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD) Duchenne muscular dystrophy (DMD) is associated with neuropsychiatric disorders, and patients often present with autism spectrum disorder (ASD) Duchenne muscular dystrophy is an X-Linked neuromuscular disorder, and the most common muscular dystrophy.",
        "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), anxiety disorders, obsessive-compulsive disorder (OCD), and depression. The prevalence rates for these disorders in the DMD population are 7.0%, 18.0%, 24.0%, 12.0%, and 11.0%, respectively. Clinically significant internalizing disorders have also been reported in males with DMD.",
        "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy include:\n\n1. Attention Deficit Hyperactivity Disorder (ADHD)\n2. Anxiety\n3. Depression\n4. Learning Disabilities\n5. Behavioral Problems\n6. Sleep Disturbances\n7. Autistic Spectrum Disorders\n8. Intellectual Disability",
        "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are attention deficit hyperactivity disorder (ADHD), anxiety, depression, autism spectrum disorder, and sleep disturbances.",
        "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD). The prevalence of these disorders in populations with DMD is estimated to be 7.0% for ASDs, 18.0% for ADHD, 11.0% for depression, 24.0% for anxiety disorders, and 12.0% for OCD.",
        "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD).",
        "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are autism spectrum disorders (ASDs), attention deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD).",
        "To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD)",
        "Duchenne muscular dystrophy (DMD) is a genetic disorder that affects muscle function and leads to progressive weakness and wasting. Neuropsychiatric disorders are common in individuals with DMD, with attention-deficit/hyperactivity disorder (ADHD) being the most prevalent. Other neuropsychiatric disorders associated with DMD include autism spectrum disorder (ASD), obsessive-compulsive disorder (OCD), anxiety, depression, and intellectual disability. The exact mechanisms underlying these associations are not fully understood, but it is thought that they may be related to the role of dystrophin (the protein affected in DMD) in brain development and function. Early identification and management of neuropsychiatric symptoms can improve quality of life for individuals with DMD and their families. Therefore, regular screening for these conditions should be an integral part of the care provided to individuals with DMD.",
        "Duchenne muscular dystrophy (DMD) is associated with a high prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD). In DMD patients, the prevalence of these disorders ranges from 7.0% for ASDs to 24.0% for anxiety disorders. Additionally, low IQ scores, epilepsy, and attention deficit disorder have also been reported in association with DMD gene mutations. These findings highlight the importance of screening for neuropsychiatric comorbidities in individuals with DMD to ensure appropriate management and treatment.",
        "Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. While it primarily affects the musculoskeletal system, DMD is also associated with various neuropsychiatric disorders. The most common neuropsychiatric manifestations in DMD patients include cognitive impairment, learning disabilities, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and behavioral problems such as anxiety and depression. Cognitive deficits are often observed in areas of verbal intelligence, working memory, and processing speed. These impairments can impact academic performance and social functioning, further exacerbating the challenges faced by individuals with DMD. It is essential to recognize and address these neuropsychiatric comorbidities through multidisciplinary care involving psychologists, psychiatrists, neurologists, and other healthcare professionals to improve the quality of life for patients with Duchenne muscular dystrophy.",
        "Duchenne muscular dystrophy (DMD) is associated with various neuropsychiatric disorders. A study aimed at estimating the prevalence of these disorders in DMD populations found that autism spectrum disorders (ASDs) had a prevalence of 7.0%, attention-deficit hyperactivity disorder (ADHD) had a prevalence of 18.0%, depression was present in 11.0% of cases, anxiety disorders were found in 24.0% of individuals, and obsessive-compulsive disorder (OCD) occurred in 12.0% of patients with DMD. Additionally, the neuropsychiatric phenotype linked to DMD gene mutations may include low IQ scores, epilepsy, autism, and attention deficit disorder. In summary, the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are anxiety disorders, ADHD, OCD, depression, and ASDs."
      ],
      "exact_answer": [
        [
          "autism spectrum disorders",
          "ASDs",
          "ASD",
          "autism"
        ],
        [
          "attention-deficit hyperactivity disorder",
          "ADHD",
          "attention deficit disorder"
        ],
        [
          "depression"
        ],
        [
          "anxiety disorders"
        ],
        [
          "obsessive-compulsive disorder",
          "OCD"
        ],
        [
          "epilepsy"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36214075",
        "http://www.ncbi.nlm.nih.gov/pubmed/34358343",
        "http://www.ncbi.nlm.nih.gov/pubmed/34236520",
        "http://www.ncbi.nlm.nih.gov/pubmed/33993501",
        "http://www.ncbi.nlm.nih.gov/pubmed/33588666"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 369,
          "text": "Dupilumab, a monoclonal antibody targeting the interleukin (IL)-4 receptor alpha to inhibit IL-4 and IL-13 signaling, has recently been shown to significantly improve the condition of patients with CRSwNP.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36214075"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 119,
          "text": "BACKGROUND: Dupilumab is an antibody against interleukin-4 receptor α, used in the treatment of atopic dermatitis (AD).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34358343"
        },
        {
          "offsetInBeginSection": 711,
          "offsetInEndSection": 976,
          "text": "The development of new therapies received great impetus by an ample research of the pathophysiological mechanisms, leading to a new era in the treatment of severe atopic eczema due to targeted treatments, e.g. the IL-4R alpha specific monoclonal antibody dupilumab.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34236520"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 136,
          "text": "BACKGROUND: The human monoclonal antibody dupilumab blocks interleukin (IL)-4 andIL-13, key and central drivers of type 2 inflammation. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33993501"
        },
        {
          "offsetInBeginSection": 538,
          "offsetInEndSection": 806,
          "text": " An emerging therapeutic option is dupilumab, a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-Rα) and the signaling pathways activated by interleukin (IL)-4 and IL-13. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33588666"
        }
      ],
      "body": "Which interleukins are affected by Dupilumab?",
      "type": "list",
      "id": "63ee5c78f36125a426000001",
      "ideal_answer": [
        "Dupilumab is a monoclonal antibody for adults and adolescents with moderate-to-severe atopic dermatitis, that inhibits interleukin-4 receptor alpha subunit (IL4-Rα) and the signaling pathways activated by interleukin (IL)-4 and IL-13."
      ],
      "exact_answer": [
        [
          "interleukin-4"
        ],
        [
          "interleukin-13"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30692826",
        "http://www.ncbi.nlm.nih.gov/pubmed/16482551",
        "http://www.ncbi.nlm.nih.gov/pubmed/15256927",
        "http://www.ncbi.nlm.nih.gov/pubmed/19649985",
        "http://www.ncbi.nlm.nih.gov/pubmed/17454427",
        "http://www.ncbi.nlm.nih.gov/pubmed/19251544",
        "http://www.ncbi.nlm.nih.gov/pubmed/24710539",
        "http://www.ncbi.nlm.nih.gov/pubmed/27721375",
        "http://www.ncbi.nlm.nih.gov/pubmed/35711627",
        "http://www.ncbi.nlm.nih.gov/pubmed/28951745",
        "http://www.ncbi.nlm.nih.gov/pubmed/28129782",
        "http://www.ncbi.nlm.nih.gov/pubmed/30251563",
        "http://www.ncbi.nlm.nih.gov/pubmed/33607469",
        "http://www.ncbi.nlm.nih.gov/pubmed/30603587",
        "http://www.ncbi.nlm.nih.gov/pubmed/22784026",
        "http://www.ncbi.nlm.nih.gov/pubmed/24759682",
        "http://www.ncbi.nlm.nih.gov/pubmed/17333068",
        "http://www.ncbi.nlm.nih.gov/pubmed/29766656",
        "http://www.ncbi.nlm.nih.gov/pubmed/21628803",
        "http://www.ncbi.nlm.nih.gov/pubmed/26559963",
        "http://www.ncbi.nlm.nih.gov/pubmed/26000333",
        "http://www.ncbi.nlm.nih.gov/pubmed/23637149",
        "http://www.ncbi.nlm.nih.gov/pubmed/26507473",
        "http://www.ncbi.nlm.nih.gov/pubmed/29018484",
        "http://www.ncbi.nlm.nih.gov/pubmed/21696723"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 309,
          "text": " Current approaches to regeneration and tissue engineering of articular cartilage include the use of chondrocytes, stem cells, scaffolds and signals, including morphogens and growth factors",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24710539"
        },
        {
          "offsetInBeginSection": 514,
          "offsetInEndSection": 732,
          "text": " Autologous cartilage regeneration is a cell-based therapy in which autogenous chondrocytes or other chondrogenic cells are cultured to constitute cartilaginous tissue according to the principles of tissue engineering.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19251544"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 166,
          "text": "Cartilage engineered from chondrocytes requires a scaffold to keep the cells in the cartilage defect and to act as a support for inducing hyaline cartilage formation ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17454427"
        },
        {
          "offsetInBeginSection": 462,
          "offsetInEndSection": 667,
          "text": "To address these challenges, the focus of gene therapy for bone and cartilage repair has shifted in recent years to the use of autologous cells, typically osteocytes or chondrocytes, or their progenitors, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19649985"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "Articular Cartilage Chondrocytes are more Advantageous for Generating Hyaline-like Cartilage than Mesenchymal Cells Isolated from Microfracture Repairs",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15256927"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 126,
          "text": "Influence of gel properties on neocartilage formation by auricular chondrocytes photoencapsulated in hyaluronic acid networks.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16482551"
        },
        {
          "offsetInBeginSection": 238,
          "offsetInEndSection": 307,
          "text": "affect neocartilage formation by encapsulated auricular chondrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16482551"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 140,
          "text": "Transplanting human umbilical cord mesenchymal stem cells and hyaluronate hydrogel repairs cartilage of osteoarthritis in the minipig model.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30692826"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 156,
          "text": "Osteoarthritis (OA) is a chronic disease of degenerative joints. Mesenchymal stem cells (MSCs) have been used for cartilage regeneration in OA. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30692826"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 129,
          "text": "BACKGROUND: Mesenchymal stem cells (MSCs) and/or biological scaffolds have been used to regenerate articular cartilage with varia",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30603587"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 451,
          "text": "le success. In the present study we evaluated cartilage regeneration using a combination of bone marrow (BM)-MSCs, HyalofastTM and/or native cartilage tissue following full thickness surgical cartilage defect in rabbits.METHODS: Full-thickness surgical ablation of the medial-tibial cartilage was performed in New Zealand",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30603587"
        },
        {
          "offsetInBeginSection": 80,
          "offsetInEndSection": 604,
          "text": "as increased. Mesenchymal Stem Cells (MSCs) have been proposed to be an attractive alternative candidate in the tissue engineering of articular cartilage primarily due to its abundant source, reduced cartilage donor site morbidity, and strong capacity for proliferation and potential to differentiate toward a chondrogenic phenotype.AREAS COVERED: A current overview of human, in vivo, and in vitro evidence on the use of MSCs in cartilage tissue engineering.EXPERT OPINION: We demonstrate robust evidence that MSCs have the",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22784026"
        },
        {
          "offsetInBeginSection": 1770,
          "offsetInEndSection": 2248,
          "text": "In this article, we review the progress on stem cell therapies for arthritic disorders, focusing on the various stem cell populations previously used for cartilage regeneration, successful cases of stem cell therapies in muscle and hemopoietic disorders, some of the reasons why these other fields have been successful (i.e., \"lessons learned\" to be applied to OA stem cell therapy), and finally, novel potential sources of stem cells for regenerating damaged cartilage in vivo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35711627"
        },
        {
          "offsetInBeginSection": 466,
          "offsetInEndSection": 623,
          "text": "Here, we provide an overview of the current status of cord blood cells and induced pluripotent stem cells derived from these cells in cartilage regeneration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30251563"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "Combination of Mesenchymal Stem Cells, Cartilage Pellet and Bioscaffold Supported Cartilage Regeneration of a Full Thickness Articular Surface Defect in Rabbits.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30603587"
        },
        {
          "offsetInBeginSection": 309,
          "offsetInEndSection": 417,
          "text": "The use of autologous mesenchymal stem cells (MSCs) for cartilage regeneration has been widely investigated.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33607469"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 211,
          "text": "Bone marrow-derived mesenchymal stem cells (BMSCs) are a good cell source for regeneration of cartilage as they can migrate directly to the site of cartilage injury and differentiate into articular chondrocytes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24759682"
        },
        {
          "offsetInBeginSection": 142,
          "offsetInEndSection": 422,
          "text": "Alginate microbeads containing adipose stem cells (ASCs) pretreated with chondrogenic media have been used successfully to regenerate hyaline cartilage in critical size defects in rat xiphoid suggesting that they may be used to treat defects in elastic cartilages such as the ear.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29766656"
        },
        {
          "offsetInBeginSection": 106,
          "offsetInEndSection": 254,
          "text": "Articular chondrocytes, cartilage progenitor cells, embryonic stem cells, and mesenchymal stem cells are candidate cells for cartilage regeneration.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000333"
        },
        {
          "offsetInBeginSection": 957,
          "offsetInEndSection": 1295,
          "text": "This review briefly summarizes chemokines and growth factors that induce recruitment, proliferation, and differentiation of endogenous progenitor cells, endogenous cell sources for regenerating cartilage, scaffolds for delivery of bioactive factors, and bioadhesive materials that are necessary to bring about endogenous cartilage repair.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26559963"
        },
        {
          "offsetInBeginSection": 87,
          "offsetInEndSection": 380,
          "text": "Mesenchymal stem cells derived from synovium have been shown to be a superior cell source for cartilage regeneration to those from other mesenchymal tissues due to their higher rates of colony formation, proliferation potential with autologous serum, and in vitro/vivo chondrogenic potentials.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21628803"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 79,
          "text": "[Use of bone marrow mesenchymal stem cells for ex vivo cartilage regeneration].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333068"
        },
        {
          "offsetInBeginSection": 216,
          "offsetInEndSection": 319,
          "text": "Here we show resident fibrocartilage stem cells (FCSCs) can be used to regenerate and repair cartilage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27721375"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Exploiting endogenous fibrocartilage stem cells to regenerate cartilage and repair joint injury.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27721375"
        },
        {
          "offsetInBeginSection": 684,
          "offsetInEndSection": 821,
          "text": "Regenerated cartilage can be derived from various cell types, including chondrocytes, pluripotent stem cells, and mesenchymal stem cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637149"
        },
        {
          "offsetInBeginSection": 208,
          "offsetInEndSection": 372,
          "text": "There are several cell sources being investigated to promote cartilage regeneration: mature articular chondrocytes, chondrocyte progenitors, and various stem cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29018484"
        },
        {
          "offsetInBeginSection": 328,
          "offsetInEndSection": 669,
          "text": "In this study, we aimed to evaluate and compare the in vitro characteristics and chondrogenic capacity of some easily available adult cell sources for use in cartilage repair which includes: bone marrow-derived mesenchymal stem cells (MSC), adipose tissue-derived MSC, articular chondrocyte progenitors, and nasal septum-derived progenitors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26507473"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Chondrocytes or adult stem cells for cartilage repair: the indisputable role of growth factors.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21696723"
        },
        {
          "offsetInBeginSection": 215,
          "offsetInEndSection": 319,
          "text": " Here we show resident fibrocartilage stem cells (FCSCs) can be used to regenerate and repair cartilage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27721375"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 174,
          "text": "The use of mesenchymal stromal cells (MSCs) for tissue engineering of hyaline cartilage is a topical area of regenerative medicine that has already entered clinical practice.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34829895"
        },
        {
          "offsetInBeginSection": 69,
          "offsetInEndSection": 201,
          "text": " Currently, ex vivo expanded chondrocytes or bone marrow-derived mesenchymal stem cells are used to regenerate the damaged cartilage",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129782"
        },
        {
          "offsetInBeginSection": 612,
          "offsetInEndSection": 758,
          "text": "In this investigation, we assessed the chondrogenic ability of human dental pulp stem cells (hDPSCs) to regenerate cartilage in vitro and in vivo.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28951745"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 219,
          "text": "Multipotent mesenchymal stromal cells (MSCs) are primitive cells capable of restoring damaged mesenchyme and with the ability to differentiate into mature cells of bone, cartilage, muscle, fat, nerve or fibrous tissues.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24726343"
        }
      ],
      "body": "What cells are used to regenerate cartilage?",
      "type": "list",
      "id": "64316f8e57b1c7a315000016",
      "ideal_answer": [
        "Current approaches to regeneration and tissue engineering of articular cartilage include the use of chondrocytes, stem cells, scaffolds and signals, including morphogens and growth factors.",
        "Chondrocytes and stem cells, including mesenchymal stem cells, are used to regenerate cartilage.",
        "Chondrocytes, mesenchymal stem cells, and induced pluripotent stem cells are all used to regenerate cartilage.",
        "Chondrocytes and stem cells are used to regenerate cartilage.",
        "Chondrocytes and stem cells, particularly mesenchymal stem cells, are commonly used to regenerate cartilage."
      ],
      "exact_answer": [
        [
          "chondrocytes"
        ],
        [
          "Stem cells",
          "progenitor",
          "Mesenchymal stem cells",
          "fibrocartilage stem cells"
        ],
        [
          "Osteocytes"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36196023",
        "http://www.ncbi.nlm.nih.gov/pubmed/36314059",
        "http://www.ncbi.nlm.nih.gov/pubmed/34130310",
        "http://www.ncbi.nlm.nih.gov/pubmed/33630241",
        "http://www.ncbi.nlm.nih.gov/pubmed/29082271",
        "http://www.ncbi.nlm.nih.gov/pubmed/31188932",
        "http://www.ncbi.nlm.nih.gov/pubmed/35748227",
        "http://www.ncbi.nlm.nih.gov/pubmed/33999093",
        "http://www.ncbi.nlm.nih.gov/pubmed/33839323",
        "http://www.ncbi.nlm.nih.gov/pubmed/23453015",
        "http://www.ncbi.nlm.nih.gov/pubmed/35095893",
        "http://www.ncbi.nlm.nih.gov/pubmed/35696004",
        "http://www.ncbi.nlm.nih.gov/pubmed/29036602",
        "http://www.ncbi.nlm.nih.gov/pubmed/35032318",
        "http://www.ncbi.nlm.nih.gov/pubmed/32867812",
        "http://www.ncbi.nlm.nih.gov/pubmed/31801551",
        "http://www.ncbi.nlm.nih.gov/pubmed/35752056",
        "http://www.ncbi.nlm.nih.gov/pubmed/34850126",
        "http://www.ncbi.nlm.nih.gov/pubmed/36407103",
        "http://www.ncbi.nlm.nih.gov/pubmed/32513173",
        "http://www.ncbi.nlm.nih.gov/pubmed/34039354",
        "http://www.ncbi.nlm.nih.gov/pubmed/32245489",
        "http://www.ncbi.nlm.nih.gov/pubmed/35406663",
        "http://www.ncbi.nlm.nih.gov/pubmed/31243897"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 405,
          "text": "Epigenetic modifications have received increasing attention and have been shown to be extensively involved in kidney development and disease progression. Among them, the most common RNA modification, N6 -methyladenosine (m6 A), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mRNA fate.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36196023"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 311,
          "text": "N6-methyladenosine (m6A) methylation is the most abundant mammalian mRNA modification. m6A regulates RNA processing, splicing, nucleation, translation and stability by transferring, removing and recognizing m6A methylation sites, which are critical for cancer initiation, progression, metabolism and metastasis.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36314059"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 259,
          "text": "The methyltransferase-like 3 (Mettl3) is a key component of the large N6-adenosine-methyltransferase complex in mammalian responsible for RNA N6-methyladenosine (m6A) modification, which plays an important role in gene post-transcription modulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34130310"
        },
        {
          "offsetInBeginSection": 116,
          "offsetInEndSection": 223,
          "text": "Methylation of the N6 position of adenosine (m6A) is a post-transcriptional epigenetic modification of RNA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31188932"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 260,
          "text": "N6-methyladenosine (m6A) is a dynamic reversible methylation modification of the adenosine N6 position and is the most common chemical epigenetic modification among mRNA post-transcriptional modifications, including methylation, demethylation, and recognition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35032318"
        },
        {
          "offsetInBeginSection": 219,
          "offsetInEndSection": 298,
          "text": "N6-adenosine methylation (m6A) is one of the most common modifications on mRNA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748227"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "N6-methyladenosine (m6A) is methylation that occurs in the N6-position of adenosine, which is the most prevalent internal modification on eukaryotic mRNA.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31801551"
        },
        {
          "offsetInBeginSection": 182,
          "offsetInEndSection": 362,
          "text": "The N6-methyl adenosine (m6A) is an important epigenetic modification primarily present on mRNA that controls the levels of transcripts and efficiency of translation in eukaryotes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32867812"
        }
      ],
      "body": "Is adenosine methylation an epigenetic modification?",
      "type": "yesno",
      "id": "6429eb8457b1c7a31500000a",
      "ideal_answer": [
        "Adenosine methylation is the most common mammalian epigenetic modification of mRNAs that is directed by a large methyltransferase complex containing Mettl3."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35868358"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 269,
          "text": "Drug delivery to the suprachoroidal space (SCS®) has become a clinical reality after the 2021 FDA approval of CLS-TA, a triamcinolone acetonide injectable suspension for suprachoroidal use (XIPERE®), administered via a microneedle-based device, the SCS Microinjector®. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35868358"
        }
      ],
      "body": "Which year was XIPERE approved by the FDA?",
      "type": "factoid",
      "id": "6440393157b1c7a31500004a",
      "ideal_answer": [
        "XIPERE was approved by the FDA in 2021."
      ],
      "exact_answer": [
        [
          "2021"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36291504",
        "http://www.ncbi.nlm.nih.gov/pubmed/35620884",
        "http://www.ncbi.nlm.nih.gov/pubmed/34983147"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1396,
          "offsetInEndSection": 1557,
          "text": "The duration between breastfeeding and heel lance may influence the perception of pain in newborns. Keeping this period short, may reduce the perception of pain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34983147"
        },
        {
          "offsetInBeginSection": 983,
          "offsetInEndSection": 1122,
          "text": "Breastfeeding and mother\u0027s heartbeat sounds, which are non-pharmacological pain relief methods, are effective in neonatal pain management. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35620884"
        },
        {
          "offsetInBeginSection": 1046,
          "offsetInEndSection": 1165,
          "text": "The best non-pharmacological methods are breastfeeding followed by non-nutritive sucking coupled with sucrose sucking. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291504"
        },
        {
          "offsetInBeginSection": 868,
          "offsetInEndSection": 1045,
          "text": " Non-pharmacological interventions, particularly breastfeeding and non-nutritive sucking as primary strategies for pain management in neonates are useful strategies to consider.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291504"
        }
      ],
      "body": "Can breastfeeding be used to alleviate the procedural pain in neonates?",
      "type": "yesno",
      "id": "64412c2757b1c7a315000055",
      "ideal_answer": [
        "Yes, breastfeeding is effective for pain management in neonates.",
        "The duration between breastfeeding and heel lance may influence the perception of pain in newborns. Keeping this period short may reduce the perception of pain.Breastfeeding and mothers heartbeat",
        "The duration between breastfeeding and heel lance may influence the perception of pain in newborns. Breastfeeding and mother\u0027s heartbeat sounds, which are non-pharmacological pain relief methods, are effective in neonatal pain management.",
        "Yes, breast milk can reduce or abolish Procedural pain in babies who require medical intervention, such as during heel lances, venipunctures and intramuscular injections. However, it\u0027s important to note that not all infants will benefit from breast milk, and other factors may also play a role in their comfort. Therefore, it\u0027s crucial that healthcare professionals work closely with parents and caregivers to determine what works best for each individual baby.",
        "The conclusion was that breastfeeding was effective in reducing pain caused by blood collection for newborn screening. Premature Infant Pain Profile scores were lower in the breastfeeding group when compared to the placebo and the group positioned in mother\u0027s arms, but were not different compared to the no-treatment and the glucose groups.",
        "The duration between breastfeeding and heel lance may influence the perception of pain in newborns. Keeping this period short, may reduce the perception of pain.",
        "Yes, breastfeeding can be used to alleviate procedural pain in neonates. Studies have shown that breastfeeding and mother\u0027s heartbeat sounds are effective non-pharmacological pain relief methods for newborns. Keeping the duration between breastfeeding and heel lance short may also reduce the perception of pain. Additionally, studies have found that breastfeeding was effective in reducing pain caused by blood collection for newborn screening.",
        "Yes, breastfeeding is effective in alleviating procedural pain in neonates.",
        "breastfeeding can be used to reduce the pain of procedures in neonates",
        "Yes, breastfeeding can be used to alleviate the procedural pain in neonates. Studies have shown that breastfeeding during painful procedures can reduce the amount of pain experienced by the baby. Breastfeeding can provide comfort and distraction, as well as the release of hormones that can help reduce stress and pain. Additionally, skin-to-skin contact between the mother and baby can help to reduce the baby\u0027s stress response.",
        "Yes, breastfeeding has been shown to reduce the pain response in neonates during medical procedures.",
        "Yes, breastfeeding can be used to alleviate the procedural pain in neonates. Keeping the duration between breastfeeding and heel lance short may reduce the perception of pain. Additionally, non-pharmacological pain relief methods such as breastfeeding and mother\u0027s heartbeat sounds are effective in neonatal pain management. The best non-pharmacological methods are breastfeeding followed by non-nutritive sucking coupled with sucrose sucking. Therefore, non-pharmacological interventions, particularly breastfeeding and non-nutritive sucking, are useful strategies to consider for pain management in neonates.",
        "Yes, breastfeeding is an effective non-pharmacological method for pain management in neonates. Breastfeeding provides comfort and pain relief by releasing endorphins and promoting relaxation in the baby.",
        "Yes, breastfeeding can be used as a non-pharmacological intervention to alleviate procedural pain in neonates. It helps provide comfort, distraction, and the release of natural analgesic substances.",
        "Breastfeeding and mother\u0027s heartbeat sounds, which are non-pharmacological pain relief methods, are effective in neonatal pain management.",
        "Breastfeeding has been shown to have analgesic effects in neonates undergoing painful procedures. The mechanism behind this effect is thought to be related to the release of endogenous opioids during breastfeeding, which can reduce pain perception. Several studies have investigated the use of breastfeeding as a non-pharmacological intervention for procedural pain management in neonates, with positive results. One study found that breastfeeding was more effective than sucrose solution or swaddling alone in reducing pain scores during heel lance procedures. Another study showed that breastfeeding combined with skin-to-skin contact resulted in lower pain scores and decreased crying time compared to standard care during venipuncture procedures. Overall, these findings suggest that breastfeeding can be an effective and safe method for alleviating procedural pain in neonates and should be considered as a first-line option for pain management in this population.",
        "Breastfeeding is an effective non-pharmacological method for managing procedural pain in neonates. Studies have shown that the duration between breastfeeding and heel lance may influence the perception of pain, with shorter periods resulting in reduced pain perception. Additionally, mother\u0027s heartbeat sounds and non-nutritive sucking coupled with sucrose sucking are also effective methods for pain relief. Breastfeeding followed by non-nutritive sucking is considered the best non-pharmacological method for neonatal pain management. Overall, non-pharmacological interventions, particularly breastfeeding and non-nutritive sucking, should be considered as primary strategies for managing procedural pain in neonates.",
        "Breastfeeding has been shown to be an effective method for alleviating procedural pain in neonates. Several studies have demonstrated that breastfeeding during painful procedures, such as heel lance and venipuncture, can significantly reduce pain-related behaviors and crying time in newborns. The analgesic effect of breastfeeding is attributed to a combination of factors, including the comforting presence of the mother, skin-to-skin contact, and the release of endogenous opioids due to suckling. Additionally, breast milk contains components like lactose and tryptophan that may contribute to its pain-relieving properties. The World Health Organization (WHO) recommends breastfeeding or providing expressed breast milk as a non-pharmacological intervention for managing procedural pain in neonates. However, it is essential to consider individual circumstances and consult healthcare professionals before implementing any pain management strategy for newborns.",
        "Breastfeeding can be used to alleviate procedural pain in neonates, as it is an effective non-pharmacological pain relief method. The duration between breastfeeding and heel lance may influence the perception of pain in newborns, with a shorter period potentially reducing pain perception. In addition to breastfeeding, mother\u0027s heartbeat sounds have also been shown to be effective in neonatal pain management. Among non-pharmacological methods, breastfeeding is considered the best, followed by non-nutritive sucking coupled with sucrose sucking. Non-pharmacological interventions like breastfeeding and non-nutritive sucking are useful primary strategies for managing pain in neonates."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34871187",
        "http://www.ncbi.nlm.nih.gov/pubmed/36272024"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "PURPOSE OF REVIEW: This review summarizes available data for lenacapavir, an investigational first-in-class agent that disrupts functioning of HIV capsid protein across multiple steps in the viral life cycle.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 145,
          "text": "Lenacapavir (Sunlenca®) is a long-acting capsid inhibitor of human immunodeficiency virus type 1 (HIV-1) being developed by Gilead Sciences Inc. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024"
        },
        {
          "offsetInBeginSection": 301,
          "offsetInEndSection": 554,
          "text": "In August 2022, lenacapavir received its first approval in the EU for use in combination with other antiretroviral(s) in adults with multi-drug resistant HIV infection, for whom it is otherwise not possible to construct a suppressive anti-viral regimen.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272024"
        }
      ],
      "body": "Can lenacapavir be used for HIV?",
      "type": "yesno",
      "id": "64042000201352f04a000020",
      "ideal_answer": [
        "Yes, lenacapavir can be used for HIV."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/17375185",
        "http://www.ncbi.nlm.nih.gov/pubmed/28650460",
        "http://www.ncbi.nlm.nih.gov/pubmed/21483674",
        "http://www.ncbi.nlm.nih.gov/pubmed/22815873",
        "http://www.ncbi.nlm.nih.gov/pubmed/23637949",
        "http://www.ncbi.nlm.nih.gov/pubmed/23366158",
        "http://www.ncbi.nlm.nih.gov/pubmed/27905012"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 529,
          "offsetInEndSection": 842,
          "text": "Here we report that targeting the codon-optimized form of the light-driven chloride pump halorhodopsin from the archaebacterium Natronomas pharaonis (hereafter abbreviated Halo) to genetically-specified neurons enables them to be silenced reliably, and reversibly, by millisecond-timescale pulses of yellow light.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17375185"
        },
        {
          "offsetInBeginSection": 661,
          "offsetInEndSection": 891,
          "text": "By using Cal-Light to drive expression of the inhibitory receptor halorhodopsin (eNpHR), which responds to yellow light, we temporarily inhibit the lever-pressing behavior, confirming that the labeled neurons mediate the behavior.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28650460"
        },
        {
          "offsetInBeginSection": 465,
          "offsetInEndSection": 723,
          "text": "We introduced enhanced halorhodopsin (eNpHR), a yellow light-sensitive, membrane-targeting chloride pump, into mouse retinal ganglion cells (RGCs) by intravitreously injecting an adeno-associated virus serotype-2 vector carrying the CMV-eNpHR-EYFP construct.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483674"
        },
        {
          "offsetInBeginSection": 597,
          "offsetInEndSection": 912,
          "text": "Hippocampal pyramidal neurons were transduced in vivo with a virus carrying an enhanced halorhodopsin (eNpHR), a yellow light activated chloride pump, and acute seizure progression was then monitored behaviorally and electrophysiologically in the presence and absence of illumination delivered via an optical fiber.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637949"
        },
        {
          "offsetInBeginSection": 1223,
          "offsetInEndSection": 1360,
          "text": "Similarly, archaeon Natronomonas pharaonis (NpHR) expresses a monovalent Cl- channel protein halorhodopsin that responds to yellow light.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27905012"
        },
        {
          "offsetInBeginSection": 141,
          "offsetInEndSection": 380,
          "text": "Towards achieving this goal, light-activated channelrhodopsin-2 (ChR2), a cation channel activated with 480 nm light, and a first generation halorhodopsin (NpHR1.0), an anion pump activated by 580 nm light, have been introduced into hiPSC.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23366158"
        },
        {
          "offsetInBeginSection": 485,
          "offsetInEndSection": 645,
          "text": "In analogy, other excitable cells can be inhibited by expressing Halorhodopsin from Natronomonas pharaonis (NpHR) and subsequent illumination with yellow light.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22815873"
        },
        {
          "offsetInBeginSection": 140,
          "offsetInEndSection": 303,
          "text": " Towards achieving this goal, light-activated channelrhodopsin-2 (ChR2), a cation channel activated with 480 nm light, and a first generation halorhodopsin (NpHR1.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23366158"
        },
        {
          "offsetInBeginSection": 441,
          "offsetInEndSection": 591,
          "text": " retino-tectal pathway. We introduced enhanced halorhodopsin (eNpHR), a yellow light-sensitive, membrane-targeting chloride pump, into mouse retinal g",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483674"
        },
        {
          "offsetInBeginSection": 724,
          "offsetInEndSection": 1042,
          "text": "Several weeks after the injection, whole-cell recordings made from sSC neurons in slice preparations revealed that yellow laser illumination of the eNpHR-expressing retino-tectal axons, putatively synapsing onto the recorded cells, effectively inhibited EPSCs evoked by electrical stimulation of the optic nerve layer.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21483674"
        }
      ],
      "body": "What color light does the the inhibitory receptor halorhodopsin (eNpHR) respond to?",
      "type": "factoid",
      "id": "6415b3b4690f196b51000009",
      "ideal_answer": [
        "Halorhodopsin responds to yellow light.",
        "The eNpHR is sensitive to yellow light.",
        "The inhibitory receptor halorhodopsin (eNpHR) responds to yellow light.",
        "eNpHR responds to yellow light.",
        "Halorhodopsin (eNpHR) is an inhibitory receptor that responds to yellow-green light (wavelength of 590 nm)."
      ],
      "exact_answer": [
        [
          "yellow"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/1409643",
        "http://www.ncbi.nlm.nih.gov/pubmed/9383448",
        "http://www.ncbi.nlm.nih.gov/pubmed/17123746",
        "http://www.ncbi.nlm.nih.gov/pubmed/1736286",
        "http://www.ncbi.nlm.nih.gov/pubmed/23801666",
        "http://www.ncbi.nlm.nih.gov/pubmed/8507207",
        "http://www.ncbi.nlm.nih.gov/pubmed/16522199",
        "http://www.ncbi.nlm.nih.gov/pubmed/9618449",
        "http://www.ncbi.nlm.nih.gov/pubmed/8502653",
        "http://www.ncbi.nlm.nih.gov/pubmed/2197561",
        "http://www.ncbi.nlm.nih.gov/pubmed/7729424"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 181,
          "text": "A critical regulatory element in many promoters transcribed by RNA polymerase II is the \"TATA\" box, which is located 25-30 nucleotides upstream of the transcription initiation site.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1409643"
        },
        {
          "offsetInBeginSection": 722,
          "offsetInEndSection": 921,
          "text": "About 24% of human genes have a TATA-like element and their promoters are generally AT-rich; however, only approximately 10% of these TATA-containing promoters have the canonical TATA box (TATAWAWR).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17123746"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "TBP binding to the TATA box induces a specific downstream unwinding site that is targeted by pluramycin.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9383448"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 281,
          "text": "The TATA-binding protein (TBP) is one of the major components of the human TFIID multiprotein complex. It is important in directing the initiation of RNA transcription at a site immediately downstream of the TATA sequence (TATA box) found in many eukaryotic promoters. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9383448"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "The TATA box-binding factor TFIID plays a primary role in the process of transcription initiation by RNA polymerase II and its regulation by various gene-specific factors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1736286"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 211,
          "text": "The canonical core promoter elements consist of the TATA box, initiator (Inr), downstream core promoter element (DPE), TFIIB recognition element (BRE) and the newly-discovered motif 10 element (MTE).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16522199"
        }
      ],
      "body": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?",
      "type": "factoid",
      "id": "6429fad757b1c7a31500000e",
      "ideal_answer": [
        "Found in about 24% of human gene promoters, the TATA box is a critical regulatory element that is mostly found in genes transcribed by RNA polymerase II, and as such, recruits this enzyme to the promoter. Additionally, the TATA-binding protein aids in unwinding DNA.",
        "The TATA box is a critical regulatory element found in many promoters transcribed by RNA polymerase II. Located 25-30 nucleotides upstream of the transcription initiation site, it promotes RNA polymerase II binding and facilitates the unwinding of DNA prior to translation. The TATA-binding protein (TBP), a major component of the human TFIID multiprotein complex, plays an essential role in directing the initiation of RNA transcription at a site immediately downstream of the TATA sequence. Approximately 24% of human genes have a TATA-like element with AT-rich promoters, but only around 10% contain the canonical TATA box (TATAWAWR)."
      ],
      "exact_answer": [
        [
          "TATA box"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 498,
          "text": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich\u0027s ataxia patients (9 subjects each cohort)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
        },
        {
          "offsetInBeginSection": 825,
          "offsetInEndSection": 920,
          "text": "Nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
        }
      ],
      "body": "How many patients with Friedreich\u0027s ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.",
      "type": "factoid",
      "id": "64402e7757b1c7a315000044",
      "ideal_answer": [
        "Each cohort of the phase I/II double-blind, comparator-controlled trial of RT001 involved 9 Friedreich\u0027s ataxia patients. In total nineteen patients enrolled in the trial, and 18 completed all safety and efficacy measurements."
      ],
      "exact_answer": [
        [
          "Nine per cohort",
          "9/cohort",
          "18 in total"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34315378",
        "http://www.ncbi.nlm.nih.gov/pubmed/21496633"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 127,
          "text": "Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34315378"
        },
        {
          "offsetInBeginSection": 171,
          "offsetInEndSection": 322,
          "text": "It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000. Overall lifespan is not affected significantly.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496633"
        }
      ],
      "body": "What is the incidence of Facioscapulohumeral Muscular Dystrophy?",
      "type": "factoid",
      "id": "64425ce357b1c7a315000059",
      "ideal_answer": [
        "Facioscapulohumeral Muscular Dystrophy has and incidence of 1:8000 to 1:20000.",
        "Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence. It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000.",
        "The estimated prevalence of facioscapulohumeral muscular dystrophy is approximately 1:8000 individuals.",
        "The estimated prevalence of facioscapulohumeral muscular dystrophy varies depending on how it\u0027s defined and who\u0027s counting. According to one study, approximately 1 in 8000 people have facioscapulohumeral muscular dystrophy - a disorder characterized by progressive weakness and loss of muscle tissue in the upper body. This number could be higher if more cases were diagnosed.",
        "Facioscapulohumeral muscular dystrophy is an autosomal dominant disorder with an incidence of 3 to 10 cases per million. Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence.",
        "Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence. Facioscapulohumeral muscular dystrophy is an autosomal dominant disorder with an incidence of 3 to 10 cases per million.",
        "The incidence of Facioscapulohumeral Muscular Dystrophy is approximately 1 in 8,000.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is a rare autosomal dominant disorder. It is present worldwide, with a prevalence of around 4 per 100000 and an incidence of 1 in 20000.",
        "The incidence of Facioscapulohumeral Muscular Dystrophy (FSHD) is estimated to be between 1 in 8,333 and 1 in 20,000 people worldwide.",
        "The incidence of Facioscapulohumeral Muscular Dystrophy (FSHD) is estimated to be 1 in 8,333 to 1 in 20,000 individuals.",
        "The incidence of Facioscapulohumeral Muscular Dystrophy (FSHD) is approximately 1:8000, with a prevalence of around 4 per 100000 and an incidence of about 1 in 20000. Overall lifespan is not affected significantly.",
        "The incidence of Facioscapulohumeral Muscular Dystrophy is approximately 1 in 8000 people.",
        "The incidence of Facioscapulohumeral Muscular Dystrophy (FSHD) is approximately 1 in 8000 individuals.",
        "Facioscapulohumeral Muscular Dystrophy (FSHD) is in the top three list of all dystrophies with an approximate 1:8000 incidence.",
        "Facioscapulohumeral Muscular Dystrophy (FSHD) is a rare genetic disorder that affects the muscles of the face, shoulders, and upper arms. The incidence of FSHD varies widely depending on the population studied and the diagnostic criteria used. In general, it is estimated to affect approximately 1 in 8,000 individuals worldwide. However, recent studies suggest that this number may be an underestimate due to underdiagnosis and misdiagnosis. FSHD can present with a wide range of symptoms and severity, making diagnosis challenging. It is caused by a deletion or mutation in the D4Z4 repeat region on chromosome 4q35, leading to abnormal expression of genes involved in muscle development and function. While there is currently no cure for FSHD, management strategies such as physical therapy and assistive devices can help improve quality of life for affected individuals. Ongoing research into the underlying mechanisms of FSHD may lead to new treatments in the future.",
        "Facioscapulohumeral Muscular Dystrophy (FSHD) is a relatively common genetic disorder with an incidence of approximately 1 in 8000 individuals worldwide. The prevalence of FSHD is around 4 per 100,000 people. Although FSHD can cause significant muscle weakness and atrophy, it does not typically affect overall lifespan. It is important to note that the severity of symptoms can vary widely among affected individuals, even within families with the same genetic mutation. Early diagnosis and management by a multidisciplinary team can help improve quality of life for those living with FSHD.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic muscle disorder characterized by progressive weakness and atrophy of the facial, shoulder, and upper arm muscles. The incidence of FSHD varies across different populations, but it is generally considered to be one of the most common forms of muscular dystrophy. Estimates suggest that FSHD affects approximately 1 in 20,000 individuals worldwide. However, these numbers may vary due to differences in diagnostic criteria and reporting methods among various studies. FSHD is caused by mutations in the DUX4 gene located on chromosome 4q35, which leads to the production of a toxic protein that damages muscle cells. There are two types of FSHD: type 1 (FSHD1), which accounts for about 95% of cases and is associated with a specific genetic deletion; and type 2 (FSHD2), which is less common and results from mutations affecting the regulation of the DUX4 gene. Early diagnosis and management are crucial for improving patients\u0027 quality of life and slowing disease progression.",
        "The incidence of Facioscapulohumeral Muscular Dystrophy (FSHD) varies in different studies. According to one study, FSHD is among the top three most common dystrophies with an approximate incidence of 1:8000 (source: http://www.ncbi.nlm.nih.gov/pubmed/34315378). Another study reports a worldwide prevalence of around 4 per 100,000 and an incidence of about 1 in 20,000 (source: http://www.ncbi.nlm.nih.gov/pubmed/21496633). Despite these differences, it is evident that FSHD is a relatively common form of muscular dystrophy. Importantly, the overall lifespan of individuals with FSHD is not significantly affected."
      ],
      "exact_answer": [
        [
          "1:8000 to 1:20000"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34620695",
        "http://www.ncbi.nlm.nih.gov/pubmed/35567422",
        "http://www.ncbi.nlm.nih.gov/pubmed/35614235"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 513,
          "offsetInEndSection": 781,
          "text": "Risdiplam (Evrysdi)-an orally bioavailable, small molecule approved by the US Food and Drug Administration and more recently by the European Medicines Agency for the treatment of patients ≥2 months of age with spinal muscular atrophy-is presented here as a case study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34620695"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35567422"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 248,
          "text": "OBJECTIVE: The US risdiplam expanded access program (EAP; NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy (SMA) who had no satisfactory treatment options access to risdiplam prior to commercial availability. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35567422"
        },
        {
          "offsetInBeginSection": 152,
          "offsetInEndSection": 560,
          "text": "SMN1 produces SMN, a ubiquitously expressed protein, that is essential for the development and survival of motor neurons. Major advances and developments in SMA therapeutics are shifting the natural history of the disease. With three relatively new available therapies, nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), and risdiplam (Evrysdi), patients survive longer and have improved outcomes. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35614235"
        }
      ],
      "body": "Risdiplam is used for treatment of which disease?",
      "type": "factoid",
      "id": "63f581e933942b094c000007",
      "ideal_answer": [
        "Risdiplam is approved for treatment of spinal muscular atrophy."
      ],
      "exact_answer": [
        [
          "spinal muscular atrophy"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36280258",
        "http://www.ncbi.nlm.nih.gov/pubmed/36376097",
        "http://www.ncbi.nlm.nih.gov/pubmed/34274959",
        "http://www.ncbi.nlm.nih.gov/pubmed/34212756",
        "http://www.ncbi.nlm.nih.gov/pubmed/34283286",
        "http://www.ncbi.nlm.nih.gov/pubmed/34313819",
        "http://www.ncbi.nlm.nih.gov/pubmed/33893614",
        "http://www.ncbi.nlm.nih.gov/pubmed/33759425",
        "http://www.ncbi.nlm.nih.gov/pubmed/35658739",
        "http://www.ncbi.nlm.nih.gov/pubmed/35582775",
        "http://www.ncbi.nlm.nih.gov/pubmed/35575811",
        "http://www.ncbi.nlm.nih.gov/pubmed/35638376",
        "http://www.ncbi.nlm.nih.gov/pubmed/35959400",
        "http://www.ncbi.nlm.nih.gov/pubmed/35750882",
        "http://www.ncbi.nlm.nih.gov/pubmed/29630554",
        "http://www.ncbi.nlm.nih.gov/pubmed/33636389",
        "http://www.ncbi.nlm.nih.gov/pubmed/30055655",
        "http://www.ncbi.nlm.nih.gov/pubmed/33108404",
        "http://www.ncbi.nlm.nih.gov/pubmed/35075461",
        "http://www.ncbi.nlm.nih.gov/pubmed/34311152"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 27,
          "offsetInEndSection": 244,
          "text": "To evaluate the predictive value of serum neurofilament light chain (sNfL) and CSF NfL (cNfL) in patients with radiologically isolated syndrome (RIS) for evidence of disease activity (EDA) and clinical conversion (CC)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36280258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 107,
          "text": "Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36280258"
        },
        {
          "offsetInBeginSection": 28,
          "offsetInEndSection": 241,
          "text": "eurodegeneration and astrocytic activation are pathologic hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 132,
          "text": "Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376097"
        },
        {
          "offsetInBeginSection": 2219,
          "offsetInEndSection": 2325,
          "text": "sNfL reflected acute disease activity in patients with MS at high risk of underlying progressive pathology",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376097"
        },
        {
          "offsetInBeginSection": 2327,
          "offsetInEndSection": 2487,
          "text": "Thus, sGFAP and sNfL levels may be used to stratify patients with progressive MS for clinical research studies and clinical trials and may inform clinical care.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36376097"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Associations between neurofilament light-chain protein, brain structure, and chronic kidney disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 350,
          "text": "Neurofilament light-chain (NfL) protein is a blood-based marker of neuroaxonal injury. We sought to (1) compare plasma NfL levels in children with chronic kidney disease (CKD) and healthy peers, (2) characterize the relationship between NfL level and kidney function, and (3) evaluate NfL as a predictor of abnormal brain structure in CKD",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959"
        },
        {
          "offsetInBeginSection": 1742,
          "offsetInEndSection": 1928,
          "text": "Within the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decreased kidney function may be linked to abnormal neuronal integrity in pediatric CKD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959"
        },
        {
          "offsetInBeginSection": 471,
          "offsetInEndSection": 644,
          "text": "Using single-molecule array assays, we evaluated longitudinal changes of serum neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and GFAP/NfL levels.R",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34212756"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 118,
          "text": "Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34283286"
        },
        {
          "offsetInBeginSection": 1394,
          "offsetInEndSection": 1633,
          "text": "erum NfL and GFAP could be potential diagnostic biomarkers for BM in patients with lung cancer. We established a model that can provide individual diagnoses of BM. Higher NfL level may be associated with poor prognosis of patients with BM.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34283286"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 410,
          "text": " The \u0027Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum\u0027 (FAS) encompasses different phenotypes, including cognitive disorders (frontotemporal dementia, FTD) and/or motor impairments (amyotrophic lateral sclerosis, ALS). The aim of this study was to apprehend the specific uses of neurofilaments light chain (NfL) and phosphorylated neurofilaments heavy chain (pNfH) in a context of FAS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34313819"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 97,
          "text": "Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34313819"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 87,
          "text": "Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33893614"
        },
        {
          "offsetInBeginSection": 1014,
          "offsetInEndSection": 1122,
          "text": "NfL is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33893614"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 134,
          "text": " The neurofilament light chain (NfL) has emerged as a versatile biomarker for CNS-diseases and is approaching clinical use.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33759425"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 134,
          "text": ": Serum neurofilament light (sNfL) chain is a promising biomarker reflecting neuro-axonal injury in multiple sclerosis (MS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658739"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 95,
          "text": "Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658739"
        },
        {
          "offsetInBeginSection": 1179,
          "offsetInEndSection": 1352,
          "text": "Serum NfL concentration was the only factor associated with disease worsening, indicating that sNfL is a useful biomarker in MS that might be relevant in a clinical setting.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35658739"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 257,
          "text": "Patients with Langerhans cell histiocytosis (LCH) may develop progressive neurodegeneration in the central nervous system (ND-CNS-LCH). Neurofilament light protein (NFL) in cerebrospinal fluid (CSF) is a promising biomarker to detect and monitor ND-CNS-LCH.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582775"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 100,
          "text": "Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582775"
        },
        {
          "offsetInBeginSection": 541,
          "offsetInEndSection": 705,
          "text": "Thus, our results suggest that p-NFL may be used to screen for ND-CNS-LCH. Further studies are encouraged, including the role of p-NFL for monitoring of ND-CNS-LCH.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582775"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 135,
          "text": "Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35575811"
        },
        {
          "offsetInBeginSection": 666,
          "offsetInEndSection": 836,
          "text": "Circulating Neurofilament light chain (NfL) levels have been recognized as a sensitive prognostic and monitoring biomarker of neuroaxonal damage in various CNS disorders.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35575811"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35638376"
        },
        {
          "offsetInBeginSection": 24,
          "offsetInEndSection": 150,
          "text": "To investigate the diagnostic and prognostic value of axonal injury biomarkers in patients with inflammatory polyneuropathies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35638376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 709,
          "text": "BACKGROUND: A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer\u0027s disease (AD).METHODS: With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in 99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n \u003d 25) or at the stage of early dementia (ADD; n \u003d 33), and in nondemented controls (n \u003d 41); in all patients, the clinical diagnoses were in accordance with the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1-42, Aβ42/40, Tau, and pTau181), interpreted according to the Erla",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30055655"
        },
        {
          "offsetInBeginSection": 110,
          "offsetInEndSection": 418,
          "text": "The levels of neurofilament light chain (NfL) in both cerebrospinal fluid (CSF) and plasma have been related to degeneration in several neurodegenerative conditions including frontotemporal dementia (FTD) and NfL is currently considered as the most promising diagnostic and prognostic fluid biomarker in FTD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33108404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u0027s disease.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30055655"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Neurofilament light chain (NfL) is a marker of brain atrophy and predictor of disease progression in rare diseases such as Huntington Disease, but also in more common neurological disorders such as Alzheimer\u0027s disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33636389"
        },
        {
          "offsetInBeginSection": 1634,
          "offsetInEndSection": 1715,
          "text": "In conclusion, NfL plasma levels are elevated during ECM confirming brain damage.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35750882"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 114,
          "text": "Neurofilament light chain plasma levels are associated with area of brain damage in experimental cerebral malaria.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35750882"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 277,
          "text": "Background: Neurofilament light chain (NfL) is an axonal cytoskeletal protein that is released into the extracellular space following neuronal or axonal injury associated with neurological conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and oth",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35959400"
        },
        {
          "offsetInBeginSection": 191,
          "offsetInEndSection": 345,
          "text": " Increased levels of circulating neurofilament light chain (NfL), a biomarker of neuro-axonal injury, have been observed in patients with severe COVID-19.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35075461"
        },
        {
          "offsetInBeginSection": 374,
          "offsetInEndSection": 661,
          "text": "Our results shown that plasma NfL levels increased with an increase in cognitive impairment across the three groups of PD patients: PD with normal cognition (PD-NC), 17.9 ± 8.9 pg/ml; PD with mild cognitive impairment (PD-MCI),21.9 ± 10.3 pg/ml; and PD dementia (PDD), 35.7 ± 21.7 pg/ml.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34311152"
        },
        {
          "offsetInBeginSection": 194,
          "offsetInEndSection": 330,
          "text": " In Alzheimer\u0027s disease (AD), neurofilament light chain (NFL), a neurofilament subunit, is elevated in the cerebrospinal fluid and blood",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29630554"
        },
        {
          "offsetInBeginSection": 1749,
          "offsetInEndSection": 1846,
          "text": "the CKD sample, NfL level is associated with abnormal kidney function and brain structure. Decrea",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34274959"
        }
      ],
      "body": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (NfL).",
      "type": "list",
      "id": "641c5201690f196b51000040",
      "ideal_answer": [
        "Neurofilament light chain (NfL) is a biomarker of neurodegeneration and is associated with many diseases such as MS, CKD, Ataxia telangiectasia, Langerhans cell histiocytosis (LCH) and acute and chronic inflammatory polyneuropathies",
        "The diseases associated with elevated levels of Plasma Neurofilament Light Chain (NfL) include Multiple Sclerosis (MS), Alzheimer\u0027s Disease (AD), Brain Trauma, Myasthenia Gravis (MG), Creutzfeldt-Jakob Disease (CJD), Amyotrophic Lateral Sclerosis (ALS), Progressive Supranuclear Palsy (PSP), Cerebral Amyloid Angiopathy (CAA), Demyelinating Lesions such as multiple sclerosis plaques and white matter hyperintensities seen on magnetic resonance imaging brain scans, Peripheral nervous system disorders including Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Paraproteinemia-related Demyelinating Polyneuropathy (PDN), Multifocal Motor Neuron Disorder (MMND), and others.",
        "The disorders linked to increased levels of NfL include neurological conditions like Alzheimer’s Disease (AD), Multiple Sclerosis (MS), Chronic Traumatic Encephalopathy (CTE), Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Other diseases where NfL levels have been reported to be altered include peripheral nervous system injuries and inflammatory responses.",
        "The diseases associated with elevations in the plasma Neurofilament Light chain (NfL) include multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer\u0027s disease, Parkinson\u0027s disease, traumatic brain injury, stroke, and spinal cord injury.",
        "Elevations in the plasma Neurofilament Light chain (NfL) have been associated with multiple sclerosis (MS), radiologically isolated syndrome (RIS), progressive multiple sclerosis (MS), chronic kidney disease (CKD), brain metastases, frontotemporal dementia-amyotrophic lateral sclerosis spectrum (FAS), ataxia telangiectasia, myotonic dystrophy type 1 (DM1), and inflammatory polyneuropathies.",
        "Elevated plasma Neurofilament Light chain (NfL) levels have been associated with several diseases, including Multiple Sclerosis, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Huntington\u0027s Disease, Langerhans Cell Histiocytosis, Myotonic Dystrophy type 1, Chronic Kidney Disease, and Brain Metastases.",
        "Plasma Neurofilament Light chain (NfL) has been associated with various diseases, including Multiple Sclerosis, Radiologically Isolated Syndrome, Progressive Multiple Sclerosis, Chronic Kidney Disease, Brain Metastases, Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum, Ataxia Telangiectasia, Langerhans Cell Histiocytosis, Myotonic Dystrophy type 1, and Inflammatory Polyneuropathies."
      ],
      "exact_answer": [
        [
          "neuroaxonal damage in various CNS disordersNS disorders",
          "neurodegenerative diseases",
          "CNS disease"
        ],
        [
          "radiologically isolated syndrome (RIS)"
        ],
        [
          "Chronic Kidney Disease"
        ],
        [
          "Brain Metastasis",
          "cancer"
        ],
        [
          "The \u0027Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum\u0027 (FAS)"
        ],
        [
          "Ataxia telangiectasia (A-T)"
        ],
        [
          "Langerhans cell histiocytosis (LCH)"
        ],
        [
          "Multiple Sclerosis"
        ],
        [
          "acute and chronic inflammatory polyneuropathies"
        ],
        [
          "ALS",
          "Amyotrophic Lateral Sclerosis"
        ],
        [
          "Creutzfeldt Jacob syndrome"
        ],
        [
          "progressive supranuclear palsy"
        ],
        [
          "Alzheimer\u0027s Disease"
        ],
        [
          "Parkinson\u0027s disease"
        ],
        [
          "Myotonic dystrophy"
        ],
        [
          "frontotemporal dementia"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36173566",
        "http://www.ncbi.nlm.nih.gov/pubmed/36264486",
        "http://www.ncbi.nlm.nih.gov/pubmed/35796986",
        "http://www.ncbi.nlm.nih.gov/pubmed/31776829",
        "http://www.ncbi.nlm.nih.gov/pubmed/30064353",
        "http://www.ncbi.nlm.nih.gov/pubmed/31160376",
        "http://www.ncbi.nlm.nih.gov/pubmed/29181276",
        "http://www.ncbi.nlm.nih.gov/pubmed/30078704",
        "http://www.ncbi.nlm.nih.gov/pubmed/25559105",
        "http://www.ncbi.nlm.nih.gov/pubmed/29490630",
        "http://www.ncbi.nlm.nih.gov/pubmed/33606259",
        "http://www.ncbi.nlm.nih.gov/pubmed/27008018",
        "http://www.ncbi.nlm.nih.gov/pubmed/28967996",
        "http://www.ncbi.nlm.nih.gov/pubmed/30948010",
        "http://www.ncbi.nlm.nih.gov/pubmed/34255854",
        "http://www.ncbi.nlm.nih.gov/pubmed/33584814",
        "http://www.ncbi.nlm.nih.gov/pubmed/33693880",
        "http://www.ncbi.nlm.nih.gov/pubmed/32312702",
        "http://www.ncbi.nlm.nih.gov/pubmed/32042188",
        "http://www.ncbi.nlm.nih.gov/pubmed/26846207",
        "http://www.ncbi.nlm.nih.gov/pubmed/34382186",
        "http://www.ncbi.nlm.nih.gov/pubmed/35478247",
        "http://www.ncbi.nlm.nih.gov/pubmed/27993786",
        "http://www.ncbi.nlm.nih.gov/pubmed/32213349",
        "http://www.ncbi.nlm.nih.gov/pubmed/24992477",
        "http://www.ncbi.nlm.nih.gov/pubmed/33191916",
        "http://www.ncbi.nlm.nih.gov/pubmed/32576878"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "Accessible chromatin often represents gene regulatory elements, including promoters and enhancers, essential for gene expression. Assay for Transposase Accessible Chromatin sequencing (ATAC-seq) is one of the most popular techniques to investigate chromatin accessibility across the genome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36173566"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 767,
          "text": "Functional cis-regulatory elements (CREs) act as precise transcriptional switches for fine-tuning gene transcription. Identification of CREs is critical for understanding regulatory mechanisms of gene expression associated with various biological processes in eukaryotes. It is well known that CREs reside in open chromatin that exhibits hypersensitivity to enzyme cleavage and physical shearing. Currently, high-throughput methodologies, such as DNase-seq, ATAC-seq, and FAIRE-seq, have been widely applied in mapping open chromatin in various eukaryotic genomes. More recently, differential MNase (micrococcal nuclease) treatment has been successfully employed to map open chromatin in addition to profiling nucleosome landscape in both mammalian and plant species.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36264486"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 331,
          "text": "Micrococcal nuclease (MNase) originating from Staphylococcus aureus is a calcium dependent ribo- and desoxyribonuclease which has endo- and exonucleolytic activity of low sequence preference. MNase is widely used to analyze nucleosome positions in chromatin by probing the enzyme\u0027s DNA accessibility in limited digestion reactions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35796986"
        },
        {
          "offsetInBeginSection": 1120,
          "offsetInEndSection": 1384,
          "text": "In this review, we discuss techniques for determining DNA accessibility and nucleosome positioning (DNase-seq, FAIRE-seq, MNase-seq, and ATAC-seq) and techniques for detecting and functionally characterizing chromatin-bound proteins (ChIP-seq, DamID, and CUT\u0026RUN).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31776829"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 520,
          "text": "Recent advancements in next-generation sequencing technologies and accompanying reductions in cost have led to an explosion of techniques to examine DNA accessibility and protein localization on chromatin genome-wide. Generally, accessible regions of chromatin are permissive for factor binding and are therefore hotspots for regulation of gene expression; conversely, genomic regions that are highly occupied by histone proteins are not permissive for factor binding and are less likely to be active regulatory regions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31776829"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 207,
          "text": "The ATAC-seq assay has emerged as the most useful, versatile, and widely adaptable method for profiling accessible chromatin regions and tracking the activity of cis-regulatory elements (cREs) in eukaryotes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33606259"
        },
        {
          "offsetInBeginSection": 356,
          "offsetInEndSection": 655,
          "text": "We have developed a method for profiling the accessibility of individual chromatin fibers, a single-molecule long-read accessible chromatin mapping sequencing assay (SMAC-seq), enabling the simultaneous, high-resolution, single-molecule assessment of chromatin states at multikilobase length scales.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32042188"
        },
        {
          "offsetInBeginSection": 327,
          "offsetInEndSection": 509,
          "text": "Recently, ATAC-seq (assay for transposase-accessible chromatin using sequencing) has emerged as one of the most powerful approaches for genome-wide chromatin accessibility profiling.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30948010"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 167,
          "text": "Assay for transposase-accessible chromatin using sequencing data (ATAC-seq) is an efficient and precise method for revealing chromatin accessibility across the genome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33584814"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 260,
          "text": "We previously developed a single-cell DNase-seq assay (scDNase-seq) to profile accessible chromatin in a limited number of single cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33693880"
        },
        {
          "offsetInBeginSection": 688,
          "offsetInEndSection": 770,
          "text": "DNase-seq and the more recent ATAC-seq are two assays that are gaining popularity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27008018"
        },
        {
          "offsetInBeginSection": 510,
          "offsetInEndSection": 691,
          "text": "This method assesses DNA accessibility using hyperactive Tn5 transposase, which simultaneously cuts DNA and inserts sequencing adaptors, preferentially in regions of open chromatin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30948010"
        },
        {
          "offsetInBeginSection": 178,
          "offsetInEndSection": 426,
          "text": "For example, assay for transposase accessible chromatin sequencing (ATAC-seq) identifies nucleosome-depleted (open) chromatin, which harbors potentially active gene regulatory sequences; and bisulfite sequencing (BS-seq) quantifies DNA methylation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31160376"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 111,
          "text": "Characterization of chromatin accessibility with a transposome hypersensitive sites sequencing (THS-seq) assay.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846207"
        },
        {
          "offsetInBeginSection": 343,
          "offsetInEndSection": 471,
          "text": "We present a transposome hypersensitive sites sequencing assay for highly sensitive characterization of chromatin accessibility.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846207"
        },
        {
          "offsetInBeginSection": 145,
          "offsetInEndSection": 261,
          "text": "DNase I and Tn5 transposase assays require thousands to millions of fresh cells for comprehensive chromatin mapping.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26846207"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "The assay for transposase-accessible chromatin using sequencing (ATAC-seq) provides a simple and scalable way to detect the unique chromatin landscape associated with a cell type and how it may be altered by perturbation or disease.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35478247"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Assay for Transposase-Accessible Chromatin using sequencing (ATAC-Seq) is a method to investigate the accessibility of chromatin in a genome-wide fashion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34382186"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 189,
          "text": "The assay for transposase-accessible chromatin using sequencing (ATAC-seq) has become the preferred method for mapping chromatin accessibility due to its time and input material efficiency.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32213349"
        },
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 200,
          "text": "Chromatin accessibility profiling assays such as ATAC-seq and DNase1-seq offer the opportunity to rapidly characterize the regulatory state of the genome at a single nucleotide resolution.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30064353"
        },
        {
          "offsetInBeginSection": 186,
          "offsetInEndSection": 414,
          "text": "Chromatin accessibility experiments such as DNaseI sequencing (DNase-seq) and Assay for Transposase Accessible Chromatin sequencing (ATAC-seq) produce genome-wide data that include distinct \u0027footprint\u0027 patterns at binding sites.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993786"
        }
      ],
      "body": "What are the most common assays to profile chromatin accessibility?",
      "type": "list",
      "id": "643c183b57b1c7a31500002c",
      "ideal_answer": [
        "Recent advancements in next-generation sequencing technologies and accompanying reductions in cost have led to an explosion of techniques to examine chromatin accessibility genome-wide. Generally, accessible regions of chromatin are permissive for factor binding and are therefore hotspots for regulation of gene expression. Therefore, identification of these regions is critical for understanding regulatory mechanisms of gene expression associated with various biological processes in eukaryotes.\n\nCurrently, high-throughput methodologies, such as DNase-seq, ATAC-seq, FAIRE-seq, and MNase-seq have been widely applied in mapping open chromatin in various eukaryotic genomes."
      ],
      "exact_answer": [
        [
          "ATAC-seq",
          "Assay for Transposase Accessible Chromatin sequencing"
        ],
        [
          "DNase-seq"
        ],
        [
          "FAIRE-seq"
        ],
        [
          "MNase-seq",
          "Micrococcal nuclease",
          "MNase"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 352,
          "offsetInEndSection": 651,
          "text": "We conducted a phase I/II double-blind, comparator-controlled trial with 2 doses of RT001 in Friedreich\u0027s ataxia patients (9 subjects each cohort). Subjects were randomized 2:1 to receive either RT001 (1.8 or 9.0 g/day), or a matching dose of nondeuterated ethyl linoleate as comparator for 28 days.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29624723"
        }
      ],
      "body": "What doses of RT001 were used in the phase I/II double-blind, comparator-controlled trial of Friedreich\u0027s ataxia patients?",
      "type": "list",
      "id": "64402f6f57b1c7a315000045",
      "ideal_answer": [
        "In the phase I/II double-blind, comparator-controlled trial of RT001 in Friedreich\u0027s ataxia patients two doses of the drug were evaluated 1.8 or 9.0 g/day."
      ],
      "exact_answer": [
        [
          "1.8 g/day"
        ],
        [
          "9.0 g/day"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35410609",
        "http://www.ncbi.nlm.nih.gov/pubmed/35362716",
        "http://www.ncbi.nlm.nih.gov/pubmed/36271296",
        "http://www.ncbi.nlm.nih.gov/pubmed/36291504",
        "http://www.ncbi.nlm.nih.gov/pubmed/32599608",
        "http://www.ncbi.nlm.nih.gov/pubmed/29282767",
        "http://www.ncbi.nlm.nih.gov/pubmed/20976299",
        "http://www.ncbi.nlm.nih.gov/pubmed/16885171",
        "http://www.ncbi.nlm.nih.gov/pubmed/29945293",
        "http://www.ncbi.nlm.nih.gov/pubmed/18446656",
        "http://www.ncbi.nlm.nih.gov/pubmed/14747965",
        "http://www.ncbi.nlm.nih.gov/pubmed/26553356",
        "http://www.ncbi.nlm.nih.gov/pubmed/9535312",
        "http://www.ncbi.nlm.nih.gov/pubmed/32401971",
        "http://www.ncbi.nlm.nih.gov/pubmed/32801846"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1037,
          "offsetInEndSection": 1129,
          "text": "The tools used to control pain in infants in the article included PIPP,NFCS,NIPS AND NPASS. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35410609"
        },
        {
          "offsetInBeginSection": 98,
          "offsetInEndSection": 226,
          "text": "The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and the Neonatal Infant Pain Scale (NIPS) are valid measures of pain. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35362716"
        },
        {
          "offsetInBeginSection": 526,
          "offsetInEndSection": 758,
          "text": "Fifteen bedside nurses trained to use the N-PASS and the NIPS prospectively completed 202 pain/agitation and sedation assessments from a convenience sample of 88 infants, including chronically ventilated, medically fragile infants. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35362716"
        },
        {
          "offsetInBeginSection": 11,
          "offsetInEndSection": 311,
          "text": "The present study evaluated the correlation of Neonatal Infant Pain Scale (NIPS) and Premature Infant Pain Profile-Revised (PIPP-R), with changes in cerebral oxygenation (ΔcrSO2; measured by near-infrared spectroscopy) in preterm infants during acute painful procedures (heel lance and venepuncture).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36271296"
        },
        {
          "offsetInBeginSection": 427,
          "offsetInEndSection": 523,
          "text": "A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291504"
        },
        {
          "offsetInBeginSection": 79,
          "offsetInEndSection": 379,
          "text": "The aim of this study was to assess the reliability, validity, and clinical utility of the Neonatal Facial Coding System (NFCS), Douleur Aiguë du Nouveau-né (DAN) scale, Neonatal Infant Pain Scale (NIPS), and Premature Infant Pain Profile (PIPP) in premature infants undergoing heel blood collection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32599608"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 462,
          "text": "BACKGROUND: Practical, valid and reliable pain measuring tools in neonates are required in clinical practice for effective pain management and prevention of the evaluator bias.METHODS: This prospective study was designed to cross-validate three pain scales: CRIES (cry, requires O(2), increased vital signs, expression, sleeplessness), CHIPPS (children\u0027s and infants\u0027 postoperative pain scale) and NIPS (neonatal infant pain scale) in terms of validity, reliabil",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16885171"
        },
        {
          "offsetInBeginSection": 2163,
          "offsetInEndSection": 2517,
          "text": "natal Infant Acute Pain Assessment Scale perform better in reliability. The Neonatal Pain, Agitation, and Sedation Scale appears to be a better choice for frontier nurses to assess procedural pain in ventilated neonates based on its good feasibility, utility and nurses\u0027 preference.RELEVANCE TO CLINICAL PRACTICE: Choosing a valid, reliable, feasible and",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945293"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 542,
          "text": "OBJECTIVE: To temporally assess a painful stimulus in premature infants using 3 neonatal pain scales.METHODS: A total of 83 premature infants were observed during airway aspiration by 3 evaluators (E1, E2 and E3) using 3 pain assessment scales (Neonatal Facial Coding System - NFCS; Neonatal Infant Pain Scale - NIPS; and Premature Infant Pain Profile - PIPP) at 5 time points: T1 (before airway aspiration), T2 (during airway aspiration), T3 (1 minute after airway aspiration), T4 (3 minutes after airway aspiration), and T5 (5 minutes after",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32401971"
        },
        {
          "offsetInBeginSection": 737,
          "offsetInEndSection": 946,
          "text": "e frequently than Norwegian units. The most frequently used scales were different versions of Astrid Lindgren\u0027s Pain Scale (ALPS) in Sweden and Echelle Douleur Inconfort Noveau-Ne (EDIN), ALPS and Premature In",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29282767"
        },
        {
          "offsetInBeginSection": 1766,
          "offsetInEndSection": 2162,
          "text": "r than those of the Premature Infant Pain Profile-Revised. The Neonatal Pain, Agitation, and Sedation Scale was mostly preferred by 55.9% of the nurses, followed by the Neonatal Infant Acute Pain Assessment Scale (23.5%) and the Premature Infant Pain Profile-Revised (20.6%).CONCLUSIONS: The three scales are all reliable and valid, but the Neonatal Pain, Agitation, and Sedation Scale and the Ne",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945293"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 247,
          "text": "OBJECTIVE: This study evaluated neonatal pain scales during procedures commonly performed in a neonatal intensive care unit.DESIGN: Evaluated were the Neonatal Infant Pain Scale (NIPS), the Comfort scale, and a new scale known as the Scale for Use",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9535312"
        },
        {
          "offsetInBeginSection": 288,
          "offsetInEndSection": 517,
          "text": "uded in the study. Video recordings of infants during heel prick blood sampling were evaluated by two observers according to the Neonatal Infant Pain Scale (NIPS), the Neonatal Facial Coding System (NFCS), and the Douleur Aiguë d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18446656"
        },
        {
          "offsetInBeginSection": 616,
          "offsetInEndSection": 832,
          "text": "Pain was assessed using indicators from three previously established scales (CRIES, the Premature Infant Pain Profile, and the Neonatal Infant Pain Scale), as well as the COVERS Scale, depending upon gestational age.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20976299"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "[Measures for the assessment of pain in neonates as well as a comparison between the Bernese Pain Scale for Neonates (BPSN) with the Premature Infant Pain Profile (PIPP)].",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14747965"
        },
        {
          "offsetInBeginSection": 427,
          "offsetInEndSection": 522,
          "text": "A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36291504"
        },
        {
          "offsetInBeginSection": 1783,
          "offsetInEndSection": 1933,
          "text": "he Premature Infant Pain Profile-Revised. The Neonatal Pain, Agitation, and Sedation Scale was mostly preferred by 55.9% of the nurses, followed by th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29945293"
        }
      ],
      "body": "What are the most common pain scales used to measure pain in neonates?",
      "type": "list",
      "id": "6440f85c57b1c7a315000051",
      "ideal_answer": [
        "The most common pain scales used to measure pain in neonates are the following: Premature Infant Pain Profile-Revised (PIPP), Premature Infant Pain Profile-Revised (PIPP-R), Neonatal Facial Coding System (NFCS), Neonatal Infant Pain Scale (NIPS), Neonatal Pain, Agitation, and Sedation Scale (NPASS), COMFORT and Douleur Aiguë du Nouveau-né (DAN).",
        "The tools used to control pain in infants in the article included PIPP,NFCS,NIPS AND NPASS. The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and the Neonatal Infant Pain Scale (NIPS) are valid measures of pain. The aim of this study was to assess the reliability, validity, and clinical utility of the Neonatal Facial Coding System (NFCS), Douleur Aiguë du Nouveau-né (DAN) scale, Neonatal Infant Pain Scale (NIPS), and Premature Infant Pain Profile (PIPP) in premature infants undergoing heel blood collection.",
        "The most commonly used pain scales for measuring pain in neonate include COMFORT, PIPP-R, NIPS and N-PASS. These scales provide reliable and valid measures of pain intensity, distress level, and ability to communicate feelings, making them valuable tools for assessing pain in infants undergoing various treatments.",
        "The most commonly used pain scales include the Behavioral Pain Scale (BPS), the Premature Infant Pain Profile (PIPP), the Neonatal infant Pain Score (NIPS), and the Neonate Passport Scales (NPAS). These scales are designed to provide a standardized method of measuring pain intensity in infants who cannot verbalize their feelings. They can also help identify potential areas for improvement in pain management practices in NICUs.",
        "Neonatal Pain, Agitation, and Sedation Scales, and Neonatal Infant acute Pain Assessment Scale (NIAPAS) have been used more frequently in recent years due to their validation, reliability, sensitivity to changes in neonate\u0027s conditions, ease of use, and nurse satisfaction with them. However, the Premature Infant Pain Profile-Revised remains an important scale as it has some unique features compared to other pain scales such as being able to distinguish degrees of pain and providing comfort ratings, which can help guide treatments and interventions. It should therefore remain a part of any neonatal unit or nursery staff\u0027s pain assessment armory.",
        "The Neonatal Pain, Agitation, and Sedation Scale appears to be a better choice for frontier nurses to assess procedural pain in ventilated neonates based on its good feasibility, utility and nurses\u0027 preference.Choosing a valid, reliable, feasible and practical measurement is the key step for better management of procedural pain for ventilated newborns. The aim of this study was to determine which of the physiological and behavioural items of 2 validated pain assessment scales (COMFORT and premature infant pain profile) are best able to detect pain during endotracheal and nasal suctioning in ventilated newborns. A comparison of postoperative pain scales in neonates.",
        "The tools used to control pain in infants in the article included PIPP,NFCS,NIPS AND NPASS. The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and the Neonatal Infant Pain Scale (NIPS) are valid measures of pain. Fifteen bedside nurses trained to use the N-PASS and the NIPS prospectively completed 202 pain/agitation and sedation assessments from a convenience sample of 88 infants, including chronically ventilated, medically fragile infants.",
        "The most common pain scales used to measure pain in neonates are the Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and the Neonatal Infant Pain Scale (NIPS). Other pain scales used in the article include PIPP, NFCS, and NPASS.",
        "The Neonatal Facial Coding System (NFCS), Premature Infant Pain Profile (PIPP), and Neonatal Infant Pain Scale (NIPS) are valid measures of pain in preterm infants.",
        "Premature Infant Pain Profile (PIPP)",
        "1. Neonatal Facial Coding System (NFCS)\n2. Premature Infant Pain Profile (PIPP)\n3. Neonatal Infant Pain Scale (NIPS)\n4. CRIES Pain Scale\n5. COMFORT Scale\n6. FLACC Scale",
        "The most common pain scales used to measure pain in neonates are the Neonatal Facial Coding System (NFCS), the Neonatal Infant Pain Scale (NIPS), the Premature Infant Pain Profile (PIPP), and the CRIES Pain Scale.",
        "The most common pain scales used to measure pain in neonates are the Neonatal Facial Coding System (NFCS), Douleur Aiguë du Nouveau-né (DAN) scale, Neonatal Infant Pain Scale (NIPS), and Premature Infant Pain Profile (PIPP).",
        "The tools used to control pain in infants in the article included PIPP,NFCS,NIPS AND NPASS. The Neonatal Pain, Agitation, and Sedation Scale (N-PASS) and the Neonatal Infant Pain Scale (NIPS) are valid measures of pain. A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS.",
        "The most common pain scales used to measure pain in neonates are PIPP, NIPS, NFCS, and N-PASS.",
        "The most common pain scales used to measure pain in neonates are PIPP, NFCS, NIPS, and NPASS.",
        "A cornerstone in pain assessment is the use of scales such as COMFORT, PIPP-R, NIPS and N-PASS.",
        "Pain assessment in neonates is a challenging task due to their inability to communicate effectively. Several pain scales have been developed and validated for use in neonates, including the Neonatal Infant Pain Scale (NIPS), the Premature Infant Pain Profile (PIPP), and the CRIES scale. The NIPS is a behavioral pain scale that assesses facial expression, cry, breathing patterns, arm movements, and state of arousal. The PIPP includes measures of heart rate, oxygen saturation, facial expression, gestational age, and behavioral state. The CRIES scale evaluates crying, oxygen saturation, vital signs, and facial expression. These scales have been shown to be reliable and valid tools for assessing pain in neonates. However, it is important to note that no single pain scale is perfect for all situations or patients. Clinicians should choose the most appropriate tool based on the patient\u0027s age, developmental stage, medical condition, and type of procedure being performed. Additionally, it is recommended that pain assessment be performed regularly during painful procedures and that appropriate interventions be implemented based on the results of the assessment.",
        "The most common pain scales used to measure pain in neonates include the Premature Infant Pain Profile-Revised (PIPP-R), Neonatal Infant Pain Scale (NIPS), Neonatal Pain, Agitation, and Sedation Scale (N-PASS), and the Neonatal Facial Coding System (NFCS). These scales have been validated as reliable measures of pain in infants undergoing painful procedures such as heel lances and venepunctures. Bedside nurses have been trained to use these scales to assess pain, agitation, and sedation in chronically ventilated and medically fragile infants. The correlation between changes in cerebral oxygenation and pain scores measured by NIPS and PIPP-R has also been evaluated. Overall, these pain scales are considered essential tools for assessing pain in neonates and improving their care.",
        "The most common pain scales used to measure pain in neonates include the Premature Infant Pain Profile (PIPP), the Neonatal Infant Pain Scale (NIPS), and the Crying, Requires oxygen, Increased vital signs, Expression, Sleeplessness (CRIES) scale. The PIPP is a widely used multidimensional tool that assesses behavioral, physiological, and contextual indicators of pain in preterm and term infants. It incorporates gestational age, heart rate, oxygen saturation levels, brow bulge, eye squeeze, and nasolabial furrow to generate a score ranging from 0 to 21. The NIPS evaluates facial expression, cry patterns, breathing patterns, arm and leg movements, and state of arousal to produce a score between 0 and 7. The CRIES scale is designed for postoperative pain assessment in neonates aged 0-6 months; it measures crying characteristics, need for supplemental oxygen to maintain saturation above 95%, changes in heart rate or blood pressure compared to baseline values, facial expressions of pain or grimacing during rest or movement-induced stressors like diaper changes or repositioning maneuvers as well as sleeplessness or agitation with scores ranging from 0 to 10. These scales are essential tools for healthcare professionals to accurately assess and manage neonatal pain effectively.",
        "The most common pain scales used to measure pain in neonates include the Premature Infant Pain Profile-Revised (PIPP-R), Neonatal Facial Coding System (NFCS), Neonatal Infant Pain Scale (NIPS), and Neonatal Pain, Agitation, and Sedation Scale (N-PASS). These tools have been validated for assessing pain in infants and are widely used in clinical settings. For instance, N-PASS and NIPS have been employed by bedside nurses for pain/agitation and sedation assessments in a sample of 88 infants, including chronically ventilated, medically fragile infants. Additionally, the correlation between NIPS and PIPP-R with changes in cerebral oxygenation during acute painful procedures has been evaluated. The reliability, validity, and clinical utility of NFCS, DAN scale, NIPS, and PIPP have also been assessed in premature infants undergoing heel blood collection. These scales serve as a cornerstone in neonatal pain assessment and help healthcare professionals monitor and manage pain effectively in this vulnerable population."
      ],
      "exact_answer": [
        [
          "PIPP",
          "Premature Infant Pain Profile-Revised"
        ],
        [
          "NFCS",
          "Neonatal Facial Coding System"
        ],
        [
          "NIPS",
          "Neonatal Infant Pain Scale"
        ],
        [
          "NPASS",
          "Neonatal Pain, Agitation, and Sedation Scale",
          "N-PASS"
        ],
        [
          "PIPP-R",
          "Premature Infant Pain Profile-Revised (PIPP-R)"
        ],
        [
          "DAN",
          "Douleur Aiguë du Nouveau-né"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/30738649",
        "http://www.ncbi.nlm.nih.gov/pubmed/31587658"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 2858,
          "offsetInEndSection": 2995,
          "text": "INTERPRETATION: Prehospital treatment with transdermal GTN does not seem to improve functional outcome in patients with presumed stroke. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30738649"
        },
        {
          "offsetInBeginSection": 1718,
          "offsetInEndSection": 1823,
          "text": "Conclusions- Prehospital treatment with GTN worsened outcomes in patients with intracerebral hemorrhage. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31587658"
        }
      ],
      "body": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?",
      "type": "yesno",
      "id": "6402c3fd201352f04a000009",
      "ideal_answer": [
        "No. Prehospital treatment with transdermal glyceryl trinitrate did not improve functional outcome in patients with presumed stroke."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35573317",
        "http://www.ncbi.nlm.nih.gov/pubmed/35663795",
        "http://www.ncbi.nlm.nih.gov/pubmed/36107856",
        "http://www.ncbi.nlm.nih.gov/pubmed/10633128",
        "http://www.ncbi.nlm.nih.gov/pubmed/30624801",
        "http://www.ncbi.nlm.nih.gov/pubmed/10982187",
        "http://www.ncbi.nlm.nih.gov/pubmed/30159187",
        "http://www.ncbi.nlm.nih.gov/pubmed/15340363",
        "http://www.ncbi.nlm.nih.gov/pubmed/35038030",
        "http://www.ncbi.nlm.nih.gov/pubmed/31020006",
        "http://www.ncbi.nlm.nih.gov/pubmed/32582297",
        "http://www.ncbi.nlm.nih.gov/pubmed/32291635",
        "http://www.ncbi.nlm.nih.gov/pubmed/9241270",
        "http://www.ncbi.nlm.nih.gov/pubmed/27343351",
        "http://www.ncbi.nlm.nih.gov/pubmed/22798143"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 250,
          "text": "Friedreich\u0027s ataxia (FRDA) is an autosomal recessive disease caused by an intronic guanine-adenine-adenine (GAA) triplet expansion in the frataxin (FXN) gene, which leads to reduced expression of full-length frataxin (1-210) also known as isoform 1. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35573317"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Friedreich\u0027s ataxia (FRDA) is an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of frataxin (FXN) gene. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35663795"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 184,
          "text": "Friedreich ataxia, the most common hereditary ataxia, is a neuro- and cardio-degenerative disorder caused, in most cases, by decreased expression of the mitochondrial protein frataxin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36107856"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 133,
          "text": "Simultaneous Quantification of Mitochondrial Mature Frataxin and Extra-Mitochondrial Frataxin Isoform E in Friedreich\u0027s Ataxia Blood.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35573317"
        },
        {
          "offsetInBeginSection": 1338,
          "offsetInEndSection": 1454,
          "text": "We now report a quantitative assay for frataxin proteoforms in whole blood from healthy controls and FRDA patients. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35573317"
        },
        {
          "offsetInBeginSection": 1925,
          "offsetInEndSection": 2122,
          "text": "The mean levels of mature frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p \u003c 0.0001) at 7.5 ± 1.5 ng/mL and 2.1 ± 1.2 ng/mL, respectively. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35573317"
        },
        {
          "offsetInBeginSection": 2315,
          "offsetInEndSection": 2511,
          "text": "he mean levels of total frataxin in whole blood from healthy controls and homozygous FRDA patients were significantly different (p \u003c 0.0001) at 34.2 ± 4.3 ng/mL and 6.8 ± 4.0 ng/mL, respectively. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35573317"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Friedreich\u0027s ataxia is caused by mutations in the FRDA gene that encodes frataxin, a nuclear-encoded mitochondrial protein.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10982187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Friedreich\u0027s ataxia (FRDA) is a progressive neurodegenerative disorder caused by a homozygous GAA repeat expansion mutation in intron 1 of the frataxin gene (FXN), which instigates reduced transcription.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32582297"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Friedreich Ataxia (FA) is a rare neuro-cardiodegenerative disease caused by mutations in the frataxin (FXN) gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35038030"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Friedreich\u0027s ataxia, characterized by decreased expression of frataxin protein, is caused by GAA trinucleotide repeats within intron 1 in 98% of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31020006"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "Friedreich\u0027s ataxia is a neurodegenerative disorder associated with a GAA trinucleotide repeat expansion in intron 1 of the frataxin (FXN) gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30159187"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 315,
          "text": "Most patients are homozygous for the expansion of a GAA triplet repeat within the FRDA gene, but a few patients show compound heterozygosity for a point mutation and the GAA-repeat expansion.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10982187"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Friedreich\u0027s ataxia (FRDA) is a genetic neurodegenerative disease that is caused by guanine-adenine-adenine (GAA) nucleotide repeat expansions in the first intron of the frataxin (FXN) gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32291635"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 198,
          "text": "Friedreich\u0027s ataxia (FRDA), the most common autosomal recessively inherited ataxia, is due to a homozygous GAA triplet repeat expansion in the first intron of the FRDA gene in about 96% of patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15340363"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 94,
          "text": "Friedreich\u0027s ataxia is due to loss of function mutations in the gene encoding frataxin (FRDA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/9241270"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 113,
          "text": "Friedreich ataxia, an autosomal recessive neurodegenerative disease, is the most common of the inherited ataxias.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10633128"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Mutations in Frataxin (FXN) cause Friedreich\u0027s ataxia (FRDA), a recessive neurodegenerative disorder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27343351"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 148,
          "text": "The genetic mutation in Friedreich ataxia (FRDA) is a hyperexpansion of the triplet-repeat sequence GAA·TTC within the first intron of the FXN gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22798143"
        },
        {
          "offsetInBeginSection": 415,
          "offsetInEndSection": 575,
          "text": "The expansion of a GAA triplet repeat within the first intron of the frataxin gene, which causes Friedreich\u0027s ataxia, was not identified in any of the patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10686465"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 208,
          "text": "BACKGROUND: Friedreich\u0027s ataxia is an autosomal-recessive cerebellar ataxia caused by mutation of the frataxin gene, resulting in decreased frataxin expression, mitochondrial dysfunction, and oxidative stress",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30624801"
        }
      ],
      "body": "What gene is mutated in Friedreich\u0027s ataxia?",
      "type": "factoid",
      "id": "6431f7de57b1c7a31500001b",
      "ideal_answer": [
        "Friedreich\u0027s ataxia (FRDA) is an inherited, multisystemic disorder predominantly caused by GAA hyper expansion in intron 1 of the frataxin (FXN) gene",
        "Friedrich\u0027s ataxia is caused by mutations in the FXN gene.",
        "The gene mutated in Friedreich\u0027s ataxia is the frataxin (FXN) gene.",
        "The gene mutated in Friedreich\u0027s ataxia is FRDA (FXN).",
        "Friedreich\u0027s ataxia is caused by a mutation in the FXN gene, which encodes the protein frataxin.",
        "Friedreich\u0027s ataxia is caused by an intronic guanine-adenine-adenine (GAA) triplet expansion in the frataxin (FXN) gene.",
        "The gene mutated in Friedreich\u0027s ataxia is called FXN (frataxin)",
        "The gene mutated in Friedreich\u0027s ataxia is frataxin (FXN)."
      ],
      "exact_answer": [
        [
          "frataxin",
          "FRDA"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34573098"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 141,
          "text": "The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098"
        },
        {
          "offsetInBeginSection": 690,
          "offsetInEndSection": 853,
          "text": "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NFκB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34573098"
        }
      ],
      "body": "Is omaveloxolone a suppressor of Nrf2?",
      "type": "yesno",
      "id": "643ff48a57b1c7a31500003d",
      "ideal_answer": [
        "No, omaveloxolone is an activator of Nrf2."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36282969"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1377,
          "offsetInEndSection": 1604,
          "text": "We observed the increase in SC concentrations in response to painful stimulus. The presence of a correlation between NIPS scores and SC increase suggests that SC can be used as an objective parameter to assess pain in neonates.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36282969"
        }
      ],
      "body": "Can salivary cortisol be used to evaluate pain in neonates?",
      "type": "yesno",
      "id": "64410f8057b1c7a315000054",
      "ideal_answer": [
        "Yes, salivary cortisol concentrations can be used to evaluate pain in neonates.",
        "We observed the increase in SC concentrations in response to painful stimulus. The presence of a correlation between NIPS scores and SC increase suggests that SC can be used as an objective paramete",
        "We observed the increase in SC concentrations in response to painful stimulus. The presence of a correlation between NIPS scores and SC increase suggests that SC can be used as an objective parameter to assess pain in neonates.",
        "Salivary cortisol can potentially be used to evaluate pain in neonates by measuring its concentration in saliva before and following a painful event or intervention. However, more research is needed to determine its effectiveness and reliability in assessing procedural pain in newborns.",
        "Yes, salivary cortisol can be used to evaluate pain in neonates.",
        "Salivary Cortisol may be useful for measuring Procedural Pain Intensity in Newborns. However, more research is needed to confirm its accuracy and reliability.",
        "The presence of a correlation between NIPS scores and SC increase suggests that SC can be used as an objective parameter to assess pain in neonates. The presence of a correlation between NIPS scores and SC increase suggests that SC can be used as an objective parameter to assess pain in neonates.",
        "Yes, salivary cortisol can be used to evaluate pain in neonates, as it has been observed to increase in response to painful stimuli and correlates with NIPS scores.",
        "No, salivary cortisol cannot be used to evaluate pain in neonates. This is because cortisol levels in neonates are too low to be accurately measured in saliva. Instead, other methods such as facial expressions, heart rate, and oxygen saturation are used to evaluate pain in neonates.",
        "Yes, salivary cortisol can be used to evaluate pain in neonates. The presence of a correlation between neonatal infant pain scale scores and salivary cortisol increase suggests that salivary cortisol can be used as an objective parameter to assess pain in neonates.",
        "Yes, salivary cortisol can be used to evaluate pain in neonates as it has been found to increase in response to painful stimuli and can be a reliable biomarker for pain assessment in neonates.",
        "Yes, salivary cortisol can be used to evaluate pain in neonates, as it has been observed to increase in response to painful stimuli and correlates with pain scores.",
        "The presence of a correlation between NIPS scores and SC increase suggests that SC can be used as an objective parameter to assess pain in neonates.",
        "Salivary cortisol has been proposed as a potential biomarker for pain assessment in neonates. Several studies have investigated the relationship between salivary cortisol levels and pain in neonates, with mixed results. Some studies have found a positive correlation between salivary cortisol levels and pain, while others have not found any significant association. One possible explanation for these discrepancies is that salivary cortisol levels may be influenced by factors other than pain, such as stress or circadian rhythm. Additionally, there are limitations to using salivary cortisol as a pain biomarker, including the need for multiple samples over time and the potential for variability in collection methods. Overall, while salivary cortisol shows promise as a non-invasive method for assessing pain in neonates, further research is needed to fully understand its utility and limitations in this population.",
        "The study observed an increase in salivary cortisol (SC) concentrations in response to painful stimulus, indicating that SC can be used as an objective parameter to assess pain in neonates. The presence of a correlation between Neonatal Infant Pain Scale (NIPS) scores and SC increase further supports this conclusion. Salivary cortisol measurement is non-invasive and has the potential to provide a reliable and valid measure of pain in neonates, which is particularly important given the challenges associated with assessing pain in this population. This finding could have significant implications for clinical practice, as it may lead to improved pain management strategies for neonates. However, further research is needed to validate these findings and determine the optimal use of salivary cortisol measurement in clinical settings.",
        "Salivary cortisol can be used as a non-invasive biomarker to evaluate pain in neonates. Several studies have demonstrated that salivary cortisol levels increase in response to painful stimuli or stressors in newborns, such as heel lance procedures and circumcision. This method offers advantages over traditional pain assessment tools, which often rely on subjective behavioral and physiological indicators that may not accurately reflect the infant\u0027s pain experience. Salivary cortisol sampling is easy to collect, minimally invasive, and causes minimal discomfort for the neonate. However, it is important to note that factors like gestational age, time of day, and previous exposure to stressors can influence cortisol levels. Therefore, while salivary cortisol has shown promise as a tool for evaluating neonatal pain, it should be used in conjunction with other established pain assessment methods to ensure accurate evaluation of an infant\u0027s pain experience.",
        "Yes, salivary cortisol (SC) can be used to evaluate pain in neonates. A study observed an increase in SC concentrations in response to painful stimuli, and a correlation was found between Neonatal Infant Pain Scale (NIPS) scores and the increase in SC levels. This suggests that SC can serve as an objective parameter for assessing pain in neonates. The use of salivary cortisol as a biomarker for pain assessment offers a non-invasive method that could potentially improve the accuracy and reliability of neonatal pain evaluation."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35421369"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 2743,
          "offsetInEndSection": 2938,
          "text": "INTERPRETATION: The addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle-invasive bladder cancer.FUNDING: Boehringer Ingelheim.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35421369"
        }
      ],
      "body": "Does nintedanib improve response rate in patients with bladder cancer?",
      "type": "yesno",
      "id": "6402c0d5201352f04a000008",
      "ideal_answer": [
        "No. The addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle-invasive bladder cancer."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/18508540",
        "http://www.ncbi.nlm.nih.gov/pubmed/32800852",
        "http://www.ncbi.nlm.nih.gov/pubmed/28064104"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 254,
          "offsetInEndSection": 494,
          "text": "Three types of nucleic acid-based gene silencing molecules can be distinguished, including DNA-base antisense oligonucleotides (ASO), nucleic acid enzymes (ribozyme and DNAzyme) and double-stranded small interfering RNA (siRNA or microRNA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18508540"
        },
        {
          "offsetInBeginSection": 228,
          "offsetInEndSection": 545,
          "text": "Antisense oligonucleotides are synthetic single stranded strings of nucleic acids that bind to RNA and thereby alter or reduce expression of the target RNA while siRNAs, on the other hand, are double-stranded RNA molecules which can hybridize with a specific mRNA sequence and block the translation of numerous genes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064104"
        },
        {
          "offsetInBeginSection": 176,
          "offsetInEndSection": 415,
          "text": "However, in practice the term \"antisense\" has been used to describe single stranded oligonucleotides (ss ASOs) designed to hybridize to RNAswhile the term \"siRNA\" has come to mean double stranded oligonucleotides designed to activate Ago2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32800852"
        }
      ],
      "body": "What is the difference between siRNA and Antisense oligonucleotide therapeutics",
      "type": "summary",
      "id": "6419fa3d690f196b5100003c",
      "ideal_answer": [
        "DNA-base antisense oligonucleotides (ASO) arw single stranded in contrast to double-stranded small interfering RNA (siRNA or microRNA)",
        "Small interfering RNAs (siRNAs) and antisense oligonucleotide (ASO) therapeutics are two classes of RNA-based therapeutics that are used to modulate gene expression. siRNAs are short double-stranded RNAs that bind to and degrade mRNA, while ASOs are single-stranded oligonucleotides that bind to mRNA and block its translation into protein.",
        "SiRNA and antisense oligonucleotide therapeutics are both nucleic acid-based gene silencing molecules, but they differ in their structure and mechanism of action. SiRNA is a double-stranded small interfering RNA, while antisense oligonucleotides are single-stranded DNA molecules. SiRNA works by binding to a specific mRNA sequence and triggering its degradation, while antisense oligonucleotides bind to the mRNA and block its translation into a protein.",
        "SiRNA and Antisense oligonucleotide therapeutics are both gene silencing molecules, but they differ in their mechanism of action. SiRNA targets mRNA degradation while Antisense oligonucleotides target mRNA blocking. Additionally, siRNA is double-stranded while Antisense oligonucleotides are single-stranded",
        "The main difference between siRNA and antisense oligonucleotide therapeutics is their mechanism of action. siRNA works by triggering the RNA interference (RNAi) pathway, which specifically targets and cleaves mRNA, resulting in gene silencing. Antisense oligonucleotides, on the other hand, bind to target mRNA and block its translation into protein or induce its degradation, also causing gene silencing"
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31663454"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 108,
          "text": "Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31663454"
        },
        {
          "offsetInBeginSection": 568,
          "offsetInEndSection": 792,
          "text": "This article will review the pharmacology and preliminary clinical data of the 0.18 mg fluocinolone acetonide intravitreal implant (YUTIQ™), to show its efficacy and safety in the treatment of noninfectious posterior uveitis",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31663454"
        }
      ],
      "body": "What is Yutiq?",
      "type": "summary",
      "id": "644036cf57b1c7a315000048",
      "ideal_answer": [
        "Yutiq is a 0.18 mg fluocinolone acetonide intravitreal implant (YUTIQ™) used in the treatment of noninfectious posterior uveitis."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35562557",
        "http://www.ncbi.nlm.nih.gov/pubmed/35754057",
        "http://www.ncbi.nlm.nih.gov/pubmed/28802771",
        "http://www.ncbi.nlm.nih.gov/pubmed/18055393",
        "http://www.ncbi.nlm.nih.gov/pubmed/1673177",
        "http://www.ncbi.nlm.nih.gov/pubmed/20080524",
        "http://www.ncbi.nlm.nih.gov/pubmed/7922631",
        "http://www.ncbi.nlm.nih.gov/pubmed/31603849",
        "http://www.ncbi.nlm.nih.gov/pubmed/29386334",
        "http://www.ncbi.nlm.nih.gov/pubmed/25996334",
        "http://www.ncbi.nlm.nih.gov/pubmed/16114258",
        "http://www.ncbi.nlm.nih.gov/pubmed/8629099",
        "http://www.ncbi.nlm.nih.gov/pubmed/7705851",
        "http://www.ncbi.nlm.nih.gov/pubmed/36012442"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 152,
          "text": "Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35562557"
        },
        {
          "offsetInBeginSection": 966,
          "offsetInEndSection": 1094,
          "text": "The cumulative incidence of disease was 19.7 per 100,000 male live births and 1 in 5076 live born males were diagnosed with DMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35754057"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 209,
          "text": "Duchenne muscular dystrophy is a genetically determined disease, linked to the X chromosome, c haracterized clinically by producing progressive muscle weakness, with an incidence of 1 per 3500-6000 males born.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31603849"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 218,
          "text": "Duchenne muscular dystrophy (DMD) is a progressive wasting disease of skeletal and cardiac muscles, representing one of the most common recessive fatal inherited genetic diseases with 1:3500-1:5000 in yearly incidence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29386334"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "INTRODUCTION: Duchenne muscular dystrophy is the most common form of muscular dystrophy, with an incidence of 1/3300 male live births and a prevalence rate in the total population of 3/10000",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996334"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 177,
          "text": "Duchenne/Becker muscular dystrophy is a severe, recessive, X-linked neuromuscular disease with an incidence of 1/3500 (Duchenne type) and 1/30,000 (Becker type) in newborn boys.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18055393"
        },
        {
          "offsetInBeginSection": 283,
          "offsetInEndSection": 474,
          "text": "Statistics Canada data on annual male births in Nova Scotia were obtained for each year.The overall incidence of 1 per 4700 male births remained stable during the 30-year period of the study.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20080524"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 214,
          "text": "Duchenne muscular dystrophy (DMD) is inherited in an X-linked recessive pattern and occurs at an incidence of 1 in 3500 male births, which means that it is a so-called \"orphan\" or rare disease (frequency \u003c 1/2000).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16114258"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 244,
          "text": "Duchenne muscular dystrophy (DMD) is the most common fatal muscle disease, with an estimated incidence of 1/3500-1/5000 male births, and it is associated with mutations in the X-linked DMD gene encoding dystrophin, the largest known human gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36012442"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 117,
          "text": "Duchenne muscular dystrophy (DMD) is a common inherited disease with a worldwide incidence of 1 in 3,500 male births.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8629099"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 149,
          "text": "Duchenne muscular dystrophy (DMD) is one of the most common and severe X-linked disorders with an incidence of approximately 1 in 3500 newborn males.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7705851"
        },
        {
          "offsetInBeginSection": 701,
          "offsetInEndSection": 955,
          "text": "The cumulative birth incidence of Becker muscular dystrophy (at least 1 in 18 450 male live births) was about one third that of Duchenne muscular dystrophy (1 in 5618 male live births), suggesting that the disorder is more common than previously thought.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/1673177"
        },
        {
          "offsetInBeginSection": 57,
          "offsetInEndSection": 207,
          "text": "scular dystrophy in childhood, with a worldwide incidence of one in 5000 live male births. It is due to mutations in the dystrophin gene leading to ab",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802771"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "INTRODUCTION: Duchenne muscular dystrophy is the most common form of muscular dystrophy, with an incidence of 1/3300 male live births and a prevalence rate in the total population of 3/100000 individuals",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25996334"
        },
        {
          "offsetInBeginSection": 577,
          "offsetInEndSection": 727,
          "text": "ur region too. The incidence of Duchenne muscular dystrophy was 1 in 4827 liveborn boys. The figure is in the range of the published data of the incid",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7922631"
        },
        {
          "offsetInBeginSection": 258,
          "offsetInEndSection": 408,
          "text": "ular dystrophies the authors estimate the incidence of DMD at 1/6500 living new born boys. The number of false positives (1,5 p. 1000) is little and, ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7334342"
        }
      ],
      "body": "What is the incidence of Duchenne Muscular Dystrophy?",
      "type": "factoid",
      "id": "643f9eeb57b1c7a31500003c",
      "ideal_answer": [
        "The incidence of Duchenne Muscular Dystrophy is approximately 1:5,000 live male births",
        "Duchenne muscular dystrophy (DMDDuchenne) is a progressive Xlinked muscular disease with an overall incidence of 15000 live male births.The cumulative incidence of disease was 19.7 per 100000 ",
        "Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births. The cumulative incidence of disease was 19.7 per 100,000 male live births and 1 in 5076 live born males were diagnosed with DMD.",
        "Duchenne muscular dystrophy (DMD), an X-linked disorder, is the most common muscular dystrophy with an incidence in boys of about 200 per million births. Duchenne muscular dystrophy, an X-linked disorder, has an incidence of one in 5000 boys and presents in early childhood with proximal muscle weakness.",
        "Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births. Duchenne muscular dystrophy (DMD), an X-linked disorder, is the most common muscular dystrophy with an incidence in boys of about 200 per million births.",
        "The overall incidence of Duchenne Muscular Dystrophy is 1:5,000 live male births.",
        "Duchenne muscular dystrophy (DMD) is a progressive X-linked muscular disease with an overall incidence of 1: 5,000 live male births.",
        "The incidence of Duchenne Muscular Dystrophy (DMD) is estimated to be 1 in 3,500 to 5,000 male births worldwide.",
        "The incidence of Duchenne Muscular Dystrophy (DMD) is estimated to be 1 in 3,500 to 5,000 male births.",
        "The incidence of Duchenne Muscular Dystrophy is 1 in 5,000 live male births, with a cumulative incidence of 19.7 per 100,000 male live births.",
        "The incidence of Duchenne Muscular Dystrophy is approximately 1 in 5,000 live male births.",
        "The incidence of Duchenne Muscular Dystrophy is approximately 1:5,000 live male births, or 19.7 per 100,000 male live births, which translates to 1 in 5076 live born males being diagnosed with DMD.",
        "Duchenne muscular dystrophy (DMD/Duchenne) is a progressive X-linked muscular disease with an overall incidence of 1:5,000 live male births.",
        "Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that primarily affects males. It is caused by mutations in the dystrophin gene, which leads to progressive muscle weakness and wasting. The incidence of DMD is estimated to be approximately 1 in every 5,000 male births worldwide. However, the incidence may vary depending on the population studied and the diagnostic criteria used. In some populations, such as those with a high degree of consanguinity, the incidence may be higher. DMD is typically diagnosed in early childhood and can significantly impact quality of life and life expectancy. While there is currently no cure for DMD, there are treatments available that can help manage symptoms and improve quality of life for affected individuals. Ongoing research into potential therapies, including gene therapy and exon skipping, offers hope for future treatments that could potentially slow or even halt disease progression.",
        "Duchenne muscular dystrophy (DMD) is a rare, progressive X-linked muscular disease that affects approximately 1 in every 5,000 live male births. The cumulative incidence of the disease was found to be 19.7 per 100,000 male live births, and one in every 5,076 live born males were diagnosed with DMD. This condition is caused by mutations in the dystrophin gene and leads to muscle weakness and wasting, ultimately resulting in respiratory and cardiac failure. Early diagnosis and treatment can help manage symptoms and improve quality of life for those affected by this debilitating disease.",
        "Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle weakness and degeneration. The incidence of DMD is estimated to be approximately 1 in 3,500 to 5,000 live male births worldwide. This X-linked recessive condition primarily affects males, although females can be carriers and occasionally manifest symptoms. DMD is caused by mutations in the dystrophin gene, which leads to the absence or dysfunction of the dystrophin protein, essential for maintaining muscle integrity. The onset of symptoms typically occurs during early childhood, with affected individuals often experiencing delayed motor milestones, difficulty walking, and frequent falls. As the disease progresses, patients may require wheelchair assistance and develop respiratory and cardiac complications. Despite advances in supportive care and ongoing research into potential therapies, there is currently no cure for DMD; however, interventions such as corticosteroid treatment, physical therapy, and respiratory support can help manage symptoms and improve quality of life for those affected by this debilitating condition.",
        "The incidence of Duchenne muscular dystrophy (DMD), a progressive X-linked muscular disease, is estimated to be around 1 in 5,000 live male births. This debilitating condition affects males predominantly due to its inheritance pattern. In a study examining the cumulative incidence of DMD, it was found that 19.7 per 100,000 male live births were diagnosed with the disease, translating to approximately 1 in 5,076 live born males being affected by DMD. These figures highlight the significant impact of Duchenne muscular dystrophy on the male population and underscore the importance of ongoing research and therapeutic development for this devastating disorder."
      ],
      "exact_answer": [
        [
          "1:5,000 live male births",
          "1 in 5076 live born males",
          "1:3500-1:5000",
          "1 per 3500-6000 males born",
          "1/3300",
          "1 in 3,500 to 5,000 male births"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35940183"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183"
        },
        {
          "offsetInBeginSection": 349,
          "offsetInEndSection": 1031,
          "text": "METHODS: TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland. Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients in the BRAFV600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35940183"
        }
      ],
      "body": "Which drugs were studied in the TRICOTEL study?",
      "type": "list",
      "id": "6402ba49201352f04a000004",
      "ideal_answer": [
        "TRICOTEL trial studied atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases."
      ],
      "exact_answer": [
        [
          "atezolizumab"
        ],
        [
          "vemurafenib"
        ],
        [
          "cobimetinib"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22425592",
        "http://www.ncbi.nlm.nih.gov/pubmed/17303237",
        "http://www.ncbi.nlm.nih.gov/pubmed/15301291",
        "http://www.ncbi.nlm.nih.gov/pubmed/29684686",
        "http://www.ncbi.nlm.nih.gov/pubmed/17254633",
        "http://www.ncbi.nlm.nih.gov/pubmed/22439042",
        "http://www.ncbi.nlm.nih.gov/pubmed/2286751"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 197,
          "text": "Amniotic fluid (AF) is created by the flow of fluid from the fetal lung and bladder and reabsorbed in part by fetal swallowing and partly by the transfer across the amnion to the fetal circulation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22425592"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 232,
          "text": "Amniotic fluid contains large amounts of proteins produced by amnion epithelial cells, fetal tissues, fetal excretions and placental tissues; thus, it is an important potential source of biomarkers for identifying fetal pathologies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29684686"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 401,
          "text": "Amniotic fluid (AF), routinely used for prenatal diagnosis, contains large amounts of proteins produced by the amnion epithelial cells, fetal tissues, fetal excretions and placental tissuesAlthough many amniotic fluid proteins have been identified and are currently used to detect potential fetal anomalies, little is known about the functions of these proteins and how they interact with one another.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22439042"
        },
        {
          "offsetInBeginSection": 225,
          "offsetInEndSection": 304,
          "text": "Amniotic fluid is created by the flow of fluid from the fetal lung and bladder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17254633"
        },
        {
          "offsetInBeginSection": 155,
          "offsetInEndSection": 255,
          "text": "Amniotic fluid is produced by fetal urines with small aliquots from fetal membranes and lung fluids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15301291"
        },
        {
          "offsetInBeginSection": 331,
          "offsetInEndSection": 482,
          "text": "As fetal urine and perhaps lung liquid combine to produce amniotic fluid, maternal dehydration may affect the amniotic fluid volume and/or composition.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2286751"
        },
        {
          "offsetInBeginSection": 225,
          "offsetInEndSection": 304,
          "text": "Amniotic fluid is created by the flow of fluid from the fetal lung and bladder.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17303237"
        }
      ],
      "body": "How is amniotic fluid produced?",
      "type": "summary",
      "id": "6431f6a857b1c7a315000018",
      "ideal_answer": [
        "Amniotic fluid (AF) is created by the flow of fluid from the fetal lung and bladder and reabsorbed in part by fetal swallowing and partly by the transfer across the amnion to the fetal circulation.",
        "Amniotic fluid (AF) is created by the flow of fluid from the fetal lung and bladder and reabsorbed in part by fetal swallowing and partly by the transfer across the amnion to the fetal circulation. ",
        "Amniotic fluid is produced by fetal urine and lung liquid mixing together. It\u0027s mostly absorbed into the fetus\u0027 bloodstream after birth, although some remains inside the placenta.",
        "Amniotic fluid is produced by the fetal kidneys, lungs, and skin, and is reabsorbed by the fetal gut. It is also produced by the mother\u0027s uterus and placenta, and is exchanged between the mother and fetus through the placenta.",
        "Amniotic fluid is produced by the flow of fluid from the fetal lung and bladder and is reabsorbed in part by fetal swallowing and partly by the transfer across the amnion to the fetal circulation.",
        "Amniotic fluid is produced by the flow of fluid from the fetal lung and bladder. It is partly reabsorbed by the fetus by swallowing and partly transferred to the fetal circulation through the amnion"
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36274226"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 109,
          "text": "Bacillus Calmette-Guerin for the Treatment of Non-muscle Invasive Bladder Cancer: History and Current Status.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36274226"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 302,
          "text": "In the past decades, the bacillus Calmette-Guerin (BCG) treatment for non-muscle invasive bladder cancer, especially for intermediate and high-risk groups, is increasingly accepted by multiple guidelines. Currently, the front-line setting for the high-risk group is still intravesical BCG instillation.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36274226"
        }
      ],
      "body": "Which cancer is the BCG vaccine used for?",
      "type": "factoid",
      "_body": "Which one was the first fragment-derived drug to be approved by the US Federal Drug Administration (FDA)?",
      "_type": "factoid",
      "id": "6415c252690f196b51000011",
      "ideal_answer": [
        "The Bacillus Calmette-Guerin vaccine is used for the teatment of non-muscle invasive bladder cancer."
      ],
      "exact_answer": [
        [
          "Non-muscle Invasive Bladder Cancer"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35562158",
        "http://www.ncbi.nlm.nih.gov/pubmed/31794464",
        "http://www.ncbi.nlm.nih.gov/pubmed/23622361",
        "http://www.ncbi.nlm.nih.gov/pubmed/29933045",
        "http://www.ncbi.nlm.nih.gov/pubmed/23288328",
        "http://www.ncbi.nlm.nih.gov/pubmed/29244830",
        "http://www.ncbi.nlm.nih.gov/pubmed/31308722",
        "http://www.ncbi.nlm.nih.gov/pubmed/10734260",
        "http://www.ncbi.nlm.nih.gov/pubmed/25653289",
        "http://www.ncbi.nlm.nih.gov/pubmed/29376585",
        "http://www.ncbi.nlm.nih.gov/pubmed/29191403",
        "http://www.ncbi.nlm.nih.gov/pubmed/34568901",
        "http://www.ncbi.nlm.nih.gov/pubmed/32444167",
        "http://www.ncbi.nlm.nih.gov/pubmed/36334577"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 211,
          "offsetInEndSection": 398,
          "text": "Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35562158"
        },
        {
          "offsetInBeginSection": 190,
          "offsetInEndSection": 451,
          "text": "This chapter reviews the most common forms of congenital muscular dystrophies, including laminin α-2 (merosin) deficiency, Ullrich congenital muscular dystrophy, fukutin-related proteinopathy, rigid spine syndrome, and glycosylation disorders of α-dystroglycan.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23622361"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 290,
          "text": "OBJECTIVES: The collagen VI related muscular dystrophies (COL6-RD), Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are among the most common congenital muscular dystrophies and are characterized by distal joint laxity and a combination of distal and proximal joint c",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29244830"
        },
        {
          "offsetInBeginSection": 521,
          "offsetInEndSection": 887,
          "text": "g more heavily on genetic findings. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and α-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod,",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794464"
        },
        {
          "offsetInBeginSection": 630,
          "offsetInEndSection": 871,
          "text": "In this review, we summarize the clinical features of two of the most common congenital muscular dystrophies, COL6-related dystrophies and LAMA2-related dystrophies, which are caused by mutations in muscle ECM and basement membrane proteins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29933045"
        },
        {
          "offsetInBeginSection": 334,
          "offsetInEndSection": 441,
          "text": "Mutations in LAMA2 cause the most common type of congenital muscular dystrophies, called LAMA2 MD or MDC1A.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29191403"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 258,
          "text": "Dystroglycanopathies are a clinically and genetically diverse group of recessively inherited conditions ranging from the most severe of the congenital muscular dystrophies, Walker-Warburg syndrome, to mild forms of adult-onset limb-girdle muscular dystrophy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23288328"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 192,
          "text": "Congenital muscular dystrophy type 1A (MDC1A), the most common congenital muscular dystrophy in Western countries, is caused by recessive mutations in LAMA2, the gene encoding laminin alpha 2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34568901"
        },
        {
          "offsetInBeginSection": 607,
          "offsetInEndSection": 784,
          "text": " most common forms were those with α-dystroglycan glycosylation deficiency (40.18%) followed by those with laminin α2 deficiency (24.11%) and collagen VI deficiency (20.24%). Th",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25653289"
        },
        {
          "offsetInBeginSection": 558,
          "offsetInEndSection": 924,
          "text": "his article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and α-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794464"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 217,
          "text": "Congenital LAMA2 related muscular dystrophy (LAMA2-RD), the most commonly recognized type of congenital muscular dystrophies, has been described in patients\u0027 cohorts from Europe and the UK but not from Middle-Eastern.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32444167"
        },
        {
          "offsetInBeginSection": 386,
          "offsetInEndSection": 536,
          "text": "s and degeneration apparent at birth or in the first 6 months of life. LAMA2 MD is the most common congenital muscular dystrophy, affecting approximat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31308722"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 227,
          "text": "Fukuyama congenital muscular dystrophy is one of the most common autosomal recessive disorders in the Japanese population, characterized by congenital muscular dystrophy in combination with cortical dysgenesis (micropolygyria).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/10734260"
        },
        {
          "offsetInBeginSection": 157,
          "offsetInEndSection": 307,
          "text": "s in Laminin a2. Turk J Pediatr 2017; 59: 338-341. Laminin α2 related congenital muscular dystrophy is one of the most common congenital muscular dyst",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29376585"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 213,
          "text": "LAMA2-related congenital muscular dystrophy (MDC1A), the most commonly recognized type of congenital muscular dystrophies, is a severe neonatal onset muscle disease caused by recessive mutations in the LAMA2 gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36334577"
        }
      ],
      "body": "What are the most common congenital muscular dystrophies?",
      "type": "list",
      "id": "641791b9690f196b51000030",
      "ideal_answer": [
        "The most common congenital muscular dystrophies (CMD) are the following: dystroglycanopathies, merosin-deficient CMDs, collagen VI-deficient CMDs and LMNA-related CMDs.",
        "Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.",
        "Congenital muscular dystrophies (CMD) can be divided into four main groups based on their inheritance pattern and age at onset: dystroglycanopathies, merosin- deficient CMD, congenital collagen VI- deficient CMD, and SELENON-related rigid spine muscular dystrophy. Dystroglycanopathies are caused by mutations in genes encoding proteins involved in the synthesis of the glycogen storage protein alpha-dystroglycan, which links muscle fibers together. Merosin-deficienct CMD results from defects in the gene coding for the laminin alpha chain. Congenital collagen VI- deficiency CMD is due to a defect in a gene encoding a type II collagen precursor, leading to disturbed development of the tendons and ligaments. Finally, SELENO-related rigid spine muscular dystrophy is caused by mutations in the seleno-oxidase 1 gene, resulting in a defective enzyme that controls signaling pathways related to muscle contraction and growth.",
        "Congenital muscular dystrophies (CMD) can be divided into two main groups based on their onset; childhood-onset CMDs tend to occur earlier than adulthood-onset CMDs.  Childhood-onset CMDs can further be divided into four distinct categories depending upon the specific gene defect causing them. Dystroglycanopathies, which affect muscles and nerves, account for about 10% to 15% of childhood CMD cases. Merosin- deficient CMD accounts for 5% to 7%, while congenital collagen VI-deficiency CMD occurs at an even lower frequency. Lastly, SELENON-related rigidity spine muscular dystrophy affects a smaller subset of CMD patients. ",
        "The congenital muscular dystrophies are a diverse group of diseases characterized by hypotonia, weakness, dystrophic changes on muscle biopsies, and usually present within the first few months of life. They can be divided into four main categories based on the genetic defect identified; laminin alpha 2 merosin deficiency, Ullrich congenital muscular dystrophy, Fukutin-related proteinopathy, and rigid spine syndrome. It\u0027s essential to have an accurate diagnosis to provide appropriate care and treatments.",
        "This chapter reviews the most common forms of congenital muscular dystrophies, including laminin α-2 (merosin) deficiency, Ullrich congenital muscular dystrophy, fukutin-related proteinopathy, rigid spine syndrome, and glycosylation disorders of α-dystroglycan. The congenital muscular dystrophies (CMDs) are a group of genetically and clinically heterogeneous hereditary myopathies with preferentially autosomal recessive inheritance, that are characterized by congenital hypotonia, delayed motor development and early onset of progressive muscle weakness associated with dystrophic pattern on muscle biopsy. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and α-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies.",
        "Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD. This chapter reviews the most common forms of congenital muscular dystrophies, including laminin α-2 (merosin) deficiency, Ullrich congenital muscular dystrophy, fukutin-related proteinopathy, rigid spine syndrome, and glycosylation disorders of α-dystroglycan. The congenital muscular dystrophies (CMDs) are a group of genetically and clinically heterogeneous hereditary myopathies with preferentially autosomal recessive inheritance, that are characterized by congenital hypotonia, delayed motor development and early onset of progressive muscle weakness associated with dystrophic pattern on muscle biopsy.",
        "Congenital muscular dystrophies (CMD) include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD. The congenital muscular dystrophies (CMDs) are a group of genetically and clinically heterogeneous hereditary myopathies with preferentially autosomal recessive inheritance, that are characterized by congenital hypotonia, delayed motor development and early onset of progressive muscle weakness associated with dystrophic pattern on muscle biopsy. The collagen VI related muscular dystrophies (COL6-RD), Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) are among the most common congenital muscular dystrophies and are characterized by distal joint laxity and a combination of distal and proximal joint contractures.",
        "The most common congenital muscular dystrophies include laminin α-2 deficiency CMD, collagen VI-related CMD, and α-dystroglycan-related CMD. Other forms include Ullrich congenital muscular dystrophy, fukutin-related proteinopathy, and rigid spine syndrome.",
        "The most common congenital muscular dystrophies are:\n\n1. Duchenne muscular dystrophy (DMD)\n2. Becker muscular dystrophy (BMD)\n3. Congenital muscular dystrophy (CMD)\n4. Limb-girdle muscular dystrophy (LGMD)\n5. Myotonic dystrophy (DM)\n6. Fukuyama congenital muscular dystrophy (FCMD)",
        "The most common congenital muscular dystrophies are dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.",
        "The most common congenital muscular dystrophies include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD.",
        "Congenital muscular dystrophies (CMDs) are a group of inherited muscle disorders that typically present at birth or in early infancy. The most common types of CMDs include: \n\n1. Collagen VI-related dystrophies: These are caused by mutations in the genes that encode for collagen VI proteins, which are important components of the extracellular matrix in muscle tissue. Patients with these types of CMDs often have muscle weakness and joint contractures.\n\n2. Laminin alpha-2-related dystrophies: These are caused by mutations in the LAMA2 gene, which encodes for laminin alpha-2 protein. Patients with these types of CMDs often have severe muscle weakness and respiratory insufficiency.\n\n3. Dystroglycanopathies: These are caused by mutations in genes that affect the glycosylation of alpha-dystroglycan, a protein that is important for maintaining the structural integrity of muscle cells. Patients with these types of CMDs often have brain abnormalities in addition to muscle weakness.\n\n4. Rigid spine syndrome: This is caused by mutations in the SEPN1 gene, which encodes for selenoprotein N. Patients with this type of CMD often have spinal rigidity and respiratory insufficiency.\n\n5. Nemaline myopathy: This is caused by mutations in genes that affect the structure and function of skeletal muscle fibers. Patients with this type of CMD often have muscle weakness and respiratory insufficiency.\n\nOverall, early diagnosis and management can improve outcomes for patients with CMDs, but treatment options remain limited and largely supportive.",
        "Congenital muscular dystrophies (CMD) are a group of inherited muscle disorders that manifest at birth or in early infancy. The most common types of CMD include dystroglycanopathies, merosin-deficient CMD, collagen VI-deficient CMD, SELENON-related rigid spine muscular dystrophy, and LMNA-related CMD. Dystroglycanopathies are the most frequent form of CMD and are caused by mutations in genes involved in the glycosylation of alpha-dystroglycan. Merosin-deficient CMD is characterized by a lack of laminin-alpha2 protein in muscle fibers. Collagen VI-deficient CMD is caused by mutations in one of the three genes encoding collagen VI proteins. SELENON-related rigid spine muscular dystrophy is a rare form of CMD caused by mutations in the SEPN1 gene. Finally, LMNA-related CMD is caused by mutations in the LMNA gene encoding lamin A/C proteins. Early diagnosis and management are crucial for improving outcomes for individuals with these conditions.",
        "Congenital muscular dystrophies (CMDs) are a group of genetically and clinically heterogeneous muscle disorders characterized by muscle weakness and hypotonia from birth or early infancy. The most common forms of CMD include Ullrich congenital muscular dystrophy (UCMD), Merosin-deficient congenital muscular dystrophy type 1A (MDC1A), Walker-Warburg syndrome (WWS), Fukuyama congenital muscular dystrophy (FCMD), and Muscle-eye-brain disease (MEB). UCMD is caused by mutations in the COL6A1, COL6A2, or COL6A3 genes, which affect collagen VI production. MDC1A results from mutations in the LAMA2 gene, leading to a deficiency of laminin-α2 protein. WWS, FCMD, and MEB are classified as alpha-dystroglycanopathies due to defects in glycosylation of alpha-dystroglycan; they are caused by mutations in different genes such as POMT1, POMT2, FKTN, and POMGNT1. These conditions present with varying degrees of muscle weakness, joint contractures, and central nervous system involvement. Early diagnosis and multidisciplinary management can help improve the quality of life for individuals affected by these disorders.",
        "The most common congenital muscular dystrophies (CMD) encompass a group of genetically and clinically heterogeneous disorders characterized by muscle weakness and hypotonia from birth or early infancy. These include dystroglycanopathies, which are caused by defects in the glycosylation of alpha-dystroglycan; merosin-deficient CMD, also known as laminin alpha-2 deficient CMD, resulting from mutations in the LAMA2 gene; collagen VI-deficient CMD, associated with mutations in the genes encoding collagen VI (COL6A1, COL6A2, and COL6A3); SELENON-related rigid spine muscular dystrophy, caused by mutations in the SELENON gene; and LMNA-related CMD, linked to mutations in the LMNA gene encoding lamin A/C proteins. Each of these subtypes presents with varying clinical features and severity but shares the hallmark symptoms of muscle weakness and hypotonia. Early diagnosis and appropriate management are crucial for improving patients\u0027 quality of life and prognosis."
      ],
      "exact_answer": [
        [
          "dystroglycanopathies"
        ],
        [
          "merosin-deficient CMD",
          "merosin-deficient congenital muscular dytrophy"
        ],
        [
          "collagen VI-deficient CMD",
          "collagen VI-deficient congenital muscular dytrophy"
        ],
        [
          "LMNA-related CMD",
          "LMNA-related congenital muscular dytrophy"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35661166",
        "http://www.ncbi.nlm.nih.gov/pubmed/35749004"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 55,
          "text": "Teclistamab in Relapsed or Refractory Multiple Myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166"
        },
        {
          "offsetInBeginSection": 199,
          "offsetInEndSection": 345,
          "text": "In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166"
        },
        {
          "offsetInBeginSection": 1946,
          "offsetInEndSection": 2102,
          "text": "CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35661166"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 105,
          "text": "Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35749004"
        }
      ],
      "body": "What disease can be treated with Teclistamab?",
      "type": "factoid",
      "id": "63eeed0af36125a426000007",
      "ideal_answer": [
        "Teclistamab can be used for Multiple Myeloma."
      ],
      "exact_answer": [
        [
          "Multiple Myeloma"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36152606",
        "http://www.ncbi.nlm.nih.gov/pubmed/33520785",
        "http://www.ncbi.nlm.nih.gov/pubmed/33002457",
        "http://www.ncbi.nlm.nih.gov/pubmed/19747125",
        "http://www.ncbi.nlm.nih.gov/pubmed/16548773",
        "http://www.ncbi.nlm.nih.gov/pubmed/12843686",
        "http://www.ncbi.nlm.nih.gov/pubmed/22382054",
        "http://www.ncbi.nlm.nih.gov/pubmed/7496058",
        "http://www.ncbi.nlm.nih.gov/pubmed/33130802",
        "http://www.ncbi.nlm.nih.gov/pubmed/34871602",
        "http://www.ncbi.nlm.nih.gov/pubmed/22145138",
        "http://www.ncbi.nlm.nih.gov/pubmed/17965966",
        "http://www.ncbi.nlm.nih.gov/pubmed/23776857",
        "http://www.ncbi.nlm.nih.gov/pubmed/18703404",
        "http://www.ncbi.nlm.nih.gov/pubmed/12189309",
        "http://www.ncbi.nlm.nih.gov/pubmed/18407084",
        "http://www.ncbi.nlm.nih.gov/pubmed/11339846",
        "http://www.ncbi.nlm.nih.gov/pubmed/8834155",
        "http://www.ncbi.nlm.nih.gov/pubmed/16487258",
        "http://www.ncbi.nlm.nih.gov/pubmed/19149542",
        "http://www.ncbi.nlm.nih.gov/pubmed/16269246",
        "http://www.ncbi.nlm.nih.gov/pubmed/15758553",
        "http://www.ncbi.nlm.nih.gov/pubmed/26961205",
        "http://www.ncbi.nlm.nih.gov/pubmed/25506340",
        "http://www.ncbi.nlm.nih.gov/pubmed/29859763",
        "http://www.ncbi.nlm.nih.gov/pubmed/11476733",
        "http://www.ncbi.nlm.nih.gov/pubmed/12783635",
        "http://www.ncbi.nlm.nih.gov/pubmed/31771521",
        "http://www.ncbi.nlm.nih.gov/pubmed/8392634",
        "http://www.ncbi.nlm.nih.gov/pubmed/8967430",
        "http://www.ncbi.nlm.nih.gov/pubmed/16565701"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 205,
          "text": "Nonlinear laser wave-mixing spectroscopy is demonstrated as a fast and sensitive detection method for heart-failure biomarkers, pro-atrial natriuretic peptide (proANP) and brain natriuretic peptide (BNP). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36152606"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 380,
          "text": "Natriuretic peptides are biomarkers of myocardial stress and are frequently elevated among patients with severe respiratory illnesses, typically in the absence of elevated cardiac-filling pressures or clinical heart failure. Elevation of brain natriuretic peptide (BNP) or NT-proBNP is associated with worse outcomes among patients with Acute Respiratory Distress Syndrome (ARDS).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33520785"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "Natriuretic peptides (NPs, B-type natriuretic peptide /BNP and NT-proBNP) are universally used biomarkers with established cut-points to aid in the diagnosis of heart failure (HF).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33002457"
        },
        {
          "offsetInBeginSection": 272,
          "offsetInEndSection": 508,
          "text": "Eight natriuretic peptides have been described so far: ANP, BNP, CNP, DNP, urodilatin, uroguanylin, osteocrin, musculin and three receptors: NPR-A, NPR-B and NPR-C thanks to which these hormones accomplish their physiological functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33130802"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34871602"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 242,
          "text": "Natriuretic peptides (atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide) are cardiac and vascular peptides with vasodilatory, diuretic, natriuretic, anti-inflammatory, antifibrotic and antimitogenic actions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16548773"
        },
        {
          "offsetInBeginSection": 135,
          "offsetInEndSection": 411,
          "text": "There are four different groups NPs identified till date [atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and dendroaspis natriuretic peptide, a D-type natriuretic peptide (DNP)], each with its own characteristic functions.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22145138"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "The natriuretic peptide family comprises atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide (DNP), and urodilatin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965966"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 164,
          "text": "The natriuretic system consists of the atrial natriuretic peptide (ANP) and four other similar peptides including the wrongly named brain natriuretic peptide (BNP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776857"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 201,
          "text": "The natriuretic peptide family is comprised of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), dendroaspis natriuretic peptide - DNP and urodilatin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19747125"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 200,
          "text": "Four major natriuretic peptides have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), and Dendroaspis-type natriuretic peptide (DNP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18703404"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 315,
          "text": "Atrial natriuretic peptides (ANPs) consist of a family of peptides (atrial natriuretic factor [ANF], long acting natriuretic peptide, vessel dilator, kaliuretic peptide, urodilatin, brain natriuretic peptide [BNP], and C type natriuretic peptide [CNP]) which are synthesized within the heart, except for urodilatin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12189309"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 286,
          "text": "Since the discovery of the natriuretic effect of atrial natriuretic peptide (ANP), a family of other natriuretic peptides similar to ANP were isolated, including atriopeptin, vessel dilator, long-acting natriuretic peptide, urodilatin, and brain natriuretic peptide (BNP) to name a few.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11339846"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 364,
          "text": "The natriuretic peptide system is a complicated system comprising at least three endogenous peptides (atrial natriuretic peptide, brain natriuretic peptide and C-type natriuretic peptide) and three receptors [the atrial natriuretic peptide-A receptor (guanylyl cyclase A), the atrial natriuretic peptide-B receptor (guanylyl cyclase B) and the clearance receptor].",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8834155"
        },
        {
          "offsetInBeginSection": 170,
          "offsetInEndSection": 332,
          "text": "126 amino acid atrial natriuretic peptide (ANP), 108 amino acid B-type natriuretic peptide (BNP) and 103 amino acid C-type natriuretic peptide (CNP) prohormones).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16487258"
        },
        {
          "offsetInBeginSection": 336,
          "offsetInEndSection": 707,
          "text": "The recent description of the C-type peptide CNP, the major brain-derived peptide, has suggested that original studies examining the endocrine actions of the natriuretic peptides using A-type (ANP) or B-type (BNP) isoforms might have underestimated some of the biopotency of the natriuretic peptides or even failed to detect the full spectrum of the family\u0027s bioactivity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18407084"
        },
        {
          "offsetInBeginSection": 274,
          "offsetInEndSection": 496,
          "text": "The NP family includes atrial natriuretic peptide (ANP, 28AA), urodilatin (INN: Ularitide, 32 AA), B-type natriuretic peptide (BNP, 32AA), C-type natriuretic peptide (CNP, 22AA), and D-type natriuretic peptide (DNP, 38AA).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19149542"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 171,
          "text": "Atrial cardiocytes in the heart of mammals produce in a regulated manner the polypeptide hormones atrial natriuretic factor (ANF, ANP) and brain natriuretic peptide (BNP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16269246"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 165,
          "text": "Three types of natriuretic peptides (NP) have been isolated: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/15758553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Natriuretic hormones (NH) include three groups of compounds: the natriuretic peptides (ANP, BNP and CNP), the gastrointestinal peptides (guanylin and uroguanylin), and endogenous cardiac steroids.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/25506340"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 195,
          "text": "The natriuretic peptide family consists of three biologically active peptides: atrial natriuretic peptide (ANP), brain (or B-type) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29859763"
        },
        {
          "offsetInBeginSection": 169,
          "offsetInEndSection": 429,
          "text": "The family consists of an atrial natriuretic peptide (ANP) and a brain natriuretic peptide (BNP) of myocardial cell origin, a C-type natriuretic peptide (CNP) of endothelial origin, and a urodilatin (Uro) which is processed from a prohormone ANP in the kidney.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26961205"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Natriuretic peptides family consists of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP), while receptors for these natriuretic peptides comprise at least three subtypes, i.e.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8392634"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 196,
          "text": "Natriuretic peptide family consists of several hormones produced by cardiomyocyte, including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22382054"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 299,
          "text": "Four types of natriuretic peptides have been found thus far: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and Dendroaspis natriuretic peptide (DNP).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12843686"
        },
        {
          "offsetInBeginSection": 111,
          "offsetInEndSection": 351,
          "text": "The natriuretic peptides - atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide - comprise a family of proteins that participate in the integrated control of intravascular volume and arterial blood pressure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11476733"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 144,
          "text": "The natriuretic peptide family consists of three members: atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7496058"
        },
        {
          "offsetInBeginSection": 128,
          "offsetInEndSection": 293,
          "text": "They consist of atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide and are elevated in patients with left ventricular dysfunction.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12783635"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 229,
          "text": "Cardiac natriuretic peptides (including ANP, BNP, CNP and urodilatin) constitute a family of peptide hormones and neurotransmitters, sharing similar chemical structure (characterized by a cysteine bridge) and biological function.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16565701"
        },
        {
          "offsetInBeginSection": 183,
          "offsetInEndSection": 333,
          "text": " that activate receptor guanylate cyclases, namely, natriuretic peptide receptor (NPR)-A and NPR-B. Exposure of cells to atrial natriuretic peptide (A",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/8967430"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 168,
          "text": "BACKGROUND: In mammals, the natriuretic system contains three natriuretic peptides, NPPA, NPPB and NPPC, that bind to three transmembrane receptors, NPR1, NPR2 and NPR3",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31771521"
        }
      ],
      "body": "Please list the natriuretic peptides.",
      "type": "list",
      "id": "643d3e6157b1c7a315000034",
      "ideal_answer": [
        "Natriuretic peptides (NPs, B-type natriuretic peptide /BNP and NT-proBNP) are universally used biomarkers with established cut-points to aid in the diagnosis of heart failure (HF)",
        "The eight natriuretic peptides described so far are ANP, BNP, CNP, DNP, urodilatin, uroguanylin, osteocrin, and musculin.",
        "1. Atrial natriuretic peptide (ANP)\n2. Brain natriuretic peptide (BNP)\n3. C-type natriuretic peptide (CNP)\n4. Urodilatin (UDN)",
        "The natriuretic peptides are a family of hormones that include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP)."
      ],
      "exact_answer": [
        [
          "B-type natriuretic peptide",
          "brain type natriuretic peptide"
        ],
        [
          "NT-proBNP"
        ],
        [
          "DNP"
        ],
        [
          "CNP"
        ],
        [
          "eurodilatin"
        ],
        [
          "uroguanylin"
        ],
        [
          "ANP"
        ],
        [
          "osteocrin"
        ],
        [
          "Musculin"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/31559909"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 88,
          "text": "Neuronal-specific microexon splicing of TAF1 mRNA is directly regulated by SRRM4/nSR100.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31559909"
        },
        {
          "offsetInBeginSection": 688,
          "offsetInEndSection": 964,
          "text": "Knockdown and ectopic expression experiments demonstrate that the neuronal-specific splicing factor SRRM4/nSR100 promotes the inclusion of microexon 34\u0027 into TAF1 mRNA, through the recognition of UGC sequences in the poly-pyrimidine tract upstream of the regulated microexon. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31559909"
        }
      ],
      "body": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?",
      "type": "yesno",
      "id": "63f9ee5c33942b094c000014",
      "ideal_answer": [
        "Neuronal-specific microexon splicing of TAF1 mRNA is directly regulated by SRRM4/nSR100."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21496633",
        "http://www.ncbi.nlm.nih.gov/pubmed/31794465",
        "http://www.ncbi.nlm.nih.gov/pubmed/30871534"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 544,
          "offsetInEndSection": 811,
          "text": "FSHD type 1 (FSHD1) is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHD type 2 (FSHD2) is due to mutations in SMCHD1 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31794465"
        },
        {
          "offsetInBeginSection": 448,
          "offsetInEndSection": 677,
          "text": "The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496633"
        },
        {
          "offsetInBeginSection": 371,
          "offsetInEndSection": 585,
          "text": "In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4, whereas FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534"
        },
        {
          "offsetInBeginSection": 213,
          "offsetInEndSection": 370,
          "text": "There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30871534"
        }
      ],
      "body": "What is the difference between Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1) and type 2 (FSHD2)?",
      "type": "summary",
      "id": "644281e557b1c7a31500005b",
      "ideal_answer": [
        "FSHD type 1 (FSHD1) and FSHD type 2 (FSHD2)  have different genetic causes but are phenotypically indistinguishable. FSHD1 is caused by a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHD type 2 (FSHD2) is due to mutations in SMCHD1 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4.",
        "FSHD type 1 (FSHD1) is due to a deletion on chromosome 4q leading to hypomethylation and derepression of DUX4. FSHD type 2 (FSHD2) is due to mutations in SMCHD1 with resulting hypomethylation of th",
        "FSHD type 1 (FSHD1) is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHD type 2 (FSHD2) is due to mutations in SMCHD1 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4. The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4) In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4, whereas FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1. There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable.",
        "FSHD1 is caused by a deletion on chromosome 4q, while FSHD2 is caused by mutations in SMCHD1. FSHD affects facial muscles, muscles that fix the scapula, and muscles overlying the humerus. The unique feature of each form of FSHD is due to specific genetic mutations. Understanding the central role of DUX4 has led to ongoing research into potential disease-modifying treatments. There are several validated outcome measures used in clinical trials, including MRI, 6-minute walk test, FSHD Composite Outcome Measure,reachable workspace, electrical impedance myography, and the FSHD Health Index.",
        "There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable. In recent years, the advances of knowledge in clinical, genetic and epigenetic features of facioscapulohumeral muscular dystrophy (FSHD) allowed the identification of two forms of FSHD, the classical autosomal dominant FSHD type 1, and FSHD type 2 characterized by an identical clinical phenotype but associated with a different (epi)genetic defect.In the large majority of FSHD1 patients, the identification of D4Z4 pathogenic contraction on a permissive chromosome 4 is sufficient for diagnosis, while FSHD2 diagnosis is complicated by the fact that the genetic defect associated with this disease is not known yet and a complete D4Z4 genotype and a D4Z4 specific methylation test are required. This article describes the clinical characteristics, diagnosis, molecular pathogenesis, and treatment of facioscapulohumeral muscular dystrophy (FSHD).FSHD comprises two genetically distinct types that converge on a common downstream pathway of the expression of the toxic protein DUX4. Facioscapulohumeral muscular dystrophy (FSHD: MIM#158900) is a common myopathy with marked but largely unexplained clinical inter- and intra-familial variability. Approximately 95% of patients have FSHD type 1 (FSHD1), in which loss of DNA repetitive elements (D4Z4 repeats) in the subtelomeric region of chromosome 4q causes decreased methylation and epigenetic derepression of DUX4, a gene contained within each D4Z4 repeat. Whereas FSHD1 is dominantly inherited, FSHD2 shows digenic inheritance, and about 80% of patients will have a mutation in the SMCHD1 gene.",
        "FSHD type 1 (FSHD1) is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHD type 2 (FSHD2) is due to mutations in SMCHD1 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4. The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4) In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4, whereas FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1. There are two types of the disease: FSHD1 (MIM:158900) and FSHD2 (MIM: 158901), which have different genetic causes but are phenotypically indistinguishable. In recent years, the advances of knowledge in clinical, genetic and epigenetic features of facioscapulohumeral muscular dystrophy (FSHD) allowed the identification of two forms of FSHD, the classical autosomal dominant FSHD type 1, and FSHD type 2 characterized by an identical clinical phenotype but associated with a different (epi)genetic defect.In the large majority of FSHD1 patients, the identification of D4Z4 pathogenic contraction on a permissive chromosome 4 is sufficient for diagnosis, while FSHD2 diagnosis is complicated by the fact that the genetic defect associated with this disease is not known yet and a complete D4Z4 genotype and a D4Z4 specific methylation test are required.",
        "FSHD type 1 (FSHD1) is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHD type 2 (FSHD2) is due to mutations in SMCHD1 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4. The molecular genetics of FSHD are complex, with current understanding focusing on epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4) In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4, whereas FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1. Facioscapulohumeral muscular dystrophy (FSHD: MIM#158900) is a common myopathy with marked but largely unexplained clinical inter- and intra-familial variability. Whereas FSHD1 is dominantly inherited, FSHD2 shows digenic inheritance, and about 80% of patients will have a mutation in the SMCHD1 gene.",
        "FSHD type 1 is caused by a partial deletion of the D4Z4 repeats on chromosome 4q, leading to hypomethylation and derepression of DUX4. On the other hand, FSHD type 2 is caused by mutations in the SMCHD1 gene, resulting in hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4. While both types have the same clinical phenotype, they have different (epi)genetic defects.",
        "FSHD1 is caused by a genetic mutation in the DUX4 gene, while FSHD2 is caused by a genetic mutation in the SMCHD1 gene. FSHD1 is characterized by progressive muscle weakness and wasting in the face, shoulder blades, and upper arms, while FSHD2 is characterized by milder muscle weakness and wasting in the same areas. FSHD1 is more common than FSHD2.",
        "Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by a deletion of 3.3 kb of DNA in the D4Z4 repeat array on chromosome 4q35. FSHD2 is caused by mutations in the SMCHD1 gene, which is located on chromosome 18q12.1. FSHD1 is the most common form of FSHD, while FSHD2 is much rarer.",
        "FSHD1 is caused by a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHD2 is caused by mutations in SMCHD1 with resulting hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4. Both types of the disease are phenotypically indistinguishable, but have different genetic causes.",
        "FSHD type 1 is caused by a partial deletion of D4Z4 repeats on chromosome 4, whereas FSHD type 2 is caused by mutations in the SMCHD1 gene. Both result in the derepression of DUX4 gene causing muscle weakness and wasting, and they are phenotypically indistinguishable",
        "FSHD1 and FSHD2 are two types of Facioscapulohumeral Muscular Dystrophy with similar symptoms but different genetic causes. FSHD1 results from a deletion in the D4Z4 repeats on chromosome 4, while FSHD2 is due to mutations in the SMCHD1 gene. Both types lead to abnormal expression of the DUX4 protein, causing muscle weakness and wasting",
        "In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4, whereas FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.",
        "FSHD type 1 (FSHd1) is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of DUX4. FSHDtype 2 (F SHD2) is caused by the mutations in the protein regulating the methylation status of chromatin - SMCHD1.",
        "FSHD type 1 (F SHHD1) is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of Dux4. FSHDtype 2 (FSH D2) isDue to mutations in SMCHD1 with resulting hypomet hylation of the same subtelomeric region of the 4th chromosome and expression of DUX4.",
        "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. FSHD can be classified into two types: FSHD1 and FSHD2. The main difference between these two types is the genetic cause of the disease. FSHD1 is caused by a deletion in a region of chromosome 4 called D4Z4, while FSHD2 is caused by mutations in a gene called SMCHD1 on chromosome 18. \n\nFSHD1 is more common than FSHD2 and tends to have an earlier onset and more severe symptoms. In addition to facial and upper body muscle weakness, individuals with FSHD1 may also experience hearing loss and retinal abnormalities. On the other hand, FSHD2 typically has a later onset and milder symptoms, although this can vary among individuals.\n\nDiagnosis of FSHD involves genetic testing to determine whether there are changes in the D4Z4 region or mutations in the SMCHD1 gene. While there is currently no cure for FSHD, treatment options such as physical therapy and assistive devices can help manage symptoms and improve quality of life for affected individuals.",
        "Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. There are two types of FSHD: type 1 (FSHD1) and type 2 (FSHD2). FSHD1 is caused by a deletion on chromosome 4q, which leads to hypomethylation and derepression of DUX4. In contrast, FSHD2 is caused by mutations in SMCHD1, resulting in hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4. Although both types have similar clinical presentations, they have different genetic causes. Understanding these differences is important for accurate diagnosis and treatment strategies for patients with FSHD.",
        "Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic muscle disorder characterized by progressive weakness and atrophy of facial, shoulder, and upper arm muscles. FSHD has two main subtypes: FSHD1 and FSHD2. The primary difference between these subtypes lies in their genetic causes. FSHD1, the more common form, is caused by a contraction of the D4Z4 repeat array on chromosome 4q35, leading to the aberrant expression of the DUX4 gene. In contrast, FSHD2 results from mutations in the SMCHD1 gene on chromosome 18p11.32, which also leads to misregulation of DUX4 expression but through an epigenetic mechanism involving DNA methylation. Both types share similar clinical features; however, disease onset tends to be earlier and more severe in FSHD1 compared to FSHD2. Additionally, while FSHD1 follows an autosomal dominant inheritance pattern with nearly complete penetrance, FSHD2 exhibits a more complex digenic inheritance pattern requiring both SMCHD1 mutation and specific permissive haplotypes on chromosome 4q35. Despite these differences in genetic etiology and inheritance patterns, both forms ultimately converge on dysregulated DUX4 expression as the key molecular driver underlying muscle pathology in FSHD.",
        "Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder with two types, FSHD1 and FSHD2, which are phenotypically indistinguishable but have different genetic causes. FSHD1 is due to a deletion on chromosome 4q, leading to hypomethylation and derepression of the DUX4 gene. This occurs through partial deletion of the D4Z4 repeats on the 4th chromosome, affecting the expression of DUX4. On the other hand, FSHD2 is caused by mutations in the SMCHD1 gene, which encodes a protein that regulates chromatin methylation status. These mutations result in hypomethylation of the same subtelomeric region of chromosome 4q and derepression of DUX4 as well. The molecular genetics of both FSHD types are complex and involve epigenetic effects related to contraction-dependent (FSHD1) and contraction-independent (FSHD2) effects of a hypomethylated repeat sequence (D4Z4)."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35789381",
        "http://www.ncbi.nlm.nih.gov/pubmed/35045228",
        "http://www.ncbi.nlm.nih.gov/pubmed/36158136"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 164,
          "offsetInEndSection": 279,
          "text": "In ECOSPOR III, SER-109, an investigational oral microbiome therapeutic, was superior to placebo in reducing rCDI. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35789381"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 85,
          "text": "SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045228"
        },
        {
          "offsetInBeginSection": 197,
          "offsetInEndSection": 343,
          "text": "SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35045228"
        },
        {
          "offsetInBeginSection": 218,
          "offsetInEndSection": 464,
          "text": "We report that the manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed to reduce risk of Clostridioides difficile recurrence, inactivate porcine epidemic diarrhea virus, a model coronavirus for SARS-CoV-2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36158136"
        }
      ],
      "body": "SER-109 is developed for prevention of which disease?",
      "type": "factoid",
      "id": "63f03ea0f36125a426000020",
      "ideal_answer": [
        "SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection."
      ],
      "exact_answer": [
        [
          "C. difficile"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/12181221",
        "http://www.ncbi.nlm.nih.gov/pubmed/11869491",
        "http://www.ncbi.nlm.nih.gov/pubmed/24972991",
        "http://www.ncbi.nlm.nih.gov/pubmed/18296754",
        "http://www.ncbi.nlm.nih.gov/pubmed/14608856",
        "http://www.ncbi.nlm.nih.gov/pubmed/34400890",
        "http://www.ncbi.nlm.nih.gov/pubmed/848859",
        "http://www.ncbi.nlm.nih.gov/pubmed/32858578",
        "http://www.ncbi.nlm.nih.gov/pubmed/18354242",
        "http://www.ncbi.nlm.nih.gov/pubmed/7789711"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 341,
          "offsetInEndSection": 550,
          "text": "hey are genetically identical and those with twin-twin transfusion syndrome(TTTS) provide an ideal natural model in whom to study the influence of differing haemodynamic stresses on the developing vascular tre",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/11869491"
        },
        {
          "offsetInBeginSection": 13,
          "offsetInEndSection": 278,
          "text": "n twin-to-twin transfusion syndrome (TTTS), genetically identical twins are exposed to different haemodynamic conditions during fetal life, which are considered to be the cause of prenatal and postnatal cardiovascular differences between the donor and the recipient",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24972991"
        },
        {
          "offsetInBeginSection": 10,
          "offsetInEndSection": 195,
          "text": " To test the hypothesis that identical twins show no inter-twin differences in cardiovascular structure or physiology in fetal life unless there has been twin-twin transfusion syndrome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12181221"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 190,
          "text": "Twin-twin transfusion syndrome (TTTS) is an unusual and serious condition that occurs in twin pregnancies when identical twins share a placenta but develop discordant amniotic fluid volumes.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34400890"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Twin-twin transfusion syndrome (TTTS) is a severe complication of monozygotic (identical) twins, which share one single monochorionic placenta.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18296754"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 147,
          "text": "Twin-twin transfusion syndrome (TTTS) is a severe complication of monozygotic (identical) twin fetuses sharing one single (monochorionic) placenta.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18354242"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 180,
          "text": "OBJECTIVE: Twin-twin transfusion syndrome (TTTS) is a severe pregnancy complication of monochorionic (identical) twins that results in markedly discordant in utero environments for",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32858578"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 673,
          "text": "BACKGROUND: In twin-to-twin transfusion syndrome (TTTS), genetically identical twins are exposed to different haemodynamic conditions during fetal life, which are considered to be the cause of prenatal and postnatal cardiovascular differences between the donor and the recipient.OBJECTIVE: To assess intertwin differences on childhood cardiac outcome after intrauterine laser coagulation therapy (LC) of severe TTTS.DESIGN AND PATIENTS: Prospective, detailed, echocardiographic follow-up of 31 twin pairs aged 9.95±0.8 years (mean±SD) with severe TTTS treated by LC, and the comparison with reference values.RESULTS: Cardiac function was normal and did not show intertwin d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24972991"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 159,
          "text": "Twin-twin transfusion syndrome is a serious complication of monozygotic, monochorionic, diamniotic twins resulting from transplacental vascular communications.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/14608856"
        },
        {
          "offsetInBeginSection": 2656,
          "offsetInEndSection": 2807,
          "text": " Most likely, the identical twin transfusion syndrome produces anoxia and brain damage during early prenatal development in the smaller identical twin.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/848859"
        },
        {
          "offsetInBeginSection": 202,
          "offsetInEndSection": 412,
          "text": " A likely explanation for the association between birthweight and intelligence among identical twins is the identical twin transfusion syndrome which occurs only between some monochorionic identical twin pairs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/848859"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 90,
          "text": "The twin-twin transfusion syndrome is a rare but severe complication in monozygotic twins.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/7789711"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 220,
          "text": "Monochorionic twins are at increased risk for unique complications including twin-twin transfusion syndrome (TTTS), selective intrauterine growth restriction (sIUGR), and twin-reversed arterial perfusion (TRAP) sequence.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22536818"
        }
      ],
      "body": "In twin-twin transfusion syndrome, are the twins identical?",
      "type": "yesno",
      "id": "6431f71057b1c7a315000019",
      "ideal_answer": [
        "In twin-to-twin transfusion syndrome (TTTS), genetically identical twins are exposed to different haemodynamic conditions during fetal life.",
        "Yes, in twin-twin transfusion syndrome, the twins are genetically identical.",
        "Yes, twin-twin transfusion syndrome occurs in identical twins.",
        "No, twin-twin transfusion syndrome (TTTS) occurs in monozygotic twins, but they are not necessarily identical twins.",
        "Yes, twins with twin-twin transfusion syndrome are genetically identical.",
        "Yes, in twin-twin transfusion syndrome, the twins are identical, meaning they share the same genetic material."
      ],
      "exact_answer": "yes"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35118122"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Trichotillomania is defined as an obsessive-compulsive or related disorder in which patients recurrently pull out hair from any region of their body. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35118122"
        }
      ],
      "body": "What is the definition of trichotillomania?",
      "type": "summary",
      "id": "6414c1ae690f196b51000003",
      "ideal_answer": [
        "Trichotillomania is defined as an obsessive-compulsive or related disorder in which patients recurrently pull out hair from any region of their body."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/28867298",
        "http://www.ncbi.nlm.nih.gov/pubmed/19461958",
        "http://www.ncbi.nlm.nih.gov/pubmed/18935728",
        "http://www.ncbi.nlm.nih.gov/pubmed/12488581",
        "http://www.ncbi.nlm.nih.gov/pubmed/24274981",
        "http://www.ncbi.nlm.nih.gov/pubmed/28028563",
        "http://www.ncbi.nlm.nih.gov/pubmed/12145744",
        "http://www.ncbi.nlm.nih.gov/pubmed/36361862",
        "http://www.ncbi.nlm.nih.gov/pubmed/24627880",
        "http://www.ncbi.nlm.nih.gov/pubmed/31661024",
        "http://www.ncbi.nlm.nih.gov/pubmed/33870095",
        "http://www.ncbi.nlm.nih.gov/pubmed/18471087",
        "http://www.ncbi.nlm.nih.gov/pubmed/2889148",
        "http://www.ncbi.nlm.nih.gov/pubmed/24014122",
        "http://www.ncbi.nlm.nih.gov/pubmed/2541343",
        "http://www.ncbi.nlm.nih.gov/pubmed/16936400",
        "http://www.ncbi.nlm.nih.gov/pubmed/28247611",
        "http://www.ncbi.nlm.nih.gov/pubmed/19078586",
        "http://www.ncbi.nlm.nih.gov/pubmed/28740938",
        "http://www.ncbi.nlm.nih.gov/pubmed/12619170",
        "http://www.ncbi.nlm.nih.gov/pubmed/6655672"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 104,
          "text": "The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28867298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 155,
          "text": "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19461958"
        },
        {
          "offsetInBeginSection": 130,
          "offsetInEndSection": 255,
          "text": "The disease is caused by deletion, duplication or point mutation of the dystrophin gene, located on the X chromosome (Xp21). ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18935728"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 96,
          "text": "DMD gene which is composed of 79 exons is the largest known gene located on X chromosome (Xp21).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24274981"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Dystrophinopathies are allelic conditions caused by deletions, duplications and point-mutations in the DMD gene, located on the X chromosome (Xp21.2).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33870095"
        },
        {
          "offsetInBeginSection": 197,
          "offsetInEndSection": 276,
          "text": "The disease is caused by mutations in the DMD gene located on the X chromosome.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36361862"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 98,
          "text": "BACKGROUND: The Duchenne muscular dystrophy (DMD) gene is located in the short arm of the X chromo",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24627880"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 154,
          "text": "Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder caused by mutations in the dystrophin DMD gene located at Xp21.1 region.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18471087"
        },
        {
          "offsetInBeginSection": 401,
          "offsetInEndSection": 678,
          "text": "Because the DMD gene is located at Xp21.2, which is one breakpoint of the inv(X), and because its defects are rarely associated with severe mental retardation, the other clinical features of this patient were deemed likely to be associated with the opposite breakpoint at Xq22.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12145744"
        },
        {
          "offsetInBeginSection": 241,
          "offsetInEndSection": 368,
          "text": "Long-range physical mapping has shown that the DMD gene, localized in Xp21, is extremely large, exceeding 2 million base pairs.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2889148"
        },
        {
          "offsetInBeginSection": 329,
          "offsetInEndSection": 415,
          "text": "The DMD gene, located on Xp21, is the largest human gene in the human genome (2.3 Mb).",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014122"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 193,
          "text": "The Duchenne muscular dystrophy (DMD) gene has been localized to chromosome Xp21 and codes for a 14-kilobase (kb) transcript and a protein called dystrophin, of relative molecular mass 427,000.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/2541343"
        },
        {
          "offsetInBeginSection": 640,
          "offsetInEndSection": 772,
          "text": " The breakpoint in our patient is also located at Xp21, adding evidence for the assignment of this band as the site of the DMD gene.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/6655672"
        },
        {
          "offsetInBeginSection": 328,
          "offsetInEndSection": 409,
          "text": " The DMD gene, located on Xp21, is the largest human gene in the human genome (2.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014122"
        },
        {
          "offsetInBeginSection": 297,
          "offsetInEndSection": 381,
          "text": " The present case supports the hypothesis that the DMD gene must be located at Xp21.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3777020"
        },
        {
          "offsetInBeginSection": 185,
          "offsetInEndSection": 272,
          "text": " The causal gene of DMD is the largest one in human that locates in the region of Xp21.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28247611"
        },
        {
          "offsetInBeginSection": 400,
          "offsetInEndSection": 441,
          "text": " Because the DMD gene is located at Xp21.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12145744"
        },
        {
          "offsetInBeginSection": 39,
          "offsetInEndSection": 189,
          "text": "n coded by the Duchenne muscular dystrophy (DMD) gene located on the X-chromosome. Truncating mutations in the DMD gene cause loss of dystrophin and t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28028563"
        },
        {
          "offsetInBeginSection": 71,
          "offsetInEndSection": 221,
          "text": "r disorder caused by mutations in the dystrophin DMD gene located at Xp21.1 region. Up to 65% of the patients present dystrophin gene deletions. Mothe",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/18471087"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 161,
          "text": "BACKGROUND: Duchenne muscular dystrophy (DMD) is caused by a defective gene located on the X-chromosome, responsible for the production of the dystrophin protein",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28740938"
        },
        {
          "offsetInBeginSection": 100,
          "offsetInEndSection": 250,
          "text": "l muscle disorders, caused by mutations in the dystrophin gene located in Xp21. DMD occurs with the incidence 1:3500, BMD with the incidence of 1:18,5",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19837995"
        },
        {
          "offsetInBeginSection": 17,
          "offsetInEndSection": 167,
          "text": "ne (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus. It spans 2.2Mb and accounts for approximately 0,1% of the enti",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28867298"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 287,
          "text": "Duchenne muscular dystrophy (DMD), glycerol kinase deficiency (GKD), and adrenal hypoplasia congenita (AHC) can occur together as part of a contiguous gene syndrome located at chromosome Xp21, GKD can manifest with recurrent episodes of vomiting, acidemia, mental retardation, or stupor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19078586"
        },
        {
          "offsetInBeginSection": 77,
          "offsetInEndSection": 227,
          "text": "inked recessive disorders caused by mutations of the DMD gene located at Xp21. In DMD patients, dystrophin is virtually absent; whereas BMD patients h",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/19461958"
        },
        {
          "offsetInBeginSection": 22,
          "offsetInEndSection": 172,
          "text": "rophy (DMD) is a dystrophinopathy, and its associated gene is located on Xp21. Moreover, utrophin, a recently identified structural homologue of dystr",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12619170"
        },
        {
          "offsetInBeginSection": 96,
          "offsetInEndSection": 246,
          "text": " disease in children, resulting from a defect in the DMD gene located on Xp21.2. The new emerging treatment using exon skipping strategy is tailored t",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/31661024"
        },
        {
          "offsetInBeginSection": 303,
          "offsetInEndSection": 453,
          "text": "resent case supports the hypothesis that the DMD gene must be located at Xp21. In this study, involvement of the father\u0027s chromosomes in the transloca",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/3777020"
        },
        {
          "offsetInBeginSection": 364,
          "offsetInEndSection": 514,
          "text": " only later was it diagnosed as DMD. Because the DMD gene is located at Xp21.2, which is one breakpoint of the inv(X), and because its defects are rar",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12145744"
        },
        {
          "offsetInBeginSection": 124,
          "offsetInEndSection": 274,
          "text": "letion, duplication or point mutation of the dystrophin gene located at Xp 21.2. In the present study DNA from seventy unrelated patients clinically d",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/16936400"
        },
        {
          "offsetInBeginSection": 60,
          "offsetInEndSection": 210,
          "text": "inked diseases resulting from a defect in the dystrophin gene located on Xp21. DMD is the most frequent neuromuscular disease in humans (1/3500 male n",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/12488581"
        }
      ],
      "body": "Where is the DMD gene located?",
      "type": "factoid",
      "id": "64179113690f196b5100002e",
      "ideal_answer": [
        "The DMD gene is located on the X chromosome, on the Xp21 locus.",
        "The dystrophin gene (DMD) is the largest gene in the human genome mapping on the Xp21 chromosome locus.Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are Xlinked recessive ",
        "The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus. The disease is caused by deletion, duplication or point mutation of the dystrophin gene, located on the X chromosome (Xp21).",
        "The dystrophin gene is located at chromosome Xp21.1, near the centromere.",
        "The DMD gene maps at Xp21.11, a region of Chromosome X containing over 37 genes including those coding for dystrophin.",
        "The disease is caused by deletion, duplication or point mutation of the dystrophin gene, located on the X chromosome (Xp21). Dystrophinopathies are allelic conditions caused by deletions, duplications and point-mutations in the DMD gene, located on the X chromosome (Xp21.2).",
        "The dystrophin gene (DMD) is the largest gene in the human genome, mapping on the Xp21 chromosome locus. Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21.",
        "The DMD gene is located on the Xp21 chromosome locus on the X chromosome.",
        "The dystrophin gene (DMD) is located on the X chromosome (Xp21).",
        "The DMD gene is located on the X chromosome.",
        "The DMD gene is located on the X chromosome at Xp21.2.",
        "The DMD gene is located on the Xp21 chromosome locus.",
        "The DMD gene is located on the X chromosome at the Xp21 locus.",
        "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X-linked recessive disorders caused by mutations of the DMD gene located at Xp21.",
        "The DMD gene, which encodes for the protein dystrophin, is located on the X chromosome. Specifically, it is found at position Xp21.2-p21.1. Mutations in this gene are responsible for Duchenne muscular dystrophy (DMD), a severe and progressive muscle-wasting disease that primarily affects boys. The dystrophin protein plays a critical role in maintaining the structural integrity of muscle fibers, and its absence or dysfunction leads to muscle degeneration and weakness. While there is currently no cure for DMD, various treatments are available to manage symptoms and improve quality of life for affected individuals. These include corticosteroids to slow disease progression, physical therapy to maintain mobility and function, and assistive devices such as braces or wheelchairs to aid with mobility. Additionally, ongoing research efforts are focused on developing new therapies that target the underlying genetic cause of DMD, including gene therapy approaches aimed at restoring functional dystrophin expression in affected muscles.",
        "The DMD gene, which is responsible for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), is located on the X chromosome at the Xp21 locus. The DMD gene is the largest gene in the human genome, and mutations such as deletions, duplications or point mutations can cause these disorders. Understanding the location of this gene is crucial for diagnosis and treatment of DMD and BMD.",
        "The DMD gene, responsible for encoding the protein dystrophin, is located on the short arm of the X chromosome at position 21.2, specifically within the genomic coordinates Xp21.2-p21.1. This gene spans over 2.4 million base pairs and comprises 79 exons, making it one of the largest genes in the human genome. Mutations in the DMD gene are associated with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), both of which are characterized by progressive muscle weakness and degeneration due to a lack or dysfunction of dystrophin protein. As these conditions are X-linked recessive disorders, they predominantly affect males while females can be carriers with milder or no symptoms. The identification of DMD gene location has facilitated genetic testing, diagnosis, and research into potential therapies for these debilitating neuromuscular diseases.",
        "The DMD gene, responsible for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), is the largest gene in the human genome and is located on the X chromosome at the Xp21 locus. These disorders are X-linked recessive, meaning they primarily affect males. Mutations in the DMD gene, such as deletions, duplications, or point mutations, lead to the development of DMD and BMD. The gene\u0027s location on the X chromosome plays a crucial role in the inheritance pattern and manifestation of these muscular dystrophies."
      ],
      "exact_answer": [
        [
          "Xp21 chromosome locus",
          "X-linked recessive disorders caused by mutations of the DMD gene located at Xp21",
          "X chromosome (Xp21)"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/36301434",
        "http://www.ncbi.nlm.nih.gov/pubmed/34724345"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 1023,
          "offsetInEndSection": 1227,
          "text": "Recently, evobrutinib and tolebrutinib have shown efficacy in phase II clinical trials, and there are numerous ongoing phase III clinical trials of various BTKIs in relapsing and progressive forms of MS. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/36301434"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34724345"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 523,
          "text": "Bruton\u0027s tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B-cell receptor and Fc-receptors. Tolebrutinib (PRN2246, SAR442168) is a potent BTK inhibitor that covalently binds the kinase, resulting in durable inhibition with the potential to target inflammation in the periphery and central nervous system (CNS). Tolebrutinib crosses the blood-brain barrier and potently inhibits BTK in microglial cells isolated from the CNS. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34724345"
        }
      ],
      "body": "What is the mechanism of action of Tolebrutinib?",
      "type": "summary",
      "id": "64040c6b201352f04a00000f",
      "ideal_answer": [
        "Bruton\u0027s tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B-cell receptor and Fc-receptors. Tolebrutinib is a potent BTK inhibitor that covalently binds the kinase, resulting in durable inhibition with the potential to target inflammation in the periphery and central nervous system (CNS). Tolebrutinib crosses the blood-brain barrier and potently inhibits BTK in microglial cells isolated from the CNS."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34429103",
        "http://www.ncbi.nlm.nih.gov/pubmed/35718324",
        "http://www.ncbi.nlm.nih.gov/pubmed/32543249",
        "http://www.ncbi.nlm.nih.gov/pubmed/26310015",
        "http://www.ncbi.nlm.nih.gov/pubmed/22245580",
        "http://www.ncbi.nlm.nih.gov/pubmed/33543619",
        "http://www.ncbi.nlm.nih.gov/pubmed/33119964",
        "http://www.ncbi.nlm.nih.gov/pubmed/27069384",
        "http://www.ncbi.nlm.nih.gov/pubmed/35204770",
        "http://www.ncbi.nlm.nih.gov/pubmed/32795553",
        "http://www.ncbi.nlm.nih.gov/pubmed/35273478",
        "http://www.ncbi.nlm.nih.gov/pubmed/35998606",
        "http://www.ncbi.nlm.nih.gov/pubmed/32601426",
        "http://www.ncbi.nlm.nih.gov/pubmed/20971436",
        "http://www.ncbi.nlm.nih.gov/pubmed/34487118",
        "http://www.ncbi.nlm.nih.gov/pubmed/34423469",
        "http://www.ncbi.nlm.nih.gov/pubmed/29118219",
        "http://www.ncbi.nlm.nih.gov/pubmed/28255969"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 12,
          "offsetInEndSection": 170,
          "text": "Optogenetics allows the experimental manipulation of excitable cells by a light stimulus without the need for technically challenging and invasive procedures.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34429103"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 349,
          "text": "Optogenetics has revolutionized the capability of controlling genetically modified neurons in vitro and in vivo and has become an indispensable neuroscience tool. Using light as a probe for selective neuronal activation or inhibition and as a means to read out neural activity has dramatically enhanced our understanding of complex neural circuits. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35718324"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 123,
          "text": "Optogenetics controls neural activity and behavior in living organisms through genetically targetable actuators and light. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32543249"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 409,
          "text": "This is a review of the current state of optogenetics-based research in the field of ophthalmology and physiology of vision. Optogenetics employs an interdisciplinary approach that amalgamates gene engineering, optics, and physiology. It involves exogenous expression of a light-activated protein in a very particular retinal cell enabling regulation (stimulation vs. inhibition) of its physiological activity",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26310015"
        },
        {
          "offsetInBeginSection": 583,
          "offsetInEndSection": 901,
          "text": "In contrast, optogenetics leverages light-sensitive proteins to control cellular signaling dynamics and target gene expression and, by virtue of precise hardware control over illumination, offers the capacity to interrogate how spatiotemporally varying signals modulate gene regulatory networks and cellular behaviors.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35273478"
        },
        {
          "offsetInBeginSection": 86,
          "offsetInEndSection": 261,
          "text": "As light-gated protein switches, signaling photoreceptors provide the basis for optogenetics, a term that refers to the control of organismal physiology and behavior by light.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22245580"
        },
        {
          "offsetInBeginSection": 546,
          "offsetInEndSection": 840,
          "text": "In this review, we summarize the main optogenetic systems implemented in the budding yeast Saccharomyces cerevisiae, which allow orthogonal control (by light) of gene expression, protein subcellular localization, reconstitution of protein activity, and protein sequestration by oligomerization.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33119964"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 83,
          "text": "Optogenetics is the genetic approach for controlling cellular processes with light.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32601426"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 151,
          "text": "The recently introduced term \u0027optogenetics\u0027 describes a variety of techniques for expressing genes in nerve cells that render them responsive to light.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/20971436"
        },
        {
          "offsetInBeginSection": 92,
          "offsetInEndSection": 238,
          "text": "Optogenetic expression systems can provide precise control over gene expression timing, location, and amplitude using light as the inducing agent.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34487118"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 70,
          "text": "Optogenetics refers to the control of biological processes with light.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33119964"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 203,
          "text": "Optogenetics refers to a technique that uses light to modulate neuronal activity with a high spatiotemporal resolution, which enables the manipulation of learning and memory functions in the human brain.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34423469"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 99,
          "text": "In optogenetics, as in nature, sensory photoreceptors serve to control cellular processes by light.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35998606"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 170,
          "text": "Optogenetics refers to the genetic modification of cells to express light-sensitive proteins, which mediate ion flow or secondary signalling cascades upon light exposure.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255969"
        },
        {
          "offsetInBeginSection": 231,
          "offsetInEndSection": 360,
          "text": " Optogenetics involves the use of genetically encoded and optically active proteins, namely opsins, to control neuronal circuits.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28726577"
        },
        {
          "offsetInBeginSection": 659,
          "offsetInEndSection": 794,
          "text": " (3) A completely different interpretation of optogenetics refers to the light activated expression of a genetically induced construct.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/32795553"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 69,
          "text": "Optogenetics is an innovative technique for optical control of cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/26412943"
        },
        {
          "offsetInBeginSection": 97,
          "offsetInEndSection": 198,
          "text": " Optogenetics refers to techniques that use light to control the cellular activity of targeted cells.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35204770"
        },
        {
          "offsetInBeginSection": 156,
          "offsetInEndSection": 306,
          "text": "basis for optogenetics, a term that refers to the control of organismal physiology and behavior by light. We establish as novel optogenetic tools the ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22245580"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 128,
          "text": "Optogenetics refers to the ability to control cells that have been genetically modified to express light-sensitive ion channels.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27069384"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 150,
          "text": "Optogenetics refers to the control of biological processes with light. The activation of cellular phenomena by defined wavelengths has several advanta",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33119964"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 143,
          "text": "Optogenetics is the use of genetically coded, light-gated ion channels or pumps (opsins) for millisecond resolution control of neural activity.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29118219"
        }
      ],
      "body": "Optogenetics refers to the study of gene expression optimization",
      "type": "yesno",
      "id": "6415b7b8690f196b5100000c",
      "ideal_answer": [
        "Optogenetics allows the experimental manipulation of excitable cells by a light stimulus without the need for technically challenging and invasive procedures.",
        "False. Optogenetics does not refer to the study of gene expression optimization. It refers to the experimental manipulation of excitable cells by a light stimulus in order to study complex neural circuits.",
        "Optogenetics is a field of neuroscience that uses light to control and study the activity of neurons in living tissue. It combines the use of genetic engineering to introduce light-sensitive proteins into cells, with the use of light to control the activity of those cells. This technique has been used to study the function of neurons in the brain, as well as to develop treatments for neurological disorders.",
        "No, optogenetics refers to the use of light to control cells in living tissue, typically neurons, that have been genetically modified to express light-sensitive ion channels.",
        "No, optogenetics is a technique that uses light to control genetically modified cells or neurons in living organisms.",
        "No, optogenetics refers to a technique that uses light to control the activity of genetically modified neurons, allowing precise manipulation of neural circuits in living organisms."
      ],
      "exact_answer": "no"
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/33983696"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 497,
          "offsetInEndSection": 724,
          "text": "The combination of chemotherapy and immunotherapy is a potential therapeutic option for PD-L1-positive mTNBC, as the FDA recently approved atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in combination with chemotherapy. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/33983696"
        }
      ],
      "body": "Which form of breast cancer has Keytruda been FDA approved for?",
      "type": "factoid",
      "id": "6415c9e9690f196b51000018",
      "ideal_answer": [
        "FDA has approved pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer in combination with chemotherapy.",
        "Keytruda has been FDA approved for use in combination with chemotherapy for treating PD-L1-positive mTNBC."
      ],
      "exact_answer": [
        [
          "triple-negative breast cancer"
        ]
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/34797383",
        "http://www.ncbi.nlm.nih.gov/pubmed/27807823",
        "http://www.ncbi.nlm.nih.gov/pubmed/22086232",
        "http://www.ncbi.nlm.nih.gov/pubmed/28280301",
        "http://www.ncbi.nlm.nih.gov/pubmed/29339778",
        "http://www.ncbi.nlm.nih.gov/pubmed/30171554",
        "http://www.ncbi.nlm.nih.gov/pubmed/29278896",
        "http://www.ncbi.nlm.nih.gov/pubmed/28865998"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 278,
          "offsetInEndSection": 431,
          "text": "exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383"
        },
        {
          "offsetInBeginSection": 518,
          "offsetInEndSection": 686,
          "text": "a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide eteplirsen received accelerated approval by the US Food and Drug Administration (FDA) in 2016. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 134,
          "text": "Eteplirsen (Exondys 51) is an antisense oligonucleotide designed to induce exon 51 skipping that is developed by Sarepta Therapeutics.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807823"
        },
        {
          "offsetInBeginSection": 380,
          "offsetInEndSection": 662,
          "text": "In September 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin production by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28280301"
        },
        {
          "offsetInBeginSection": 120,
          "offsetInEndSection": 356,
          "text": "Recently, eteplirsen, a phosphorodiamidate morpholino oligomer-based splice-switching oligonucleotide (SSO) targeting DMD exon 51, was approved by the U.S. Food and Drug Administration as the first antisense-based drug for DMD patients.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29339778"
        },
        {
          "offsetInBeginSection": 345,
          "offsetInEndSection": 495,
          "text": "The FDA conditionally approved the first exon-skipping AON, called eteplirsen (brand name ExonDys51), targeting exon 51 of the DMD gene, in late 2016.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171554"
        },
        {
          "offsetInBeginSection": 321,
          "offsetInEndSection": 519,
          "text": "In 2016, the US Food and Drug Administration (FDA) conditionally approved the first phosphorodiamidate morpholino oligomer (morpholino)-based AO drug, eteplirsen, developed for DMD exon 51 skipping.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865998"
        },
        {
          "offsetInBeginSection": 242,
          "offsetInEndSection": 468,
          "text": "Currently, there is no cure, though exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, is considered especially promising.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/34797383"
        },
        {
          "offsetInBeginSection": 362,
          "offsetInEndSection": 733,
          "text": "in protein. Eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), is designed to skip exon 51, restore the reading frame, and induce production of internally shortened dystrophin in patients with mutations amenable to such treatment.OBJECTIVE: Describe lung function assessed throughout eteplirsen studies 201/202.METHODS: Studies 201/202 included 12 patients treat",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29278896"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 371,
          "text": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.)",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/22086232"
        }
      ],
      "body": "What is eteplirsen\u0027s mechanism of action?",
      "type": "summary",
      "id": "64178f94690f196b51000027",
      "ideal_answer": [
        "Eteplirsen is a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide designed to skip exon 51 of the dystrophin gene.",
        "Eteplirsen is a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene. It has received accelerated approval by the US Food and Drug Administration (FDA) in 2016.",
        "Eteplirsen is a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene. It has been approved by the US Food and Drug Administration (FDA) in 2016.",
        "Eteplirsen works by binding to specific sites on DNA known as guanine nucleotide sequences and recruiting the splicing machinery which results in skipping of the mutated exon 51.",
        "Eteplirsen works by binding to messenger RNA of the dystrophin gene, causing it to be degraded. Without dystrophin, muscles become weaker and more susceptible to damage, which can lead to heart failure and other complications. Eteplirsen was shown to restore dystrophin levels in mouse models of DMD and also improve walking distance in dogs with the disease. However, like many drugs used to treat diseases, eteplirsen faces challenges such as producing enough dystrophin to provide significant benefit and ensuring patient safety. As such, further research and development is needed to optimize its use as a potential treatment for DMD.",
        "ETEPLIREN is an ASO which can alter genetic expression by binding complementary DNA sequences on genes known to cause diseases like DMD or CFTR defects, thus preventing incorrect translation into proteins and causing their destruction.",
        "Eteplirsen\u0027s mechanism of action is to skip exon 51 of the dystrophin gene, which promotes dystrophin production by restoring the translational reading frame of Duchenne muscular dystrophy (DMD) in patients with genetic mutations amenable to exon 51 skipping. This is achieved through the use of a phosphorodiamidate morpholino oligomer-based splice-switching oligonucleotide (SSO).",
        "Eteplirsen is an antisense oligonucleotide (ASO) drug that works by targeting and binding to a specific messenger RNA (mRNA) sequence in the dystrophin gene. This binding prevents the mRNA from being translated into the dystrophin protein, which is essential for muscle function. By blocking the production of dystrophin, eteplirsen helps to reduce the symptoms of Duchenne muscular dystrophy (DMD).",
        "Eteplirsen is an antisense oligonucleotide that binds to exon 51 of the dystrophin gene, resulting in exon skipping and the production of a truncated but functional dystrophin protein.",
        "Eteplirsen is a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene. It is a phosphorodiamidate morpholino oligomer (PMO) that received accelerated approval by the US Food and Drug Administration (FDA) in 2016. Its mechanism of action is to bind to the pre-mRNA of the dystrophin gene and block the splicing of exon 51, resulting in the production of a truncated but functional dystrophin protein.",
        "Eteplirsen is a synthetic antisense oligonucleotide that works by skipping exon 51 of the dystrophin gene, allowing the remaining exons to link together and produce a shorter but still functional form of dystrophin, which is important for muscle development and maintenance",
        "Eteplirsen\u0027s mechanism of action involves binding to a specific region of the dystrophin gene, causing exon 51 to be skipped during the gene\u0027s processing. This results in the production of a shorter, partially functional dystrophin protein, which helps improve muscle function in patients with Duchenne muscular dystrophy",
        "exon-skipping therapy including eteplirsen (brand name Exondys 51), a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene",
        "Eteplirsen is a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene. It is approved for treatment of Duchenne muscular dystrophy.",
        "Eteplirsen is a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene. It received accelerated approval by the US Food and Drug Administration (FDA) in 2016.",
        "Eteplirsen is a drug used to treat Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle degeneration and weakness. The drug works by targeting the underlying cause of DMD, which is a mutation in the dystrophin gene that leads to the absence of functional dystrophin protein in muscle cells. Eteplirsen is an antisense oligonucleotide that binds to a specific region of the dystrophin pre-mRNA, allowing for the skipping of exon 51 during mRNA splicing. This results in the production of a truncated but functional form of dystrophin protein, which can partially restore muscle function and slow disease progression. Eteplirsen has been shown to improve walking ability in some patients with DMD and has been approved for use in several countries, although its efficacy remains controversial and further research is needed to fully understand its mechanism of action and long-term effects.",
        "Eteplirsen is a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, which is responsible for Duchenne muscular dystrophy (DMD). By skipping this exon, eteplirsen allows for the production of a truncated but functional form of dystrophin protein. This therapy received accelerated approval by the US Food and Drug Administration (FDA) in 2016 as a treatment for DMD. Eteplirsen\u0027s mechanism of action involves restoring the reading frame of the dystrophin mRNA transcript, thereby allowing for the production of a partially functional protein that can improve muscle function and slow disease progression. While eteplirsen has shown promising results in clinical trials, it is important to note that its efficacy and safety are still being evaluated through ongoing studies.",
        "Eteplirsen is an antisense oligonucleotide drug designed to treat Duchenne muscular dystrophy (DMD) caused by specific mutations in the dystrophin gene. Its mechanism of action involves exon skipping, which allows for the production of a partially functional dystrophin protein. Eteplirsen specifically targets exon 51 in the pre-mRNA transcript, binding to it and preventing its inclusion during mRNA splicing. This results in the generation of an mRNA with an altered reading frame that can be translated into a truncated but still partially functional dystrophin protein. By restoring some level of dystrophin expression, eteplirsen aims to slow down or halt the progression of muscle degeneration and weakness associated with DMD, thereby improving patients\u0027 quality of life and potentially extending their lifespan.",
        "Eteplirsen (brand name Exondys 51) is a synthetic antisense oligonucleotide designed to skip exon 51 of the dystrophin gene, which plays a crucial role in Duchenne muscular dystrophy (DMD). Its mechanism of action involves binding to specific sequences within the pre-mRNA transcript, promoting exon-skipping during mRNA splicing. This process results in the production of a truncated but partially functional dystrophin protein, which can alleviate some symptoms associated with DMD. Eteplirsen is classified as a phosphorodiamidate morpholino oligomer (PMO) and received accelerated approval by the US Food and Drug Administration (FDA) in 2016 for the treatment of DMD patients amenable to exon 51 skipping therapy."
      ]
    },
    {
      "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/35767439",
        "http://www.ncbi.nlm.nih.gov/pubmed/29088386",
        "http://www.ncbi.nlm.nih.gov/pubmed/29594041",
        "http://www.ncbi.nlm.nih.gov/pubmed/24718705"
      ],
      "snippets": [
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 72,
          "text": "Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35767439"
        },
        {
          "offsetInBeginSection": 322,
          "offsetInEndSection": 503,
          "text": "METHODS: We conducted a single-center, dose-escalation study of DNX-2401, an oncolytic adenovirus that selectively replicates in tumor cells, in patients with newly diagnosed DIPG. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35767439"
        },
        {
          "offsetInBeginSection": 1971,
          "offsetInEndSection": 2236,
          "text": "CONCLUSIONS: Intratumoral infusion of oncolytic virus DNX-2401 followed by radiotherapy in pediatric patients with DIPG resulted in changes in T-cell activity and a reduction in or stabilization of tumor size in some patients but was associated with adverse events.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/35767439"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 101,
          "text": "Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088386"
        },
        {
          "offsetInBeginSection": 419,
          "offsetInEndSection": 641,
          "text": "OBJECTIVE: To determine the safety, tolerability, and toxicity of an oncolytic adenovirus, DNX-2401, injected into the cerebellar peduncle in pediatric subjects with DIPG and to collect tumor samples of this type of tumor.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29088386"
        },
        {
          "offsetInBeginSection": 0,
          "offsetInEndSection": 116,
          "text": "DNX-2401, an Oncolytic Virus, for the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Gliomas: A Case Report.",
          "beginSection": "title",
          "endSection": "title",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594041"
        },
        {
          "offsetInBeginSection": 824,
          "offsetInEndSection": 1047,
          "text": "To this aim, we have designed a clinical Phase I trial for newly diagnosed pediatric DIPG to investigate the feasibility, safety, and preliminary efficacy of delivering DNX-2401 into tumors within the pons following biopsy.",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594041"
        },
        {
          "offsetInBeginSection": 1506,
          "offsetInEndSection": 1620,
          "text": " To our knowledge, this is the first report of intratumoral DNX-2401 for a patient with DIPG in a clinical trial. ",
          "beginSection": "abstract",
          "endSection": "abstract",
          "document": "http://www.ncbi.nlm.nih.gov/pubmed/29594041"
        }
      ],
      "body": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?",
      "type": "yesno",
      "id": "63f03155f36125a426000019",
      "ideal_answer": [
        "Yes. DNX-2401 is tested for treatment of Diffuse Intrinsic Pontine Glioma."
      ],
      "exact_answer": "yes"
    }
  ]
}